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Abstract 
 
HIV-infected individuals are at increased risk of age-related non-AIDS morbidity and 
mortality compared with HIV-uninfected persons. It is speculated that HIV-infected 
individuals may not only be aging chronologically, but also undergoing accelerated 
biological aging. This is supported by clinical reports of conditions classically 
associated with the normal aging process appearing at an earlier age in HIV-infected 
persons compared to age-matched controls.  
 
Chronological age is an imprecise measure of biological aging due to inter-individual 
differences in rates of aging and therefore ‘biomarkers of aging’ may be used to 
assess biological age. The eye may be a uniquely useful site as a model of aging. It is 
easily accessible for examination and several components can be measured and 
assessed objectively e.g. lens density, retinal vascular calibre, corneal endothelial cell 
counts and the retinal nerve fibre layer thickness.  
 
This case-control study of 504 adults recruited from one district in Cape Town, 
South Africa assessed whether HIV-infected individuals have more advanced ocular 
aging, systemic frailty and cellular senescence than an HIV-uninfected group of similar 
age. Accelerated biological aging was demonstrated in HIV-infected individuals 
compared to their uninfected counterparts. HIV infection was also associated with 
frailty. Ocular parameters provided evidence of greater aging within the HIV-infected 
group, particularly objective measurement of retinal vascular calibre and lens density. 
These data suggest that as well as increased biological aging at a cellular and systemic 
level, ocular aging occurs as part of the accelerated aging phenotype in HIV infection.  
 
This study provides novel data about accelerated biological aging in sub-
Saharan Africa and a platform for addressing future research questions relating to 
accelerated aging trajectories in HIV infection, the relative contributions of the 
infection and antiretroviral therapy, and whether biological age is dependent upon 
the duration of untreated disease or nadir CD4 count. As the HIV-infected 
population continues to age and expand, accelerated biological aging may have wide-
ranging implications for the burden and management of HIV-related morbidity. 
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Preface 
 
 
 
The thesis for this PhD uses the “research/review papers” format, recently 
introduced by the London School of Hygiene and Tropical Medicine. It therefore 
includes a number of papers which have either been published in, accepted by, or are 
formatted for submission to peer-reviewed journals. The chapters listed in italics in 
the Contents are in this research/review paper format and include publication details 
in a cover sheet, including acknowledgement of the contributions of other people. 
The other chapters of the thesis are composed of “linking material” which includes 
information/data not covered in the papers and helps to make the thesis a coherent 
body. The linking material was written by Sophia Pathai.  
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Chapter 1 
HIV infection and accelerated aging 
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1. Background 
1.1 Aging, frailty and immunosenescence 
Aging can be conceptualized as ‘a process of accumulation of deficits, taking place in 
different individuals in different ways, with a variety of rates for different organ 
systems, depending on the interplay of intrinsic and extrinsic factors’ [1,2]. A 
functional definition is the ‘time-dependent decline of functional capacity and stress 
resistance associated with increased risk of morbidity and mortality’ [3]. Aging 
ranges from ‘successful’ aging to ‘pathological’ aging depending on the functional 
reserves of different physiological systems and the consequent appearance of 
disease. Frailty may reflect an intermediate, but distinct state between these two 
extremes [2]. Frailty is a concept of decreased physiologic reserve that increases 
patient risk of morbidity and mortality [4]. A core feature of frailty is ‘increased 
vulnerability to stressors due to impairments in multiple systems that lead to decline 
in homeostatic reserve and resiliency’ [5]. It is apparent that many of the attributes 
of frailty also apply to ‘biological’ aging, as well as an inter-relation with chronic 
disease (Figure 1a). Systemic low-level inflammation is strongly associated with aging 
and chronic age-related diseases, and is also associated with frailty [6]. Low-grade 
inflammation is linked to alterations of the immune response in the elderly, termed 
immunosenescence (Section 1.2). At a cellular and molecular level, aging is manifest 
as cellular (or replicative) senescence. Old/senescent cells are characterized by an 
arrest of cell proliferation and an altered pattern of gene expression with telomere 
shortening (Section 1.5). Thus, aging is a complex phenomenon occurring at 
molecular, cellular, organ and physiological levels. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a: Inter-relation between aging and disease and relationship to frailty, from Fulop 
et al [2]. Reproduced with permission from publisher.  
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1.1.1 Aging in treated HIV infection 
Highly active antiretroviral therapy (HAART) has resulted in a reduction in mortality 
in HIV-infected people, largely due to prevention of AIDS-related events, but also 
due to a decrease in non-AIDS related events and deaths [7,8]. The age at diagnosis 
of HIV-infected individuals is increasing, as is the frequency of age-related conditions 
[9]. In the USA it is estimated that by 2015 more than 50% of the HIV-infected 
population will be over 50 years of age [10]. This trend is beginning to become 
apparent in some parts of sub-Saharan Africa where scale-up of effective HAART 
programmes and continued viral suppression are leading to a cohort of HIV-infected 
individuals who are in their fifties and sixties [11,12]. An emerging challenge is to 
understand the changing demography of the HIV-infected population, particularly in 
resource-constrained settings, and a shift from primarily treatment of acute 
opportunistic Infections (OIs) to the management of age-related conditions in 
the long term[13-15].  
The Strategies for Management of Antiretroviral Therapy Study (SMART) group 
showed that HIV is associated with higher risk of several non-AIDS complications, 
and HAART reduces the risk of these events [16]. Although HAART can prevent 
AIDS and non-AIDS related morbidity and mortality, treatment does not fully 
restore health (Figure 1b). Patients receiving HAART are at increased risk of age-
related non-AIDS-related morbidity and mortality compared with HIV-seronegative 
persons [17,18]. Several of these conditions are classically associated with the 
normal aging process but appear to occur at an earlier age in HIV-infected persons 
compared to age-matched controls. The emerging scenario is that of HIV population 
cohorts who are aging chronologically, but also likely to be undergoing accelerated 
physiological and immunological senescence. 
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 Figure 1b: From Lohse et al [18] Cumulative survival curve for HIV-infected persons 
(without hepatitis C co-infection) and persons from the general population. Reproduced with 
permission from publisher. 
 
 
1.1.2 Which non-AIDS-related diseases are involved? 
In the context of premature or accelerated aging and HIV, the conditions involved 
should already be known to be associated with aging in the general population, and 
the rate of these conditions should be greater among young-HIV-infected patients 
than uninfected patients of similar age [19]. Conditions where this phenomenon has 
been noted are discussed: 
Cardiovascular disease: Patients with HIV infection are at increased risk of 
cardiovascular disease compared to age- and gender-matched uninfected 
counterparts [20,21]. Studies using administrative and clinical databases in the USA 
have compared rates of cardiovascular events (outcome definitions vary) between 
HIV-infected and uninfected groups. Age-adjusted hospital-admission rates for 
coronary heart disease (CHD) in HIV-infected versus HIV-uninfected populations 
were 6.5 versus 3.8 per 1000 person-years respectively, p=0.003 [22]. Review of the 
clinical registry for two tertiary hospitals in Massachusetts found higher proportions 
of diabetes, hypertension and dyslipidemia in HIV-infected patients compared to 
HIV-uninfected individuals. The mean myocardial infarction (MI) rates were 11.13 vs. 
6.98 per 1000 person-years, respectively (P<0.0001). MI rates were higher in HIV-
infected patients in all age groups [23]. However in all of these studies it was not 
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possible to adjust for all cardiovascular risk factors (BP, lipids, smoking, family 
history). These studies could have been subject to ascertainment bias as HIV-infected 
individuals may have had more hospital encounters providing the opportunity for 
CHD diagnosis compared to their HIV-uninfected counterparts. Data from over 
28,000 patients in the Veterans Administration (VA) cohort showed a significantly 
increased risk of acute MI in HIV-infected patients versus non-HIV-infected patients, 
with an adjusted hazard ratio of 1.94 (95% CI, 1.58–2.37) [24]. The increased risk of 
cardiovascular disease is thought to be mediated via inflammatory and immunologic 
pathways, ultimately leading to vascular damage and dysfunction, however the 
contribution of HIV-related parameters is unclear: In the VA cohort [24], HIV viral 
load and current CD4 count were not associated with acute MI risk. In contrast, 
increased vascular aging (as measured by coronary artery calcium levels) was 
associated with current CD4 count in an Italian cohort of HIV-infected individuals 
[25]. Low nadir CD4 count, high current CD8 count and viral load >50 copies/mL 
were associated with an increased risk of MI in a French case-control study [26]. In a 
Dutch cohort, high-level viremia (400 copies/mL) in participants on HAART, was 
associated with cardiovascular disease [27]. Cardiovascular risk may also increase 
with some classes of HAART, particularly protease inhibitors [21,28,29]. Subclinical 
structural and functional abnormalities of the cardiac and vascular system have also 
been noted in HIV infection, with a higher than expected prevalence of 
echocardiographic abnormalities in the Study to Understand the Natural History of 
HIV/AIDS in the Era of Effective Therapy (SUN Study) cohort [30]. Early 
atherosclerosis is also thought to play a key role in the increased risk of 
cardiovascular disease in HIV infection, in particular endothelial dysfunction [31-33]. 
Host responses to cytomegalovirus (CMV) may be abnormal in HIV infection and 
associated with clinical disease (see section 1.2.1). Cytomegalovirus antibody titers 
are increased in HIV-infected women and associated with sub-clinical cardiovascular 
disease [34]. 
Renal disease: The incidence of end-stage renal disease (ESRD) in US Veterans was 
compared to a matched population of HIV-uninfected US veterans [35]. Among the 
white population there was no raised risk of ESRD for HIV-infected patients 
compared to HIV-uninfected patients. However, Afro-Caribbean individuals with HIV 
were as likely to develop ESRD as Afro-Caribbean individuals with diabetes and 
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almost twice as likely to develop ESRD as white individuals with diabetes.  Further 
analysis of this cohort showed that compared with patients with only HIV or 
diabetes, patients with both diagnoses were at significantly increased risk of 
progressive chronic kidney disease (CKD) even after adjusting for traditional CKD 
risk factors [36]. Impaired renal function has also been found to identify HIV-infected 
patients at increased risk of cardiovascular events [37]. 
Bone disease: A meta-analysis of studies published between 1966 and 2005 
investigating the prevalence of reduced bone mineral density (BMD) in HIV-infected 
patients found that 67% of patients had reduced BMD, with 15% of this group having 
osteoporosis. Risk of fracture is also increased in older HIV-infected men, but has 
not been fully established in younger HIV-infected men, and does not appear to be 
increased in younger HIV-infected women [38,39].  
Pulmonary disease: Analysis of the Veterans Aging Cohort Study Virtual Cohort 
found infectious and non-infectious pulmonary diseases to be increased among HIV-
infected compared to HIV-uninfected Veterans. The two most common incident 
pulmonary diseases were bacterial pneumonia and COPD; opportunistic diseases 
were less common [40]. Similar findings of increased respiratory symptoms and 
higher prevalence of COPD in HIV-infected individuals were noted in a case-control 
study from Italy [41]. HAART is also a risk factor for irreversible airway obstruction 
after adjustment for smoking [42]. Higher plasma HIV viral load is associated with 
increased risk of spirometry-defined obstructive lung disease [43]. HIV is thought to 
have an effect on lung function and damage such that the effect of HIV on lung age 
was approximated to smoking an additional 25 pack-years in a case-control study of 
HIV-infected and uninfected injecting drug users [44]. 
 
Cancer: In resource-limited settings, the prevalence of some AIDS-defining cancers 
(ADCs) such as cervical cancer, Kaposi’s sarcoma and non-Hodgkin’s lymphoma still 
remains high. However, increasing numbers of non-AIDS-defining cancers (NADCs) 
are now seen in resource-limited settings and well-resourced environments [45]. 
The most commonly reported NADCs regardless of setting include Hodgkin’s 
lymphoma, lung, hepatocellular and breast cancer [46]. Premature aging would 
manifest not only as an overall elevated cancer risk but also as a downward shift in 
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the distribution of ages at cancer diagnosis. This is supported by studies of lung [47], 
liver [48], anal [49], and colorectal cancer [50] that have noted ages at diagnosis 10 
to 20 years younger among HIV-infected individuals compared with the general 
population. However, differences in age distribution between the underlying HIV and 
general populations may account for these observations. Shiels et al [51] evaluated 
the ages at diagnosis of several types of non-AIDS-defining cancers in HIV and 
general populations using data from the U.S. HIV/AIDS Cancer Match Study, 
adjusting for differences in age and other demographic characteristics between these 
populations. The age at cancer diagnosis did not differ between HIV-infected persons 
and the general population for most types of cancer. However, ages at diagnosis of 
lung (median, 50 vs. 54 years) and anal cancer (42 vs. 45 years) were significantly 
younger in persons with AIDS than expected in the general population (p<0.001), 
and the age at diagnosis of Hodgkin’s lymphoma was significantly older (42 vs. 
40years; p<0.001).   
 
Frailty: is a concept of decreased physiologic reserve that increases patient risk of 
morbidity and mortality [4]. A ‘frailty-related’ phenotype has been defined in the 
aged population as at least three of the following characteristics: unintentional weight 
loss (10lbs in past year), self-reported exhaustion, weakness (grip strength), slow 
walking speed, and low physical activity [52]. Using this definition the frailty 
prevalence for 55-year-old men infected with HIV for ≤4 years (3.4%; 95% CI, 1.3–
8.6) was similar to that of uninfected men ≤65 years old (3.4%; 95% CI, 1.5–7.6) 
[53,54]. A prevalence of 9% was reported from a clinic population in the United 
States (US) (mean age 42 years) [55]. The Women’s Interagency HIV Study (a 
prospective cohort in five US cities) found a prevalence of 12% in HIV-infected 
women with clinical AIDS (median age 41 years)[56]. In the Multicenter AIDS 
Cohort Study (MACS) (a longitudinal study of men who have sex with men), a frailty 
prevalence of 5-14% depending on age and duration of HIV infection was reported 
from 1994-2005 data [57,58] and 8% in 2009-2010 among men aged 40-49 years 
[59].  In the SUN study (a US observational cohort of HIV-infected adults, median 
age 47 years), 5% of participants were frail [60]. The variation in estimates is likely to 
be attributable to differences in study design and clinical demographics of patients 
recruited (e.g. HAART status, degree of immunodeficiency). Current CD4 count is a 
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strong, independent predictor of frailty [56-59]. Central obesity and fat 
redistribution have also been suggested as part of the frailty-like phenotype in HIV-
infected individuals [61]. HIV-infected individuals are also at greater risk of falls with 
middle-aged HIV-infected adults having a high fall risk [62]. Multiple comorbidities, 
medications and functional impairment were predictive of falls, however HIV-related 
parameters were not.  
 
Neurological disease: HIV-infected individuals have an increased risk of 
cerebrovascular events (non-traumatic subarachnoid haemorrhage, intra-cerebral 
haemorrhage, cerebral infarction, unspecified stroke or transient ischemic attack), 
and this risk is associated with IDU, low CD4 count and exposure to abacavir [63]. 
Aging independently raises the risk of a range of neurocognitive disorders including 
memory impairment and mild-to-severe dementia. Neuro-degeneration associated 
with HIV infection combined with increased life expectancy can also accelerate 
neurocognitive decline and development of HIV-1-associated neurocognitive dis-
orders (HAND) in up to 50% of HIV-1-infected individuals [64-66]. HAND includes 
asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder 
(MND), and the most severe form, HIV-1-associated dementia (HAD). The current 
higher prevalence of the milder form of HAND coincides with the aging population 
of HIV-infected individuals, and so aging may be an important risk factor for HAND 
[65,66]. In sub-Saharan Africa, there is a growing recognition of HAND in patients in 
care and treatment (33% for ANI 12% for MND and 2% for HAD) [67]. The 
Veterans Aging Cohort Study (VACS) Index is a combined index of age, traditional 
HIV biomarkers (HIV-1 plasma RNA and current CD4 count) and non-HIV 
biomarkers (i.e. indicators of renal and liver function, anaemia [haemoglobin], and 
Hepatitis C co-infection). Higher VACS Index scores are predictive of mortality and 
some types of morbidity [68,69]. Higher VACS Index scores are also associated with 
neurocognitive impairment (NCI). Among the VACS components, older age, lower 
hemoglobin and Hepatitis C co-infection were most strongly linked to HIV-
associated NCI. Hemoglobin and Hepatitis C continue to be associated with NCI in 
models including AIDS status [70]. Frail HIV-infected men participating in the MACS 
cohort were also found to have a 2-fold risk of HAND after adjustment for socio-
economic and HIV-related factors [71]. 
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1.1.3 Contributing factors – why are patients on treatment still at risk? 
 
There are likely to be several contributing factors why antiretroviral-treated patients 
remain at risk for premature morbidity and mortality compared with HIV-uninfected 
individuals. Differential risk exposures may play an important role - HIV-infected 
individuals may differ from a general population not only in being infected with HIV 
but also in terms of ‘risk’ behaviours (e.g. alcohol, substance abuse, smoking) and 
socioeconomic factors.  In the US Veterans Aging Cohort, HIV-infected veterans 
were more likely to have co-morbid conditions such as kidney disease, liver disease, 
substance misuse and multi-morbidity compared to age- and sex- matched 
uninfected veterans [72]. The MACS/WIHS (Multicenter AIDS Cohort Study/ 
Women’s Interagency HIV Study) found a higher prevalence of risk factors such as 
low levels of high-density lipoproteins, elevated levels of triglycerides and smoking in 
HIV-infected individuals compared to matched controls when assessing coronary 
heart disease risk [28]. The differential exposures to risk factors between HIV-
infected and uninfected populations and residual confounding could result in an 
apparent increased risk of age-related outcomes. To account for such confounding 
factors in epidemiologic analyses requires very well-characterized patients [19].  
The direct toxicities of HAART may also contribute to age-related complications. 
The Data Collection on Adverse Events of Anti-HIV Groups (D:A:D) studies showed 
that long-term exposure to protease inhibitor (PI) treatment was independently 
associated with the risk of cardiovascular disease (due to their tendency to cause 
dyslipidemia), and also with recent use of nucleoside reverse transcriptase inhibitors 
(abacavir and didanosine) [73,74]. In general, antiretroviral drug toxicity may 
contribute to the risk of age-related complications.  
Overall, it appears that non-AIDS-related events are more common in HIV disease, 
even after adjusting for age, exposure to HAART and differential risk exposures. 
There may be an independent role of HIV infection in causing accelerated aging, 
mediated by elevated inflammation levels despite HAART, and chronic T-cell 
activation. 
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1.2 Immunosenescence and inflammation in HIV infection 
 
1.2.1 Immunosenescence 
Immunosenescence is impairment in immunity resulting from age-associated changes 
in function in a variety of cells, involving changes to both innate and adaptive 
immunity and an imbalance between the two arms [75]. The immune system in the 
elderly is characterized by progressive enrichment of terminally differentiated T cells 
(CD8+ effector cells), a reduction in T-cell renewal, reversed ratio of CD4+ to 
CD8+ cells, increased T-cell activation and increased levels of several inflammatory 
markers. This translates into a general decline of the immune system, leading to 
immunosenescence [76]. Several of the immunological changes that occur in HIV-1-
infected individuals are similar to those associated with normal aging in the HIV-1-
uninfected elderly [4] (Table 1a and Figure 1c).  
 
Continuous stimulation of the immune system by HIV may lead to a progressive loss 
of the naïve and memory T-cell pools, resulting in an imbalance of T cell phenotypes. 
Chronic HIV infection leads to T cell differentiation with the expansion of antigen-
experienced cells that lose the expression of immune marker CD28, with increased 
expression of CD57. CD28 is a co-stimulatory molecule on T cells; binding to its 
ligand CD80 on antigen presenting cells leads to interleukin-2 (IL-2) production, 
telomerase activation and ‘survival signals’ for other T cells (Figure 1c). Loss of 
CD28 on CD4+ cells also alters its capacity to drive B cell proliferation and antibody 
production. Loss of CD28 on T cells is a key predictor of immune aging [76]. 
HAART-treated patients (median age 56 years, <50 HIV-1 RNA copies/ml, median 
CD4 count 724 cells/mm3) were found to have frequencies of senescent CD8+ T 
cells (CD57+ CD28- phenotype) similar to older HIV-negative individuals (median 
age 88 years) [77].  
 
Clinically, T cell activation and senescence predict subclinical carotid artery disease 
in HIV-infected women. Compared with HIV-uninfected women, frequencies of 
CD4+CD38+HLA-DR+, CD8+CD38+HLA-DR+, and CD8+CD28-CD57+ T cells were 
higher among HIV-infected women, including those who achieved viral suppression 
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while receiving HAART. Among HIV-infected women, adjusted for age, antiretroviral 
medications, and viral load, higher frequencies of activated CD4+ and CD8+ T cells 
and immunosenescent CD8+ T cells were associated with increased prevalence of 
carotid artery lesions as determined by carotid ultrasound [78]. 
 
Chronic cytomegalovirus (CMV) infection is also implicated in accelerated aging in 
the healthy elderly population [79,80]. Elderly CMV seropositive adults have lower 
CD4/CD8 ratios, lower naïve T-cell numbers and higher frequencies of the CD8+ 
CD28- phenotype compared to CMV seronegative adults [81]. Long-term 
successfully treated HIV-infected individuals (with undetectable plasma HIV RNA 
levels) have also been found to have high levels of CMV-specific effector cells, similar 
to that observed in the elderly, but occurring at much younger ages [82]. These 
levels were similar to that observed in the elderly, but occurred at much younger 
ages in the HIV-infected cohort (median age 45 years). The possible role of CMV in 
vascular aging has also been described (Section 1.1.2) with HIV-positive women with 
increased CMV IgG levels more likely to have carotid artery stiffness [34]. In a 
longitudinal study, CMV/HIV co-infection was associated with the risk of non-AIDS 
events/deaths independently of other prognostic factors [83]. CMV and HIV may 
influence immunological aging possibly in an additive manner, however it has also 
been suggested that CMV may be the ‘smoking gun’ in immunosenescence among 
persons co-infected with both pathogens, increasing the rate of immunological aging 
and the development of chronic diseases of inflammatory aetiology, especially among 
those undergoing HAART [84]. Thus, CMV or HIV may be co-drivers of 
immunosenescence, or it may be that CMV accentuates or accelerates this 
mechanism. 
A unifying concept of the immunological changes that occur with physiological aging 
has been coined “inflammaging” by Franceschi and colleagues [6]. Characteristics 
include increased serum levels of pro-inflammatory cytokines (e.g. IL-6) and 
coagulation markers, a role for common viruses such as CMV in driving an ‘immune 
risk phenotype’, and also a genetic component which may explain why some 
individuals age faster than others. These changes are also consistent with the 
inflammatory and immunological processes reported in HIV, and add weight to the 
concept of accelerated aging in HIV.  
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Whether HIV alone drives immunosenescence, acting as an accelerator of true 
biological aging, or as an independent causal factor for one or more co-morbid 
conditions remains to be established [19]. Measuring subclinical aging could be an 
important method to establish whether HIV is a true accelerant of the aging process. 
Table 1a: Age and HIV-associated immune responses – adapted from Effros et al. [4] 
Adaptive immune 
response 
Change in HIV-infected 
patients, compared with 
age-matched controls 
Change in aging 
persons, compared 
with young adults 
B cells   
Naïve cell number Normal to low Normal to low 
Memory cell number Increased Increased 
Cytokine production Increased  Normal 
Primary responses Decreased Decreased 
Memory responses Low to normal Normal 
T cells   
Naïve cell number Low Low 
Memory cell number Low Normal to high 
Cytokine production Low Normal to high 
CD28 expression Very low Very low 
Senescent phenotype* Very high High 
*Senescent phenotype consists of low CD28 expression, shortened telomeres, replicative 
incompetence and excessive production of inflammatory cytokines. 
Reproduced with permission from publisher. 
 
Figure 1c: Proposed mechanisms of immunosenescence, from Appay et al [85]. 
Reproduced with permission from publisher. 
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1.2.2 Inflammation  
A potential mechanism to explain the increased risk of serious non-AIDS conditions 
could be via HIV-induced activation of inflammatory and coagulation pathways. The 
SMART study showed that several pro-inflammatory biomarkers (high-sensitivity C-
reactive protein (hsCRP), interleukin-6 (IL-6) and D-dimer were elevated in HIV-
infected individuals, and remained so even with suppressed HIV RNA levels [86]. HIV 
virions (which may be non-infectious) continue to replicate and activate the innate 
and adaptive immune system to release pro-inflammatory mediators such as IL-6 that 
are associated with age-associated co-morbidities. Fibrinogen is an inflammatory 
biomarker in the clotting cascade. HIV-infected participants with fibrinogen levels in 
the highest tertile had a 2.6-fold higher adjusted odds of death than those with 
fibrinogen in the lowest tertile [87]. However the study designs mean that causality 
cannot be definitively established; reverse causality may even be a factor where an 
already present disease process causes an increase in the biomarker level. In older 
people with the ‘frailty phenotype’, levels of IL-6, CRP and D-dimer are elevated 
[88]. Similarly, it is not known if elevated IL-6 or CRP causes this morbidity and 
mortality or if they are simply surrogate markers of a global inflammatory state. 
 
1.2.3 Biomarkers of immune dysfunction in HIV 
The similarities that HIV infection shares with aging in the general population, in 
terms of ‘inflammaging’ and immune senescence is driven by chronic immune system 
activation has permitted the use of plasma and cellular biomarkers of immune system 
activation and dysfunction to predict outcomes, particularly opportunistic disease 
and mortality, in HIV-infected individuals [89]. 
Markers of inflammation (IL-6, hs-CRP), coagulopathy (protein S, protein C, and D-
dimer) and gut microbial translocation (bacterial lipopolysaccharide [LPS] soluble 
CD14 [sCD14]) and cellular markers of immune dysfunction (CD38, CD57) are 
associated with chronic immune system activation and likely contribute to systemic 
inflammation, all of which may persist with HAART. Elevations of certain 
inflammatory or coagulopathic biomarkers, notably IL-6, hs-CRP, and D-dimer have 
been independently associated with mortality and other clinical endpoints in large 
randomized clinical trials (Table 1b). As these biomarkers appear to add to the 
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predictive value of traditional tests used in management of HIV (e.g., CD4+ T-cell 
counts and HIV RNA), they have the potential to help guide treatment decisions 
[89].  
Inflammatory markers are increasingly being evaluated in studies assessing their 
association with mortality and clinical endpoints in HIV infection – refer to Table 1b 
for further detail.  Markers of immune dysfunction for further evaluation in clinical 
outcome studies have been presented in a review by Nixon and Landay [89] and in a 
report to the NIH Office of AIDS Research [90]. 
Indices and scores have also been developed using the biomarkers in tandem with 
clinical characteristics to provide practical and generalizable mortality risk index for 
HIV-infected individuals on ART [69]. The Veterans Aging Cohort Study (VACS) was 
used to develop the VACS Index, based on age, CD4 count, HIV-1 RNA, 
hemoglobin, AST, ALT, platelets, creatinine and Hepatitis C status. Among HIV-
infected patients treated with ART, the VACS Index more accurately discriminates 
mortality risk than traditional HIV markers and age alone [91]. Addition of D-dimer 
and sCD14, but not IL-6, improves the predictive accuracy of the VACS Index for 
mortality [68]. VACS Index scores have also been shown to discriminate risk and 
provide accurate mortality estimates over 1-5 years of exposures to ART for diverse 
patient subgroups from North America [92]. Indices that take into account ocular 
parameters have not been developed to date.  
 
Table 1b (Overleaf): Summary of studies assessing mainly inflammatory biomarkers 
and their association with mortality and clinical endpoints in HIV infection 
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First author, year, 
country  
Biomarkers 
measured 
Study design and population Results Overall conclusions 
Ross, 2009 [93] 
USA 
 
Common carotid 
artery and internal 
carotid artery IMT, 
TNF–α, hsCRP, IL-
6, MLO, sVCAM-1  
  
Case-control 
73 HIV+, 21 HIV- 
All biomarkers at higher level in HIV group 
 
Hs-CRP positively correlated with 
carotid IMT in both groups.  
In the HIV+ group: 
sVCAM-1 positively correlated with 
all inflammatory cytokine levels. 
sVCAM-1, MLO, TNF-a all 
associated with internal carotid artery  
 Neuhaus, 2010 [86] 
USA 
hs-CRP, IL-6, 
cystatin C 
Individuals 45–76 years: 494 
HIV+ individuals in the SMART 
study and 5386 uninfected 
participants in the MESA study.  
Individuals 33–44 years: hs-CRP 
and IL-6 levels compared in 287 
HIV+ participants in the SMART 
study and 3231 participants in the 
CARDIA study. 
hsCRP and IL-6 levels 55% (P=0.001) and 62% 
(P=0.001) higher among HIV+ group than 
CARDIA group.  
Compared with levels in MESA study 
participants, hsCRP, IL-6, D-dimer, and cystatin 
C levels were 50%, 152%, 94%, and 27% 
higher, respectively (P=0.001, for each), among 
HIV+ participants. 
HIV+ participants receiving HAART who had 
HIV RNA levels ≤400 copies/mL had levels 
higher (by 21% to 60%) (P= 0.001) than those 
in the general population, for all biomarkers. 
hsCRP, IL-6, D-dimer, and cystatin C 
levels are elevated in persons with 
HIV infection  
Remain so even after HIV RNA levels 
are suppressed with HAART 
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Kuller, 2008 [94] 
USA 
hsCRP, IL-6, 
amyloid A, amyloid 
P, D-dimer, 
prothrombin 
fragment 1þ2. 
Case-control study as part of 
SMART 
85 HIV+ deaths 
170 HIV+ ‘controls’ 
Higher levels of hsCRP, IL-6, and D-dimer at 
study entry significantly associated with an 
increased risk of all-cause mortality.  
Unadjusted ORs (highest versus lowest 
quartile) 2.0 (95% CI, 1.0–4.1; p= 0.05), 8.3 
(95% CI, 3.3–20.8; p =0.0001), and 12.4 (95% 
CI, 4.2–37.0; p =0.0001), respectively. 
IL-6 and D-dimer strongly related to 
all-cause mortality. 
Sandler, 2011 [95] 
USA 
I-FABP, LPS, 
sCD14, EndoCAb, 
and 16S (rDNA) 
measured in 
baseline plasma 
samples. 
Nested case control from SMART 
study 
HIV+ group composed of: 
74: died; 120: developed CVD; 
81: developed AIDS 
 
Matched uninfected controls 2:1 
Subjects with highest quartile of sCD14 levels 
had a 6-fold higher risk of death than did those 
in the lowest quartile (95% confidence interval, 
2.2–16.1; P=0.001) 
No other marker was significantly associated 
with clinical outcomes.  
I-FABP, LPS, and sCD14 were increased and 
EndoCAb was decreased in study subjects, 
compared with healthy volunteers. 
sCD14 level correlated with levels of IL-6, C-
reactive protein, serum amyloid A and D-dimer. 
sCD14, is an independent predictor 
of mortality in HIV infection. 
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Ledwaba, 2012 [96],  
South Africa 
  
  
  
  
  
Pre-ART plasma 
from patients with 
advanced HIV was 
used to measure 
hs-CRP, IL-6 and 
D-dimer  
Nested case-control study 
187 HIV+ deaths 
359 HIV+ ‘controls’ 
matched on age, sex CD4 count 
  
  
  
  
Median baseline biomarkers levels for cases 
and controls, respectively: 
11.25 vs. 3.6 mg/L for hs-CRP; 1.41 vs. 0.98 
mg/L for D-dimer; 9.02 vs. 4.20 pg/mL for IL-6 
(all p=0.0001).  
Adjusted OR for the highest versus lowest 
quartile of baseline biomarker levels: 3.5 (95% 
CI: 1.9–6.7) for hs-CRP; 2.6 (95%CI 1.4–4.9) 
for D-dimer; 3.8 (95% CI: 1.8– 7.8) for IL-6.  
D-dimer and IL-6, but not hs-CRP, significantly 
lower at month 6 after commencing ART 
compared to baseline (p=0.0001) 
Among patients with advanced HIV 
disease, elevated pre-ART levels of 
hs-CRP, IL-6 and D-dimer strongly 
associated with early mortality after 
commencing ART. 
Gerena, 2012 [97]  
USA 
  
  
Soluble and cell-
associated IR 
levels, 
IRS-1 levels 
IRS-1 tyrosine 
phosphorylation 
Presence and 
severity of HAND  
Retrospective cross-sectional 
study 
34 HIV+ females 
10 controls 
Hispanic-Latino Longitudinal 
Cohort of Women 
HIV+ women had significantly increased levels 
of intact or full-length sIR in plasma (p=0.001) 
and CSF (p=0.005) relative to controls.  
Stratified by HAND, increased levels of full-
length sIR in plasma were associated with the 
presence (p=0.001) and severity (p=0.005) of 
HAND.  
A significant decrease in IRS-1 tyrosine- 
phosphorylation in the WCP was also 
associated with the presence (p=0.02) and 
severity (p=0.02) of HAND. 
IR secretion is increased in HIV+ 
women 
Increased IR secretion is associated 
with cognitive impairment in these 
women.  
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Armah, 2012 [98] 
USA 
  
IL-6, D-dimer, and 
sCD14  
1525 HIV+  
843 uninfected VACS participants 
  
  
Elevated IL-6 in HIV+ individuals with HIV-1 
RNA ≥500 copies/mL or CD4 count <200 
cells/μL (OR:1.54; 95%CI: 1.14–2.09; OR, 2.25; 
95% CI, 1.60–3.16, respectively)  
Elevated D-dimer (OR, 1.97; 95% CI, 1.44–
2.71, OR, 1.68; 95% CI, 1.22–2.32, 
respectively).  
Higher prevalence of elevated sCD14 in HIV-
infected veterans with a CD4 cell count <200 
cells/μL compared to uninfected veterans (OR, 
2.60; 95% CI, 1.64–4.14). 
Ongoing HIV replication and immune 
depletion significantly contribute to 
increased prevalence of elevated 
biomarkers of inflammation, altered 
coagulation, and monocyte 
activation. 
 
Associations persisted after 
restricting analysis to veterans 
without known confounding comorbid 
conditions.  
Keating, 2011 [99] 
USA 
  
  
  
  
Multiplex assays of 
32 cytokines  
Cross-sectional study - 
participants in the Women’s 
Interagency HIV Study. 
HIV+ on HAART, n=17 
Non-controllers*, n=14 
Uninfected, n=17 
  
  
  
Significant differences between non-controllers 
and uninfected participants for several markers: 
Elevated IP-10 and TNF-a 
Decreased IL-12(p40), IL-15, and FGF-2.  
Biomarker levels among HAART women more 
closely resembled the uninfected group, with 
the exception of TNF-a and FGF-2.  
Secondary analyses of combined HAART and 
non-controller groups: IP-10: positive 
correlation with viral load and negative 
correlation with CD4
+
 T-cell counts.  
VEGF, EGF, and FGF-2: positive correlation 
with increased CD4
+
 T-cell counts. 
Untreated, progressive HIV infection 
associated with decreased serum 
levels of cytokines important in T-cell 
homeostasis (IL-15) and T-cell 
phenotype determination (IL-12 and 
increased levels of innate 
inflammatory mediators such as IP- 
10 and TNF-a.  
HAART associated with cytokine 
profiles that more closely resembled 
those of HIV-uninfected women. 
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 Kaplan, 2012 [100] 
USA 
  
 
 
Six semi-annual 
measurements: 
soluble sCD14, 
TNF-a, soluble IL-2 
receptor, IL-6, IL-
10, monocyte 
chemoattractant 
protein 1, D-dimer, 
fibrinogen, and 
cIMT.  
  
  
Women’s Interagency HIV Study: 
127 HIV+ women pre and post 
HAART 
127 HIV-uninfected controls. 
  
Relative to HIV-uninfected controls, HAART-
naive HIV-infected women had elevated levels 
of sCD14, TNF-a, soluble IL-2 receptor, IL-10, 
monocyte chemo-attractant protein 1and D-
dimer (all P<0.01). Elevated biomarker levels 
declined after HAART.  
Although most biomarkers normalized to HIV-
uninfected levels, in women on effective 
HAART, TNF-a levels remained elevated 
compared with HIV-uninfected women (+0.8 
pg/mL, P = 0.0002).  
Higher post-HAART levels of soluble IL-2 
receptor IL-6, and D-dimer associated with 
increased cIMT 
Untreated HIV infection is associated 
with abnormal hemostasis (eg, D-
dimer), proatherogenic (eg, TNF-a), 
and anti-atherogenic (eg, IL-10) 
inflammatory markers. 
HAART reduces most inflammatory 
mediators to HIV-uninfected levels.  
Increased inflammation and 
hemostasis are associated with 
subclinical atherosclerosis in recently 
treated women. 
Mangili, 2012 [101] 
USA 
 
cIMT and hs-CRP  Longitudinal study 
327 HIV+ participants 
Median follow-up time 3.1 years  
 
38 (11.6%) participants died since study 
enrolment. 
cIMT significantly higher in those who died and 
more likely to have cIMT above the 75th 
percentile 
Those who died had higher hsCRP than those 
alive and more had hsCRP values above 3 
mg/L 
cIMT and hsCRP levels significantly associated 
with mortality (HR = 2.74, 95% CI 1.26–5.97, p 
= 0.01; HR = 2.38, 95% CI 1.15–4.9, p = 0.02). 
Strong association of carotid IMT and 
hsCRP with all-cause death despite 
being similar with respect to 
exposure to HAART medications. 
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Margolick, 2012 [102] 
USA 
 
FP+ or FP- at two 
consecutive study 
visits 
MACS cohort – 602 men 
117 HIV-/FP- 
20 HIV-/FP+ 
393 HIV+/FP- 
72 HIV+/FP+ 
In HIV+ FP+ men higher concentrations of IL-6, 
TNF-α; IL-8, IP-10, MCP-4, and TARC; and C-
reactive protein  
Differences between FP+ and FP- HIV- men of 
similar magnitude but not significant 
CRP similar between HIV- FP+ and FP-. 
Inflammatory markers had significant 
associations with FP in HIV+ men. 
Elevated IL-6, TNF-α, and CRP 
suggest monocyte activation. 
Elevation of IP-10 consistent with T-
cell activation. 
Kalayjian, 2010 [103] 
USA 
sTNFR-1, sCD27, 
sCD40L, sTRAIL, 
HIV RNA level, 
CD4 cell count, IL-
6, CD8 T cell 
activation, CD-38 
and HLA. 
Case control study  
Cases, n=41; Controls, n=111 
HAART-naive in ACTG protocol 
384 received either stavudine 
and didanosine/ lamivudine and 
zidovudine, in combination with 
either nelfinavir, efavirenz, or 
both. Follow-up every 4 weeks to 
24 weeks. 
HAART-naive in ACTG protocol 
5015 received a uniform regimen 
of stavudine and emtricitabine 
with ritonavir-boosted lopinavir. 
Follow-up every 8 weeks or every 
12 weeks. 
Higher levels of sTNFR-1 associated with older 
age, lower Hb level, lower CD4 cell count, lower 
eGFR, higher pVL, and higher levels of each of 
the other activation markers (except TRAIL and 
CD8 T cell activation). 
 
New AIDS-defining illness or death 
was associated with: older age, 
female sex, lower baseline Hb, and 
higher baseline sTNFR-1, sCD27, 
sCD40L, and IL-6. 
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Abbreviations: (arranged alphabetically) 
16S(rDNA), 16S ribosomal DNA; 95% CI, 95% Confidence Interval; ACGT, AIDS Clinical Trials Group; AIDS, Autoimmune deficiency syndrome; CARDIA, Coronary Artery 
Development in Young Adults; cIMT, carotid intima-media thickness; CSF, cerebrospinal fluid; HIV, Human immunodeficiency virus; CVD, Cardiovascular Disease; EGF, 
Epidermal Growth Factor; eGFR, estimated Glomerular Filtration Rate; EndoCAb, endotoxin core antibody; FGF-2, Fibroblast Growth Factor; FP, Frailty Phenotype; HAART, 
Highly Active Anti-Retroviral Treatment; HAND, HIV-1-associated neurocognitive disorders; Hb, Haemoglobin; HLA, human leukocyte antigen; hsCRP, high-sensitivity C-
reactive protein; I-FABP, Intestinal fatty acid-binding proteins; IL-12, Interleukine-12; IL-15, Interleukine-15; IL-2, Interleukine-2; IL-6, Interleukine-6; IP-10,  Interferon gamma-
induced protein-10; IQR, Interquartile range; IR, Insulin Receptor; IRS-1, Insulin Receptor Substrate-1; LPS, lipopolysaccharide; MACS cohort, the Multicenter AIDS cohort 
study; MESA, Multi-Ethnic Study of Atherosclerosis; MLO, myeloperoxidase; OR, Odds Ratio; pVL, plasma viral load; RNA, Ribonucleic acid; sCD14, soluble CD14; sCD40L, 
soluble CD40 ligand;  sIR, soluble IR; SMART, Strategies for Management of Antiretroviral Therapy Study; sTNFRs, soluble TMF superfamily receptors; sTRAIL, TNF-related 
apoptosis-inducing ligand; sVCAM-1, soluble vascular cell adhesion molecule-1; TNF-a, tumor necrosis factor-alpha; VACS, Veterans Aging Cohort Study; VEGF, Vascular 
endothelial growth factor; WCP, (CSF) white cell pellets. 
*Antiretroviral therapy naïve and had a viral load more than 10000 RNA copies/ml for at least one of two time points separated by 6 months 
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1.3 Para-inflammation and aging 
The immune response is thought to vary under different physiological conditions, 
and responds according to the type of ‘insult’. In basal conditions, the immune 
system maintains tissue homeostasis. Infection and tissue injury lead to full 
inflammation, whereas chronic tissue stress (noxious stress conditions such as 
hyperglycemia or hypercholestrolemia) initiates mild low-grade inflammation. 
Medzhitov has coined the term “para-inflammation” to describe this intermediate 
tissue adaptive response (Figure1d) [104]. The outcome of para-inflammation is to 
maintain tissue homeostasis and monitor tissue malfunction. However, chronic para-
inflammation can lead to disease progression due to changes in homeostatic set 
points. Several conditions are thought to have characteristics of para-inflammation; 
allergy and obesity may have maladaptive responses to noxious stressors due to shift 
of homeostatic set points. Type 2 diabetes, atherosclerosis and neurodegenerative 
disorders may occur as a result of dysregulation of para-inflammation [104]. Aging is 
one of the main factors that may lead to increased tissue stress, and an imbalance in 
tissue homeostasis that may ultimately lead to pathology. The magnitude of a para-
inflammatory response may also increase and produce age-related diseases.   
 
 
 
 
 
 
Figure 1d: Concept of para-inflammation - from Medzhitov [104]. Reproduced with 
permission from publisher. 
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1.4 Para-inflammation and retinal aging  
Xu et al [105] suggest that para-inflammation is an important process within the 
aging retina. The retina is a highly differentiated neuro-ectodermal tissue. The 
neuroretina and retinal pigment epithelium (RPE) form a functional unit of the visual 
system (Figure 1e). In the retina, a number of conditions are age-related, including 
primary open angle glaucoma, diabetic retinopathy and age-related macular 
degeneration. The retina has an endogenous immune system that is coordinated by 
immune cells such as microglia, dendritic cells and perivascular macrophages in 
tandem with the immunological functions of the RPE [105,106]. Together, these cells 
are involved in maintaining retinal homeostasis in the presence of stressors (e.g. 
tissue injury). Retinal aging is accompanied by activation of gene sets either modifying 
immune responses or tissue stress/injury responses, which are involved in local 
inflammatory responses [107]. In the aging retina, two inflammatory pathways are 
affected as a result of age-related tissue stress: the complement cascade and retinal 
microglia activation [108].  Excessive uncontrolled complement or microglial 
activation may produce overt inflammatory responses with marked release of 
cytokines/chemokines causing irreparable damage to the neuroretina [105]. 
Immunological changes that occur in HIV infection could lead to excessive 
uncontrolled complement or microglial activation within the retina. This in turn 
could cause low-grade tissue stress and para-inflammation leading to changes in the 
retina normally seen in physiological aging. 
 
Figure 1e: From Xu et al [105] – Histology of the retina and para-inflammatory processes. 
Reproduced with permission from publisher. 
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1.5 Biomarkers of aging  
Given the potential differences in lifespan, rate of aging, and differences in the same 
parameters between individuals, the chronological passage of time may not represent 
the best measure of rate of aging. The disconnect between chronological age and 
lifespan has led to the search for biomarkers of aging (BoA). The term biomarker of 
aging has been defined as a “biological parameter of an organism that either alone or 
in some multivariate composite will better predict functional capability at some late 
age, than will chronological age” [109]. It may be difficult to separate biomarkers of 
disease from BoA, as aging could reflect the sum of a lifetime of disease processes 
[110].  
1.5.1 Telomeres 
Cellular senescence is characterized by critical telomere shortening. Telomeres are 
repeating sequences of DNA at the extreme ends of eukaryotic chromosomes. They 
have roles in chromosomal protection, nuclear attachment and replication. They 
shorten with cell division due to the inability of the DNA-copying mechanism (DNA 
polymerase) to synthesize the very end of the DNA sequence. When telomeres 
reach a critically short length, a DNA damage signal is transmitted leading to 
irreversible cell cycle arrest or replicative senescence [111]. Progressive shortening 
of lymphocyte telomeres is characteristic of immune senescence, and may affect 
lymphocyte function [112].  
Telomeres in man shorten with increasing chronological age [113] and telomere 
attrition has been noted in an increasing number of diverse pathologies e.g. 
cardiovascular disease, hypertension [114-116], renal transplant dysfunction [117], 
and psychological disorders [118]. Telomere erosion has also been associated with 
high mortality in kidney disease and heart disease [119,120]. A U-shaped association 
has been noted for telomere length in colorectal cancer in women, with both very 
short and very long telomeres associated with increased risk of colorectal cancer 
[121]. In healthy subjects, shortened lymphocytic telomeres are associated with 
increased mortality, particularly after infection [122]. Interpretation of 
epidemiological studies using telomere length can be difficult, as short telomeres 
could be both a cause and consequence of biological aging [123]. Given the variability 
of telomere length between individuals of the same chronological age and between 
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different tissues, and that there are no "normal" values, large sample sizes are 
required as well as inclusion of suitable controls [124]. Longitudinal studies, including 
birth cohort studies, would be the preferred study design. Telomere length does not 
satisfy the strict criteria for a BoA, but does add predictive power to that of 
chronological age [125]. 
 
Cytotoxic CD8 T-cells that lose expression of CD28 (as in aging) have shorter 
telomere lengths compared to any other T and B cell subsets [126]. Chronic HIV 
infection appears to exacerbate the situation: CD28- CD8+ T-cells from HIV-
infected patients had significantly shorter telomere lengths compared to CD28- 
CD4+ T-cells of uninfected controls. The telomere lengths in the HIV-infected group 
were similar to those found in elderly non-infected controls [127].  
 
Telomere attrition is affected by psychosocial confounders, genetics and potentially 
by nucleoside reverse transcriptase inhibitors (NRTIs) [128], particularly as human 
telomerase comprises a reverse transcriptase sharing homology with the HIV 
reverse transcriptase [129]. It is plausible that ART may inhibit its activity, leading to 
differences in telomere lengths between ART-naïve and treated groups. Previous 
studies have produced inconsistent findings regarding such an association [130,131]. 
In utero or childhood exposure to NRTIs does not affect leukocyte telomere length 
(LTL), and uncontrolled viremia rather than duration of ART exposure may be 
associated with acceleration of blood telomere attrition [132,133]. There are few 
data to date evaluating biological aging in HIV-infected individuals compared to age- 
and gender-matched controls. A case-control in Canada found that beyond advancing 
age, HIV+ status, active HCV infection and low income were the strongest 
predictors of LTL with no evidence that ART-related factors impact LTL [134].  
 
1.5.2 Other biomarkers of aging 
Measurement of the cell cycle regulator CDKN2A also provides a method of 
assessing bio-aging [124]. CDKN2A functions to hold a cell in a state of growth 
arrest. Levels of CDKN2A can be measured by reverse transcriptase polymerase 
chain reaction and generating a standard assay is feasible. Increasing levels of 
CDKN2A transcriptional expression occur with increasing age and in solid organs 
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and peripheral blood leucocytes [135-137]. Levels of CDKN2A also increase with 
decreasing organ function, and levels positively associate with levels of IL-6 [136].  
 
A major marker of oxidative damage of nucleic acids is the 8-hydroxy-2’- 
deoxyguanosine (8-OHdG) adduct. It is formed when reactive oxygen species (ROS), 
especially the hydroxyl radical (OH•) act on deoxyguanine in DNA [138]. 8-OHdG 
can alter gene expression and of 8-OHdG are inversely related to life span in 
mammals and increase especially in mitochondrial DNA with age [3,139]. 8-OHdG is 
also elevated in degenerative diseases such as Parkinson’s disease, diabetes, cystic 
fibrosis and muscular dystrophy [140]. Inflammation accelerates telomere attrition 
[111] and prolonged oxidative damage inhibits telomerase activity and accelerates 
telomere shortening; this effect may be mediated by the formation of 8-OH-dG 
[141].  
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Abstract:  
The eye and visual system are valuable in many areas of translational research such as stem cell 
therapy, transplantation research and gene therapy.  Changes in many ocular tissues can be measured 
directly, easily and objectively in vivo (e.g. lens transparency; retinal blood vessel calibre; corneal 
endothelial cell counts) and so the eye may also be a uniquely useful site as a model of ageing.  This 
review details cellular, molecular and epigenetic mechanisms related to ageing within the eye, and 
describes ocular parameters that can be directly measured clinically and which might be of value in 
ageing research as the translational “window to the rest of the body”. The eye is likely to provide a 
valuable model for validating biomarkers of ageing at molecular, epigenetic, cellular and clinical levels. 
A research agenda to definitively establish the relationship between biomarkers of ageing and ocular 
parameters is proposed.  
 
Keywords: 
Biomarker; eye; ophthalmology; epigenetics; translational research 
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MAIN TEXT 
1. Introduction 
Ophthalmology is increasingly recognized as being at the forefront of translational research (Stahl and 
Smith, 2010). The unique access to and visibility of ocular tissues and range of visual functions permits 
investigation of a wide variety of physiological and pathological mechanisms. Stem cell biology, 
transplantation and gene therapy are all areas of research where the eye plays a prominent role in 
animal models as well as in clinical research. In this review we make the case that the eye can also play 
a key role in ageing research, with many ocular age-related changes having translational applications to 
other body systems. Further support for this argument comes from studies which show that visual 
impairment is a significant predictor of mortality (Lott et al., 2010). Cataract, glaucoma and age-related 
macular degeneration (AMD) are important causes of low vision in the elderly. Moreover, poor visual 
function is related to frailty (Klein et al., 2003; Kulmala et al., 2011), which is an age-related clinical 
concept of increased vulnerability to stressors due to impairment of multiple systems, resulting in 
increased risk of morbidity and mortality (Bergman et al., 2007; Fried et al., 2001; Fulop et al., 2010).  
AMD and low vision are also related to depression and increased morbidity (Brody et al., 2001; Huang 
et al., 2010; Mathew et al., 2011; Popescu et al., 2012) 
 
Evolution, and behavioural studies of humans and animals, demonstrate the vital importance of vision. 
Studies of infants who are blind from birth show that vision is vital for early sensory-motor and 
psychosocial development, as it is the sense that co-ordinates the other sensory inputs. However, light 
energy is highly damaging to tissues, and the human eye has developed a range of mechanisms that 
protect its unique structures and functions from oxidative stress and other damaging insults. Failure of 
these mechanisms can lead to pathology and presentation of age-related ocular conditions such as 
cataract, primary open angle glaucoma and age-related macular degeneration (AMD).  Virtually all 
tissues of the eye are affected by ageing; the most well known pathologies are age-related development 
of opacification of the lens (cataract) and age-related macular degeneration. Indeed, epidemiological 
research has demonstrated that individuals with cataracts have a significantly higher mortality rate than 
those without, even after adjusting for known confounders. This suggests that biochemical mechanisms 
in ocular lens may reflect ageing processes elsewhere in the body (Hennis et al., 2001; Truscott, 2005; 
Truscott and Zhu, 2010; West et al., 2000).  The retinal ganglion cells in the eye can also provide 
information relating to neuronal ganglion function in ageing and age-related disease such as 
Alzheimer’s disease and glaucoma (Curcio and Drucker, 1993; Nag and Wadhwa, 2012; Osborne, 
2008). Further examples of the age-related changes within the eye include loss of corneal endothelial 
cells, changes in the calibre of the retinal vasculature, loss of visual function (e.g. visual acuity; contrast 
sensitivity) and thinning of the retinal tissue layers, all of which can be measured easily, quickly, 
objectively and non-invasively. Many of these ocular age-related changes also have systemic 
associations or correlates with ageing in other end-organs or body systems, and these changes may be 
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easier or less invasive to measure in the eye than other organs or systems (Table 1).  
 
We present a comprehensive overview that proposes that the eye represents an ideal model for 
studying age-related processes at biological, clinical, epigenetic and molecular levels. The structural 
organization of the review leads the reader through (i) the rationale for the eye to be considered a 
model of ageing (ii) cellular and molecular mechanisms of ageing in the eye, (iii) epigenetic 
mechanisms and their role in age-related eye disease and  (iv) ocular parameters that can be readily 
measured which might be of value in ageing research, using the eye as the translational “window to the 
rest of the body”.  We conclude by discussing how the eye might represent a powerful new model for 
validating potential biomarkers of ageing and propose a research agenda to establish whether the eye 
is a suitable model.  
 
2. Global ageing demographics and the need for biomarkers of ageing 
Population ageing is rapidly changing: by 2017, for the first time in history, the number of people 
globally aged 65 years and older will outnumber children younger than 5 years (World Heatlh 
Organisation, 2011). In addition there are substantial differences in the health and functional status of 
older populations in many developing countries as well as marked differences in health status within the 
UK and other developed countries (Lloyd-Sherlock et al., 2012). These complex variations in health and 
functional status are not fully understood, highlighting the need for translational age-related research 
within a global context. Basic science ageing research often employs survival curves and maximum life 
span as key end points for studies of effects of interventions, rather than healthspan or function. 
However disability, frailty and age-related disease onset are critical end points that need to be 
addressed in older populations (Kirkland and Peterson, 2009). Many age-related systemic diseases 
have ophthalmic manifestations including diabetes, hypertension, cerebrovascular disease, rheumatoid 
arthritis and systemic lupus erythematosus (SLE). Furthermore, there is increasing evidence that HIV 
infection may lead to premature ageing in infected individuals even with viral suppression and long-term 
anti-retroviral treatment (Deeks, 2009; Deeks and Phillips, 2009; Lohse et al., 2007; Onen et al., 2010).  
As the research agenda for ageing expands to address these new concepts and hypotheses it is vital to 
have easily measurable, objective and validated parameters or biomarkers of ageing that can be 
translated to other body systems.  
 
Given the potential differences in lifespan, the concept of healthspan, rate of ageing, and differences in 
the same parameters between individuals, the chronological passage of time may not represent the 
best measure of ageing of biological systems. The disconnection between chronological age and 
lifespan has led to the search for biomarkers of ageing (BoA). The term biomarker of ageing has been 
defined as a “biological parameter of an organism that either alone or in some multivariate composite 
will better predict functional capability at some late age, than will chronological age” (Sprott, 2010). A 
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research agenda for developing ageing research in the UK acknowledges that many lifestyle- and age-
related chronic diseases share common pathways of early dysregulation (e.g. cardiovascular disease, 
Alzheimer’s disease), and that the development of markers, diagnostic techniques and interventions 
that can be applied to prevent late stage disease is fundamental (Franco et al., 2007). The need for 
research into how to achieve healthy ageing in the context of life-time trajectories has also led to 
concept of the ‘Healthy Ageing Phenotype’ defined as “ the condition of being alive, while having highly 
preserved functioning metabolic, hormonal and neuro-endocrine control systems at the organ, tissue 
and molecular levels” (Franco et al., 2009). With demonstrable molecular, epigenetic and clinical 
correlates of ageing, the eye may be a model system for validating potential biomarkers.  
 
2.1 Criteria for a biomarker of ageing 
Baker and Sprott (1988) have suggested the following criteria satisfy the requirement for a parameter to 
be considered a biomarker of ageing: 
1. The rate of change of a biomarker must, at least in mathematical terms, reflect some measurable 
parameter which can be predicted at a later chronological age. 
2. The biomarker should reflect some basic biological process of ageing and certainly not the 
predisposition toward a disease state or some error in metabolism. 
3. The biomarker should have high reproducibility in cross species comparisons of functional or 
physiological age versus chronological age, particularly within the same classes and certainly within the 
same families of species. 
4. Biomarkers should change independently with the passage of time and reflect physiologic (functional) 
age. 
5. Assessment of biomarkers should be nonlethal in animal systems and should cause minimal trauma 
in humans. 
6. The biomarker should be reproducible and measurable during a relatively short time interval 
compared to the life span of the animal. 
 
3 Cellular and molecular mechanisms of ageing in the eye:  
3.1 Para-inflammation and retinal ageing  
Xu et al., (2009) have suggested that para-inflammation is an important process within the ageing 
retina. The retina is a highly differentiated neuroectodermal tissue. The neuroretina and retinal pigment 
epithelium (RPE) form a functional unit of the visual system.  The retina has an endogenous immune 
system that is coordinated by immune cells such as microglia, dendritic cells and perivascular 
macrophages in tandem with the immunological functions of the RPE (Xu, 2009). Together, these cells 
are involved in maintaining retinal homeostasis in the presence of stressors (e.g. tissue injury). Retinal 
ageing is accompanied by activation of gene sets either modifying immune responses or tissue 
stress/injury responses (Chen et al., 2010). In the ageing retina, two inflammatory pathways are 
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affected as a result of age-related tissue stress: the complement cascade and retinal microglia 
activation (Chen et al., 2010). Excessive uncontrolled complement or microglial activation may produce 
overt inflammatory responses with marked release of cytokines/chemokines causing irreparable 
damage to the neuroretina (Xu et al., 2009). This modified form of low-grade chronic inflammation 
(para-inflammation) may be initiated by several stressors, including oxidative stress or advanced 
glycation end products (see sections 5 and 6). Dysregulation of the complement pathway is also 
implicated in AMD; altered levels of both intrinsic complement proteins and activated products have 
been found in the circulation of patients with AMD. Complement activation may be triggered by 
oxidative stress, resulting from retinal exposure to incoming light (Khandhadia et al., 2012).  This is, in 
part modified by genetic mechanisms: variation of the complement factor H gene (CFH) is associated 
with AMD (Edwards et al., 2005; Haines et al., 2005; Klein et al., 2005), with the Y402H variant 
conferring a 2-fold higher risk of late-AMD per copy in individuals of European descent (Sofat et al., 
2012) 
 
3.2 The retina as a model in neurodegenerative disease 
The retina is derived from the neural tube, a precursor of the central nervous system (CNS). Because of 
their common origin and anatomical features, AMD in the retina and Alzheimer’s Disease (AD) are 
thought to have many parallel characteristics (Ohno-Matsui, 2011). An important characteristic common 
to both is the presence of amyloid β (Aβ) in the senile plaques of the AD brain and in the drusen of 
AMD patients. Extracellular deposits are a common pathological hallmark of both AMD and AD. In 
AMD, the deposits are called drusen, and in AD, the deposits in the brain are referred to as senile 
plaques (Ohno-Matsui, 2011). The deposits share similar biochemical characteristics and contain 
amyloid forms with the presence of a wide spectrum of amyloid structures in drusen (Isas et al., 2010). 
Amyloid deposition may trigger chronic inflammation including complement activation in both disorders. 
Although Aβ is deposited in the brain and in drusen, the phenotype is different between AD and AMD, 
and the genetic epidemiology of the two conditions is different. In sporadic or late-onset AD, the 
apolipoprotein-E (APOE) ε4 allele increases the risk of developing the disease in all ethnic groups 
(Farrer et al., 1997). Three additional genes, the complement receptor 1 (CR1), clusterin (CLU), and 
phosphatidylinositol- binding clathrin assembly protein (PICALM) are also novel susceptibility loci for 
late-onset AD in European ancestry populations (Jun et al., 2010). In contrast, variants of the 
complement factor H gene are associated with AMD (see Section 3.1).  


Microglia are the resident immune cells of the CNS having vital immuno-surveillance and tissue repair 
functions. One of the major proposed mechanisms for the pathological changes in the brains of AD 
patients is the activation of microglial cells. In a retinal microglia model of neurodegenerative disease, 
dynamic microglial responses to injury were found to be age dependent (Damani et al., 2011), and 
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senescent alterations in their morphological and behavioural phenotypes may contribute to the 
pathogenesis of age-related neurodegenerative disease. The retina is thought to be an ideal model of 
the cellular and molecular characteristics of neurodegenerative diseases. This may be manifest 
functionally as loss of retinal ganglion cells and may reflect degenerative changes in the brain in these 
conditions. Indeed loss of retinal ganglion cells is implicated in the pathogenesis of glaucoma (Osborne, 
2008), and CNS damage has been associated with glaucoma (Nucci et al., 2012), including atrophy of 
the lateral geniculate nucleus (Gupta et al., 2009). Retinal nerve fibre layer thinning in particular may act 
as a biological marker of neurological disease (see section 8.7).  
 
3.3 Ocular basement membranes as a model for other basement membranes 
Visualisation of the ultrastructure of the retina by electron microscopy has provided significant insight in 
to how basement membranes alter with increasing chronological age. The inner limiting membrane 
(ILM) is a basement membrane located at the border of the vitreal surface of the retina and the vitreous 
body. Human ILM undergoes age-dependent alterations including a dramatic increase in thickness, loss 
of the typical basement membrane ultrastructure and an increase in stiffness (Candiello et al., 2010). 
Physiologically this may lead to a lower rate of filtration and diffusion and a loss of vascular elasticity. 
Recently, a nanometer scale topographic and biomechanical profile of human ILM has been created 
under physiological conditions using Atomic force microscopy (ATF; a very high-resolution type of 
scanning probe microscopy) (Henrich et al., 2012). The ILM has an ultrastructure and a protein 
composition typical of most other basement membranes and, thus, provides a suitable model for 
determining their biophysical properties. Biological characteristics of the ILM from human eyes may 
provide information about how other basement membranes from other tissues undergo age-related 
changes (Candiello et al., 2007). Bruch's membrane (BM) is a pentalaminar structure, located between 
the retinal pigment epithelium (RPE) and the fenestrated choroidal capillaries of the eye. BM is an 
elastin- and collagen-rich extracellular matrix that acts as a ‘molecular sieve’ (Booij et al., 2010). The 
changes occurring in BM with age include increased cross-linkage of collagen fibres and increased 
turnover of glycosaminoglycans. In addition, advanced glycation end products (AGEs) (section 5) and 
fat accumulate in BM. These age-related changes may influence the normal age-related health of 
photoreceptor cells within the retina, but also the onset and progression of diseases like retinitis 
pigmentosa (RP) and AMD with formation of drusen deposits (Okubo et al., 1999). Within the cornea, 
Bowman’s layer provides support to the anterior epithelial layer and is an acellular interface between 
the corneal epithelium and stroma. It may be visualised using spectral domain optical coherence 
tomography (SD-OCT) (Tao et al., 2011; Vajzovic et al., 2011). Similarly, Descemet’s membrane in the 
cornea can also be visualised using in vivo confocal microscopy where changes with age have been 
noted (Jun et al., 2006).  
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Section 3.4 The vitreous and ageing 
The vitreous is a highly hydrated, almost acellular structure comprising 0.1% macromolecules, of which 
collagens are the most important building blocks (Ponsioen et al., 2010). Morphological age-related 
changes in the vitreous include a progressive increase in fluid-filled areas (synchisis), and an increase 
in optically dense structures (syneresis). These changes are less dependent on stressors, reactive 
oxygen species and disease, and thus represent physiological ageing changes. The age-related 
changes in the vitreous may also affect local structures; for example, low pO2 is maintained at the 
posterior surface of the lens by the physical and physiological properties of the vitreous body, the gel 
filling the space between the lens and the retina. Destruction or degeneration of the vitreous body 
increases exposure of the lens to oxygen from the retina. Oxygen reaches the lens nucleus, increasing 
protein oxidation and aggregation and may lead to cataract formation (Beebe et al., 2011).  
 
4. The lens as a model for macromolecular ageing  
4.1 Long-lived proteins in the eye  
There are several sites in the body where proteins are ‘long-lived’, including the eye, lungs and brain. 
These proteins may be subject to modification, either due to the intrinsic instability of some amino acid 
residues in proteins, or due to covalent modification by biochemicals produced during cellular 
metabolism (Hipkiss, 2006; Truscott, 2010). Truscott proposes that progressive damage to these long-
lived proteins may contribute to the age-related decline in function, and that cumulative denaturation of 
proteins ultimately limits human life span (Truscott, 2010). In this way both presbyopia (age-related 
reduction in near vision; section 8.6) and cataract can be thought of as being direct outcomes of 
denaturation of lifelong proteins in the lens. For example, diminished function over time is related to 
protein damage, rather than DNA damage in the lens (McGinty and Truscott, 2006). Ageing may be 
partly attributable to loss of function due to protein damage rather than direct DNA damage per se, 
however it is equally possible that it is cumulative damage to genetic material (through loss of 
physiological repair processes) and thus consequential protein dysfunction and loss of function that 
leads to phenotypic ageing.   
 
The lens is thought to be an ideal tissue for studying ‘macromolecular ageing’ in humans (Truscott and 
Zhu, 2010). It is also recognised as an excellent model of physiological and ‘pathological’ ageing 
(Michael and Bron, 2011). The lens is one of the few sites in the body which is also an avascular and 
immune privileged site (Wormstone and Wride, 2011). Thus, it is possible to explore roles for specific 
molecules in cell proliferation, differentiation and development because cells remain in place for life, and 
go through extreme differentiation, including removal of nuclei and cessation of protein synthesis. In 
addition, the centre of the lens is an enzyme free zone with a lack of active metabolism. This means the 
impact of thermal and chemical denaturation of proteins can be studied without confounding factors 
such as enzyme modifications. Lens nuclear proteins could be ideal to discover which reactive 
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metabolites in the body are quantitatively of most importance for post-translational modifications of long-
lived proteins (Zhu et al., 2010). This may be useful to understand if and how accumulation of altered 
polypeptides in the heart, lung and brain directly affects lifespan (Truscott, 2011). Human lenses contain 
crystallins; these proteins are soluble, compared to collagens and elastin elsewhere in the body that are 
insoluble.  
 
4.2 Telomere length in lens epithelial cells  
Telomeres are nucleoprotein complexes at chromosome ends, consisting of (TTAGGG)n direct repeats 
bound to a range of proteins involved in maintaining cellular stability and viability (Shiels et al., 2011). 
They shorten with every cell division in response to intrinsic molecular factors and DNA damage, and 
short telomeres trigger a DNA damage response leading to cell death or senescence (von Zglinicki, 
2012). Increased oxidative stress accelerates telomere attrition in somatic cells, resulting in premature 
cellular senescence and reduced organ function (Carrero et al., 2008)(see Section 6). Studies of human 
lens epithelial cells suggest that cataract formation is characterised by senescence of lens cells, 
accelerated by oxidative stress-induced DNA damage, modulation of the antioxidative capabilities by 
the normal and cataractous lens, and marked telomere shortening (Babizhayev et al., 2011; Babizhayev 
and Yegorov, 2010). 
 
4.3 Cataract as a ‘bio-indicator’ for severe systemic disorders – role of the crystallins 
Crystallins represent the major structural proteins of the eye lens - they make up 90% of its total dry 
mass and are responsible for the refractive power of the lens (Horwitz, 2000). The crystallins have been 
classified into α, β and γ-crystallins, reflecting their molecular weight. Besides their refractive roles, 
crystallins are also involved in several cellular pathways involving the stress response, apoptosis and 
cell survival at a systemic and ocular level (Andley, 2008). In particular, the α-crystallins (composed of 
two subunits, αA- and αB crystallins) are recognised as heat shock proteins (Hsps) and function as 
‘molecular chaperones’ (Arrigo and Simon, 2010). Hsps are synthesised in response to diverse 
stressors such as elevated temperatures, hypoxia, inflammation and ischaemia (Lindquist and Craig, 
1988). Their role is to prevent undesired protein aggregation by binding with mal-folded proteins that 
may arise in response to cellular stress protein translation (Andley et al., 1998; Voellmy and Boellmann, 
2007). The αA- and αB-crystallins function as chaperones not only within the lens but also within other 
areas of the body. αA-crystallin is expressed mainly in the lens, whereas αB-crystallin exists in heart, 
skeletal muscle, skin, lung and the central nervous system (Graw, 2009). Indeed, the absence of 
crystallins normally found in the lens, brain, heart, skin, and skeletal muscle is associated with ageing 
phenotypes (Andley, 2008; Graw, 2009).  
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Point mutations in the Cryaa gene, encoding αA-crystallin causes hereditary cataract (Graw, 2009). 
The functional consequence of the mutant protein may be reduced chaperone activity (Kumar et al., 
1999) and a weaker anti-apoptotic effect (Mao et al., 2004). Mutations in the Cryab gene, encoding αB-
crystallin, are associated with neurological, cardiac and muscular disorders (Graw, 2009). αB-crystallin 
has also been implicated in the pathogenesis of Alzheimer’s disease (Mao et al., 2001), as αB-crystallin 
is present in the limbic and paralimbic regions, areas which are commonly affected in Alzheimer’s 
disease. αB-crystallin may have a chaperone effect against aggregation of the disease-related amyloid 
fibrils (Ecroyd and Carver, 2008). Sarcopenia is the loss of skeletal muscle mass and strength, and a 
feature of senescent organisms. Studies of aged rat gastrocnemius muscle (an animal model of 
sarcopenia) were compared to young adult muscle from 3-month old rats. Ageing skeletal muscle 
showed a drastic increase in αB-crystallin and another Hsp, cvHsp/HspB7 (Doran et al., 2007). The 
upregulation of these Hsp may represent an auto-protective mechanism in degenerating muscle fibres.  
Crystallins therefore are not only involved in regulatory, cell survival roles within the eye but also play 
important roles in several other organs. It has therefore been suggested that cataract might be viewed 
as a ‘bio-indicator’ for less obvious, more severe age-related disorders (Graw, 2009). Lens 
transparency has also been described as a possible primary ageing phenotype, distinct from cataract, 
which may instead represent a disease phenotype (Sanders et al., 2011) (see section 8.5). The Cryaa 
and Cryab genes are just two examples of genes associated with hereditary cataract; other examples 
include the connexin (gap junction proteins) genes and those genes for syndromic cataract (Shiels et 
al., 2010). For a comprehensive overview, the reader is recommended to visit the Cat-Map database, 
an online chromosome map and reference database for cataract in humans and mice (http://cat-
map.wustl.edu/). A few genes have been directly related to age-related cataracts. Genetic risk factors 
may account up to 75% of the heritability for age-related cataract (Hammond et al., 2001; Hammond et 
al., 2000a; Heiba et al., 1995). Variations in genes linked with inherited cataract have been associated 
with age-related cataract, including EPHA2 (Shiels et al., 2008; Sundaresan et al., 2012; Tan et al., 
2011). Additionally, there are variations in genes not directly associated with inherited cataract that may 
be associated in age-related cataract, such as the genes that function in antioxidant metabolism 
(GSTM1; GSTT1) (Sireesha et al., 2012). The reader is referred to the Cat-Map database for 
contemporaneous information and data. 
 
5. Glycation end products – their role in the eye and the ageing phenotype  
Advanced glycation end products (AGEs) are a heterogenous group of macromolecules formed by the 
non-enzymatic glycation of proteins, lipids and nucleic acids (Semba et al., 2010). Reducing sugars 
such as glucose react with amino groups in proteins, lipids and nucleic acids. This occurs via the 
Maillard reaction with the formation of a Schiff base between glucose and ε-amino groups (e.g. lysine or 
arginine) that slowly rearrange to form relatively stable Amadori adducts (Glenn and Stitt, 2009). The 
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most widely known Amadori product is the modification of haemoglobin (HbA1c), which is used clinically 
to monitor exposure to elevated blood glucose levels in the context of diabetes. Humans are exposed to 
two main sources of AGEs. Exogenous AGEs are ingested from foods, and formed when food is 
processed at elevated temperatures such as deep-frying, roasting, grilling and in the preparation of 
commercial foods (e.g. breakfast cereals, processed cheeses). Endogenous AGEs are formed in the 
body and production may be accelerated in diabetes and during normal physiological ageing.  
 
AGE adducts are irreversible and form covalent cross-links with proteins. AGEs bind with the receptor 
for advanced glycation end products (RAGE); this evokes downstream inflammatory responses and 
oxidative stress that could play a role in age-related diseases (Schmidt et al., 2000; Yan et al., 2007). 
Ligand binding with RAGE leads to increased reactive oxygen species, upregulation of inflammatory 
cytokines, adhesion molecules and of its own receptors via NF-kB (Bierhaus et al., 2001; Semba et al., 
2010). AGEs have been implicated in accelerated ageing by instigating a strong inflammatory response. 
Activation of RAGE by various ligands is associated with several age-related conditions such as 
Alzheimer’s disease (Takeuchi and Yamagishi, 2008), atherosclerosis (Basta et al., 2004), skin ageing 
(Lohwasser et al., 2006) and sarcopenia (Snow et al., 2007). Using a murine model of AMD, glycation 
altered proteolysis has been suggested as a pathobiologic mechanism that links ageing, dietary 
glycaemic index and age-related disease in non-diabetics (Uchiki et al., 2012). 
 
Ageing of ocular tissues has been linked to the presence of AGEs in the cornea, the lamina cribrosa of 
the optic nerve head and the retina and lens. AGE adducts have been detected within the lamina 
cribrosa of the optic nerve, and it is postulated that AGE-mediated cross-linking at this location may 
reduce flexibility within the tissue matrix and induce age-related optic nerve damage, a characteristic 
feature of glaucomatous optic neuropathy (Albon et al., 1995; Glenn and Stitt, 2009). AGE accumulation 
has also been demonstrated immunoshistochemically within human glaucomatous optic nerve and 
retina, and associated with ganglion cell degeneration, also characteristic of age-related glaucoma 
(Tezel et al., 2007). RAGE is also upregulated in the optic neuropathy associated with Alzheimer’s 
disease (Wang et al., 2009). AGEs can accumulate in the retinal pigment epithelium (RPE), and 
immunoreactive AGEs have been demonstrated in drusen from ageing eyes (Schutt et al., 2003) and at 
elevated levels in patients with AMD (Howes et al., 2004). RAGE has also been observed in AMD 
(Hammes et al., 1999) and AGE accumulation on Bruch’s membrane is associated with age-related 
dysfunction of the RPE (Glenn et al., 2008). A RAGE-mediated pro-inflammatory response within the 
outer retina is thought to be important in the context of retinal ageing and para-inflammation (Glenn and 
Stitt, 2009). In an in vivo model of retinal ageing, presence of RAGE ligands is associated with chronic 
inflammation within the outer retinal layers (Tian et al., 2005). Lens crystallins are subject to glycation 
and AGE cross-linking (Nagaraj et al., 2010). Glycation occurs at a higher rate during diabetes in both 
human (Garlick et al., 1984) and rat lenses (Yano et al., 1989). The accelerated cataract formation in 
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diabetes is related to glycaemic control (Larsen et al., 1989), supporting this view. A stable AGE 
product, CML, is present in human lenses (Ahmed et al., 1986), and higher levels of CML are seen in 
cataractous lenses compared to age-matched controls (Franke et al., 2003). Accumulation of the AGE 
argpyrimidine (the end product of a protein modification at the arginine residue by methylglyoxal (MGO) 
increases apoptosis of lens epithelial cells in vitro and in vivo (Kim et al., 2012). Trabecular meshwork cells 
play an important role in the regulation of aqueous outflow and open-angle glaucoma. AGEs have been 
found to not only decrease cell survival by inducing apoptosis, but also promotes the senescence of 
trabecular meshwork cells accompanied by increased oxidative stress (Park and Kim, 2012). 
 
6. Mitochondrial dysfunction in the eye and age-related conditions 
Mitochondrial damage can occur due to inherited mitochondrial mutations (e.g. Leber’s hereditary optic 
neuropathy), but stochastic, cumulative oxidative damage is also likely to play a role in age-related 
disorders (Jarrett et al., 2010). Mitochondrial DNA (mtDNA) is maternally inherited. Due to the polyploid 
nature of the mitochondrial genome, wild-type and mutated mtDNA may coexist in individual organelles, 
or within a single cell or tissue; this condition is known as heteroplasmy. Most mtDNA mutations related 
to diseases are found in heteroplasmy, and the levels of normal and mutated mtDNA can vary 
considerably between cells of the same tissue (Jarrett et al., 2008). Specific mtDNA “polymorphisms” 
have been classified into a number of specific mitochondrial haplogroups (Torroni et al., 1996). 
Mitochondrial DNA haplogroups have recently been shown to be associated with a number of 
neurodegenerative conditions, such as Parkinson’s disease (Autere et al., 2004; van der Walt et al., 
2003). 
 
The mitochondrial theory of ageing is related to the production of reactive oxygen species (ROS). 
Harman (2009) noted that oxygen free radicals are formed routinely during endogenous metabolism, 
and these may be involved in the ageing process. Other ROS can arise endogenously from the activity 
of cellular (particularly mitcochondrial) enzymes such as peroxisomes, lipooxygenases, and cytochrome 
P450, as well as the respiratory activity of mitochondria themselves. Exogenous ROS can arise from 
UV light, visible light, ionising radiation and environmental toxins. Mitochondria play an important role in 
maintaining the redox balance that is crucial for cellular homeostasis. Production of ROS such as the 
hydroxyl radical (.OH), hydrogen peroxide (H2O2), and peroxynitrite (OONO-) is balanced with the 
production of antioxidants (such as superoxide dismutase, SOD), and other repair systems within the 
mitochondria (Brennan et al., 2012; McCord and Fridovich, 1969).  Oxidative stress occurs when there 
is an imbalance between cellular ROS production and the ability of the cell to regulate ROS levels and 
repair damage caused by ROS (Brennan et al., 2012). Harman (1972) proposed that mitochondria play 
a key role in ageing. The theory proposes that ROS production leads to an accumulation of 
mitochondrial DNA (mtDNA) mutations, leading to mitochondrial dysfunction, and subsequent increased 
ROS production. ROS are thought to play an integral role in many age-related diseases, acting as the 
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main drivers of ageing. The ROS-mediated damage is thought to have a causative role in the 
pathogenesis of several age-related conditions such as Alzheimer’s disease, Parkinson’s disease, 
hereditary spastic paraplegia and cerebellar degenerations (Beal, 2005).  
 
mtDNA contains the genes encoding the proteins of the electron transport chain and those required for 
protein synthesis. Mitochondrial dysfunction may arise through changes in the mitochondrial genome or 
mutations in the nuclear genome affecting proteins needed by mitochondria. The replication and repair 
mechanisms of the mitochondrial genome are distinct from those of the nucleus, and continue in post 
mitotic cells such as the RPE and photoreceptors (Jarrett et al., 2010). mtDNA is thought to be more 
sensitive to ROS and other insults compared to nuclear DNA (Yakes and Van Houten, 1997). 
Mitochondria are less able to undergo DNA repair compared to nuclei; however, DNA repair 
mechanisms do exist including base excision repair (Jarrett et al., 2008). Other methods of 
mitochondrial protection include the presence of repair enzymes such as the glutathione system and 
thioltransferase system. These enzymes act as reducing agents to repair oxidative damage by 
maintaining the redox balance (Brennan et al., 2012).  Antioxidants (e.g. methinonine, cysteine, 
vitamins C and E) can directly scavenge ROS, and act as ‘sinks’ for ROS without permanent adverse 
consequences. The methionine sulfoxide reductase repair system is also believed to have a role in 
protection against oxidative stress; they are a family of enzymes that reduce methionine sulfoxide back 
to its reduced form (Brennan and Kantorow, 2009). The MsrA enzyme has been associated with the 
ageing process, with MsrA knockout mice showing a 40% reduction in lifespan compared to wildtype 
(Moskovitz et al., 2001). Loss of Msr activity has also been implicated in the pathogenesis of age-
related cataract (see below).  
 
6.1 Mitochondria and the eye 
Tissues with high energy demands have higher numbers of mitochondria per cell (Brennan and 
Kantorow, 2009). The retina is the most oxygen consuming tissue in the body (Rattner and Nathans, 
2006); mitochondria are found throughout the tissue, with the highest concentration within the retinal 
photoreceptors (Brennan and Kantorow, 2009). Mitochondria are crucial for ocular function, 
representing the major source of a cell’s supply of energy (Jarrett et al., 2010). The ocular tissues are 
subject to highly oxidizing microenvironments with constant exposure to damaging agents such as 
visible light and/or UV wavelengths, environmental agents (e.g. tobacco smoke) and radiation. 
Oxidative stress and subsequent mitochondrial dysfunction may play an important role in cataract 
formation. Oxidative stress in the lens has been proposed as a model for understanding the role of 
oxidative stress systems in age-related human disease (Brennan et al., 2012). Lens crystallins must 
remain in a homogenous state to maintain lens clarity, and for this to occur, redox balance must be 
maintained. Mitochondrial dysfunction and imbalance of ROS have been implicated in cataract 
formation (Brennan et al., 2012), as has depletion of the reduced form of the GSH system, which helps 
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to maintain the lens in a transparent state. (Calvin et al., 1991; Spector, 1995). Proteins in the 
cataractous lens are oxidised and form insoluble aggregates (Lou, 2003), for example an increase in 
oxidised methionines is seen with age (Truscott, 2005). The Msr enzymes may play an important role in 
age-related cataract formation, as oxidation of methionines and cysteines appears to play a significant 
role in the development of cataract (Brennan and Kantorow, 2009; Brennan et al., 2010). Decreased 
expression of base excision repair (BER) enzymes occurred with increasing age in the lenses of aged 
rats, suggesting that increased mtDNA damages causes a ‘vicious cycle’ of oxidative stress leading to 
accumulation of mtDNA mutations and cataract formation (Zhang et al., 2010). Genetic polymorphisms 
of BER enzymes have also been associated with age-related cataract in a Chinese population (Zhang 
et al., 2012). Clinically, antioxidants in the form of vitamins C and E have been investigated in 
epidemiological studies of cataract. Plasma measures of vitamins C and E taken at the eye examination 
were inversely associated with the prevalence of nuclear opacities in US and Indian populations (the 
latter an anti-oxidant depleted sample) (Dherani et al., 2008; Jacques et al., 2001).  
 
Animal and clinical studies also support a role for mitochondrial genomic dysfunction and defects in 
ROS systems in AMD (Brennan and Kantorow, 2009; Jarrett et al., 2010). Histologically, there is a 
decrease in number and area of RPE mitochondria with increasing age, with significant increases in the 
eyes of AMD donors (Feher et al., 2006). There is also a significant association between mtDNA 
haplotypes and AMD prevalence (Canter et al., 2008; SanGiovanni et al., 2009). The variants 
associated with a higher risk for AMD occur within the mt coding region that encodes for proteins of the 
electron transport chain, suggesting that the resultant altered biogenetics may be expressed clinically in 
macular RPE as maculopathy. MtDNA is preferentially damaged with AMD progression in all regions of 
the mt genome (compared to just one region in ‘physiological’ ageing), beyond levels found in age-
matched controls (Kaarniranta et al., 2011). Total mtDNA decreases with age, however there is no 
significant AMD-dependent change. Increased mtDNA deletions have also been noted in human and 
rodent retinas (Barreau et al., 1996; Wang et al., 2008). Mitochondrial dysfunction is also thought to 
contribute to the pathogenesis of primary open angle glaucoma (POAG), where a major risk factor is 
ageing (Leske et al., 2007).  POAG has been associated with mtDNA mutations (Abu-Amero et al., 
2006), and oxidative stress has been implicated in the pathogenesis of glaucoma (Tezel, 2006). The 
link between increasing age and prevalence of glaucoma suggests that ageing may increase the 
vulnerability of the optic nerve to stressors such as oxidative stress. Oxidative stress with increasing 
age may also be related to neurodegeneration in glaucoma (Lee et al., 2011).   
It has been hypothesized that a vascular role is involved in glaucoma pathophysiology particularly as 
reduced ocular perfusion pressure is a risk factor for the disease (Leske, 2009). Cherecheanu et al., 
(2012) propose that the primary insult occurs at the optic nerve head. Increased intraocular pressure 
and ischemia at the post-laminar optic nerve head affects retinal ganglion cell axons. Following this 
primary insult retinal ganglion cells function at a reduced energy level and are sensitive to secondary 
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insults. These secondary insults may happen if ocular perfusion pressure falls below the lower limit of 
auto-regulation. The mechanisms appear to involve vascular endothelial dysfunction and impaired 
astrocyte-vessel signalling.  
  
Prohibitins are ubiquitous highly conserved membrane-associated proteins that can stabilize the 
mitochondrial genome. They are seen as ‘mitochondrial chaperones’, modulating the response to 
oxidative stress (Nijtmans et al., 2000). Proteomic in vivo mice models suggest that prohibitin is 
involved in oxidative stress signalling in the retina and RPE, and could act as a biomarker protein. 
Prohibitin levels were found to be perturbed in aged and diabetic rodent eyes (Lee et al., 2010), while 
down-regulation of prohibitin occurred in the RPE. Upregulation of prohibitin occurred in the ganglion 
cell and inner nuclear layers of diabetic eyes, suggesting links between prohibitin and diabetic pathways 
when accompanied by oxidative stress and inflammation. Prohibitin could be an oxidative stress 
biomarker in ageing and diabetes, and a possible therapeutic target (Schrier and Falk, 2011).   
 
7. Epigenetic mechanisms and their role in age-related eye disease 
Epigenetics is the study of phenotypic changes that may occur in a cell independent of changes in the 
underlying genetic code (Rando, 2010). Epigenetics originally related to the study of how genotypes 
give rise to phenotypes through programmed changes during embryonic development (Waddington, 
1942). Epigenetics refers to both heritable changes and any mechanism that changes genes without 
changing the nucleotide sequence, and may be conceptualized as a developmental cascade where 
earlier or concurrent events act sequentially during cell proliferation and maturation to influence the 
developmental destiny of the cell (Kahn and Fraga, 2009). Genetic programmes for development, 
differentiation, and response to stress at a cellular or organ level can be altered by epigenetic 
modifications. The most well studied epigenetic regulatory mechanisms include covalent chemical 
modification of DNA (methylation), chromatin (covalent histone post-transcriptional modifications) and 
non-coding RNAs (miRNAs). These mechanisms are ultimately related to the regulation of gene 
expression and chromatin structure.  
 
The vertebrate eye is thought to be an excellent model to study epigenetic mechanisms of gene 
regulation as regulatory genes and their hierarchies in the eye are among the best understood in 
mammalian systems (Cvekl and Mitton, 2010). The epigenome has also been described as a ‘lens’ 
through which genomic information is filtered, which deteriorates with age due to loss of integrity of 
genetic information and environmental stresses (Rando and Chang, 2012). The epigenetic ‘lens’ is 
thought to be essential for establishing the aged phenotype and may be the target for reprogramming 
the ageing process towards rejuvenation instead (Rando and Chang, 2012). The management of ocular 
disease in future may also employ manipulation of epigenetic pathways (Nickells and Merbs, 2012).  
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7.1. DNA methylation 
 
DNA methylation consists of the addition of a methyl group to the aromatic ring of a single DNA base 
(Calvanese et al., 2009) and is generally associated with silencing of gene expression (Kahn and Fraga, 
2009). Genomic global DNA methylation decreases with age (DNA hypomethylation), first demonstrated 
by Berdshev et al in spawning humpbacked salmon (Berdyshev et al., 1967). However, 
hypermethylation of specific loci (CpG island promoters) have also been described during ageing 
(Fraga and Esteller, 2007; Oakes et al., 2003). Global hypomethylation and aberrant promotor 
hypermethylation have also been linked to cancer (Esteller, 2008). DNA methylation patterns can also 
change as a result of ageing or diet (Calvanese et al., 2009). DNA methylation is tissue-specific and 
may be cell type-specific, thus a certain DNA methylation pattern found in one tissue may not reflect 
patterns in other tissues (Michels, 2010). It is hypothesized that in age-related eye disease, 
environmental factors in combination with ageing can influence DNA methylation of critical genes 
required for normal function of the visual system (Cvekl and Mitton, 2010). The link between epigenetic 
mechanisms and the environment is highlighted in the external ocular tissues that are directly exposed 
to environmental toxins. Pterygia are abnormal proliferations of the conjunctiva adjacent to or 
encroaching onto the cornea, and aberrant DNA methylation has also been demonstrated in several key 
genes associated with wound healing processes in pterygia (Riau et al., 2011). Hypermethylation of the 
p16 gene promoter (which encodes for a negative cell cycle controller) and expression of a DNA 
methyltransferase is strongly correlated to reduced expression of the p16 protein (Chen et al., 2006). 
DNA methylation is also associated with altered gene expression in AMD - comparison of DNA 
methylation together with mRNA levels between AMD versus normal retinas showed significant 
differences in the GSTM1 and GSTM5 gene promoters, suggesting they undergo epigenetic repression 
in AMD RPE/choroid, which may increase susceptibility to oxidative stress (Hunter et al., 2012).  
 
7.2 Micro-RNAs  
Non-protein coding RNAs, microRNAs (miRNAs), are endogenous, small, non-coding, regulatory RNAs, 
approximately 22 nucleotides (nts) in size. miRNAs are regulatory molecules of chromatin structure and 
transcriptional elongation (Cvekl and Mitton, 2010; Xu, 2009). They can induce the breakdown of the 
targeted mRNAs and/or inhibition of translation from the mRNAs. Approximately 30% of protein-coding 
genes are regulated by miRNAs, and miRNAs play important roles in cellular proliferation, 
differentiation, and cell death. Mutations in miRNAs and/or the target sites in the transcripts of their 
downstream target genes, and dysregulation of miRNA biogenesis can result in a wide variety of 
diseases, including cancers.  
 
The miRNA transcriptomes of the retina, lens, and cornea have been established. Many miRNAs show 
unique tissue-specific and developmental stage-specific expression patterns, suggesting potential 
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unique functions in the retina and other ocular tissues (Xu, 2009). For example, several miRNAs are 
involved with retinal development (Huang et al., 2008). In addition, Dicer, a ribonuclease essential for 
miRNA processing, is necessary for the developmental changes of retinal progenitor cells (Georgi and 
Reh, 2010). Dicer is also highly expressed in developing mouse cornea and lens, where targeted 
deletion of Dicer disrupts lens morphogenesis, corneal epithelial stratification, and whole eye 
development (Li and Piatigorsky, 2009). The retina is amenable to experimental manipulation, and 
genetic manipulations that disrupt visual system development or physiology but which do not cause 
premature death, and thus permit detailed study of the phenotypic consequences (Sundermeier and 
Palczewski, 2012). For example, miRNAs are involved in the pathogenesis of retinopathy in diabetic 
rats by modulating multiple pathogenetic pathways (Kovacs et al., 2011) and miRNA profiling of 
ischemic retinas reveals that some may be upregulated whereas others are down-regulated which 
suggest a role in the pathogenesis of ocular neovascularisation as seen in AMD and diabetic 
retinopathy (Shen et al., 2008). During ageing, dysregulated expression of miRNAs can occur which 
may contribute to the pathogenesis of several age-dependent disease states (Lanceta et al., 2010). For 
example, distinct expression profiles of miRNAs in the central epithelium of transparent and age-related 
cataractous human lenses have been detected suggesting differential expression of miRNAs has a 
potential role in lens development and/or cataract formation (Wu et al., 2012). A local increase of the 
let-7b miRNA may represent a risk factor in the formation of age-related cataracts (Peng et al., 2012). 
The miRNA MIR204 is also thought to play an important role in the regulation of multiple functions in 
human trabecular cells including apoptosis, accumulation of damaged proteins, and expression of 
inflammatory mediators (Li et al., 2011) 
 
 
7.3 Histone modifications and the role of sirtuins in the retina 
Histone modifications occur at the level of the nucleosome. The nucleosome is the fundamental unit of 
chromatin, which contains an octamer of histones. DNA makes approximately 1.67 turns around this 
octamer unit. Some histone tails are not embedded fully in the nucleosome structure, which permits 
access to histone modifying enzymes, and subsequent post-translational modifications (PTMs). Histone 
PTMS work in concert to form a ‘histone code’ that is read by other proteins to regulate gene expression 
(Willis-Martinez et al., 2010). Histone modifying enzymes are thought to have an important role in 
ageing, particularly histone deacetylases (HDACs), which are important for signal regulation. The class 
III HDACs are NAD+ dependent proteins called sirtuins. They are orthologues of the yeast 
transcriptional regulator SIR2. In humans, seven Sirtuins have been identified (Sirt1–7) (Frye, 2000; 
Michishita et al., 2005), all with unique characteristics, functions, and localisations allowing increased 
functional complexity than in yeast through these distinct orthologous forms. Sirtuins are involved in 
chromatin remodelling, transcriptional silencing, mitosis and control of lifespan (Calvanese et al., 2009). 
SIRT1 expressed in mammals is the orthologue displaying the strongest homology to Sir2. In yeast Sir2 
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deletion shortens replicative lifespan, and an extra copy increases it, suggesting the Sir2 family plays a 
role in ageing (Kaeberlein et al., 1999). SIRT1 is expressed in most tissues and down-regulated in 
senescent cells and ageing (Sasaki et al., 2006; Sommer et al., 2006). SIRT1 may have a role in 
regulating DNA stability, and promotion of cell survival via anti-apoptotic processes (Ozawa et al., 
2010). SIRT1 may confer protection against age-related metabolic and inflammatory processes 
(Donmez and Guarente, 2010). Sirtuins have a pivotal role in the expansion of lifespan in lower 
organisms via caloric restriction, better fuel utilisation and ultimately reduced production of ROS 
(Kaeberlein et al., 1999; Muller et al., 1980; Rogina and Helfand, 2004). Sirt1 also acts as a ‘tumour 
keystone’ (McGuinness et al., 2011), where its level and action maintain a fine and delicate balance 
between suppression and promotion of oncogenesis, by providing both tumour suppressor and tumour 
promoter functionality (Deng, 2009). Sirtuins have not yet been extensively investigated in the eye, but 
SIRT1 is expressed throughout the retina (Greiss et al., 2008; Jaliffa et al., 2009). Redu ed expression 
of Sirt1 has been found in a mouse model of retinal degeneration, possibly reducing the functions of 
Sirt1 in DNA repair mechanisms which may be important in the pathogenesis of age-related conditions 
(Jaliffa et al., 2009).    
 
7. 5 Epigenetic epidemiology and age-related eye disease 
Epigenetic epidemiology is the study of the association between epigenetic variation and the risk of 
disease in humans (Michels, 2010). Epigenetic modifications are stable and heritable but can be 
modulated by many factors, including physiological and pathological conditions and the environment 
(Calvanese et al., 2009). In this way environmental factors could influence gene expression and 
phenotype and provide a molecular link between ageing and the environment (Feil and Fraga, 2011). 
Epigenetic traits such as CpG methylation can be used as markers in epidemiologic studies and 
comparisons can be made of the degree of global methylation, DNA methylation patterns, or gene-
specific methylation between population groups defined by the presence or absence of a specific 
exposure or disease. For example, global DNA hypomethylation has been observed in the most socio-
economically deprived individuals in a Scottish population cohort (McGuinness et al., 2012). 
 
Epigenetic changes accumulate over time, and can account for observed inter-individual differences in 
expression and phenotype (Thompson et al., 2010). Twin studies of monozygotic twins have provided 
useful insights, demonstrating the  influence of non-genetic factors on the generation of epigenetic 
changes over time (Fraga et al., 2005), which may explain phenotypic discordance between MZ twins 
(Calvanese et al., 2009). In another study of elderly MZ twin pairs who lived apart, greater phenotypic 
discordance was associated with greater epigenetic differences than young and phenotypically similar 
MZ twins reared together (Fraga et al., 2005). A genome-wide analysis of DNA-methylation patterns in 
MZ and dizygotic (DZ) twins demonstrated significant epigenetic differences in both groups (Kaminsky 
et al., 2009). A heritable component to AMD has previously been demonstrated (Hammond et al., 
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2002), with genetic factors explaining 31-71% of disease severity. Further evidence of the epigenetic 
differences between twins has been reported in AMD: in another study of MZ twins with different AMD 
phenotypes, heavier smoking was significantly associated with advanced AMD, whereas dietary intakes 
of vitamin D, methionine and betaine were associated with smaller lesions (Seddon et al., 2011). These 
findings suggest that smoking and some nutritional factors may induce epigenetic changes that modify 
gene expression and hence phenotype (Seddon et al., 2011).  
 
8. Ophthalmology and translational research 
Ophthalmology lends itself to translational research. Examples of basic age-related research translated 
clinically include the anti-VEGF (vascular endothelial growth factor) drug ranibizumab used as a therapy 
for ‘wet’ age-related macular degeneration (AMD) (Adamis et al., 1996; Aiello et al., 1995), a leading 
cause of irreversible blindness in elderly persons in developed countries which accounts for 9% of 
visual impairment worldwide (Klein et al., 2011; Ngai et al., 2011; Pascolini and Mariotti, 2012). Clinical 
trials showed that intraocular injection of ranibizumab improved vision in one-third of patients with ‘wet’ 
AMD (typically the AMD form least amenable to treatment), while stabilizing the condition in 90% of 
cases, in contrast to previous therapies that did not lead to clinically significant improvements in visual 
acuity (Brown et al., 2006; Rosenfeld et al., 2006). Another example of translational research is gene 
therapy, an example being transfer of the RPE65 gene into the RPE of individuals with Leber’s 
congenital amaurosis (LCA). This intervention can partially restore visual function (Bainbridge et al., 
2008; Maguire et al., 2008). In addition, about a third of entries in the Online Mendelian Inheritance in 
Man database for which a clinical synopsis is provided, include a term referring to the structure or 
function of the eye (Sheffield and Stone, 2011). Ocular stem cell therapy in animal eye models also has 
translational applications: endothelial cell precursor cells (EPCs) have been successfully used in retinal 
degeneration models to promote photoreceptor survival as well as promoting vascular repair in models 
of ischaemic retinopathy (Otani et al., 2004; Ritter et al., 2006; Sasahara et al., 2008). In addition, some 
of the first applications of nanot chnology and nanomedicine have occurred in this field (Zarbin et al., 
2010a, b). There is also growing interest in exploring the suitability of gene delivery strategies in ocular 
therapy as they may represent drug delivery mechanisms that occur within the CNS (Diebold and 
Calonge, 2010).   
 
Ophthalmology and clinical research findings 
Global estimates of blindness show that age-related cataract, AMD and glaucoma account for a large 
proportion of low vision and blindness (Pascolini and Mariotti, 2012; Resnikoff and Keys, 2012); these 
conditions also most prevalent in the elderly and contribute to overall disability in elderly people (Sousa 
et al., 2009). Several large-scale epidemiological studies have been performed globally, providing 
strong evidence for genetic susceptibilities to age-related eye disease. One such example is the Y402H 
complement H variant conferring a 2-fold higher risk of late-AMD per copy in individuals of European 
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descent (Sofat et al., 2012); the Blue Mountains Eye Study conducted in Sydney additionally found that 
individuals with the Y402H variant had an increased likelihood of bilateral compared with unilateral 
involvement of AMD lesions (Pai et al., 2009). The association of Y402H with AMD was also confirmed 
in the Rotterdam Study, accounting for a substantial proportion of AMD particularly in the presence of 
environmental and genetic stimulators of the complement cascade (Boekhoorn et al., 2007; Despriet et 
al., 2006; Hofman et al., 2009). Genetic variants also contribute to AMD in the Chinese population (Tian 
et al., 2012). A global genome-wide association study for intra-ocular pressure (IOP), a risk factor for 
glaucoma, has identified two clinically relevant genes, GAS7 and TMCO1, involved in IOP regulation 
(van Koolwijk et al., 2012). A heritable component to age-related cataract has been established in twin 
studies (Hammond et al., 2000b), and single nucleotide polymorphisms (SNPs) associated with age-
related cataract have been identified within the GJA8 and CRYBB3 genes in a German population-
based study (Graw et al., 2011). Age-related eye disease is also associated with systemic co-
morbidities and lifestyle effects. For example, age-related cataract is associated with smoking, alcohol 
consumption and blood glucose control (Kanthan et al., 2010, 2011; Tan et al., 2008a; Tan et al., 
2008b). Smoking and cardiovascular risk factors are also associated with AMD (Chakravarthy et al., 
2010). Cataract prevalence is also reported as being higher in women (Graw et al., 2011), but may also 
reflect differing access to cataract surgery services in resource-constrained settings (Lindfield et al., 
2012).  
 
8.1. Ocular parameters that could be used in ageing research:   
Clinically, the eye is relatively easy to examine compared to other organ systems and most ocular 
structures can be examined at a magnified view with minimal discomfort to the patient. There are few 
other locations in the body where cells, vasculature and neurological tissues are directly and readily 
visible. Several instruments not requiring ophthalmological expertise can provide objective 
measurement e.g. endothelial cell counts of the cornea, intra-ocular pressure, thickness of the retinal 
layers, the diameter of retinal v ssels. Furthermore, visual function can be assessed using a variety of 
tests to measure visual acuity, contrast sensitivity, colour vision etc. Many of these parameters change 
with chronological age. Validated methods are listed in Table 2; a detailed description of parameters 
and their measurement follows and is represented in Figure 1.  
 
8.1.1 Visual acuity 
Large-scale epidemiological studies have shown that visual acuity decreases with increasing 
chronological age (Foran et al., 2003; Klein et al., 2006). It is probably one of the easiest parameters to 
measure and requires minimal training.  Visual acuity can be measured using logarithmic visual acuity 
charts as per the protocol developed for the Early Treatment Diabetic Retinopathy Study (ETDRS) 
(Ferris and Bailey, 1996) where acuity is expressed as log MAR (the logarithmic value of the minimum 
angle of resolution). A grading system assigns a visual acuity score according to the number of letters 
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read correctly. On this scale, a Snellen visual acuity of 20/20 corresponds to logMAR = 0.00; 20/40 
corresponds to log MAR = 0.30, and 20/200 corresponds to log MAR = 1.00 (Bailey et al., 1991). The 
letter sizes on the chart progress in 0.10-log unit steps and there are five letters on each row and each 
letter is assigned a value of 0.02 log units. Results can either be given as number of letters read, or the 
Snellen equivalent. Near visual acuity can be measured in a similar manner. 
 
8.1.2 Colour vision 
Colour vision, which is a function of cone photoreceptors, is the ability to discriminate objects based on 
the different wavelengths (or frequencies) of light they reflect, emit, or transmit.  Colour vision can result 
from retinal or optic nerve pathology, and decreases with age (Roy et al., 1991).  The latter may reflect 
changes in the crystalline lens, the retina, or the pupil size, either separately or in combination (Nguyen-
Tri et al., 2003; Roy et al., 1991). Colour vision can be measured in several ways: the Farnsworth-
Munsell 100 hue test (FM100) consists of 85 coloured caps which represent the entire colour circle. 
Colour discrimination is assessed by asking the person being tested to place the caps in the appropriate 
order starting at a fixed colour, under standard illumination conditions (Mäntyjärvi, 2001). Total error 
score can be calculated and the square root of the total error score used in analyses. Simpler tests exist 
for example in the form of Ishihara colour plates, typically used to evaluate red-green colour blindness.  
 
8.3 Contrast sensitivity  
Contrast sensitivity is the visual ability to see objects that may not be outlined clearly or that do not 
stand out from their background. Contrast sensitivity decreases with increasing chronological age, even 
after adjusting for visual acuity (Hashemi et al., 2012; Nomura et al., 2003; Shandiz et al., 2011; Sia et 
al., 2012). Low contrast sensitivity can be more disabling than visual acuity loss (Leat et al., 1999), and 
is a better predictor of mobility performance than visual acuity (Marron and Bailey, 1982).  Decreased 
contrast sensitivity is associated with ischaemic retinal disease and cataract (Shandiz et al., 2011; 
Shoshani et al., 2011) and may be a sensitive indicator of generalized ageing in the most elderly (Lott et 
al., 2010). Contrast sensitivity loss can be present even when visual acuity and fields are relatively 
intact (Elliott and Whitaker, 1992). The ability to detect objects of different sizes at lower contrasts is 
expressed as a contrast sensitivity function (CSF) and determines the person’s contrast detection 
threshold, the lowest contrast at which a pattern can be seen.  Contrast sensitivity scores, which are 
linear on a log scale, can be determined using a Pelli-Robson contrast sensitivity chart; lower logCS 
values reflect worse contrast sensitivity.  
                                
8.4 Corneal endothelium  
The corneal endothelium consists of a monolayer of non-replicating, mosaic-like cells, which vary from 4 
to 6 μm in thickness and span 20 μm in width, and have a stable and metabolically efficient hexagonal 
shape (Bourne and McLaren, 2004). Morphological characteristics of the endothelium evolve with 
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ageing: some cells enlarge as others disappear. The monolayer can be viewed via specular microscopy 
using the technique of specular reflection (Figure 2) (Amann et al., 2003). Polymegethism (cell size) and 
polymorphism (geometric cell parameters) of the cells can be ascertained by this technique as well as 
the number of cells within a defined area, to give a measure of  endothelial cell density (ECD) (Wörner 
et al., 2011). Endothelial cell density is negatively correlated with age (Laing et al., 1976; Sanchis-
Gimeno et al., 2005; Wilson and Roper-Hall, 1982) and decreases throughout life at an average rate of 
about 0.6%/year (Bourne et al., 1997). Mean cell density is approximately 3400 cells/mm2 at age 15 
years declining to approximately 2300 cells/mm2 by 85 years (Yee et al., 1985). However racial or 
geographic differences appear to exist (Hashemian et al., 2006; Rao et al., 2000; Snellingen et al., 
2001; Yunliang et al., 2007). Endothelial cells from human corneas and mouse senescence models also 
show increased expression of senescence-related genes with increasing age (Song et al., 2008; Xiao et 
al., 2009). The gene encoding CDKN2A (p16ink4a) (a negative cell cycle regulator) is thought to play a 
key role in the process of senescence of corneal endothelial cells (Song et al., 2008). Human corneal 
endothelial cells (HCECs) also exhibit signs of oxidative DNA damage: 8-hydroxy-2′-deoxyguanosine 
levels (8-OHdG; a marker of oxidative DNA damage) were significantly higher in the central 
endothelium of older donors than of young donors (Joyce et al., 2009).Human corneal endothelial cells 
have been demonstrated to have long telomeres throughout life (Egan et al., 1998), and it is suggested 
that their limited replicative ability does not result from critically short telomere lengths. The limited 
replicative potential of the endothelium has functional consequences as there is a minimal cell density 
that is compatible with a clear cornea (and therefore good visual acuity). More recent work suggests 
‘stress-induced premature senescence” (caused by exposure of cells to environmental stressors) leads 
to age-related and topographical reduction in replicative capacity and senescence characteristics 
(Konomi and Joyce, 2007), and that this mechanism (rather than critical telomere shortening) leads to 
lack of proliferation.  
 
8.5 Lens opacities 
The prevalence of lens opacities increases exponentially with age (Hodge et al., 1995), and the human 
lens is considered an ideal tissue for studying macromolecular ageing in man (Truscott and Zhu, 2010). 
Affected individuals have a higher mortality risk than those without lens opacities (Wang et al., 2001). 
Assessment of lens opacity for research purposes have used clinical grading systems such as the Lens 
Opacities Classification System (LOCS) III (Chylack et al., 1993) and the Age-Related Eye Disease 
Study (2001). However, these systems are subjective, requiring slit-lamp evaluation with comparison 
against standard photographs and are, therefore subject to observer bias with low interobserver and 
intraobserver reliability (Pei et al., 2008). Objective quantification of lens opacity would be ideal. The 
Pentacam (Oculus, Germany) is a recently developed 360-degree rotating non-contact camera 
Scheimpflug imaging system with a lens densitometry function which provides an objective, quantitative 
assessment of lens opacity on a continuous scale from 0 to 100%. The Pentacam measures the light 
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scatter of the lens that becomes visible by illumination with blue light (wavelength 475nm) (Figure 3) 
(Kirkwood et al., 2009). The images of lens density acquired from the Pentacam have been validated 
against the LOCSIII system and repeatability of measurements and correlation with LOCSIII grading 
has been demonstrated (Grewal et al., 2009; Kirkwood et al., 2009; Pei et al., 2008); To date, the 
Pentacam has not been used in studies of biological ageing or to assess lens opacity as a putative 
biomarker of ageing, but has been used clinically. Recently, the phenotype of ‘lens transparency’ has 
been described as a possible biomarker of ageing, and it has been suggested that cataract (which 
refers to lens density or opacification on clinical assessment) may be viewed as a “clinical disease 
phenotype” (Sanders et al., 2011)).  

8.6 Amplitude of accommodation 
Accommodation is the ability of the eye to change the refractive power of the lens to focus on objects at 
a range of distances. The point at which accommodation is maximally exerted is called the near point. 
The reduction of this ability in which the near point recedes further away from a comfortable distance for 
the task being undertaken (e.g. reading, close work) is called presbyopia (Abraham et al., 2010). As the 
lens protein α-crystallin decreases with age in the human lens, there is a steady increase in the 
stiffness of the lens centre (nucleus), and this loss of elasticity may account for the loss of 
accommodation and hence presbyopia (Glasser and Campbell, 1999; Truscott, 2009). The age at which 
an individual becomes symptomatic varies, and is related to the refractive state of the eye (Abraham et 
al., 2005). An ecological study suggested high average temperature can accelerate the onset of 
presbyopia (Miranda, 1979). The amplitude of accommodation (AA) is the amount of accommodation 
exerted to move the focus from the far point to the near point. It decreases from childhood from about 
15 diopters (D) in early childhood to 1 D before the age of 60 years (Abraham et al., 2005). The near 
point of accommodation can be measured clinically using non-invasive methods (‘RAF rule’), and from 
this AA can be calculated.  
 
8.7 Retinal nerve fibre layer (RNFL) and retinal cells: 
The RNFL is formed by expansion of the fibres of the optic nerve and is affected in conditions such as 
glaucoma, AMD and choroidal pathologies. Thinning of the RNFL is associated with older age (Chi et 
al., 1995; Kanamori et al., 2003), and has also been detected in HIV-infected individuals, compared to 
age- and gender-matched controls (Faria et al., 2010; Kozak et al., 2005).  Thinning of the RNFL may 
be manifest functionally as deficits in visual field testing, colour vision and contrast sensitivity. RNFL can 
be assessed using optical coherence tomography (OCT), a non-invasive, non-contact method which 
gives a cross sectional image of the retina and its substructures in a real time mode and in vivo (Hee et 
al., 1995). RNFL thickness is calculated from the reflectivity distribution within the retina, using a special 
algorithm. OCT is used extensively in clinical practice to aid management of posterior segment 
conditions (Sakata et al., 2009) (Figure 1).  
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Thinning of the RNFL in Alzheimer’s disease has been observed particularly within the superior 
quadrants of the peripapillary area (surrounding the optic nerve head) (Berisha et al., 2007; Kesler et 
al., 2011; Lu et al., 2010; Paquet et al., 2007). Similar findings have also been noted in Parkinson’s 
disease and spinocerebellar ataxias (Hajee et al., 2009; Pula et al., 2011). These parameters may also 
be of practical importance as OCT is a quick non-invasive procedure and faster acquisition is important 
for patients with cognitive impairment such as AD. The retrograde loss of nerve fiber layer tissue in the 
retina and optic nerve may be an early biomarker of Alzheimer’s disease, and deficits in the RNFL and 
optic nerve may be the earliest sign of disease, even prior to damage to the hippocampal region that 
impacts memory (Valenti, 2011). OCT may be of particular value in research of conditions such as 
Alzheimer’s disease as assessment is quick and does not require high levels of cognitive function.   
 
Fourier domain OCT has been used to identify subclinical RNFL thinning in patients with Parkinson’s 
disease (Garcia-Martin et al., 2012) and to quantify retinal neural loss in multiple sclerosis (Monteiro et 
al., 2012). The technique of autofluorescence can also be used to assess the health and integrity of the 
RPE which is altered in AMD (Caramoy et al., 2012). The current gold standard for retinal vessel 
visualization is fluorescein angiography, which is used widely in clinical practice (Bernardes et al., 2011; 
Lim et al., 2012) A non-invasive alternative to image blood vessels is based on functional Fourier 
domain OCT, namely non-invasive wide-field angiography (Blatter et al., 2012; Campbell et al., 2012). 
Using the technique of ‘adaptive optics’, which overcomes wavefront distortions produced as light 
passes through the pupil of the eye, it is now possible to image single cells such as cone 
photoreceptors, within the living retina (Kocaoglu et al., 2011; Williams, 2011). Adaptive optics scanning 
laser ophthalmoscopy has demonstrated that the density of cone photoreceptors decreases with 
increasing age in healthy human subjects (Song et al., 2011).  
 
8.8 Retinal vessel calibre  
Retinal vessel diameters decrease with ageing. After adjustments for gender, hypertension and body 
mass index, retinal arteriolar diameter decreases between 2.1- 4.8μm per decade increase in age, and 
venular diameter 2.0-4.1μm per decade increase in age in Australian (non-indigenous) populations 
(Leung, 2003; Wong, 2003). Retinal vascular calibre is a structural marker of microvascular changes in 
the fundus and is strongly associated with hypertension, diabetes, and other systemic vascular 
diseases (Wong et al., 2002a; Wong et al., 2002b). It has been proposed that advancing age promotes 
oxidative stress and endothelial dysfunction in the vessel walls (Ehrlich et al., 2009). Structural changes 
in blood vessels (affecting retinal diameter) and impaired autoregulation may promote ischaemic 
changes. Noxious stressors can further disrupt retinal blood flow and may initiate a para-inflammatory 
process (see section 3.1). Validated quantitative measurement of retinal vessel diameters is possible 
using semi-automated software applied to digitized fundus photographs (Wong et al., 2004).  The 
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caliber and pathology of cerebral small vessels is difficult to assess in vivo. Most non-invasive markers 
of vascular pathology are related to major blood vessels outside the brain and may not represent local 
cerebral abnormalities. The retinal vessels provide unique opportunities to study cerebral small vessel 
disease, because they share similar anatomy, physiology and embryology (Wong et al., 2001).  Retinal 
venular dilatation is related to progression of cerebral small vessel disease (Ikram et al., 2006). Larger 
venular calibres are associated with an increased risk of dementia, in particular vascular dementia but 
not Alzheimer’s disease (de Jong et al., 2011). The association between larger retinal venular calibres 
and dementia may reflect cerebral hypoperfusion and subsequent ischemia. A meta-analysis of over 
20,000 middle- to older-aged individuals without diabetes confirmed that wider retinal venular caliber is 
independently associated with an increased risk of stroke events. No association with narrower retinal 
arteriolar caliber was observed (McGeechan et al., 2009). The microvascular changes occurring in the 
retinal vasculature may correlate with macrovascular systemic changes that are often not as easy to 
image or require interventional techniques. In relation to cardiovascular disease, larger retinal venular 
diameters are related to atherosclerosis, higher levels of total cholesterol, lower levels of HDL, higher 
levels of inflammatory markers (such as erythrocyte sedimentation rate and leucocyte count) and 
smoking (Ikram et al., 2004). A decreased arteriolar diameter is a risk factor, after adjusting for 
confounders, for developing hypertension within three to 10 years in normotensive individuals (Mimoun 
et al., 2009).   
 
9. Conclusions 
Several mechanisms have been postulated to explain the ageing process; none are comprehensive and 
indeed this reflects the hypothesis that ageing occurs at cellular, organ and physiological levels (Fulop 
et al., 2010). The eye provides an excellent model in which to further study mechanisms such as 
genetic control of lifespan and healthspan, oxidative stress, macromolecular ageing and glycation, as 
these processes are all well represented in the eye. The eye also provides an interface between 
molecular, epigenetic and cellular mechanisms and how they are manifest clinically. The eye is likely to 
continue to play an important role in translational research, as well as functioning as an excellent 
system for testing the Baker and Sprott criterion for validating biomarkers of ageing.   
 
At present data are limited regarding the role of the eye as a model of ageing. Some parameters have 
been more extensively researched than others and are likely to fulfil Baker and Sprott’s criteria better 
than others. For example, retinal vessel calibre correlates with age and would be an ideal candidate for 
further research to investigate if it does fulfil the criteria as an ageing biomarker. Lens transparency can 
now be measured objectively and as cataract has already been established as a biomarker of morbidity 
and mortality, it may be that lens density can serve as a marker of healthy ageing. In comparison, 
parameters such as endothelial cell count and the retinal nerve fibre layer probably require more 
detailed study in larger population cohorts to establish their relationship with ageing in health and 
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disease before warranting investigation as possible biomarkers of ageing. Many previously suggested 
ageing biomarkers do not fulfil the criteria as most of the markers under discussion are related not only 
to age, but also to disease, and thus none of these markers discussed is a ‘pure’ biomarker of ageing 
(Simm et al., 2008). It is not clear yet if this may affect some of the proposed ocular parameters. The 
authors therefore propose a research agenda to establish whether the eye may be a suitable research 
model (Box 1):   
 
It is likely that biomarkers of ageing will act in synchrony, so that for example, biomarkers in peripheral 
blood lymphocytes (such as telomere length) reflect ageing in terms of a general measure of ‘miles on 
the clock’, and other biomarkers may provide more organ-specific information. Ultimately the purpose of 
developing an optimal model of ageing is to understand the mechanisms that permit healthy ageing in 
the face of age-related stressors, and to subsequently develop and assess potential interventions to 
increase or maintain healthspan, to enhance function and well-being, and to delay frailty and age-
related disability. This should go some way in understanding the complex differences in the health and 
functional status of older populations that are now occurring at a global level, and assist with planning of 
public health interventions and resource delivery, as well as predicting clinical outcomes at the 
individual level.  
 
 
Box 1: 
Research agenda to assess the eye as a model of ageing and validation of BoA 
1. Cross-sectional studies of the ocular parameters that have not been fully investigated as biomarkers 
of ageing e.g. endothelial cell count, amplitude of accommodation, contrast sensitivity. It is known that 
these parameters change with increasing chronological age in the eye, but associations with other 
putative biomarkers of ageing or systemic age-related parameters have not been assessed. Studies will 
need to be performed in cohorts of varying ages (not just elderly populations) to fully understand the 
influence of stressors and disease, as well as the pattern of aging trajectories for the different ocular 
parameters.  
2. Longitudinal studies of well-defined ocular parameters in parallel with other biomarkers of ageing to 
verify and validate their use (e.g. Pentacam lens measurement with telomere length)  
3. Elucidate a panel of biomarkers that can be further validated in longitudinal studies. In a cohort of 85-
year olds in northeast England, 74 candidate biomarkers were evaluated, and 10 were identified as 
possible biomarkers of ageing (including vitamin D status, systolic blood pressure and hand grip 
strength), however no ocular parameters were assessed (Martin-Ruiz et al., 2011).  
4. In terms of a ‘healthy ageing phenotype’, longitudinal measurements of e.g. lens density, retinal 
nerve fibre layer, retinal vessel calibre should be taken from early adult life or even younger in order to 
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characterise the development of biological capital as well as ageing trajectories in terms of a ‘life 
course’ approach (Kuh, 2007).   
5. Combine validated ocular parameters with other simple assessments of physical capability (e.g. grip 
strength, walking speed) to form a ‘healthy ageing index’ that could be used to predict risk of morbidity 
or mortality.  
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Figure legends 
Figure 1: Anatomy of the eye and examples of measurement of age-related parameters that may have 
translational research applications 
Figure 2: Endothelial cells viewed by specular microscopy – A; endothelial cell density (ECD) of 1745 
cells/mm2 in a 65-year old female. B; ECD of 3014 cells/mm2 in a 30-year old female. Endothelial cells 
typically have a hexagonal shape; this changes with ageing due to the non-replicative nature of the 
cells.   
Figure 3: Imaging of lens density using the Pentacam – A; lens appearance in a 35-year old female with 
a near-transparent lens. B; lens in a 65-year old female with a dense lens. Clinically this would be 
visible as a cataract.  
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Table 1: How ocular ageing correlates with systemic ageing 
Ocular Parameter Correlation with ageing 
systemically 
Example Reference 
Vessel calibre Neurological  
 
 
 
Cardiovascular  
 
Retinal venular dilatation associated 
with dementia and CVA 
 
 
Retinal venular dilatation associated 
with cardiovascular ischaemic changes  
Retinal arteriolar narrowing associated 
with hypertension 
de Jong et al., 2011; 
McGeechan et al., 
2009 
 
Ikram et al., 2004; 
Mimoun et al., 2009 
Lens opacity Mortality Mixed lens opacities predictors of 
mortality after adjusting for confounders 
West et al., 2000; 
Hennis et al., 2001 
Lens transparency Leukocyte telomere length 
(LTL) 
Lens transparency associated with 
longer telomere length 
Sanders et al., 2011 
Retinal nerve fibre layer Neurological Thinning in Alzheimer’s disease, 
spinocerebellar ataxias, Parkinson’s 
disease 
Lu et al., 2010; 
Hajee et al., 2009; 
Pula et al., 2011; 
Kesler et al., 2011 
Amplitude of accommodation Neurological  Impaired convergence – leading to 
difficulties reading and viewing close 
objects in Parkinson’s disease 
Almer et al., 2012 
Visual function (including 
Visual acuity, contrast 
sensitivity, colour vision) 
Mortality  
 
 
 
 
Frailty 
 
 
 
 
Neurological 
Visual acuity and other ‘non-standard’ 
vision measures are predictors of 
mortality in community-dwelling elderly 
population 
 
Poorer visual function associated with 
greater frailty 
Visual function biomarkers of ageing 
associated with increased risk of falls  
 
Decreased contrast sensitivity and 
difficulties in visual perception in 
Parkinson’s disease 
Lott et al., 2010 
 
 
 
 
Klein et al., 2003; 
Knudtson et al., 2009 
 
 
 
Armstrong, 2011 
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Table 2: Ocular parameters, methods of measurement and the impact of ageing 

 


Anatomical 
site 
 
Parameter Method of measurement Age-related changes 
Cornea Corneal endothelium Specular microscopy Reduced cell count 
Lens Lens opacity 
 
Amplitude of accommodation 
Subjective grading systems 
Pentacam – lens densitometry 
RAF rule to measure near point of 
accommodation 
Opacification at different sites in 
the lens (cataract) 
Reduced amplitude 
Retina Retinal nerve fibre layer (RNFL) 
Retinal vessel caliber 
 
Retinal ganglion cells 
 
Retinal photoreceptors 
 
Optical coherence tomography 
Semi-automated retinal analysis 
software 
Confocal scanning ophthalmoscopy 
 
Confocal scanning ophthalmoscopy 
Thinner RNFL 
Reduced diameter of arterioles 
and venules  
Apoptosis 
 
Reduction in cone photoreceptor 
density 
 
Visual function Visual acuity 
Contrast sensitivity 
Colour vision 
Visual acuity chart (ETDRS) 
Pelli-Robson chart 
Farnsworth-Munsell 100 hue test 
 
All reduced 
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	
	
Highlights 
- The eye and visual system may be a uniquely useful site as a model of ageing 
- Oxidative stress, macromolecular ageing and glycation are well represented in the eye 
- Retinal vessel calibre and lens transparency may be novel biomarkers of ageing 


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Chapter 3 
Research questions, hypotheses,  
study aims and objectives 
 
 
 
     Traffic intersection in Nyanga district of Cape Town with sign highlighting directions to the two study sites 
 
Linking material summarizing a statement of the problem, 
research questions and hypotheses and  
aims and objectives of the study 
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3. 1 Statement of the problem 
Increasing numbers of HIV-infected individuals are able to access HAART due to effective 
scale-up programmes in resource-constrained settings. This is likely to lead to an increased 
number of people living with HIV (See Figure 3c). Knowledge relating to accelerated aging in 
this group is important as the management of HIV may shift over time from primarily 
treatment of acute OIs to the management of age-related conditions in the long term. There 
are limited data/studies investigating accelerated aging and HIV in Africa, and the 
epidemiology of age-related diseases (as a function of increasing chronological age and 
accelerated aging) within the African HIV-infected population is poorly understood at 
present. Knowledge about the concept of accelerated aging in HIV may lead to the ability to 
predict it so that it can be modulated, or even prevented. Data on the burden and types of 
age-related conditions will assist in planning the best methods to screen for, prevent and 
manage these conditions. From a health policy perspective this information can also aid in 
anticipating the infrastructure and health systems needed to deliver care and treatment for 
individuals affected or at risk from these conditions. 
Studies investigating accelerated aging in HIV have been conducted in the USA and Europe. 
However, these studies are likely to be confounded as the HIV-infected population in these 
locations are more likely to be exposed not only to risk factors known to accelerate aging 
(e.g. smoking and alcohol) but also to other exposures (e.g. recreational drugs, other 
‘lifestyle’ factors) compared to their non-HIV-infected counterparts. The advantage of 
examining an HIV-infected cohort in a country such as South Africa (and comparing findings 
with a non-infected group) is that these two groups are more likely to be similar in terms of 
socio-demographic characteristics and risk factors, so reducing differential risk exposure. 
The NIH Office of AIDS Research has highlighted the need for carefully designed studies of 
HIV and aging that takes these factors into account [1]. 
Few studies have evaluated patients on HAART versus those who are treatment naïve – it 
may be that HIV itself is an accelerant of aging or that some of the immunosenescent effects 
are mediated by HAART. It may be difficult to assess the effect of HAART on accelerated 
aging. If HAART-naive patients exhibit greater signs of aging (compared to treated patients) 
it would strongly suggest the likelihood of a (partially?) reversible process. Conversely, if 
HAART-treated patients show more signs of aging then this may suggest a cumulative, 
irreversible process. (Refer to Figure 3a for a pictorial representation of these hypotheses) 
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Examination of the eye in the context of HIV-related aging has not been undertaken to date. 
The eye may be a uniquely useful site as a model of aging. It is easily accessible and several of 
its components can be measured objectively and directly. The relationship between serum 
biomarkers of aging and clinical and/or ocular parameters of aging has also not been widely 
investigated. Understanding the changes in ocular parameters that occur with HIV may help 
to understand who is at risk of visual morbidity or blindness. Changes in eye (as a model of 
aging) may even be useful as a predictor of mortality. 
 
3.2 Research questions  
 Do HIV-infected individuals experience accelerated aging compared to age and 
gender-matched HIV-uninfected individuals in resource-constrained settings (where 
baseline CD4 counts are often low and viral loads high at HAART initiation)? 
 Does the accelerated aging process also affect the ocular tissues (perhaps mediated 
by retinal para-inflammation) leading to visual loss or blindness? Can ocular 
parameters of aging predict who is at risk of visual loss? 
 Are serum BoA levels raised in HIV-infected individuals demonstrated to have 
accelerated aging at the organ level? Do they correlate to ocular age-related 
parameters too? 
 Does HAART affect accelerated aging? Or is HIV primarily responsible, with HAART 
exacerbating the process? Or does HAART ameliorate the process such that the 
aging trajectory is nearer to that of uninfected individuals? (See Figure 3b).  
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3.3 Study hypothesis, aims and objectives 
Study hypotheses – HIV and accelerated aging: 
 
The overall study hypothesis is that the processes of immunosenescence and accelerated 
aging, proposed to occur in HIV-infected individuals will be manifest in this population of 
South African HIV-infected adults. In particular: 
 Age-related ocular parameters representing an ‘ocular aging’ phenotype will occur 
with greater frequency and severity in HIV-infected individuals compared with 
uninfected controls.  
 Physical capability levels related to ‘frailty’ will be higher in HIV-infected individuals 
compared to non-infected counterparts. 
 Serum biomarkers of aging (BoA) levels will be raised in HIV-infected individuals 
compared to age and gender-matched controls. 
 Serum BoA levels will correlate with ocular and systemic measures of aging. 
 HIV-infected individuals with ocular signs of aging are more likely to have a low nadir 
CD4 count and high viral load pre-ART. 
 In HIV-infected individuals who are treatment-naïve, the ocular aging phenotype will 
be expressed at a higher frequency compared to HIV-uninfected individuals.  
 HIV-infected individuals who are on HAART will express the ocular aging phenotype 
at a higher frequency compared to those who are treatment-naïve, suggesting that 
the change in ocular signs is a cumulative and irreversible process.  
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Figure 3a: Conceptual framework for study hypotheses 
            
 
 
 
Sophia Pathai PhD Thesis Page 100
Figure 3b: Hypotheses relating to effect of HIV and HAART on accelerated aging – adapted from Kuh, 2007 [2] 
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3.4 Aim 
To assess whether HIV-infected individuals demonstrate greater levels (frequency 
and severity) of ocular aging, systemic frailty and cellular senescence than a HIV-
uninfected group of similar age.  
Objectives: 
1. To measure age-related parameters among a cohort of HIV-infected 
individuals in South Africa, including clinical evaluation of ophthalmic 
parameters and objective measures of physical capability.  
2. To compare the measures of age-related parameters in the HIV-infected 
study population with a population of HIV-uninfected individuals who are 
gender- and age-matched.  
3. To determine risk factors for ocular aging (among HIV-infected cohort) 
using a priori risk factors (e.g. nadir CD4 count; body mass index; history 
of TB; smoking; on HAART; duration on HAART). 
4. To measure serum biomarkers of aging (telomere length, CDKN2A) and 
determine whether levels differ between the two study populations. 
5. To determine whether clinical age-related parameters are correlated to 
serum biomarkers of aging. 
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3.5 Research Setting 
3.5.1 Sub-Saharan Africa 
In sub-Saharan Africa, 3 million people aged 50 years and older are living with HIV 
[3].  As ART scale-up continues, the prevalence of HIV in people over 50 years of 
age in South Africa will nearly double over the next 30 years [4]. Thus, 
understanding of the concepts of HIV and accelerating aging within the population 
has important healthcare and social implications.  
 
 
 
Figure 3c: HIV prevalence in Sub-Saharan Africa in 2011, 2025, and 2040 in the 
population 15 to 49 years of age and the population 50 years of age or older. 
Reproduced with permission from (Mills et al. N Engl J Med 366;14:1270-73), Copyright 
Massachusetts Medical Society. 
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3.5.2 Cape Town, South Africa 
HIV epidemiology in South Africa: 
Estimates from 2011 indicate 5.6 million (4.9-6.6 million) people are infected with 
HIV in South Africa (Figures 3d-f) [5]. Overall prevalence in adults is 18.1% (15.4-
20.9%), but varies throughout the country, with some provinces more severely 
affected than others (Figure 3d). In 2005 the highest antenatal prevalence was in 
KwaZulu-Natal (39.1%) and lowest in the Western Cape (15.7%). Women account 
for approximately 55% of HIV-infected individuals. The prevalence in women aged 
25-29 years is up to 40%. For men, the peak is at older ages, with prevalence 
estimated at 10% among men older than 50 years. HAART availability is being scaled 
up and recent estimates suggest 28-55% coverage for adults (Figure 3g). Eligibility to 
initiate HAART is according to the 2010 guidelines released by the South African 
National AIDS Council and the Department of Health i.e. CD4 count <200cells/mm3 
irrespective of clinical stage; CD4 count <350cells/mm3 in patients with TB/HIV 
and/or Pregnant women; WHO stage IV irrespective of CD4 count; MDR/XDR-TB 
irrespective of CD4 count [6].  
 
Figure 3d: Adult (aged 15-49 years) HIV prevalence in South Africa. Source UNAIDS, 2012 
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Figure 3e: HIV prevalence – Ages 15 to 49 years (%) in South Africa 
 
 
 
Figure 3f: Estimated number of people living with HIV in South Africa 
 
 
Figure 3g: Estimated number of people receiving ART vs. AIDS deaths  
(Figures 3d-3g: Report on the global AIDS epidemic, 2012, UNAIDS; with permission) 
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Study sites: The Hannan Crusaid Treatment Centre is a joint project between the 
Desmond Tutu HIV Foundation and the Western Cape Department of Health. 
(Figure 3h). It is situated on the site of the Gugulethu Community Health Centre in 
the Gugulethu/Nyanga district, approximately 20km from the centre of Cape Town 
(see Map, Figure 3k). The clinic is a state of the art facility for HIV care in South 
Africa and has excellent levels of attendance and follow-up. This cohort of HIV-
infected individuals is extremely well-characterised [7-12], and all clinical case 
records are updated into a computerised database, so detailed historical clinical and 
demographic information is easily accessible. The Department of Ophthalmology, 
Groote Schuur Hospital had space and facilities made available for this project.  
 
Figure 3h: The Hannan Crusaid Treatment Centre, Gugulethu Township 
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 Figure 3i: The Emavundleni Centre for HIV Research, Crossroads Township 
Study populations: In 2005, the Gugulethu/Nyanga district HIV prevalence was 
29.1%, the second highest in the province [13]. This is in contrast to the generally 
low prevalence in the Western Cape (Figure 3d). HIV vaccine trials are carried out 
at the Emavundleni Centre for HIV Research, also run by the Desmond Tutu HIV 
Foundation (Figure 3i). The centre is also located in the Gugulethu/Nyanga district. 
Community HIV education and awareness, free voluntary testing, counselling and 
basic health information is offered at this centre, and patients attending this centre 
are likely to have similar socio-demographics to those attending the Hannan Crusaid 
Treatment Centre. All individuals participating in vaccine trials had laboratory 
evidence of HIV-seronegative status. The district has basic amenities and consists of 
both formal and informal housing sectors. Many of the ‘new’ settlements surrounding 
Gugulethu have predominantly informal housing, with high levels of crowding and 
poverty (Figure 3j). The vast majority of the population are of African ancestry.  
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 Figure 3j: Typical community housing and informal setttlments at recruitment sites  
 
Figure 3k: Map of Cape Town showing relative positions of Gugulethu (black circle) 
and Crossroads (red circle) [From Google Maps] 
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Chapter 4 
Study protocol and description of  
data collection methods 
 
 
 
 
Study clinical examination room, Dept. of Ophthalmology, Groote Schuur Hospital  
 
 
 
Linking material detailing the study protocol, 
participant enumeration and examination techniques 
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4.1 Pilot work undertaken to inform main study 
Pilot study of age-related conditions in HIV-infected individuals in the 
Gugulethu HIV-infected study population 
This was part of a pilot study to evaluate the prevalence of HIV-related eye disease 
within a cohort of HIV-infected individuals initiating HAART (Pathai et al. [1]) 
In this study data were collected on all eye conditions (not just HIV-related) in HIV-
infected individuals attending the Gugulethu clinic. Demographic and clinical data 
were obtained from clinic case records. Standardised ocular symptom screening was 
conducted relating to impairment of vision, pain and floaters/flashing lights. 
Ophthalmic examination comprised visual acuity measurement, anterior segment 
examination (via portable slit lamp) and dilated indirect ophthalmoscopy. . Cataract 
was defined as any lens opacity regardless of impact on visual acuity. Maculopathy 
refers to presence of any pigmentary change at the macula. Functional presbyopia 
was defined as requiring at least +1 dioptre in order to read the N8 optotype (on a 
near visual acuity chart) at a distance of 40cm in the participant’s usual visual state 
(with or without a spectacle correction for distance vision). 
Data were available for 157 participants (314 eyes) of whom 65% were female. The 
median age was 34 years [interquartile range (IQR) =28-42). The median baseline 
CD4 count was 143 cells/L (IQR=59-199), and viral load 37,328 copies/mL 
(IQR=8,936 -176,882). Past or current TB was present in 51% (n=80), and 62% 
(n=97) were staged at WHO clinical stages 3 and 4. Ophthalmic manifestations of 
HIV were detected in 12.1% (95%CI: 7.4-18.2; n=19) of the cohort. In those with 
CD4 counts <200 cells/L (n=118), 13.6% (95%CI: 8.0-21.0, n=16) had HIV-related 
ocular conditions. The most common manifestation was HIV retinopathy, present in 
4.5% (95%CI: 1.8-9.0; n=7) of the cohort. CMVR was seen in 2 cases (1.3%, 95%CI: 
0.2-4.2).  
Table 3.1 shows the distribution of the age-related conditions within the HIV-
infected cohort. It is apparent that conditions typically associated with older age 
(cataract, maculopathy, presbyopia) are present before the age of 50 years in this 
population (note: presbyopia tends to occur at approximately 40 years of age). 
Similarly, these changes only become manifest in this population after the age of 30 
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years. Therefore, examination of participants aged 30 years and over from both study 
populations would be ideal for this study, and the proportion of individuals affected ≥30 
years has been used to inform for sample size calculations (see Chapter 4, section 4.3). 
A limitation of this data is that outcomes were made solely on clinical examination, 
rather than using standardised grading systems, or with the use of photographic 
evidence (due to logistical and budgetary constraints).  
 
Table 4.1: Prevalence of age-related conditions within HIV-infected study population* 
(Hannan Crusaid Clinic, Gugulethu) (total individuals sampled=157) 
*All findings were based on clinical examination only and recorded as binary (absent/present) outcomes. 
Findings were recorded ‘per person’ rather than ‘per eye’ (if one eye had the condition this was considered 
presence of the condition at a person level, equally presence of the condition in both eyes was still recorded as 
affecting one individual) 
 
Condition 
Age group 
0-29 
n=49 
30-35 
n=41 
36-40 
n=23 
41-45 
n=18 
46-50 
n=12 
51-55 
n=7 
56-60 
n=5 
>61 
n=2 
Overall 
n= 157 
Cataract 0% 
(0) 
0% 
(0) 
4.3% 
(1) 
5.6% 
(1) 
16.7% 
(2) 
28.6% 
(2) 
40.0% 
(2) 
100.0% 
(2) 
6.4% 
(10) 
Maculopathy 0% 
(0) 
4.9% 
(2) 
4.3% 
(1) 
0% 
(0) 
16.7% 
(2) 
14.3% 
(1) 
0% 
(0) 
0% 
(0) 
3.8% 
(6) 
Presbyopia 0% 
(0) 
7.3% 
(3) 
8.7% 
(2) 
66.7% 
(12) 
91.7% 
(11) 
85.7% 
(6) 
100% 
(5) 
100% 
(2) 
26.1% 
(41) 
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4.2 Study protocol  
 
Study design: Case-control study of two clinic-based populations. 
Setting: Nyanga/Gugulethu District, Cape Town (recruitment of participants). 
Department of Ophthalmology, Groote Schuur Hosptial, Cape Town 
(examination of participants). 
Study population:   
i) HIV-infected individuals: Potential participants recruited from the 
Hannan Crusaid Treatment Centre, Gugulethu, Cape Town. Once a 
week the study coordinator recruited potential participants using the 
database held in the clinic.  
 
Inclusion criteria:  
1. Adults ≥ 30 years. 
2. Participant groups will be stratified into: 
i. HAART-naive.  
ii. On first-line HAART of known duration.  
3. Give informed consent to undergo full ophthalmic examination, 
physical capability measures, and drawing of blood for serum 
biomarker analysis. 
 
Exclusion criteria:  
1. Adults <30 years. 
2. Acute opportunistic infection (systemic or ocular). 
3. Pre-existing ocular inflammatory disease (offered referral and further 
management as required). 
4. Consent not given. 
5. Known diabetic. 
 
ii) HIV-uninfected individuals: Potential participants were recruited from 
the Emavundleni Centre for HIV Research, Crossroads district, Cape 
Town. HIV vaccine trials are carried out at the Emavundleni Centre and 
participants had a negative HIV test within the preceding two months. 
These controls were frequency matched on gender and age using 5-year 
categories. 
 
 
Inclusion criteria:  
1. Adults ≥ 30 years. 
2. Give informed consent to undergo full ophthalmic examination, 
physical capability measures, and drawing of blood for serum 
biomarker analysis. 
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Exclusion criteria: 
1. Adults <30 years. 
2. Pre-existing ocular inflammatory disease (offered referral and further 
management as required). 
3. Consent not given. 
4. Known diabetic. 
 
 
Ethics approval: 
Approval obtained from: a) Ethics Committee, London School of Hygiene and 
Tropical Medicine, b) Ethics Committee, University of Cape Town Medical School.  
(See Appendix 1: Ethics Approvals). An Export Permit was obtained from the 
Government of South Africa to export blood samples to the UK for analysis. 
 
Participant logistics: 
Potential participants were informed about the nature of the study at both 
recruitment centres (Hannan Crusaid ART Clinic and Emavundleni Centre), and 
asked if they would be willing to undergo ophthalmic and physical examination. The 
study patient information document was either given for the potential participant to 
read or read to them in an appropriate language (Appendix 3: Patient Information 
Documents). Enrolment into the study was dependent on completion of a 
‘willingness to participate’ form with a date and time to attend for assessment 
(Appendix 4). Participants were given partial remuneration to attend the 
examination site (Department of Ophthalmology, Groote Schuur Hospital) for 
formal assessment. At the examination site witnessed informed consent was 
recorded on a consent form marked by the participant’s signature or thumbprint 
using forms in English/Xhosa after translation and back translation (Appendix 5: 
Consent forms). The participant then underwent assessment as detailed below 
(Figure 4a: Flowchart of participant evaluation). 
 
Referral mechanisms and access to ophthalmic treatment: Eye/other 
conditions were managed accordingly by referral to the Dept. of Ophthalmology, 
Groote Schuur Hospital. Participants requiring presbyopic correction were given 
free spectacles. Treatment was provided free of charge.  
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Key:  
.Red-boxed area:  Measurement of age-related ophthalmic parameters 
 
Figure 4a: Flowchart of participant evaluation 
 
 
 
 
Demographic Data Collection
Anthropometric Data
Visual Acuity (VA)
Physical Capacity Measures
From existing data records
Direct questioning
Dilation
Anterior Segment Examination 
(slit lamp)
Corrected VA > 20/25
Autorefraction
Amplitude of Accommodation
Contrast sensitivity 
Colour vision
OCT
Pentacam
Fundus photography
Near and Distance
Specular Microscopy
Fundus Examination
Red-boxes 
Sophia Pathai PhD Thesis Page 115
 4.3   Data collection and participant evaluation  
Included data on the following (See Appendix 6: Data Collection form) 
Demographic characteristics 
HIV 
infected on 
HAART 
HIV infected 
HAART-
naive  
HIV 
uninfected 
Socioeconomic data (to include 
smoking/alcohol) 
X X X 
Occupation: mainly indoor/mainly 
outdoor as proxy for UV exposure 
X X X 
Educational status X X X 
Medical history of e.g. hypertension, 
diabetes, cardiovascular disease 
 
X X X 
Ophthalmic history    
Family history of eye disease 
 
X X X 
Date first documented to have HIV 
infection and route of transmission X X - 
WHO clinical staging of AIDS-
defining illness X X - 
Tuberculosis status  X X X 
Nadir and current CD4+ count X X - 
Highest/most recent HIV viral load 
(HIV RNA levels) 
 
 
 
X X - 
HAART treatment history (when 
commenced, regimen) 
 
X - - 
History/number of opportunistic 
infections 
 
X X - 
Clinical/anthropometric data    
Height (metres) 
 
X X X 
Weight (kg) 
 
X X X 
Blood pressure 
 
X X X 
Fasting blood glucose X X X 
 
Data were collected in particular relating to exposures known to affect aging and 
age-related parameters (e.g. smoking and UV exposure both risk factors for aging 
and lens opacities). Changes in practice at the clinic meant that not all HAART-naïve 
participants had a HIV RNA level taken pre-treatment.  
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 Figure 4b: Participant interview in preferred language 
 
Participant examination (refer to flowchart, Figure 4a) 
 
1. Ophthalmic examination – full ophthalmic examination by PI and study 
coordinator 
 
 
 
Figure 4c: Slit lamp examination by ophthalmologist 
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 2. Measurement of age-related ocular parameters: 
(Refer to Chapter 2 ‘The eye as a model for aging’ for further information)  
Parameter Method of 
measurement 
Measurement obtained 
Distance/near visual acuity ETDRS visual acuity chart No of lines/letters read 
Amplitude of 
accommodation 
RAF rule Diopteric value 
Contrast sensitivity Pelli-Robson chart CS score 
Colour vision Ishihara plates Total score 
Corneal endothelial cell 
count 
Specular microscopy Endothelial cell count 
Lens opacity (cataract) Pentacam with lens 
densitometry software 
Lens density value 
Retinal nerve fibre layer 
(RNFL) 
Optical coherence 
tomography (OCT) 
Thickness in m 
Retinal vessel diameter Fundus photography then 
IVAN retinal vessel 
analysis software 
Thickness in m 
 
 
 
Figure 4d: Assessment of visual acuity using LogMAR chart 
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 Figure 4e: Assessment of contrast sensitivity using Pelli-Robson chart  
 
 
Figure 4f: Corneal endothelium assessment using specular microscope 
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 Figure 4g: Pentacam acquisition (typically acquired in darkened environment, taken in light 
for illustrative purposes) 
 
Figure 4h: Measurement of retinal nerve fibre layer (RNFL) using optical coherence 
tomography (OCT) 
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 Figure 4i: Fundus photography to obtain images for retinal vessel calibre assessment 
3. Objective measures of physical capability.  
1. Grip strength – with grip dynamometers 
2. Walking speed – over 6 metres 
3. Chair rising – from a standard chair, with or without arms 
4. Standing balance – over a 6 metre long narrow path 
 
Figure 4j: Example of participant undertaking chair rises as part of physical 
capability assessment 
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4. Evaluation of serum biomarkers 
Blood samples were taken for DNA/RNA and plasma extraction, and subsequent 
evaluation of levels of BoAs (telomere length, CDKN2A, 8-OHDG). Samples were 
taken from all participants excluding the first 79 participants due to difficulties in 
obtaining appropriate consumables at initiation of the study. Refer to Chapter 5 for 
details of sample extraction. 
 
Figure 4k: DNA extraction machine (Maxwell™ Automated Purification System, Promega, 
USA). Whole blood mixed with Trizol reagent (Invitrogen, UK) for RNA extraction 
 
Following extraction, all samples were transferred to a deep freezer and stored at 
minus 800C and then shipped to the University of Glasgow on dry ice.  
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4.4 Power and sample size calculations 
4.4.1 Need for pilot data collection from both study 
populations 
 
To obtain an approximation of the sample size required for this study, reference to 
published data was made. Where possible, estimates were derived from 
epidemiological population-based studies in African populations or from studies 
where the proposed ocular parameters have been measured in an HIV-positive 
population.  
Outcome measures 
The main outcome measures related to presence of lens opacity, change in RNFL, 
amplitude of accommodation, and change in retinal vessel diameter. Secondary 
outcome measures included measures of contrast sensitivity, colour vision, 
endothelial cell count, physical capability measures and levels of serum biomarkers.  
Sample size calculations – using normative data 
Normative data for age-related eye conditions is generally limited to populations 
over the age of 40-50 years (as these conditions typically affect the older age 
groups). Data on cataract prevalence were obtained from a large population-based 
study conducted in Nigeria [2]. Data on RNFL was obtained from publications 
comparing this parameter between HIV-infected and non-infected individuals [3,4]. 
For assessment of retinal vessel calibre and amplitude of accommodation, 
publications were reviewed that compared these parameters in different age groups 
[5-7] (Tables 4.2 and 4.3). 
Table 4.2: Estimated sample size for two-sample comparison of proportions (assuming 
equal numbers of HIV infected and HIV uninfected individuals). 
Outcome Proportion 
in HIV+ 
population 
(≥30 years)$ 
Proportion 
in HIV –
population 
(≥30 years) 
Odds 
ratio 
detected 
Signifi-
cance 
level 
(%) 
Power 
(%) 
Required 
HIV 
infected 
Required 
HIV 
uninfected 
Cataract 9.3% 3.5%# 2.8 95 90 406 406 
    95 80 312 312 
$ - refers to HIV-infected individuals attending Hannan Crusaid Clinic, Gugulethu 
# - crude prevalence of cataract with presenting vision <6/12-6/60 
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Table 4.3: Estimated sample size for two-sample comparison of means. 
 
Outcome Significance 
level 
Power 
(%) 
Number 
required 
HIV 
infected 
Number 
required 
HIV-
uninfected 
Difference 
detected* 
RNFL 95 90 52 52 
10% difference in 
retinal thickness, 
 95 80 40 40 
assuming SD of 
15.0m 
Retinal vessel 
diameter 
95 90 141 141 
5% difference in 
diameter, 
95 80 108 108 
assuming SD of 
21.0m 
Amplitude of 
accommodation 
95 90 60 60 
15% difference in 
AA assuming  
95 80 45 45 
SD of 0.5 
dioptres 
*Difference reported as statistically significant in published data 
4.4.2   Feasibility and logistics 
The sample size calculations indicate that a sample size of 640 (320 HIV infected and 
HIV uninfected) would have at least 80% power to detect a statistically significant 
difference for all parameters listed (in terms of the given proportions and means). 
This sample size was thought to be practically and logistically feasible at the 
proposed study site based on the discussion with local coordinators and staff. In 
practice, the sample size was smaller – refer to following section.  
The power achieved for the different parameters with 640 participants is listed in 
Table 4.3. In summary, a sample size of 320 cases and 320 controls will be sufficient 
to detect the differences outlined in Tables 4.2 and 4.3, at a 95% significance level, 
and greater than 80% power for the outcome variables listed (Table 4.4). 
Table 4.4: Power for study assuming 95% significance level 
Outcome Power with this sample size (%) 
HIV infected/uninfected: 
320/320 
HIV infected/uninfected: 
160/320** 
Cataract 81 60 
Retinal diameter 99 97 
RNFL 99 99 
Amplitude 
accommodation 
99 99 
** Secondary analyses initially planned with stratification of the HIV-infected group into those on 
HAART and those who are HAART-naive. If half of HIV-infected group are HAART-naive, then 
analysis of this group (n=160) with the HIV-uninfected cohort (n=320) will still have sufficient power 
to detect a difference for the majority of outcomes 
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4.4.3   Actual power with sample size obtained:  
The actual number of participants recruited during the data collection period was 
504, composed of 248 HIV-infected individuals and 256 HIV-seronegative 
participants.  
Table 4.5 illustrates the power obtained with this sample size (assuming 1:1 ratio of 
252:252 HIV+/HIV-).  
Table 4.5: Power achieved with actual sample size obtained assuming 95% significance level 
 
The table indicates that good power was still achieved despite the reduced sample 
size obtained for the study. 
 
Data management:  
Dedicated Access databases were made for all the data, with range and consistency 
checks. All data was double entered. Data forms were kept in secure cabinets, data 
in the database was anonymized and databases password protected. Patient 
identifiers were stored as two separate databases, so that an individual’s unique 
information was not accessible from just one database.  
 
Analytical approach for ophthalmic data 
Murdoch et al [8] have outlined the methods of analysis that can be undertaken for 
clinical ophthalmic studies.  
1. The level of the individual –where both eyes are required for a diagnosis (e.g. 
blindness/visual impairment) 
Outcome Difference detected Power 
(%) 
Cataract Difference in cataract prevalence as Table 4.1 70% 
Retinal diameter 10% difference in retinal thickness, assuming SD of 
15.0m 
98% 
RNFL 5% difference in diameter, assuming SD of 21.0m 98% 
Amplitude of 
accommodation 
15% difference in AA assuming SD of 0.5 dioptres 99% 
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2. One eye per individual to be used in the analysis – one eye is chosen at random or 
‘right only’ or ‘left only’ – can be used in studies of risk factors that act at the 
individual level. 
3. Overall summary of ocular findings per individual – pooled data from both eyes, 
and the average taken.  
4. Analysis at ocular level – to overcome correlation between eyes random effects 
models can be used [9,10], or generalised estimating equations [11]. This correlation 
between observations must be taken into account in the statistical analyses; if not 
there are likely to be errors in the result such as falsely precise confidence intervals. 
As parameters will be related to the HIV status of the individual, data were analysed 
at the individual level. One eye per individual was used in the analysis, chosen at 
random. However not all eyes were suitable for measurement, for example eyes that 
have had significant cataract were unlikely to optimal RNFL or vessel calibre images, 
and so these measures would not be valid. In this case the contralateral eye will be 
chosen for measurement of eye parameters.  
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Abstract 
Background: Little is known about the impact of HIV infection on biological aging 
in sub-Saharan Africa. We assessed two validated biomarkers of aging, telomere 
length and CDKN2A expression (a mediator of cellular senescence), in South African 
HIV-infected adults and HIV-seronegative individuals. 
 
Methods: Case-control study of 236 HIV-infected adults aged ≥30 years and 250 age- 
and gender frequency-matched HIV-seronegative individuals. Biological aging was 
evaluated by measurement of telomere length and CDKN2A expression in peripheral 
blood leukocytes. 
 
Results: The median ages of the HIV-infected and HIV-seronegative participants 
were 39 years and 40 years respectively. Among HIV-infected participants, 87·1% 
were receiving anti-retroviral therapy (ART), their median CD4 count was 468 
cells/μL and 84·3% had undetectable viral load. Both biomarkers were validated 
against chronological age in HIV-seronegative individuals. Telomere length was 
significantly shorter in HIV-infected individuals compared to HIV-seronegative 
individuals (mean relative T/S ratio±SE:0·91±0·007 vs. 1·07±0·008, p<0·0001). 
CDKN2A expression was higher in HIV-infected participants compared to HIV-
seronegative individuals (mean expression: 0·45±0·02 vs. 0·36±0·03, p=0·003). In 
participants on ART with undetectable viral load, biomarker levels indicated greater 
biological aging in those with lower current CD4 counts. Lower income was 
associated with increased CDKN2A expression in HIV-seronegative individuals, but 
socio-economic factors were not associated with biological aging in HIV-infected 
participants. 
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Conclusions: 
Telomere length and CDKN2A expression both indicated increased biological aging 
in HIV-infected individuals compared to HIV-seronegative individuals. These 
findings have potentially important implications for age-related morbidity among the 
millions of patients receiving ART in Africa.  
 
Abstract word count: 237 
 
Keywords: HIV; telomeres; CDKN2A; accelerated aging; biomarkers of aging; 
Africa 
Suggested running head: Accelerated biological aging in HIV infection 
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MAIN TEXT 
Background 
HIV-infected individuals are at increased risk of age-related non-AIDS morbidity and 
mortality compared with HIV-uninfected persons [1]. It is speculated that HIV-
infected individuals may not only be aging chronologically, but also undergoing 
accelerated biological aging mediated by increased cellular senescence [2]. 
Chronological age is an imprecise measure of biological aging, due to inter-individual 
differences in rates of aging. The disconnection between chronological age and 
lifespan has led to a search for effective and validated biomarkers of aging (BoA), 
defined as “biological parameters of an organism that either alone or in some 
multivariate composite will better predict functional capability at some late age, than 
will chronological age” [3].  
Telomeric DNA length is a widely used BoA. Telomeres are nucleoprotein 
complexes at the ends of eukaryotic chromosomes. Their DNA component shortens 
with somatic cell division and upon reaching a critically short length, a DNA damage 
signal leads to cell cycle arrest, resulting in replicative senescence [4]. Telomere 
shortening is associated with increasing chronological age, and a wide range of 
pathologies, including cardiovascular disease [5] and renal dysfunction [6]. Telomere 
attrition is affected by psychosocial confounders, genetics and potentially by 
nucleoside reverse transcriptase inhibitors (NRTIs) [7]. Expression levels of the cell 
cycle regulator CDKN2A may represent a more robust BoA [8]. CDKN2A acts as a 
tumour suppressor and maintains cells in a state of growth arrest both in replicative 
and stress induced premature senescence. Increasing levels of CDKN2A 
transcriptional expression occur with increasing age both in solid organs and 
peripheral blood leucocytes (PBLs) [9]. In the former, increasing CDKN2A 
expression correlates directly with decreasing function. 
Data from industrialized countries on the impact of HIV on accelerated aging 
may be confounded by differential risk exposure by HIV status to risk factors, such as 
smoking and alcohol consumption. Moreover, lower socio-economic status and poor 
diet are also associated with accelerated biological aging [10]. Thus, the NIH Office 
of AIDS Research has highlighted the need for carefully designed studies of HIV and 
aging that takes these factors into account [11]. Few studies have evaluated biological 
aging in resource-limited settings, where the AIDS epidemic is most severe. In sub-
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Saharan Africa, 3 million people aged 50 years and older are living with HIV [12], 
and as ART scale-up continues, the prevalence of HIV in people over 50 years of age 
in South Africa will nearly double over the next 30 years [13]. If premature biological 
aging is associated with HIV, then age-related morbidity in HIV-infected individuals 
is likely to place a significant burden on healthcare systems in sub-Saharan Africa. 
The aim of this study was to test the hypothesis that HIV-infected individuals display 
advanced biological aging by directly comparing telomere length and CDKN2A 
expression in South African HIV-infected and HIV-seronegative individuals.  
Methods 
Ethics statement 
The study was approved by the Ethics Committees of the London School of Hygiene 
and Tropical Medicine and the University of Cape Town Faculty of Health Sciences, 
and adhered to the tenets of the Declaration of Helsinki. Written informed consent 
was obtained from all participants. 
 
Study participants: 
HIV-infected individuals aged > 30 years were enrolled from a community-based 
HIV treatment centre in Nyanga district in Cape Town [14]. All participants had a 
confirmed serological diagnosis of HIV and either about to commence ART (ART-
naïve) or were already on first-line ART. HIV-seronegative participants were 
recruited using frequency-matching by gender and 5-year age categories. HIV-
seronegative individuals were enrolled from participants confirmed to be HIV-
seronegative attending an HIV prevention trials centre (Emavundleni Centre). These 
two centres were chosen, as attendees were drawn from the same community and 
therefore likely to have similar socio-demographic characteristics. 
 
Data and sample collection 
Socio-demographic information and medical history were obtained by questioning 
participants in their first language (Xhosa or English). Data collected included factors 
known to affect aging (e.g. indoor/outdoor occupation as a proxy for UV exposure). 
Clinical information was available relating to current and nadir CD4 counts, peak and 
current HIV plasma viral load (VL) and WHO clinical status. Venous blood was 
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collected at the time of participant interview to measure telomere length and 
CDKN2A expression in PBL. 
DNA/RNA extraction 
DNA was extracted from PBLs using the Maxwell™ Automated Purification System 
according to manufacturer’s instructions (Promega, USA). DNA concentration and 
purity was quantified by Nanodrop Spectrophotometer (ThermoFisher Scientific, 
USA). RNA was extracted using Trizol reagent (Invitrogen, UK) following 
manufacturer’s guidelines. DNA/RNA extraction was performed in Cape Town and 
samples shipped on dry ice to the University of Glasgow.  
 
Telomere length determination 
Telomere lengths were determined by QPCR following the method of Cawthon [15]. 
Telomere length determination was performed blindly using a Roche Light Cycler 
LC480. Briefly, telomere length analyses were performed in triplicate for each 
sample, using a single-copy gene amplicon primer set (acidic ribosomal 
phosphoprotein, 36B4) and a telomere-specific amplicon primer set [16]. Quality 
control parameters for the amplifications comprised a cut off  0·15 for the standard 
deviation (SD) of the threshold cycle (Ct) for sample replicates. At a SD above 0·15 
the sample was reanalysed. The average SD across plates was 0·05. Relative telomere 
length was estimated from Ct scores using the comparative Ct method after 
confirming that telomere and control gene assays yielded similar amplification 
efficiencies. This method determines the ratio of telomere repeat copy number to 
single copy gene number (T/S) ratio in experimental samples relative to a control 
sample DNA. This normalised T/S ratio was used as the estimate of relative telomere 
length (Relative T/S).  The inter-assay variation was assessed by comparing the 
relative telomere estimates (T/S ratio) estimates across assays for the positive 
controls, assayed on every assay plate. The average inter-assay coefficient of variance 
was 0·6% for telomere length and 0·23% for 36B4.   
CDKN2A expression determination  
Relative quantitative real-time PCR (qRT-PCR) was used to estimate mRNA levels 
corresponding to the candidate senescence associated gene - CDKN2A. Expression 
levels were measured against a reference hypoxanthine phosphoribosyltransferase 
(HPRT) housekeeping gene on an ABI Prism(R) 7500 Sequence Detection System. 
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Sequences of human TaqMan™ Primer/Probe sets were designed by Primer Express 
algorithm (Applied Biosystems, Austin, TX, USA). The comparative threshold cycle 
method (CT)[17] was employed to quantify relative gene expression.  
 
Statistical Analysis 
Analyses were performed using Stata 12 (Stata Corp, USA). Clinical and biochemical 
data were summarized as the median with interquartile range (IQR) or mean with 
standard error (SE), as appropriate. Analyses were conducted on log10-transformed 
values of telomere length and mean CDKN2A expression to satisfy the assumption of 
normally distributed residuals. Results are displayed back-transformed to the original 
scale. Univariable analyses were performed to assess the relationships between mean 
telomere length, CDKN2A expression, HIV status and other clinical/demographic 
categories. Multivariable linear regression was used to examine the relationships of 
biomarker expression with HIV status adjusting for confounders identified in the 
univariable analysis and for a priori defined confounders (age and gender).  
 
Results  
Participant characteristics  
Characteristics of the 236 HIV-infected individuals and 250 age/gender frequency 
matched HIV-seronegative individuals are reported in Table 1. All participants were 
of African ancestry. Telomere data were available for all participants, and CDKN2A 
data for 444 participants (91·4%). The majority (75%) of the study population was 
female.  The median age of the HIV-infected population was 39 years (IQR 35-46 
years), similar to the HIV-seronegative group (median 40 years (IQR 35-49 years) 
(p=0·17). HIV-infected participants tended to be of higher socio-economic status, and 
were less likely to smoke or consume alcohol (Table 1).  Cases also had a lower mean 
BMI and were more likely to have current or previous TB than HIV-seronegative 
individuals.  Overall, 87·1% of HIV-infected participants were receiving ART and the 
current CD4 count among these participants was 468 cells/L (IQR: 325-607 
cells/L) and 84·3% had undetectable VL (<50 copies/mL). All participants on ART 
received a regimen that contained an NRTI.  
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Biological age and chronological age in HIV-seronegative individuals 
Telomere length and CDKN2A levels were validated against chronological age in 
HIV-seronegative individuals. As expected, there was a negative association between 
chronological age and telomere length (Pearson r=-0·13, p=0·05), and a positive 
association with CDKN2A expression (r=0·16, p=0·02). The relationship between 
CDKN2A expression and age was similar in males and females. However, for 
telomere length, age-related attrition was somewhat greater in males than in females 
but this difference did not reach statistical significance (r=-0·25 vs. r=-0·09, p-
interaction=0·13).  
 
Biological age and HIV status 
Telomere length was significantly shorter in HIV-infected individuals compared to 
HIV-seronegative individuals (mean relative T/S ratio [Rel T/S]±SE: 0·91±0·007 vs. 
1·07±0·008, p<0·0001, Figure 1a). Telomere length decreased with chronological age 
in HIV-infected individuals (r=-0·15, p=0·03). Mean CDKN2A expression was 
higher in HIV-infected participants compared to HIV-seronegative individuals 
(0·45±0·02 vs. 0·36±0·03, p=0·003, Figure 1b, Table 2), and there was little evidence 
of correlation between chronological age and CDKN2A expression in HIV-infected 
individuals (r=0·09, p=0·17). No interactions were detected with HIV status when 
assessing the relationship between biomarkers and chronological age (data not 
shown).  
Among the HIV-infected patients, there was no evidence that either telomere length 
or CDKN2A expression were associated with ART status (p=0·71 telomere length; 
p=0·80 CDKN2A; Table 2).   
 Among the 172 participants on ART with viral suppression, current CD4 count was 
positively associated with telomere length and negatively associated with CDKN2A 
expression (p-trend=0·02 telomeres; p-trend=0·05 CDKN2A; Table 3). There was no 
evidence of an association between these BoA and CD4 count in patients with 
detectable VL (data not shown). 
Biological age and socio-demographic characteristics  
Since socio-demographic characteristics may be associated with biological aging 
[10,18], we analyzed their association with the two BoA, stratified by HIV status 
(Tables 4a&b). HIV-infected participants aged ≥50 years had significantly shorter 
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telomeres than HIV-seronegative individuals in the same age group (mean RelT/S 
0·84 vs. 1·01, p=0·03; Table 4a). There were no significant associations between 
telomere length and other socio-demographic variables for HIV-infected participants. 
In HIV-seronegative individuals, an association with alcohol consumption and 
telomere length was detected, with those who did not consume alcohol and those who 
consumed >1L/week having the shortest telomere lengths (p=0·04) (Table 4a). For 
CDKN2A expression, the only evidence of an association was among HIV-
seronegative individuals, where CDKN2A expression was higher among those with 
lower incomes than higher incomes (mean RelT/S 0·39 vs. 0·30, p=0·03; Table 4b).   
 
Discussion  
Two validated biomarkers of aging (telomere length and CDKN2A expression) were 
found to be consistent with increased biological aging in South African HIV-infected 
individuals compared with age- and gender-matched HIV-seronegative controls. This 
important finding is supported by our previous observations in this same study 
population that HIV infection is associated with increased frailty [19], as well as 
changes in retinal vessel calibre that are consistent with aging and increased 
cardiovascular risk [20]. Among patients receiving ART and in whom plasma viral 
load was suppressed, the biological aging estimated by both biomarkers was greatest 
in those with low current CD4 counts. These findings have potentially important 
implications for age-related morbidity among the millions of patients receiving ART 
in Africa.  
Both biomarkers were strongly associated with chronological age in HIV-
seronegative individuals, validating their use as BoAs. Reduced telomere length is 
associated with markers of low socio-economic status in industrialized countries 
[10,18]. Lower income was associated with increased CDKN2A expression in HIV-
seronegative individuals, but socio-economic factors were not associated with either 
BoA in HIV-infected participants. Adjustment for socio-economic factors did not 
alter estimates of BoA between HIV-infected participants and HIV-seronegative 
individuals, suggesting that HIV infection, rather than social deprivation, is the main 
driver of biological aging in this population.  
Aging reflects an accumulation of multiple molecular deficits in varying organ 
systems [21]. Inter-individual differences in rates of aging have prompted the search 
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for informative biomarkers of biological aging. Measurement of telomere length in 
PBLs is the standard method of evaluating biological aging, with changes in PBL 
telomere length in effective synchrony with changes in telomere length in solid 
organs, thus providing a suitable surrogate for biological age in the whole organism 
[22]. However, there is potential for confounding by methodological and design 
difference between studies [8]. The number of techniques available for telomere 
length measurement highlight that no one technique is entirely satisfactory. Southern 
blotting of terminal restriction fragments, single telomere length analysis (STELA) 
and real-time quantitative PCR (qPCR) may also be used to assess telomere length in 
PBLs. We chose to use qPCR, as it is the most suitable methodology for high 
throughout analyses [8,23]. Although inter-assay comparisons are very good (as 
evidenced by our CV of 0·6%), intra-laboratory comparisons can be poor [24]. In 
view of these methodological issues, we elected to measure an additional BoA, 
CDKN2A. CDKN2A expression increases with increasing chronological age in PBLs 
and solid organs [9,16,25], and it functions as a direct marker of cellular growth arrest 
[9]. CDKN2A represents a superior BoA to telomere length when judged by the 
Baker and Sprott criterion [3]. It can be a stronger predictor of function than 
chronological age and displays less inter-individual variation [16,25]. 
CDKN2A expression was substantially greater in HIV-infected adults in 
comparison to age-matched HIV-seronegative individuals. As well as functioning as a 
tumour suppressor, CDKN2A is also a component of stress-induced premature 
senescence [26] which prevents T-cell replication following acute insult [27]. The 
decoupling of the relationship between CDKN2A expression and chronological age in 
HIV infected individuals is a direct consequence of HIV-associated premature T-cell 
senescence [2], and lack of further T cell replication with HIV infection. Nelson et al 
[28] found that ART-naïve individuals had higher levels of CDKN2A expression 
compared to HIV-seronegative individuals, and suggested that active HIV replication 
accounted for elevated expression. Our data show that with viral suppression and 
ART, high levels of CDKN2A are still detectable. Thus, high rates of HIV replication 
are not a pre-requisite for continued, elevated expression of this biomarker.  
Both biomarkers were significantly associated with current CD4 count in 
those receiving ART in whom viral load was undetectable. Increased CDKN2A 
expression was associated with lower CD4 counts, consistent with the finding that 
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CDKN2A expression is inversely related to T-cell replicative capacity [27]. Telomere 
length was also shorter in participants on ART with lower current CD4 counts. Thus, 
levels of both BoA suggested that lower current CD4 cell counts were associated with 
greater biological aging. Human telomerase comprises a reverse transcriptase sharing 
homology with the HIV reverse transcriptase [29]. It is plausible that ART may 
inhibit its activity, leading to differences in telomere lengths between ART-naïve and 
treated groups. Previous studies have produced inconsistent findings regarding such 
an association [30,31]. Comparison of levels in treated and ART-naïve groups in our 
study did not support this potential mechanism and furthermore, neither BoA was 
associated with ART duration.  
Although we have demonstrated a substantial effect of HIV infection on 
biological aging, estimating the magnitude of the effect is challenging. One important 
reason is because disease states can cause stress induced premature senescence [26], 
leading to acute growth arrest (in contrast to gradual replicative senescence). Thus, 
the ‘rate of biological aging’ may not be accurately predicted in HIV infection. In 
other words, HIV-infected individuals effectively display a biological age observed in 
older uninfected individuals due to disease-induced stress. Therefore, quantification in 
terms of an effective biological age difference between infected and uninfected 
individuals is problematic as the component of stress induced premature senescence 
in infected individuals will be missing in uninfected controls, while in turn replicative 
senescence may be accelerated due to disease stress. Estimation of telomere length as 
a function of given chronological age has been quantified [32,33], however telomere 
length as an isolated measure at a given age may be imprecise, reflecting 
psychosocial, genetic and epigenetic confounders. The predictive capability of 
CDKN2A in determining effective biological age is relatively novel [9], and as 
CDKN2A expression is related to cellular growth arrest it may not be subject to 
similar attrition phenomena [16,23,25]. Future work should involve development of 
methods to establish quantification of differences in effective biological age in disease 
states where stasis is involved. Any measure of the difference in biological 
age between HIV-infected and HIV-seronegative individuals will also have to be 
viewed in a functional context between these two groups, where differences in 
biochemical parameters, such as interleukin-6, CD14 and D-dimer are also addressed 
[34].  
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A key strength of our study is the inclusion of an age- and gender-matched 
control group with a similar socio-demographic profile as the HIV-infected 
participants. The hypothesis of accelerated aging in HIV has received criticism due to 
limitations in characterization of participants, particularly the possibility of 
differential exposure to potential risk factors between HIV-infected and uninfected 
populations [35]. Since the HIV epidemic in South Africa is generalized and 
recruitment took place from the same community, the likelihood of differential 
exposure was minimized. The study design means that ‘survivor effects’ cannot be 
excluded. Individuals with poor biological aging may die earlier, thus participants 
comprise survivors with different biological characteristic to non-survivors. However, 
recruitment of individuals from similar socio-economic backgrounds should have 
limited potential confounding and survivor effects. The differences in smoking and 
alcohol consumption between the two groups could be due to HIV-infected 
participants modifying their smoking and alcohol consumption behaviours in response 
to lifestyle counselling.  However, it is also plausible that the reported differences are 
due to misclassification, with HIV-infected participants wanting to demonstrate 
‘healthy behaviour’, possibly leading to confounding. We used location of work as a 
proxy measure of ultra-violet exposure which may also have been confounded by 
socio-economic status. The gender composition of participants was three-quarters 
female, consistent with the characteristics of the clinic cohort from where our 
participants were enumerated [36], and reflective of the African AIDS epidemic. 
Lastly, as all our study participants are of African ancestry, our results are only 
generalizable to the African population.  
The AIDS epidemic in sub-Saharan Africa is entering a new phase where 
HIV-infected individuals are living longer and may be aging faster [12,13]. Our data 
indicate increased biological aging in HIV-infected individuals compared to HIV-
seronegative individuals. The increased number of older HIV-infected individuals in 
this region, compounded by accelerated biological aging may have wide-ranging 
implications for HIV management. Delivery of healthcare systems integrating HIV 
treatment and age-related morbidity may be necessary to manage this phase of the 
epidemic. 
In light of these findings, important research questions arise: prospective 
assessment of biological age in HIV-infected and HIV-seronegative individuals is 
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needed to ascertain whether the accelerated aging trajectory develops as soon as HIV 
infection is acquired. Further questions include whether biological age is dependent 
upon the duration of untreated disease or nadir CD4 count, and if the biological age of 
the two groups continues to diverge during long-term ART, or rather is modified by 
ART. Finally, assessment of the relative contributions of HIV and ART towards 
biological aging may provide mechanistic insight. 
In summary, greater biological age, as determined by shorter telomere length 
and higher CDKN2A expression, is associated with HIV infection in South Africa. 
The ‘aging of the HIV epidemic’ poses many challenges and these may be amplified 
by accelerated biological aging, potentially resulting in important health and social 
implications for the millions of patients receiving ART in Africa.   
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Figure legends 
Figure 1a: Measurement of telomere length in peripheral blood leukocytes in HIV-
seronegative and HIV-infected individuals. Telomere length measured as mean 
relative T/S ratio: RelT/S±SE: 0·91±0·007 vs. 1·07±0·008, p<0·0001  
 
Figure 1b: Measurement of CDKN2A expression in HIV-seronegative and HIV-
infected individuals. Relative expression 0·45±0·02 vs. 0·36±0·03, p=0·003· 
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FIGURES AND TABLES  
Figure 1a:  
 
 
Figure 1b:  
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Table 1: Characteristics of study population  
Variable 
 
HIV-infected 
participants 
(236) 
% (n) 
HIV-
seronegative 
participants 
 (250) 
% (n) 
P-value 
Age  (years) 39  (35-46)a 40 (35-49)a 0·17 
Age (years) by group 
30-39 
40-49 
>50 
 
50·4 (119) 
32·6 (77) 
17·0 (40) 
 
46·4 (116) 
32·0 (80) 
21·6 (54) 
 
 
0·41 
Male gender 25·4 (60) 24·0 (60) 0·72 
Education 
< High school 
High school or tertiary education  
 
11·9 (28) 
88·1 (208) 
 
17·6 (44) 
82·4 (206) 
 
0·08 
Income 
<USD 125/month 
>USD125/month 
 
56·8 (134) 
43·2 (102)  
 
67·2 (168) 
32·8 (82) 
 
0·02 
Housing 
Informal 
Formal  
 
47·9 (113) 
52·1 (123) 
 
40·4 (101) 
59·6 (149) 
 
0·10 
Water supply 
Shared 
Own  
 
75·0 (177) 
25·0 (59) 
 
74·0 (185) 
26·0 (65) 
 
0·80 
Alcohol (amount per week) 
Nil 
Up to 1L/week 
>1L/week  
 
69·5 (164) 
20·3 (48) 
10·2 (24) 
 
56·4 (141) 
21·6 (54) 
22·0 (55) 
 
 
0·001 
 
Duration of smoking (years) 
Nil 
<10 years 
>10 years 
 
84·8 (200) 
5·1 (12) 
10·2 (24) 
 
72·0 (180) 
12·8 (32) 
15·2 (38) 
 
 
0·002 
Illicit drugs 
Never taken 
Ever taken 
 
97·4 (222) 
2·6 (6) 
 
98·0 (240) 
2·0 (5) 
 
 
0·67 
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BMI (kg/m
2
) 27·8±0·4 31·5±0·6 <0·0001 
Co-morbidity (including hypertension) 
None 
One or more 
 
64·4 (152) 
35·6 (84) 
 
55·2 (138) 
44·8 (112) 
 
 
0·04 
TB status 
No history 
Current  
Previous  
 
32·6 (77) 
4·2 (10) 
63·1 (149) 
 
87·6 (219) 
0·4 (1) 
12·0 (30) 
 
 
 
<0·0001 
HIV characteristics  %(n) or median 
(IQR) 
   
WHO stage 
1/2 
3/4 
 
27·1 (67) 
72·3 (181) 
  
ART naïve  12·9 (32)   
CD4 count in ART naïve group (n=32) 
(cells/L) 
182 (84-202)   
Log10VL in ART naïve group (n=21) 4·88 (4·21-5·18)   
Current CD4 count in ART group 
(cells/L) 
468 (325-607)   
Nadir CD4 count in ART group  
(cells/L) 
128 (76-171)   
% with undetectable VL* in ART 
group  
84·3 (172)   
Peak Log10VL in ART group  4·56 (3·84-4·98)   
Duration of ART, months  58 (34-75)   
a – values expressed as median (interquartile range); *Undetectable VL refers to VL<50 
copies/mL 
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Table 2: Association of HIV states with telomere length and CDKN2A expression 
Clinical 
group 
N Telomere 
length  
Mean Rel T/S 
(95% CI) 
P-value N Mean CDKN2A 
Mean expression 
(95% CI) 
P-value 
HIV-
seronegative  
 
250 
 
1·07  
(1·04-1·11) 
 
<0·0001
a
 
 
217 
 
0·35  
(0·32-0·39) 
 
0·006
a
 
HIV-
infected; 
On ART 
 
204 
 
0·91  
(0·87-0·94) 
 
 
 
199 
 
0·45 
 (0·40-0·50) 
 
 
HIV-
infected; 
ART-naïve  
 
32 
 
0·89 
 (0·81-0·98) 
 
0·71
b
 
 
28 
 
0·46 
 (0·34-0·62) 
 
0·80
b 
a- indicates p-value for HIV-seronegative individuals vs. HIV-infected participants overall 
b- indicates p-value between HIV group (i.e. on ART and ART-naïve) 
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Table 3: Association of biomarkers with HIV-related co-variates. Linear 
regression adjusted for age in participants on ART with suppressed VL  
(i.e. <50 copies/mL) (*indicates P-value test for trend) 
Variable N 
=172 
Telomere length  
Mean Rel T/S 
(95% CI) 
P-
value 
N 
=168 
Mean CDKN2A 
(95% CI) 
P-
value 
WHO stage 
1/2 
3/4 
 
33 
139 
 
0·89 (0·81-0·97) 
0·92 (0·88-0·96) 
 
 
0·48 
 
32 
136 
 
0·44 (0·35-0·56) 
0·46 (0·41-0·51) 
 
 
0·81 
Duration of ART, 
months  
0-36 
36-72 
>72 
 
 
40 
80 
52 
 
 
0·86 (0·80-0·93) 
0·91 (0·87-0·97) 
0·95 (0·88-1·01) 
 
 
 
0·10* 
 
 
39 
79 
50 
 
 
0·51 (0·41-0·63) 
0·45 (0·39-0·52) 
0·42 (0·35-0·51) 
 
 
 
0·17* 
Current CD4 count 
 (cells/μL)  
<200 
201-350 
>351 
 
 
7 
37 
128 
 
 
0·85 (0·70-1·02) 
0·83 (0·77-0·91) 
0·93 (0·90-0·98) 
 
 
 
0·02* 
 
 
7 
37 
124 
 
 
0·63 (0·38-1·03) 
0·52 (0·42-0·64) 
0·43 (0·38-0·48) 
 
 
 
0·05* 
Nadir CD4 count  
(cells/μL) 
<200 
>201 
 
 
153 
19 
 
 
0·91 (0·87-0·94) 
0·93 (0·83-1·05) 
 
 
 
0·58 
 
 
151 
17 
 
 
0·46 (0·41-0·51) 
0·44 (0·32-0·61) 
 
 
0·80 
Peak viral load  
<10,000 copies 
>10,000 copies 
 
52 
120 
 
0·92 (0·86-0·99) 
0·91 (0·87-0·95) 
 
 
0·68 
 
51 
117 
 
0·50 (0·42-0·61) 
0·44 (0·38-0·48) 
 
 
0·27 
TB status 
No history 
Current /Previous 
history 
 
48 
124 
 
0·91 (0·84-0·97) 
0·91 (0·87-0·95) 
 
 
0·92 
 
47 
121 
 
0·47 (0·39-0·57) 
0·45 (0·40-0·51) 
 
 
0·69 
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Table 4a: Mean telomere length (RelT/S) in HIV-infected participants and HIV-
seronegative individuals, adjusted for age (*indicates P-value test for trend) 
Variable  HIV-infected 
participants 
Telomere length 
  HIV-seronegative 
participants 
Telomere length 
P-
value 
 N Mean Rel T/S 
 (95% CI) 
P N Mean Rel T/S  
(95% CI) 
 
Age, years 
30-39 
40-49 
>50 
 
119 
77 
40 
 
0·92 (0·88-0·96) 
0·93 (0·88-0·98) 
0·84 (0·77-0·91) 
 
 
0·11 
 
 
116 
80 
54 
 
1·10 (1·04-1·15) 
1·09 (1·02-1·15) 
1·01 (0·94-1·08) 
 
 
0·09* 
 
Gender 
Male 
Female 
 
60 
176 
 
0·92 (0·86-0·99) 
0·90 (0·87-0·94) 
 
 
0·56 
 
60 
190 
 
1·04 (0·97-1·12) 
1·08 (1·04-1·12) 
 
 
0·30 
Income/month (US$)  
<USD 125/month 
>USD125/month 
 
134 
102 
 
0·91 (0·87-0·95) 
0·90 (0·85-0·95) 
 
 
0·86 
 
168 
82 
 
1·07 (1·02-1·12) 
1·07 (1·00-1·14) 
 
 
0·94 
UV exposure/ 
Occupation 
Outdoor worker 
Indoor worker 
 
 
155 
81 
 
 
0·90 (0·86-0·94) 
0·92 (0·87-0·97) 
 
 
 
0·69 
 
 
178 
72 
 
 
1·08 (1·04-1·13) 
1·04 (0·98-1·12) 
 
 
 
0·30 
Education 
< High school  
High school /college 
 
28 
208 
 
0·91 (0·82-1·01) 
0·91 (0·87-0·94) 
 
 
0·91 
 
44 
206 
 
1·04 (0·96-1·11) 
1·08 (1·04-1·12) 
 
 
0·49 
Housing 
Formal 
Informal 
 
123 
113 
 
0·91 (0·87-0·96) 
0·90 (0·86-0·95) 
 
 
0·69 
 
149 
101 
 
1·06 1·02-1·11 
1·09 1·03-1·15 
 
 
0·77 
Duration of smoking 
Nil 
<10 years 
≥10 years 
 
200 
12 
24 
 
0·91 (0·88-0·95) 
0·93 (0·80-1·08) 
0·85 (0·77-0·95) 
 
 
0·36 
 
180 
32 
38 
 
1·08 (1·03-1·12) 
1·07 (0·97-1·17) 
1·07 (0·98-1·16) 
 
 
0·92 
Alcohol (per week) 
Nil 
<1L 
>1L 
 
164 
48 
24 
 
0·92 (0·86-0·96) 
0·89 (0·82-0·95) 
0·86 (0·77-0·95) 
 
 
0·18* 
 
141 
54 
55 
 
1·08 (1·03-1·13) 
1·13 (1·05-1·22) 
1·00 (0·93-1·08) 
 
 
0·04 
 
Sophia Pathai PhD Thesis Page 149
Body mass index 
(kg/m
2
) 
<25 
25-29·9 
>30 
 
 
87 
71 
78 
 
 
0·88 (0·83-0·93) 
0·96 (0·90-0·98) 
0·90 (0·85-0·95) 
 
 
 
0·08 
 
 
60 
55 
135 
 
 
1·04 (0·97-1·11) 
1·12 (1·04-1·20) 
1·07 (0·98-1·12) 
 
 
 
0·35 
Co-morbid condition 
No 
Yes 
 
152 
84 
 
0·91 (0·87-0·95) 
0·90 (0·85-0·95) 
 
 
0·88 
 
138 
112 
 
1·08 (1·04-1·14) 
1·06 (1·00-1·11) 
 
 
0·65 
TB status 
No history 
Current/past 
 
77 
159 
 
0·90 (0·85-0·96) 
0·91 (0·87-0·95) 
 
0·88 
 
219 
31 
 
1·07 (1·03-1·11) 
1·09 (0·99-1·20) 
 
 
0·71 
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Table 4b: Relative CDKN2A expression in HIV-infected participants and HIV-
seronegative individuals, adjusted for age. (*indicates P-value test for trend) 
Variable HIV-infected 
participants 
HIV-seronegative 
participants 
 N Mean 
CDKN2A 
P-
value 
N Mean 
CDKN2A 
P-
value 
Age, years 
30-39 
40-49 
>50 
 
113 
74 
40 
 
0·41 (0·36-0·47) 
0·45 (0·38-0·53) 
0·54 (0·43-0·68) 
 
 
0·04* 
 
98 
70 
49 
 
0·29 (0·25-0·35) 
0·44 (0·37-0·54) 
0·38 (0·30-0·48) 
 
 
0·006 
 
Gender 
Male 
Female 
 
59 
168 
 
0·42 (0·35-0·50) 
0·45 (0·41-0·51) 
 
 
0·46 
 
53 
163 
 
0·37 (0·30-0·47) 
0·35 (0·31-0·40) 
 
 
0·71 
Income/month (US$) 
<USD 125/month 
>USD125/month 
 
129 
98 
 
0·43 (0·38-0·48) 
0·47 (0·41-0·54) 
 
 
0·44 
 
145 
72 
 
0·39 (0·34-0·44) 
0·30 (0·23-0·37) 
 
 
0·03 
UV exposure/Occupation 
Outdoor worker 
Indoor worker 
 
147 
80 
 
0·45 (0·40-0·50) 
0·45 (0·38-0·52) 
 
 
0·81 
 
155 
62 
 
0·36 (0·32-0·41) 
0·34 (0·28-0·42) 
 
 
0·86 
Education 
< High school  
High school /college 
 
27 
200 
 
0·48 (0·36-0·64) 
0·44 (0·40-0·49) 
 
 
0·60 
 
39 
178 
 
0·34 (0·26-0·44) 
0·36 (0·32-0·41) 
 
 
0·66 
Housing 
Formal 
Informal 
 
121 
106 
 
0·44 (0·39-0·50) 
0·45 (0·40-0·52) 
 
 
0·63 
 
126 
91 
 
0·34 (0·30-0·40) 
0·37 (0·31-0·44) 
 
 
0·47 
Duration of smoking 
Nil 
<10 years 
>10 years 
 
192 
12 
23 
 
0·45 (0·40-0·49) 
0·65 (0·43-0·93) 
0·36 (0·28-0·49) 
 
 
 
0·08 
 
157 
27 
33 
 
0·36 (0·31-0·40) 
0·43 (0·31-0·58) 
0·30 (0·22-0·43) 
 
 
 
0·23 
Alcohol (amount per week) 
Nil 
<1L 
>1L 
 
155 
48 
24 
 
0·45 (0·40-0·50) 
0·44 (0·36-0·54) 
0·41 (0·31-0·55) 
 
 
 
0·72 
 
126 
42 
49 
 
0·35 (0·30-0·40) 
0·36 (0·28-0·47) 
0·37 (0·29-0·47) 
 
 
 
0·87 
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Body mass index (kg/m
2
) 
<25 
25-29·9 
>30 
 
82 
69 
76 
 
0·41 (0·36-0·49) 
0·49 (0·41-0·57) 
0·45 (0·38-0·52) 
 
 
 
0·44 
 
55 
46 
116 
 
0·33 (0·26-0·41) 
0·38 (0·30-0·48) 
0·36 (0·31-0·42) 
 
 
 
0·59 
Co-morbid condition 
No 
Yes 
 
144 
83 
 
0·44 (0·38-0·48) 
0·46 (0·41-0·55) 
 
 
0·73 
 
119 
98 
 
0·39 (0·34-0·46) 
0·32 (0·26-0·38) 
 
 
0·08 
TB status 
No history 
Current/past 
 
73 
154 
 
0·45 (0·38-0·53) 
0·44 (0·40-0·50) 
 
0·93 
 
191 
26 
 
0·36 (0·32-0·40) 
0·34 (0·25-0·48) 
 
0·80 
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Chapter 6 
Frailty in HIV-infected individuals in  
South Africa 
 
 
 
Participants undergoing evaluation of frailty status; participant interview (top), measuring walking time (lower 
left), assessing grip strength (lower right) 
 
Research paper assessing prevalence and predictors of 
frailty in HIV-infected individuals  
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CLINICAL SCIENCE
Frailty in HIV-Infected Adults in South Africa
Sophia Pathai, MSc, MRCOphth,*¶ Clare Gilbert, FRCOphth, MSc, MD,* Helen A. Weiss, DPhil,‡
Colin Cook, FCOphth (SA),§k Robin Wood, MMed, FCP,¶ Linda-Gail Bekker, FCP, PhD,¶
and Stephen D. Lawn, FRCP, MD†¶#
Objectives: Some evidence suggests that HIV infection is
associated with premature frailty—a syndrome typically viewed as
being related to ageing. We determined the prevalence and predictors
of frailty in a population of HIV-infected individuals in South Africa.
Design: Case-control study of 504 adults more than the age of
30 years, composed of 248 HIV-infected adults and 256 age- and
gender-matched, frequency-matched HIV-seronegative individuals.
Methods: Frailty was deﬁned by standardized assessment com-
prised of $3 of weight loss, low physical activity, exhaustion, weak
grip strength, and slow walking time. Independent predictors of
frailty were evaluated using multivariable logistic regression.
Results: The mean ages of the HIV-infected and HIV-seronegative
groups were 41.1 6 7.9 years and 42.6 6 9.6 years, respectively.
Of the HIV-infected adults, 87.1% were receiving antiretroviral treat-
ment (median duration, 58 months), their median CD4 count was
468 cells/mL (interquartile range = 325–607 cells/mL) and 84.3% had
undetectable plasma viral load. HIV-infected adults were more likely
to be frail than HIV-seronegative individuals (19.4% vs. 13.3%;
P = 0.07), and this association persisted after adjustment for con-
founding variables [adjusted OR = 2.14; 95% conﬁdence interval
(95% CI): 1.16–3.92, P = 0.01]. Among HIV-infected individuals,
older age was a strong predictor of frailty, especially among women
(women: OR = 2.55 per 10-year age increase; men: OR = 1.29 per
10-year age increase, P-interaction = 0.01). Lower current CD4
count (,500 cells/mL) was also independently associated with frailty
(OR = 2.84; 95% CI: 1.02 –7.92, P = 0.04).
Conclusions: HIV infection is associated with premature devel-
opment of frailty, especially in women. Since higher CD4 counts
were associated with lower risk of frailty, earlier initiation of
antiretroviral treatment may be protective.
Key Words: HIV, AIDS, frailty, premature ageing, South Africa
(J Acquir Immune Deﬁc Syndr 2013;62:43–51)
INTRODUCTION
Major reductions in HIV-associated mortality have
occurred as a result of the global scale-up of highly active
antiretroviral therapy (ART). This is largely due to prevention
of AIDS-related events but is also due to a decrease in non-
AIDS–related events and deaths.1–3 Despite these beneﬁts, evi-
dence is emerging that patients receiving ART are at an
increased risk of age-related non-AIDS morbidity and mortal-
ity compared with HIV-seronegative individuals.4–6 Several of
these conditions are classically associated with the normal age-
ing process but seem to occur at an earlier age in HIV-infected
persons compared with age-matched HIV-seronegative indi-
viduals. It is possible that not only are HIV cohorts ageing
chronologically, but they may also be undergoing accelerated
physiologic and immunologic senescence.
Frailty is a clinical syndrome initially described in geri-
atric populations. It reﬂects a concept of decreased physio-
logic and functional reserve and a subsequent decrease in
adaptation to external or intrinsic stressors. Frailty is charac-
terized by multiple pathologies, low physical activity, and
slow motor performance,7,8 and leads to cognitive and phys-
ical decline manifest as an increased risk of mortality, falls,
and hospitalization. HIV infection has been associated with
premature development of frailty, and it has been speculated
that this may emerge as an important clinical syndrome in
HIV-infected individuals. The prevalence of premature pre-
sentation of frailty in HIV-infected populations is reported to
range between 5% and 20%, depending on the study popula-
tion.9–12 However, limitations of these reports include study-
ing single sex cohorts and differences in frailty criteria. There
is also substantial potential for confounding because of dif-
ferential exposure to potential risk factors between the study
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population and the reference uninfected population (if used),
thereby altering their risk of age-related outcomes.
The epidemiology of HIV and AIDS in sub-Saharan
Africa is changing; extensive ART scale-up has led to reduced
mortality rates and a rapidly expanding cohort of HIV-infected
African patients who are living much longer than they were
previously.13,14 However, it is unclear whether these individ-
uals will also be subject to premature ageing in the longer
term. Estimates from previous studies from Europe and North
America where the epidemiology of HIV differs substantially
from that in sub-Saharan Africa, may not be generalizable to
African HIV cohorts. In this study, we determined the prev-
alence and predictors of frailty in an HIV-infected population
in sub-Saharan Africa.
METHODS
Study Participants
Between March and December 2011, unselected
HIV-infected individuals older than 30 years were enrolled
from a community-based HIV treatment center in Nyanga
district of Cape Town, which has been previously described.15,16
All participants had a conﬁrmed serological diagnosis of HIV
and were either about to commence ART (ART-naive) or were
already on ﬁrst-line ART. Participants who had active opportu-
nistic infections (OIs) were not recruited; however, participants
who had active tuberculosis (TB) (ie, non-symptomatic but still
receiving treatment for TB) were enrolled.
A control group of HIV-uninfected participants was
recruited using frequency matching by gender and 5-year age
categories. HIV-seronegative individuals were enrolled from
participants conﬁrmed to be HIV-negative attending an HIV
prevention trials site (Emavundleni Centre), located within
the same district as the HIV treatment center. These 2 centers
were chosen as individuals attending them were drawn from
the same community and were therefore likely to have similar
sociodemographic characteristics.
The study was approved by the London School of
Hygiene and Tropical Medicine Ethics Committee and the
University of Cape Town Faculty of Health Sciences
Research Ethics Committee and adhered to the tenets of the
Declaration of Helsinki. Written informed consent was
obtained from all participants.
Assessment of Frailty and Data Collection
Physical frailty was deﬁned by the presence of 3 or more
of the 5 criteria: (1) unintentional weight loss (self-report of
weight loss was veriﬁed in 100 (20%) participants by weighing
of the participant at the time of data collection followed by
referral to clinic records. Self-report and clinical records were
congruent in 80 participants), (2) self-reported low physical
activity, (3) self-reported exhaustion, (4) weak grip strength, and
(5) slow walking time (see Appendix, Supplemental Digital
Content, http://links.lww.com/QAI/A358). All of these 5 com-
ponents described in the original phenotype by Fried et al17 were
used to determine the presence of frailty. However, we used the
proxy described by Onen et al10 for the physical activity measure
(for description, see Appendix, Supplemental Digital Content,
http://links.lww.com/QAI/A358). Grip strength of the dominant
hand was measured 3 times using a grip dynamometer (Jamar
Plus+ Digital Hand Dynamometer, Jamar, Sammons Preston,
Rolyan, Bolingbrook, IL). The average of 3 weight measure-
ments was recorded in kilograms (kg) to one decimal point.
Walking time was assessed using the method of Cesari et al.18
The average of 2 trials (in meters per second) was used for
analysis. Participants were excluded from the determination of
grip strength if they had pain or arthritis of the dominant hand
and excluded from the walking test if they had paralysis of an
extremity or side of the body or needed to use a walking aid.
Sociodemographic information and medical history
were obtained via a questionnaire administered in the
participant’s ﬁrst language (Xhosa or English). Sociodemo-
graphic and behavioral variables of interest included educa-
tion, alcohol consumption, smoking history, and income
(salaried income and/or social welfare grant). Clinical infor-
mation was obtained from medical case notes where required.
Comorbidity was deﬁned as the concurrent presence of one or
more chronic diseases or conditions, including cardiovascular
disease, chronic renal failure, airways disease, and malig-
nancy (both AIDS and non-AIDS deﬁning). Cardiovascular
diseases included myocardial infarction and cerebrovascular
disease. Blood pressure (BP) was measured using a digital
sphygmomanometer. Hypertension was deﬁned as a systolic
BP of 140 mm Hg or higher, diastolic BP of 90 mm Hg or
higher, or the combination of self-reported high BP diagnosis
and the use of antihypertensive medications. Height was mea-
sured in meters, weight in kilograms, and body mass index
(BMI) was calculated as weight per height.2 HIV-related con-
ditions were classiﬁed according to the WHO staging system
and were based on historical assessment done at the time of
enrolment into the ART service. ART was deﬁned as the use
of 3 or more antiretroviral drugs, and treatment duration was
recorded in months. Nadir and current CD4 count and HIV
RNA plasma viral load (VL) were available from medical
records, current values being measured within an 8-week
period before frailty assessment. VL suppression was deﬁned
as HIV RNA ,50 copies/mL.
Statistical Analysis
Analyses were conducted on participants with criteria
available for determination of frailty phenotype (3 or more of
the criteria present). Participants were categorized as “frail”
and “non-frail,” using the criteria given above. Comparisons
between categorical groups were performed using x2 tests.
Continuous variables were compared using Student t test if
normally distributed and the Mann–Whitney U test if non-
normally distributed. Variables were log transformed where
appropriate. All P values were 2-tailed and considered signif-
icant if P , 0.05. Univariable logistic regression was per-
formed to estimate odds ratio (OR) and 95% conﬁdence
intervals (CIs) of factors associated with frailty. Multivariable
logistic regression was then used to evaluate independent
factors associated with frailty overall and within the case
and control groups, respectively. HIV-infected individuals
were also analyzed based on their ART status (naive or on
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treatment). All analyses were performed with Stata 11 (Stata
Corp, College Station, TX).
RESULTS
Participant Characteristics
Of the 504 participants, 248 had HIV-infection and
256 were HIV-seronegative individuals. The 2 groups of
participants were similar in terms of age and gender
(Table 1), but HIV-infected individuals tended to have
higher levels of education (87.9% vs. 81.6%, P = 0.05)
and reported lower levels of alcohol use and smoking con-
sumption than HIV-seronegative individuals (P , 0.05).
HIV-infected individuals reported a greater income than
HIV-seronegative individuals (41.6% vs. 32.0% received
more than ZAR1000 a month (approximately USD125),
which was related to a greater proportion of the HIV-
infected group receiving social welfare grants compared
with HIV-seronegative individuals (data not shown).
Although TB in the form of current or past disease was
more common in the HIV group, other comorbidity was
slightly higher in the control group. BMI was lower in
HIV-infected individuals compared with HIV-seronegative
individuals (27.7 6 6.5 vs. 31.3 6 8.8 kg/m2, P , 0.0001).
Among females, HIV-infected individuals reported fewer
pregnancies than HIV-seronegative individuals (P = 0.006).
Clinical characteristics of the HIV-infected individuals
are also reported in Table 1. Overall, 72.9% had a history of
WHO stage 3 or stage 4 deﬁning illness. The current CD4
count among participants receiving ART was 468 cells/mL
[interquartile range (IQR) = 325–607 cells/mL] and 84.3%
had undetectable VL. Median treatment duration on ART
was 58 months (IQR, 34–75 months). About 12.9% of the
HIV-infected group were ART naive and had correspond-
ingly lower CD4 counts and higher VL (Table 1).
Prevalence of Frailty and Association
With HIV
Assessment of frailty was possible in all participants
(n = 504, with 3 participants excluded from the walking test
but still contributing frailty data). Frailty outcomes within
TABLE 1. Characteristics of Study Population
Variable
HIV-Infected
(248), % (n)
HIV-Seronegative
(256), % (n) P
Age (yrs),
mean 6 SD
41.1 6 7.9 42.6 6 9.6 0.07
Age (yrs) by
group
30–39 49.6 (123) 49.1 (118)
40–49 33.1 (82) 32.8 (84) 0.09
50–59 15.3 (38) 14.5 (37)
.60 2.0 (5) 6.7 (17)
Male gender 26.6 (66) 25.0 (64) 0.68
Education
,High school 12.1 (30) 18.4 (47) 0.05
Income
,USD 125/mo 58.4 (145) 68.0 (174) 0.03
Marital status
Single 68.6 (170) 63.7 (163)
Married 25.4 (63) 29.3 (75) 0.68
Divorced 1.6 (4) 2.3 (6)
Widowed 4.4 (11) 4.7 (12)
Housing
Informal 47.2 (117) 40.6 (104) 0.14
Water supply
Shared 74.2 (184) 73.8 (189) 0.93
Alcohol (amount
per week)
Nil 70.5 (172) 54.4 (136)
Up to 1 L/wk 18.4 (45) 22.8 (57) ,0.0001
.1 L/wk 11.1 (27) 22.8 (57)
Duration of
smoking (yrs)
Nil 84.7 (210) 72.3 (185)
5 yrs or less 2.4 (6) 7.4 (19) 0.008
6–15 3.2 (8) 7.0 (18)
16–20 4.4 (11) 6.3 (16)
.20 5.2 (13) 7.0 (18)
Illicit drugs
Ever taken 2.5 (6) 2.4 (6) 0.94
BMI (kg/m2) 27.7 6 6.5 31.3 6 8.8 ,0.0001
Comorbidity
None 64.5 (160) 56.3 (144)
One or more 35.5 (88) 43.7 (112) 0.06
TB status
No history 31.9 (79) 87.9 (225) ,0.0001
Current 4.0 (10) 0.4 (1)
Previous 64.1 (159) 11.7 (30)
Number of
pregnancies
(n = 374)
2 or less 62.1 (113) 47.9 (92)
$3 37.9 (69) 52.1 (100) 0.006
HIV characteristics (n = 248) Median (IQR) or % (n)
WHO stage
1/2 27.1 (67)
3/4 72.3 (181)
ART naive 12.9 (32)
TABLE 1. (Continued ) Characteristics of Study Population
HIV characteristics (n = 248) Median (IQR) or % (n)
CD4 count in ART naive group
(n = 32)
182 (84–202)
Log10 VL in ART naive group (n = 21) 4.88 (4.21–5.18)
Current CD4 count in ART group 468 (325–607)
Nadir CD4 count in ART group 128 (76–171)
Percentage with undetectable VL in
ART group
84.3 (182)
Peak Log10 VL in ART group 4.56 (3.84–4.98)
Duration of ART, months 58 (34–75)
ART regimen
Containing AZT/3TC 59.7 (129)
Other 40.3 (87)
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the study population are reported in Table 2. The prevalence
of frailty was greater among HIV-infected individuals than
HIV-seronegative individuals (19.4%, 95% conﬁdence inter-
val [CI]: 14.4% to 24.3% vs. 13.3%, 95% CI: 9.1% to
17.5%; P = 0.07). Levels of “prefrailty” (ie, scoring 1 or
2 of the frailty criteria) were similar between the 2 groups.
Of the frailty indicators, weight loss and slow walking time
were more common in the HIV-infected group, however,
these differences did not reach statistical signiﬁcance.
Multivariable analysis adjusting for baseline charac-
teristics and a priori confounders showed that HIV infec-
tion was independently associated with frailty ( adjusted
OR = 2.14; 95% CI: 1.16 to 3.92; Table 3). Age was also
a strong predictor, and this association was stronger in
females (P for interaction = 0.03). A higher level of edu-
cation reduced the odds of frailty (OR = 0.44; 95% CI: 0.21
to 0.90). Low BMI was also strongly associated with
frailty. TB was not included in the model because of its
high correlation with HIV status. When TB was analyzed as
a potential binary outcome of interest (no history vs. cur-
rent/past) the association with frailty was not as strong as
that for HIV (OR = 1.73; 95% CI: 0.94 to 3.08) and did not
reach statistical signiﬁcance.
Predictors of Frailty in the HIV-Infected Group
Among the 216 HIV-infected individuals on ART, the
prevalence of frailty was 18.0% (95% CI: 13.2% to 23.8%).
In univariable analyses, older age and lower socioeconomic
status (including education level) and alcohol consumption
were associated with higher odds of frailty.
In the multivariable model, there was evidence of an
interaction between gender and age with a strong association
between increasing age and frailty within females but not
males (P for interaction = 0.001). Low BMI was also a strong
predictor of frailty (P trend = 0.01). Among the HIV-related
covariates, a current CD4 count less than 500 cells/mL was
associated with increased risk of frailty (OR = 2.84; 95% CI:
1.02 to 7.92). No associations were found with HIV RNA
levels (current or nadir), duration of treatment, or ART
regimen. Socioeconomic variables were not associated with
frailty in this model. In a multivariable analysis restricted to
females on ART, a similar association was seen with current
CD4 count. Age continued to act as a strong predictor and
low BMI. A history of 3 or more pregnancies was also asso-
ciated with frailty in this group [OR = 3.42 (1.03–11.36),
P = 0.04] (data not shown).
TABLE 2. Frailty-Related Outcomes Within Study Population
Frailty Outcome
HIV-Infected
(248), % (n)
HIV-Seronegative
(256), % (n) P
Frailty levels
Robust (0) 31.8 (78) 35.9 (92)
Prefrail (1–2) 49.2 (122) 50.8 (130) 0.16
Frail (3+) 19.4 (48) 13.3 (34)
Overall frailty
(3+ from 5)
No 80.7 (200) 86.7 (222) 0.065
Yes 19.4 (48) 13.3 (34)
Contribution to frailty
criteria
Frailty + HIV+
(48)
Frailty+ HIV2
(34)
Exhaustion 95.8 (46) 94.1 (32) 0.72
Low physical activity 83.3 (40) 91.1 (31) 0.31
Weight loss 64.6 (31) 47.1 (16) 0.11
Weak grip strength 43.8 (21) 58.8 (20) 0.18
Slow walking time 58.3 (28) 47.1 (16) 0.31
TABLE 3. Multivariable Logistic Regression Model to Identify
Predictors of Frailty in All Study Participants (n = 504)*
Variable OR P
HIV 2.14 (1.16–3.92) 0.01
Sex
Male 1
Female 1.29 (0.41–4.08) 0.03 for interaction
Male: (per 10 yr increase) 0.94 (0.41–2.15)
Female (per10 yr increase) 2.55 (1.75–3.71)
Alcohol (amount per week)
Nil 1
,500 mL 0.75 (0.22–2.60) 0.10
500 mL–1 L 0.57 (0.24–1.39)
.1 L 0.24 (0.08–0.77)
Education
,High school 1
High school/college 0.44 (0.21–0.90) 0.02
BMI (kg/m2)
,20 1
20–24.9 0.22 (0.08–0.61)
25–29.9 0.21 (0.08–0.60) 0.02
.30 0.20 (0.07–0.58)
BP
None 1
Hypertensive 0.83 (0.45–1.53) 0.54
Comorbid condition
No 1
Yes 3.20 (0.76–13.50) 0.11
Duration of smoking (yrs)
Nil 1
5 yrs or less 0.78 (0.15–4.04)
6—15 2.70 (0.63–11.52) 0.37
16—20 2.48 (0.79–7.77)
.20 0.76 (0.16–3.59)
Income/month (ZAR)
,USD 125/mo 1
.USD125/mo 1.05 (0.58–1.90) 0.87
Occupation
Unemployed/grant 1
Employed 0.65 (0.35–1.20) 0.17
Housing
Formal 1
Informal 0.70 (0.40–1.24) 0.23
*Adjusted for all variables displayed within table.
USD, US dollars.
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TABLE 4. HIV Predictors of Frailty in HAART HIV+ Group (n = 216)*
Unadjusted OR P Fully Adjusted OR P
Variable
Sex
Male 1 Males 1
Female 1.65 (0.68–4.00) 0.27 Female 0.66 (0.13–3.22)
Age, yrs Male (per 10 yr increase) 0.37 (0.08–1.77) 0.01 (for interaction)
30–39 1 Female (per 10 yr increase) 2.50 (1.35–4.58)
40–40 1.10 (0.45–2.68)
50–59 5.90 (2.40–14.48) 0.0008
.60 2.36 (0.23–24.40)
HIV-related characteristics
WHO clinical stage
1/2 1 1
3/4 1.10 (0.47–2.57) 0.83 1.19 (0.26–5.38) 0.83
Duration of ART, mo
0–36 1 1
36–72 0.42 (0.18–0.98) 0.49 (0.16–1.49)
.72 0.80 (0.34–1.85) 0.11 1.03 (0.31–3.41) 0.30
Current CD4 count, cells/mL
,500 1.77 (0.84–3.72) 0.12 2.84 (1.02–7.92)
.500 1 1 0.04
Nadir CD4 count, cells/mL
,200 0.62 (0.23–1.69) 0.37 0.42 (0.11–1.56)
.201 1 1 0.19
Current Log10 VL
,10,000 copies 1 1
.10,000 copies 0.82 (0.17–3.83) 0.80 0.41 (0.05–3.63) 0.40
Peak Log10 VL
,10,000 copies 1 1
.10,000 copies 1.39 (0.62–3.12) 0.42 2.38 (0.82–6.92) 0.11
ART Regimen
Containing AZT/3TC 1 1
Other 1.03 (0.51–2.10) 0.91 0.60 (0.24–1.51) 0.28
TB status
No history 1 1
Current infection 1.48 (0.15–15.66) 0.93 0.65 (0.02–17.61) 0.96
Previous history 0.96 (0.44–2.09) 0.89 (0.22–3.54)
Demographic characteristics
BMI (kg/m2)
,20 1 1
20–24.9 0.60 (0.18–2.03) 0.29 (0.06–1.36)
25–29.9 0.53 (0.16–1.80) 0.48 0.18 (0.03–0.99) 0.01
.30 0.38 (0.11–1.31) 0.09 (0.01–0.55) p-trend
Comorbid condition (non-HIV related)
No 1 1
Yes 1.01 (0.48–2/15) 0.97 0.67 (0.25–1.77) 0.42
Income per month (US dollars)
,USD 125/mo 1 1
.USD125/mo 1.26 (0.63–2.53) 0.51 1.34 (0.57–3.16) 0.48
Occupation
Unemployed/welfare grant 1 1
Employed 0.50 (0.23–1.06) 0.07 0.54 (0.21–1.36) 0.23
Education
,High school 1 1
(continued on next page)
J Acquir Immune Defic Syndr  Volume 62, Number 1, January 1, 2013 HIV-Related Frailty in Africa
 2012 Lippincott Williams & Wilkins www.jaids.com | 47
Sophia Pathai PhD Thesis Page 163
In the ART naive group (n = 32), 28.1% (95% CI:
13.7% to 46.7%; n = 9) were frail. The only factor associated
with frailty in a multivariable analysis was WHO clinical
stage 3 or 4. Age and gender and other HIV-related covariates
were not associated.
To assess the possibility of current diagnoses of TB
(the most common OI in this setting)15 causing false misclas-
siﬁcation of frailty, we constructed a separate multivariable
model excluding such patients (n = 10). In this model, HIV
still remained strongly predictive of frailty (OR = 2.08; 95%
CI: 1.12 to 3.86, P = 0.02). In a further model of HIV-infected
participants that similarly excluded those with a current
diagnosis of TB, CD4 count remained a strong predictor of
frailty (OR = 2.89; 95% CI: 1.02 to 7.92, P = 0.04) (Table 4).
Predictors of Frailty in the Control Group
Among HIV-seronegative individuals, frailty was inde-
pendently associated with older age, female gender, and
smoking (Table 5). There was also some evidence that TB
was associated with frailty. In view of the strong association
of female gender with frailty, we performed subanalyses
restricted to females. In adjusted analyses, increasing age
was still a strong predictor of frailty.
DISCUSSION
This study provides clear evidence that HIV infection is
strongly associated with a 2-fold risk of premature frailty in
this African population. Premature frailty was most prevalent
in women who comprise the majority of the HIV-infected
population in sub-Saharan Africa. These ﬁndings have
potentially important implications for long-term morbidity
among the millions of patients receiving ART long-term in
Africa and may have an important bearing on the optimum
timing of ART initiation.
Our HIV-related frailty prevalence of 19.4% is higher
than estimates from other regions. A prevalence of 9% was
reported from a clinic population in the United States (mean
age of 42 years).10 The Women’s Interagency HIV Study
(a prospective cohort in 5 US cities) found a prevalence of
12% in HIV-infected women with clinical AIDS (median age
of 41 years).11 In the Multicenter AIDS Cohort Study
(a longitudinal study of men who have sex with men), a frailty
prevalence of 5%–14% depending on age and duration of
HIV infection was reported from 1994–2005 data9,12 and
8% in 2009–2010 among men aged 40–49 years.19 In the
SUN study (a US observational cohort of HIV-infected
adults, median age of 47 years), 5% of participants were
frail.20 The variation in estimates is likely to be attributable
to differences in study design and clinical demographics
of patients recruited (eg, ART status and degree of
immunodeﬁciency).
In agreement with previous studies of participants on
ART, current CD4 count was a strong independent predictor
of frailty.9,11,12,19 However, we did not ﬁnd an association
with duration of ART or nadir CD4 cell count. These ﬁndings
are entirely consistent with previous analyses of factors asso-
ciated with the risk of incident TB and of mortality in this
cohort.21,22 Thus, although these 3 variables are interrelated,23
it seems that current CD4 count best captures current
“well-being” in this ART cohort. Thus, the best way to
prevent frailty may be to maintain high CD4 counts through
early initiation of ART. Potential reductions in non-AIDS–
related morbidity and mortality from earlier initiation of
ART are currently under investigation in the Strategic Timing
of AntiRetroviral Treatment study24 and prevention of frailty
may be another important beneﬁt of such a strategy.
It is possible that frailty status could be misclassiﬁed in
some HIV-infected participants because of recent or current
OIs. However, we think this unlikely for several reasons.
Participants with acute symptomatic OIs were not eligible for
enrolment in the study and a large majority of patients were
clinically stable on long-term ART (median 58 months). They
had a median CD4 count of 468 cells/ mL and so were at low
risk of current comorbidity, and previous WHO stage 3 and 4
deﬁning illnesses were remote. A small number of partici-
pants had current diagnoses of TB for which continuation
TABLE 4. (Continued ) HIV Predictors of Frailty in HAART HIV+ Group (n = 216)*
Unadjusted OR P Fully Adjusted OR P
High school/college 0.33 (0.13–0.82) 0.02 0.76 (0.21–2.82) 0.69
Housing
Formal 1 1
Informal 0.91 (0.45–1.82) 0.78 0.52 (0.23–1.28) 0.16
Alcohol (amount per week)
Nil 1 1
,500 mL 0.88 (0.18–4.32) 1.40 (0.15–12.18)
500 Ml–1 L 0.26 (0.06–1.15) 0.03 0.17 (0.03–1.10) 0.07
.1L 0.15 (0.02–1.17) 0.08 (0.01–0.88) p-trend
Duration of smoking
Nil 1 1
,10 yrs 0.47 (0.06–3.86) 1.20 (0.09–15.92)
.10 yrs 0.67 (0.19–2.40) 0.62 0.78 (0.13–4.67) 0.95
*Fully adjusted model adjusted for all variables displayed within table.
USD, US dollars.
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phase treatment was being received. Estimates of HIV as a
predictor of frailty did not greatly change when these partic-
ipants were excluded from analyses, suggesting that misclas-
siﬁcation was minimal. Thus, we believe that the observed
association of frailty with the HIV-infected group is likely to
be related to HIV infection itself rather than as a consequence
of symptoms related to current OIs.
Female gender was an important predictor of frailty in
both study populations. In the general population, frailty is
more common among females.25,26 Men may be protected by
greater muscle mass and higher testosterone levels27,29 reﬂect-
ing the greater biological capital they achieve before age-
related decline. Two US-based studies did not ﬁnd an asso-
ciation of female gender with frailty,10,20 possibly due to the
gender composition (predominantly male) of the study pop-
ulations or reduced statistical power to detect an interaction.
The interaction of gender and age in the HIV-infected group
in our study is a novel ﬁnding. This interaction may be related
TABLE 5. Predictors of Frailty in Uninfected Control Group (n = 256)*
Variable Unadjusted OR P Adjusted OR P
Age, yrs
30–39 1 1
40–49 6.39 (1.74–23.41) 8.59 (2.03–36.32)
50–59 14.20 (3.65–55.12) ,0.0001 8.71 (1.75–43.31) 0.0006
.60 43.13 (9.71–191.40) 24.10 (3.19–182.20) p-trend
Sex
Male 1 1
Female 3.95 (1.15–13.27) 0.03 11.03 (1.68–72.37) 0.01
Income per month (US dollars)
,USD 125/mo 1 1
.USD 125/mo 1.82 (0.88–3.81) 0.10 0.92 (0.28–1.93) 0.88
Occupation
Unemployed/welfare grant 1 1
Employed 0.45 (0.20–1.04) 0.06 0.64 (0.21–1.93) 0.44
Housing
Formal 1 1
Informal 0.48 (0.21–1.08) 0.09 0.45 (0.16–1.25) 0.13
Duration of smoking
Nil 1 1
,10 yrs 0.20 (0.02–1.53) 0.05 0.67 (0.13–3.52) 0.03
.10 yrs 1.71 (0.79–4.14) 6.01 (1.51–23.85)
Alcohol (amount per week)
Nil 1 1
,500 mL 0.98 (0.20–4.78) 1.04 (0.16–6.86)
500 mL–1 L 0.61 (0.22–1.72) 0.12 1.31 (0.34–5.06) 0.92
.1 L 0.27 (0.08–0.95) 0.67 (0.13–3.53)
Education
,High school 1 1
High school/college 0.34 (0.16–0.77) 0.008 0.47 (0.17–1.32) 0.15
BMI (kg/m2)
,20 1 1
20–24.9 0.35 (0.15–0.82) 0.07 (0.01–1.11) 0.64
25–29.9 0.42 (0.19–0.94) 0.10 0.28 (0.03–2.39) p-trend
.30 0.43 (0.21–0.90) 0.40 (0.05–3.11)
TB status
No history 1 1
Current/previous infection 1.68 (0.63–4.48) 0.29 3.65 (0.96–13.81) 0.06
Hypertension
Normotensive 1 1
Hypertensive 2.79 (1.31–5.93) 0.008 1.09 (0.38–3.09) 0.87
Comorbid condition
No 1 1
Yes 4.8 (1.28–18.00) 0.02 3.04 (0.47–19.86) 0.24
*Fully adjusted model adjusted for all variables displayed within table.
USD, US dollars.
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to effects of decreased circulating estrogens with increasing
age and subsequent inﬂammation. In physiological ageing,
low levels of estrogens may be associated with increased
levels of proinﬂammatory cytokines that have been linked
to sarcopenia.28 This effect may be exacerbated or modulated
by HIV infection or ART. In resource-constrained settings, it
is possible that women are nutritionally deﬁcient compared
with men, exacerbated by multiple pregnancies.
In sub-Saharan Africa, the proportion of elderly people
infected with HIV is increasing.13 In 2007, approximately
3 million people aged 50 years or older were living with HIV
in sub-Saharan Africa, comprising 14% of the adult HIV pop-
ulation.30 With 5.1 million people in sub-Saharan Africa hav-
ing started ART by the end of 2010, the number of people aged
50 years or older living with HIV will inevitably continue to
increase.31 These evolving demographicsmay necessitate a shift
from treatment of primarily OIs toward management of non-
AIDS–related conditions. Furthermore, if premature ageing is
scientiﬁcally validated, HIV-infected patients.50 years of age
or older may come to be considered “old.”32 Chronic age-
related disease within African HIV-infected populations is
likely to place a signiﬁcant burden on health care budgets
and human resources. The high prevalence of HIV-related
frailty also has additional economic implications. Those
who are frail are less likely to be economically productive
and more likely to need assistance from families and welfare
grants. Interventions to improve frailty may be simple such as
progressive resistance exercises. This intervention improved
the strength of HIV-infected adults in Brazil.33 However,
given the multifactorial aetiology of frailty, other systemic
mechanisms may also require intervention.
A key strength of this study is the inclusion of an age/
gender-matched control group with a similar sociodemo-
graphic proﬁle to the HIV-infected individuals. The hypoth-
esis of premature ageing in HIV has received criticism
primarily due to limitations in characterization of participants,
in particular the possibility of differential exposure to poten-
tial risk factors between HIV-infected and HIV-uninfected
populations.32,34,35 For example, in the US Veterans Aging
Cohort, HIV-infected veterans were more likely to have
a history of substance misuse compared with age- and sex-
matched uninfected veterans.36 The differential exposures to
risk factors between HIV-infected and HIV-uninfected pop-
ulations and residual confounding could result in an apparent
increased risk of age-related outcomes. By recruiting from
the same community, we aimed to reduce the likelihood of
differential risk exposure. Compared with HIV-seronegative
individuals, the HIV-infected group in this study tended to be
more afﬂuent (likely reﬂecting receipt of welfare grants) and
also more educated as has been observed elsewhere in South
Africa.37 HIV remained strongly associated with frailty even
after adjustment for socioeconomic factors.
This study has some limitations. We studied a frailty-
like phenotype rather than the previously deﬁned and
validated frailty phenotype.17 However, this modiﬁed pheno-
type is comparable to phenotypes used in other studies of
HIV-related frailty.9,10,12 The frailty phenotype within the
context of HIV has not been fully established or validated
to date. The main limitation of the frailty criteria relates to
their subjective nature. Grip strength and walking time mea-
sured at the time of data collection may not necessarily rep-
resent the participant’s overall ability, and a longitudinal
evaluation of these parameters would be optimal. Similarly,
reports of exhaustion relied on self-report. The original phe-
notype used a weighted score of kilocalories expended to
assess low physical activity. This may be difﬁcult to ascertain
in resource-limited settings, and the approximate adopted by
Onen et al10 may be more useful in these environments.
Although we relied on self-report of weight loss, validation
of a proportion of the reports was favorable and no differen-
tial misclassiﬁcation between groups was observed.
The study design means that a causal relationship
between HIV and frailty cannot be concluded, nor can
a temporal relationship be established. We are unable to infer
whether HIV infection or ART is primarily responsible for the
strong association with frailty, partly due to a low proportion
of ART-naive participants (12.9%). Often such patients are
more acutely ill and may be less willing or able to take part in
research studies. In the Multicenter AIDS Cohort Study
cohort, the presence of frailty before ART initiation was an
independent predictor of the development of AIDS or death
despite ART.38 Thus, frailty status may assist in establishing
risk of morbidity and mortality. In the present study, we were
unable to assess whether a diagnosis of frailty was related to
outcomes typically associated with the syndrome in older
adults, such as falls, hospitalization, and death. To fully
assess if individuals in sub-Saharan Africa meeting the deﬁ-
nition of frailty are at increased risk of these outcomes will
require longitudinal studies.
In conclusion, HIV is an important predictor of frailty in
this African population. Sub-Saharan Africa is undergoing
signiﬁcant HIV-related demographic changes, leading to an
ageing HIV-infected population. Chronic age-related condi-
tions will impact this population and HIV-related premature
ageing will likely compound this disease burden. Early
initiation of ART at higher CD4 counts may maintain CD4
counts at higher levels and protect against development of the
frailty phenotype. As access to ART expands, and patients
continue to age and live with HIV infection, longitudinal stud-
ies are needed to assess the evolution of frailty within HIV-
infected populations and its impact on morbidity and mortality.
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Estimator of Vascular Risk in HIV?
Sophia Pathai1,2*, Helen A. Weiss3, Stephen D. Lawn2,4, Tunde Peto5, Leris M. D’Costa1, Colin Cook6,
Tien Y. Wong7, Clare E. Gilbert1*
1 International Centre for Eye Health, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London,
United Kingdom, 2Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town,
South Africa, 3MRC Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United
Kingdom, 4Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom, 5NIHR
Biomedical Research Centre for Ophthalmology, at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom,
6Department of Ophthalmology, Faculty of Health Sciences, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa, 7 Singapore Eye Research
Institute, National University of Singapore, Singapore, Singapore
Abstract
Objectives: HIV infection is associated with an increased risk of age-related morbidity mediated by immune dysfunction,
atherosclerosis and inflammation. Changes in retinal vessel calibre may reflect cumulative structural damage arising from
these mechanisms. The relationship of retinal vessel calibre with clinical and demographic characteristics was investigated
in a population of HIV-infected individuals in South Africa.
Methods: Case-control study of 491 adults $30 years, composed of 242 HIV-infected adults and 249 age- and gender-
matched HIV-negative controls. Retinal vessel calibre was measured using computer-assisted techniques to determine
mean arteriolar and venular diameters of each eye.
Results: The median age was 40 years (IQR: 35–48 years). Among HIV-infected adults, 87.1% were receiving highly active
antiretroviral therapy (HAART) (median duration, 58 months), their median CD4 count was 468 cells/mL, and 84.3% had
undetectable plasma viral load. Unadjusted mean retinal arteriolar diameters were 163.67617.69 mm in cases and
161.34617.38 mm in controls (p = 0.15). Unadjusted mean venular diameters were 267.77618.21 mm in cases and
270.81618.98 mm in controls (p = 0.07). Age modified the effect of retinal arteriolar and venular diameters in relation to HIV
status, with a tendency towards narrower retinal diameters in HIV cases but not in controls. Among cases, retinal arteriolar
diameters narrowed with increasing duration of HAART, independently of age (167.83 mm,3 years of HAART vs. 158.89 mm
.6 years, p-trend = 0.02), and with a HIV viral load .10,000 copies/mL while on HAART (p = 0.05). HIV-related venular
changes were not detected.
Conclusions: Narrowing of retinal arteriolar diameters is associated with HAART duration and viral load, and may reflect
heightened inflammatory and pro-atherogenic states of the systemic vasculature. Measurement of retinal vascular calibre
could be an innovative non-invasive method of estimating vascular risk in HIV-infected individuals.
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Introduction
HIV infection and highly active antiretroviral therapy
(HAART) exacerbate a range of systemic age-related conditions
such that HIV-infected patients are at increased risk of age-related
non-AIDS-related morbidity and mortality compared with HIV-
uninfected persons [1–3]. The emerging scenario is that of HIV
population cohorts who are aging chronologically, but also likely
to be undergoing accelerated physiological and immunological
senescence. Mechanisms underlying accelerated aging include
increased inflammation and immune dysfunction. The micro-
vascular circulation may reflect cumulative structural damage
arising from these processes. However, current methods to
investigate the micro-circulation are invasive and require specialist
expertise.
The retina represents a unique location where the micro-
vasculature can be directly and non-invasively visualised. Validat-
ed and objective quantitative measurement of retinal vessel
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diameters is possible using semi-automated software applied to
digitized retinal photographs [4]. This technique has been used in
several population-based studies, and is established as a valid and
efficient biomarker of systemic vascular disease [5–8]. Retinal
vascular calibre is considered a structural marker of vascular
pathology reflecting the interplay of systemic, environmental and
genetic factors [9]. For example, changes in arteriolar calibre are
strongly associated with chronological age, hypertension and
cardiovascular disease, whereas venular calibre changes represent
chronological age as well as inflammatory and cerebrovascular
diseases. [10,11]. Seemingly small reductions in retinal arteriolar
calibre are associated with clinically relevant changes in blood
pressure, e.g., a 10-mmHg increase in systolic BP is associated with
a 1.1 mm reduction in arteriolar calibre [12]. A 20 mm increase in
retinal venular calibre is associated with a coronary heart disease
hazard ratio of 1.16 (95% CI: 1.06–1.26) in women.
There is limited information regarding relationships between
retinal vessel calibre and HIV status, particularly in the context of
premature aging and risk of age-related co-morbidities such as
cardiovascular disease. Furthermore, data are lacking within sub-
Saharan Africa, a region where the population of older HIV-
infected persons is rapidly growing as individuals initiate HAART
at increasingly early stages of the disease [13]. Assessment of
retinal vessel calibre can provide a non-invasive and representative
model to objectively assess changes in the micro-circulation in
HIV infection and with HAART.
The objective of this study was to investigate the relationship of
retinal vessel calibre with clinical and demographic characteristics
in a cohort of HIV-infected individuals in South Africa in
comparison with a matched population of uninfected individuals.
We hypothesized that retinal vascular calibre would be altered in
patients with HIV, who are known to have both elevated
cardiovascular risk and chronic, systemic inflammation related to
HIV-related accelerated aging [14,15]. Cases and controls were
recruited from neighbouring townships in Cape Town. The
hypothesis of accelerated aging in HIV has received criticism
primarily due to limitations in characterization of participants, and
the possibility of differential exposure to potential risk factors (e.g.
smoking, substance abuse) between HIV-infected and uninfected
populations [16]. By recruiting from the same community, we
aimed to reduce the likelihood of differential risk exposure in line
with the recommendation for careful study design when investi-
gating premature aging in HIV [17].
Methods
Ethics Statement
The study was approved by the London School of Hygiene and
Tropical Medicine Ethics Committee and the University of Cape
Town Faculty of Health Sciences Ethics Committee, and adhered
to the tenets of the Declaration of Helsinki. Written informed
consent was obtained from all participants.
Study Participants
HIV-infected participants (cases) aged $30 years were enrolled
from a community-based HIV treatment centre in Nyanga district
of Cape Town [18,19]. All participants had a confirmed
serological diagnosis of HIV and were either about to commence
HAART (HAART-naı¨ve), or were already on first-line HAART.
A control group of HIV-uninfected participants was recruited
using frequency-matching by gender and 5-year age categories.
Controls were enrolled from participants confirmed to be HIV-
negative attending an HIV prevention trials site (Emavundleni
Centre), located within the same district as the HIV treatment
centre. These two centres were chosen as individuals attending
them were drawn from the same community and were therefore
likely to have similar socio-demographic characteristics.
Data Collection
Socio-demographic information and medical history were
obtained by questioning participants in their first language (Xhosa
or English). Clinical information was obtained from medical case
notes where required. Co-morbidity was defined as the concurrent
presence of one or more chronic diseases or conditions including
cardiovascular disease, chronic renal failure, airways disease and
malignancy (both AIDS and non-AIDS defining). Cardiovascular
diseases included myocardial infarction and cerebrovascular
disease. Blood pressure (BP) was measured with a digital
sphygmomanometer with a cuff of appropriate size. Mean arterial
blood pressure (MABP) was defined as two-thirds of the diastolic
plus one-third of the systolic BP. Hypertension was defined as a
systolic BP of 140mmHg or higher, diastolic BP of 90mmHg or
higher, or the combination of self-reported high BP diagnosis and
the use of anti-hypertensive medications [20]. Body mass index
(BMI) was defined as weight (in kilograms)/height2. HIV infection
characteristics including duration of HAART, type of HAART
regimen, nadir and current CD4 count and viral load (VL) were
available from the clinic database.
Retinal Vessel Measurement
All participants had stereoscopic 30 degree colour retinal
photographs taken of both eyes under pharmacological pupil
dilation with a fundus camera (model CF-2; Canon Inc., Tokyo,
Japan). Images were centred on the optic disc. Vessel calibre
indices were determined in a semi-automated manner using the
IVAN computer program (Singapore Eye Research Institute,
Singapore) using a standardized protocol described previously [4].
In summary, the 6 largest arterioles and venules in a ring-shaped
area located between 0.5 and 1.0 disc diameter from the optic disc
margin were identified (Figure 1). Computer software measured
the calibre of these individual vessels, then combined them into 2
summary variables for the eye: the projected calibre size of the
central retinal artery (central retinal artery equivalent [CRAE]),
and the projected calibre size of the central retinal vein (central
retinal vein equivalent [CRVE]), using formulas derived by Parr
and Spears [21,22] and Hubbard [23], with revision by Knudtson
[24]. A retinal photograph was considered ungradable if eyes had
,4 acceptable measurements of either vessel type. The inter-
grader and intra-grader grading reliabilities were assessed using a
random subsample of 100 photographs reviewed four weeks after
the initial grading. The intra- and inter-grader intraclass
correlation coefficients ranged from 0.71 to 0.93.
Data Analysis and Statistical Methods
If gradable images were available for both eyes, one eye was
randomly selected for vessel calibre assessment as good correlation
between eyes has been demonstrated using this software, and is
considered sufficient for assessing relationships to systemic health
status [25]. If there was only one gradable image, this one was
used, and if neither eye had a gradable image the participant was
excluded. Retinal vessel data (CRAE and CRVE) were analyzed
as continuous variables. Univariable linear regression was
performed to compare mean retinal arteriolar and venular
diameters respectively by gender and HIV status (no; yes).
Multivariable linear regression models were used to examine the
relationships of retinal vessel diameters as the dependent variable
with HIV status and explanatory variables (age group (30–39; 40–
49; .50 years), gender, mean arterial blood pressure; BMI,
Retinal Vessel Calibre in HIV
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e51405Sophia Pathai PhD Thesis Page 171
smoking and diastolic blood pressure). Models included an
interaction term between HIV and each explanatory variable.
Marginal adjusted means for retinal vessel diameters were
estimated at the mean value of covariates in the model. The
Wald test was used to assess statistical significance of the
interaction of HIV status with each explanatory variable on
retinal vessel diameter. Retinal arteriolar and venular calibre are
highly correlated, and to account for potential confounding we
adjusted for the fellow vessel in multivariable analyses (i.e.
adjustment for arteriolar calibre in analyses of venular calibre
and vice versa) [26]. All analyses were performed with Stata 12
(Stata Corp, USA).
Results
Participant Characteristics
491 participants were evaluated, of whom 242 had HIV-
infection, and 249 were uninfected controls. The mean age of the
HIV-infected population was 41.260.5 years, and 42.560.6 years
in the uninfected group (p = 0.10). Cases had lower BMI, were less
likely to be smokers, and more likely to have current or previous
TB than controls (Table 1). Overall, 72.7% of cases had a history
of WHO stage 3 or stage 4 defining illness. The current CD4
count among participants receiving HAART was 468 cells/mL
(interquartile range [IQR], 325–607 cells/mL) and 84.0% had
undetectable VL. Median treatment duration on HAART was 58
months (IQR: 34–75 months). 12.0% were HAART naı¨ve, and
had correspondingly lower CD4 counts and higher VL.
Retinal Photography and Vessel Grading
All participants underwent retinal photography. Photographs
were ungradable for retinal vessel diameters in 12 individuals
(2.4%), who were older than those with gradable photographs
(p = 0.001) but otherwise had similar characteristics (p.0.05 for all
characteristics; data not shown). The proportion of cases and
controls with ungradable photos was similar (2.48% vs. 2.41%;
p = 0.96).
Overall Retinal Vessel Measurements
Measurements are summarised in Table 2. The following
comparisons were not statistically different: arteriole diameters
between cases and controls, overall (p = 0.15) nor by gender
(p = 0.68 for males, p = 0.14 for females). However, venules were
narrower in cases than controls although this did not reach
statistical significance (p = 0.07). Male cases had significantly
narrower venules (265.72618.04 mm) than male controls
(274.55621.66 mm; p = 0.02) but this association was not seen in
females (p = 0.55).
Retinal Vessel Calibre and Association with HIV and Age
In unadjusted analyses, there was a significant trend of narrower
arteriolar diameters (P-trend = 0.002), and venular diameters (P-
trend = 0.001) with increasing age in the HIV-infected group, also
evident when stratified by gender (data not shown). This trend was
not seen consistently in the control group. Table 3 reports adjusted
mean vascular diameters by HIV status, stratified by other
covariates. In relation to mean arteriolar diameters, age and
hypertension status modified the association in relation to HIV
status (P values for interaction 0.01). Mean arteriolar diameters
tended to decrease with age among HIV-infected cases, and to
increase among controls. Among controls, those with hypertension
had wider arteriolar diameters than those without hypertension
(167.97 vs. 158.28 mm; p = 0.002), whereas among HIV cases
there was little association with hypertension (164.82 vs.
163.53 mm; p = 0.69). Mean venular diameter also decreased with
age among HIV cases, but there was no association among
controls (p-interaction = 0.07). In addition, venular diameter
tended to be greater among males than females, and smokers
than non-smokers among controls, but little difference was seen
among cases.
Retinal Vessel Calibre in HIV-infected Participants on
HAART
We investigated the associations between mean arteriolar and
venular diameter and clinical/demographic factors in participants
Figure 1. Retinal vessel grading assessment. Right: fundus with automated measurements (red = arterioles, blue = venules). Left: venular
diameters output.
doi:10.1371/journal.pone.0051405.g001
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on HAART (Table 4). There was a trend of increasing age being
associated with narrowing of retinal arterioles (P-trend = 0.08). A
longer duration of HAART was associated with narrowing of
arterioles. Mean arteriolar diameter ranged from 167.83 mm in
Table 1. Demographic characteristics of study population.
Variable Cases (242) % (n) Controls (249) % (n) P-value
Age (mean6SD) 41.260.5 42.560.6 0.10
Age (years) by group
30–39 49.2 (119) 47.0 (117) 0.54
40–49 33.5 (81) 31.7 (79)
.50 17.3 (42) 21.3 (53)
Male gender 25.6 (62) 24.1 (60) 0.70
Hypertension status
Hypertensive 27.3 (66) 29.3 (73) 0.62
Mean arterial blood pressure 94.37614.64 95.53613.90 0.37
BMI (kg/m2) 27.866.5 31.568.8 ,0.0001
Co-morbidity
None 71.1 (172) 69.5 (173)
One or more 28.9 (70) 30.5 (76) 0.70
Smoking status
Smoker 15.3 (37) 27.3 (68) 0.001
TB status
No history 30.6 (74) 88.0 (219) ,0.0001
Current 4.1 (10) 0.4 (1)
Previous 64.3 (158) 11.7 (29)
HIV characteristics (n=242) (%) n or median (IQR)
WHO stage
K 27.3 (66)
3/4 72.7 (176)
HAART naı¨ve 12.0 (29)
CD4 count in HAART naı¨ve group (n = 29) 170 (84–201)
Log10VL* in HAART naı¨ve group (n = 19) 4.81 (4.11–5.14)
Current CD4 count in HAART group 468 (325–607)
Nadir CD4 count in HAART group 127 (76–171)
% with detectable VL in HAART group 16.0 (34)
Peak Log10VL in HAART group 4.56 (3.84–4.98)
Duration of HAART, months 58 (34–75)
HAART Regimen
NNRTI-based* 59.6 (127)
Other 40.4 (86)
*VL = HIV RNA Viral load; NNRTI - non-nucleoside reverse transcriptase inhibitor;
doi:10.1371/journal.pone.0051405.t001
Table 2. Retinal vessel calibre in study population.
Mean arteriolar diameter Mean venular diameter
HIV+ cases Uninfected controls P-value HIV+ cases Uninfected controls P-value
Overall 163.67617.69 161.34617.38 0.15 267.77618.21 270.81618.98 0.07
Males 162.00617.68 160.53620.48 0.68 265.72618.04 274.55621.66 0.02
Females 164.24617.71 161.60616.33 0.14 268.47618.27 269.62617.94 0.55
Measurements are in mm and represent mean 6 standard deviation.
doi:10.1371/journal.pone.0051405.t002
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those with less than 3 years duration of HAART to 158.89 mm
with more than 6 years of treatment (P-trend = 0.02). A higher
current viral load while on HAART (.10,000 copies/ml) was
associated with narrower arterioles (p = 0.05). There was an
association of narrowed arterioles with hypertension (p = 0.03) in
this group, however this association was not apparent after
adjustment for HIV-related factors (data not shown). Venular
diameters narrowed with increasing age (P-trend = 0.02). A higher
current viral load was associated with wider venular diameters in
the unadjusted estimates (266.36 mm for VL ,10, 000 copies/ml
vs. 279.10 mm for VL.10,000 copies/ml (p = 0.02). The trend of
wider venules with higher viral load was apparent in the fully
adjusted model, but did not reach statistical significance (p = 0.20).
Discussion
We assessed retinal vessel calibre in HIV-infected individuals in
South Africa. This study provides clear evidence that retinal
arteriolar diameters narrow with increasing duration of HAART
and with higher HIV viral load, independently of age. The excess
age-related morbidity demonstrated in HIV-infected individuals
has a significant vascular component including cardiovascular,
renal and cerebrovascular disease, and retinal vessel calibre
measurement has been demonstrated as a strong biomarker of
systemic vascular disease.
We found an 8.9 mm decrease in arteriolar diameter in
participants who had been on HAART for .6 years after
adjustment for age and HIV-related factors. Our findings are in
alignment with data from the Longitudinal Studies of the Ocular
Complications of AIDS (LSOCA) [27], in particular, the
association of narrower retinal arteriolar diameter with exposure
to HAART. In our study population we additionally demonstrated
that retinal arteriolar diameter decreases with increasing duration
of HAART. The association of retinal arteriolar calibre with
cardiovascular risk is well documented. Retinal arteriolar diameter
(CRAE) is independently associated with increased carotid intima
thickness [12], and with higher cardiovascular mortality risk in
older persons [5,28]. An important cause of premature morbidity
and mortality in HIV-infected individuals is from cardiovascular
complications [29]. HAART-treated patients have a greater
prevalence of atherosclerosis and vascular dysfunction than age-
matched uninfected adults [30]. Enhanced endothelial dysfunction
(measured by flow-mediated dilation) and increased carotid intima
media thickness have been demonstrated in HIV cases compared
to controls, despite antiretroviral therapy and adjustment for
traditional CVD risk factors [31–35]. It is plausible that narrower
Table 3. Retinal Arteriolar and Venular Diameters in Relationship to HIV status, Stratified by Potential Effect Modifiers*.
Mean arteriolar diameter mm (SE) Mean venular diameter mm (SE)
HIV-infected
(n =236) Controls (n=243)
P-value for
interaction
HIV-infected
(n =236) Controls (n =243)
P-value for
interaction
Overall 163.95 (1.14) 161.08 (1.12) 268.17 (1.22) 270.43 (1.20)
Age group
30–39 165.86 (1.64) 161.27 (1.60) 0.01 271.34 (1.77) 269.49 (1.73) 0.07
40–49 163.47 (1.93) 157.94 (1.94) 265.59 (2.07) 271.43 (2.10)
.50 159.13 (2.72) 166.24 (2.55) 264.45 (2.92) 270.96 (2.75)
P-value 0.11 0.03 0.05 0.76
Sex
Male 161.02 (2.41) 158.29 (2.56) 0.22 266.68 (2.56) 276.13 (2.72) 0.02
Female 164.92 (1.34) 162.00 (1.36) 268.73 (1.44) 268.54 (1.44)
P-value 0.17 0.23 0.50 0.02
Cigarette use
No 163.73 (1.24) 160.21 (1.34) 0.16 268.46 (1.32) 268.69 (1.44) 0.03
Yes 164.20 (3.09) 163.93 (2.25) 265.47 (3.29) 275.69 (2.38)
P-value 0.89 0.17 0.41 0.01
Hypertension status
No 163.53 (1.45) 158.28 (1.42) 0.01 270.21 (1.57) 271.86 (1.54) 0.38
Yes 164.82 (2.60) 167.97 (2.46) 262.94 (2.78) 266.70 (2.66)
P-value 0.69 0.002 0.04 0.12
BMI
,20 166.73 (3.71) 166.06 (4.36) 0.13 262.20 (3.96) 274.52 (4.66) 0.77
20–24.9 166.48 (2.20) 159.24 (2.75) 266.10 (2.36) 267.22 (2.94)
25–29.9 160.77 (2.04) 160.77 (2.43) 266.56 (2.19) 270.04 (2.60)
.30 163.95 (2.00) 161.18 (1.55) 271.78 (2.14) 271.93 (1.66)
P-value 0.24 0.59 0.11 0.41
Adjusted for gender, age, hypertension status, smoking status, BMI, diastolic BP and associate vessel diameter (i.e. CRVE for CRAE analyses, and CRAE for CRVE analyses),
categorised as shown in the Table.
CRAE/CRVE = Central retinal artery equivalent/central retinal vein equivalent.
doi:10.1371/journal.pone.0051405.t003
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retinal arteriolar diameter is related to excess cardiovascular risk in
patients on HAART. The risk of cardiovascular disease appears to
be greatest with protease inhibitors (PIs) compared to non-
nucleoside reverse transcriptase inhibitors (NNRTIs) [36,37]. The
majority of our study population were treated with NNRTIs, and
we postulate that the magnitude of arteriolar narrowing might be
greater in populations where treatment is PI-based.
Higher viral load while on HAART (.10,000 copies/mL) was
associated with wider venular calibre in unadjusted estimates; this
trend remained in an adjusted model, but did not achieve
statistical significance. Endothelial dysfunction is associated with
larger retinal venules independent of traditional cardiovascular
risk factors [38]. Larger venular calibre is also associated with
higher levels of inflammatory markers such as interleukin-6
[39,40]. We postulate that in our HIV-infected population higher
HIV viral loads may cause inflammation and/or endothelial
dysfunction manifest as retinal venular dilation. The association of
narrow venular diameter with increasing age was stronger in an
adjusted model. This may reflect lack of statistical power, or
possibly that the ‘aging’ phenotype plays a larger role in
determining venular calibre in HIV. Narrow arteriolar calibre is
also associated with inflammation in diabetes possibly explaining
the finding of narrower CRAE with higher viral load [11].
The strong association between increasing age and narrowed
retinal vessels has been demonstrated in several study populations
[41–43]. This association was demonstrated in our cohort of HIV-
infected individuals, and in a US HIV population [27]. We
hypothesized that retinal vascular changes typically occurring in
older populations might occur earlier in life in HIV-infected
individuals. For venular diameters this appears to be consistent,
however, this trend was not apparent in retinal arterioles. The
interaction of age with HIV status in determining retinal arteriolar
diameter is novel and biologically difficult to explain. Graders
were masked to the HIV status of the participants, and mis-
grading would have caused random misclassification. There may
be residual confounding and bias accounting for this finding, or
this scenario could have occurred by chance. The effect of age in
relation to HIV status, and possible effect modification warrants
further investigation.
The strengths of this study include the high proportion of
gradable digital retinal photographs, and use of a well-established,
standardized computer-based technique to measure retinal vascu-
Table 4. Retinal vessel diameters in association to HIV-related factors in participants on HAART.
Arteriolar diameter (n=207) Venular diameter (n =207)
N Mean (SE), mm P Mean (SE), mm P
Age group (years)
30–39 99 164.81 (1.87) 269.93 (1.91)
40–49 73 163.40 (2.17) 0.08* 266.49 (2.21) 0.02*
.50 35 157.31(3.20) 260.37 (3.26)
Sex
Male 50 160.67 (3.05) 265.78 (3.12)
Female 157 163.80 (1.49) 0.37 267.52 (1.53) 0.64
Hypertension status
No 148 161.58 (1.93) 268.31 (1.98)
Yes 59 166.72 (4.00) 0.35 264.06 (4.08) 0.42
HAART duration, months
0–36 60 167.83 (2.56) 269.70 (2.63)
37–72 86 162.65 (1.97) 265.91 (2.01)
.73 61 158.89 (2.38) 0.02* 266.22 (2.45) 0. 57
Current CD4 count
,500 cells/mL 120 163.04 (1.66) 266.80 (1.70)
.501 cells/mL 87 163.05 (1.99) 0.98 267.51 (2.03) 0.78
Nadir CD4 count
,200 cells/mL 184 162.85 (1.29) 266.37 (1.31)
.201 cells/mL 23 164.58 (3.94) 0.67 272.92 (4.01) 0.13
Current HIV viral load
,10,000 copies/ml 195 163.71 (1.25) 266.65 (1.27)
.10,000 copies/ml 12 152.21 (5.64) 0.05 274.40 (5.79) 0.20
Peak HIV viral load
,10,000 copies/ml 59 164.32 (2.37) 268.59 (2.42)
.10,000 copies/ml 148 162.54 (1.45) 0.50 266.51 (1.48) 0.46
Adjusted for age, gender, hypertension status, mean arterial blood pressure (MABP), smoking status, BMI, diastolic BP, associate vessel diameter (i.e. CRVE for CRAE
analyses, and CRAE for CRVE analyses), current CD4 count and nadir CD4 count, current VL and peak VL, HAART duration, HAART regimen, WHO clinical stage (1/2 or 3/
4) and TB status (current or past history vs. no history).
*P-value for test of trend.
doi:10.1371/journal.pone.0051405.t004
Retinal Vessel Calibre in HIV
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e51405Sophia Pathai PhD Thesis Page 175
lar calibre. The study design also permitted inclusion of an age/
gender matched control group with a similar socio-demographic
profile as the cases. The hypothesis of accelerated aging in HIV
has received criticism primarily due to limitations in character-
ization of participants, and the possibility of differential exposure
to potential risk factors between HIV-infected and uninfected
populations [16,44,45]. By recruiting from the same community,
we aimed to reduce the likelihood of differential risk exposure.
Despite overall high reproducibility using computer-assisted
methods, many factors may affect vessel measurement, some of
which are inherent. For example, slight changes in vessel diameter
with the cardiac cycle (due to pulsatility) may result in variation in
vessel measurements [46] but fluctuations are small and random
[9], causing non-differential misclassification. Measurement of
vessel diameters from colour retinal photographs may underesti-
mate true vascular width because only the red blood cell column is
measured, and not the peripheral plasma cuff. Other factors relate
to the population studied e.g. clarity of the ocular media and hence
photographs, and the presence of greater retinal pigment, as in
African retinas, may overestimate retinal vessel diameter [47]. Our
study design does not permit conclusions about the temporal
relationship between changes in retinal calibre and subsequent risk
of morbidity (e.g. cardiovascular events) or mortality from these
data. In addition, we cannot make any inference about whether
HIV infection or HAART is primarily responsible for the changes
in vascular calibre due to the low proportion of HAART-naı¨ve
individuals recruited. Finally, as both case and control populations
are of African ancestry these findings may not be generalisable to
other ethnic groups.
We present novel data on retinal vascular calibre in HIV. It is
reassuring that our findings are in alignment with a US HIV
cohort [27]. However, compared to US HIV populations, it is
likely that African HIV populations will have experienced a
shorter duration of HAART and initiated treatment at lower CD4
counts. The atherogenic, inflammatory and aging effects of HIV
and HAART and related changes in retinal vascular calibre may
thus follow a different trajectory, with longitudinal data needed to
assess this definitively. It is also unclear whether HIV infection or
treatment with HAART is primarily responsible for changes in
vascular calibre. In addition, epigenetic and genetic variation may
contribute to an individual’s susceptibility to non-HIV age-related
morbidity and to vascular structural changes.
The challenge of managing excess age-related morbidity in
HIV-infected individuals will increase as HIV populations live
longer and HAART coverage expands. Stratification of vascular
risk among HIV-infected individuals, particularly cardiovascular
risk, and implementing preventive strategies will be important
priorities for patient management. Cardiovascular risk assessment
tools already exist such as the Framingham Risk Scores [48],
however, specific tools tailored to HIV-infected populations are
necessary [49]. Measurement of retinal vessel calibre is validated,
non-invasive, and can be performed quickly by non-clinical
personnel. Our data support the hypothesis that retinal vascular
calibre changes occur in HIV infection, reflecting systemic
vascular pathology. Longitudinal studies are needed to confirm
this hypothesis as well as validation studies to explore the role of
retinal vessel measurement as a tool in HIV-related vascular risk
estimation.
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 Chapter 8 
Increased ocular lens density in HIV-
infected individuals with low nadir CD4 
counts in South Africa:  
evidence of accelerated aging 
 
 
Pentacam evaluation of lens density – this amount of lens opacity would be clinically apparent as cataract 
 
Research paper investigating the relationship of lens 
density measurements with clinical and demographic 
characteristics in HIV-infected individuals in 
comparison with HIV-seronegative individuals 
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 Abstract 
Background 
HIV infection is thought to be associated with an increased risk of age-related 
morbidity and premature aging. Lens density increases with age and may function as 
a biomarker of aging. We investigated the relationship of lens density measurements 
with clinical and demographic characteristics in HIV-infected individuals in 
comparison with a matched population of HIV-seronegative individuals.  
 
Methods: 
Case-control study of 490 adults aged ≥ 30 years, composed of 242 HIV-infected 
adults and 248 age- and gender-matched HIV-seronegative individuals. Lens density 
was assessed using lens densitometry (Pentacam) imaging. Measurements were 
divided into quartiles and comparison of HIV status and HIV-related factors was 
assessed by multivariate and multinomial logistic regression. 
 
Results: 
The mean age was 41.2 years in HIV-infected adults and 42.3 years in HIV-
seronegative individuals (p=0.14). Of the HIV-infected adults, 88% were receiving 
antiretroviral therapy (ART) (median duration, 58 months), and within this group 
their median CD4 count was 468 cells/L, and 84% had undetectable viral load. 
Although adjusted lens densities were similar by HIV serostatus, participants on ART 
and who had nadir CD4 counts <200 cells/L had a higher risk of high lens density 
compared to HIV-seronegative individuals (p-trend=0.04).  Lens density was weakly 
associated with detectable HIV viremia despite ART, but not with current CD4 
count.  
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Conclusions: 
HIV-infected individuals on ART with nadir CD4 counts <200 cells/µL had increased 
risk of higher lens density. Lens density may represent a novel biomarker of aging, 
providing insight into accelerated aging trajectories in HIV infection.   
 
 
Word count: 242 
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 MAIN TEXT  
Introduction:  
Antiretroviral therapy (ART) has reduced mortality among HIV-infected 
people, largely due to prevention of AIDS-related events, but also due to a decrease 
in non-AIDS related events and deaths.1,2 However, it is now of concern that ART 
cohorts are aging. In the USA, for example, it is estimated that by 2015 more than 
50% of the HIV-infected population will be over 50 years of age.3 This trend is 
becoming apparent in sub-Saharan Africa where there is an expanding cohort of HIV-
infected individuals who are aged over 50.4,5 Patients receiving ART are thought to 
be at increased risk of age-related non-AIDS morbidity and mortality compared with 
HIV-seronegative persons.6,7 Several of these conditions are classically associated 
with the normal aging process but occur at an earlier age in HIV-infected persons 
compared to age-matched HIV-seronegative individuals.8 Thus, HIV infection may be 
associated with accelerated senescence, and the increased risk of systemic age-
related morbidities in HIV-infected people has frequently been found to be 
associated with nadir CD4 count and ART duration.9-12 
 
Cataracts are opacities of the intraocular lens and the prevalence of lens 
opacities increases exponentially with age.13 They are a leading cause of blindness and 
visual impairment worldwide.14 Individuals with cataract have an increased mortality 
risk than those without, even after adjusting for known confounders.15,16 The human 
lens is considered an ideal tissue for studying macromolecular aging as biochemical 
mechanisms in lens proteins may reflect aging processes elsewhere in the body.17-20 
In the context of lens opacities and HIV, two possible scenarios exist. Firstly, 
although the prevalence of HIV-related opportunistic ocular infections (such as 
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 cytomegalovirus retinitis) has decreased,21 the introduction and scale-up of ART has 
led to immune-recovery phenomena.22 This may manifest in the eye as ‘immune 
recovery uveitis’ (IRU). It is characterized by ocular inflammation following ART 
initiation, and can lead to cataract formation.23 Secondly, if premature aging does 
occur in HIV-infected individuals, an increased risk of ocular age-related conditions 
such as cataract might be expected. To date, there is minimal information about age-
related eye conditions and the possibility of accelerated aging in HIV-infected 
patients, particularly within sub-Saharan Africa.  
 
 The Pentacam (Oculus, Germany) is a 360-degree rotating non-contact camera 
that provides a rapid and precise three-dimensional view of the lens, cornea and 
anterior chamber.24 The Pentacam uses a blue light-emitting diode (wavelength 
475nm) to image the anterior eye segment, capturing 25 single-slit images in 2 
seconds while rotating around the eye from 0 to 180 degrees. The instrument 
acquires data points that provide a representative image of the whole lens.25 The 
Pentacam contains integral software that can automatically quantify lens ‘density’ by 
measuring the light-scattering intensity of the lens layers. This provides a form of 
objective lens opacity (cataract) grading. The objective of the study was to assess 
differences in lens density using the Pentacam in a cohort of HIV-infected individuals 
in comparison to an age- and gender-matched HIV-seronegative group. Our study 
hypotheses were that (a) HIV-infected individuals will have a greater lens density 
compared to gender- and age-matched HIV-seronegative individuals and (b) low 
nadir CD4 count at ART initiation is associated with an increased risk of higher lens 
density. Our study was conducted in Cape Town, South Africa, with recruitment of 
cases and controls from the same communities to reduce the likelihood of 
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 differential risk exposure in line with the recommendation for careful study design 
when investigating premature aging in HIV.26 
 
Methods: 
Study participants: 
HIV-infected participants aged > 30 years were enrolled from a community-based 
HIV treatment centre in Nyanga district in Cape Town.27,28 Participant recruitment 
has been reported in detail elsewhere.29 In brief, all participants had a confirmed 
serological diagnosis of HIV and were either about to commence ART (ART-naïve), 
or were already on first-line ART. A control group of HIV-seronegative participants 
were frequency-matched to cases by gender and 5-year age categories. Participants 
who reported ocular symptoms (other than relating to decreased vision), or were 
found to have active ocular pathology (excluding lens opacities) at study enrolment 
were excluded from the study to reduce any potential biases, and were referred for 
treatment where necessary. In addition, participants with diabetes were not 
recruited due to the possible confounding effect of diabetes on premature aging and 
increased risk of lens opacities.   
Pilot data obtained from the HIV-infected population was used to inform sample size 
calculations, as well as reference to published data relating to cataract prevalence in 
Africa.30 A sample size of 480 (240 HIV-infected and 240 HIV-seronegative 
individuals) provided 80% power at a 95% significance level to detect a difference in 
moderate lens density (i.e. clinically detectable cataract, with visual acuity <20/40) 
between the two groups.   
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 Data collection: 
Data collected included factors known to affect aging and age-related parameters 
(e.g. smoking and work location (indoor/outdoor) as a proxy for UV exposure). 
Clinical information was obtained from medical case notes where required. All 
participants underwent a full ophthalmic examination including measurement of 
visual acuity, evaluation by slit lamp microscopy (for anterior segment structures e.g. 
cornea, anterior chamber) and indirect ophthalmoscopy (for retina and vitreous). 
Participants also underwent refraction in order to assess their refractive state (i.e. 
emmetropia [no refractive error], myopia [short-sightedness] or hypermetropia 
[long-sightedness] as this can contribute to the development of lens opacities.  
 
Lens density measurement:  
Following pupil dilatation with 1% tropicamide, two lens density measurements were 
made on each eye, and the mean value calculated. The instrument automatically 
calculated the quality and reliability of a captured image. If an image was found to be 
of poor quality (i.e. not ‘OK’ on the image quality specification), the measurement 
was repeated. Reproducibility of the lens density evaluation in two scans was 
performed for 50 eyes. Lens densitometry output values were extracted from the 
image captures in a masked fashion. Image section 90-270 degrees was used for the 
right eye and image section 270-90 degrees was used for the left eye.25 All of the 
densitometry metrics available from the scan (linear, peak and 3D) were analysed as 
they reflect different parameters of the lens. Figure 1 shows an example of the 
metrics. For the linear metric, a line was drawn through the visual axis and a mean 
lens densitometry value given. The peak metric indicated the point at which lens 
densitometry was greatest on the lens densitogram. For the 3D metric, a fixed, 
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 circular 3.0 mm area of the lens was selected and a mean lens densitometry value 
given.25 The lens density output was presented on a continuous standardized scale 
from 0 (transparent) to 100 (fully opaque). Further examples of Pentacam images 
obtained and the relevant metrics are presented as Supplementary Figures S1-S5.  
 
The study was approved by the Ethics Committees of the London School of 
Hygiene and Tropical Medicine and the University of Cape Town Faculty of Health 
Sciences, and adhered to the tenets of the Declaration of Helsinki. Written informed 
consent was obtained from all participants 
 
Statistical analyses: 
One eye was randomly selected for analysis. Where an eye was not available, for 
example due to trauma or corneal opacity, the contralateral eye was used. Although 
the Pentacam has been validated against clinical grading scores, there are no standard 
reference scores as to what might constitute a clinically significant degree of lens 
opacity, thus lens density measurements were divided into quartiles defined by 
control group measurements. The association of HIV status with lens density was 
assessed in univariable and multivariable logistic regression models adjusted for risk 
factors and a priori confounders (UV exposure, smoking). Multinomial logistic 
regression was used to assess the association of lens density with 4 different 
outcome groups (e.g. uninfected, HIV-infected on ART with nadir CD4 count <200 
cells/µL, HIV-infected on ART with nadir CD4 count >200 cells/µL, HIV-infected 
ART naive). In analyses restricted to HIV-infected participants on ART, we assessed 
relationships between quartiles of lens density and HIV-related variables of interest 
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 including duration of ART, nadir CD4 count, current CD4 count and viral load. All 
analyses were performed with Stata 11 (Stata Corp, USA).  
 
Results 
Participant characteristics: 
Characteristics of the 242 HIV-infected individuals and 248 age/gender frequency 
matched HIV-seronegative individuals are shown in Table 1. Overall, the groups 
were well matched. The HIV-infected group tended to have a greater income 
(attributable to a government health-related grant), less reported consumption of 
alcohol (p=0.002) and fewer cigarettes (p=0.001). They were also most likely to 
report a previous eye condition than HIV-negative controls (p=0.01).  None of the 
participants had undergone ophthalmic surgery, and in particular none had cataract 
surgery for either eye or had had clinically active uveitis (a risk factor for cataract).  
Visual acuities were similar in the two groups (p=0.62). The majority of the HIV-
infected group were on already on ART, 12% were treatment naïve. The median 
duration on ART was 58.5 months, [interquartile range (IQR); 34-75.8], and 84% of 
participants had an undetectable plasma viral load. The median current CD4 count in 
this group was 468 cells/L (IQR: 325-607) 
 
Lens density measurements: 
Lens density values of sufficient quality were available for 484 (98.0%) of the 490 
study participants. None of the participants had high myopia or hypermetropia.  
Acquisition of sub-optimal densitometry images was mainly related to participant 
movement and rapid blinking during image capture (preventing acquisition of all 25 
slit images). Participants who did not have good quality lens density images had 
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 similar characteristics to those who did (P-value for all characteristics >0.10, data 
not shown).  
 
Unadjusted median lens density values were similar between HIV-infected individuals 
and HIV-seronegative individuals. The median linear value was 9.8 (IQR: 9.2-10.0) in 
HIV-infected individuals and 9.8 (9.6-9.9) in HIV-seronegative individuals (p=0.75). 
Corresponding peak values in the two groups were 17.9 (15.4-19.9) and 18.0 (15.4-
20.5) (p=0.43) and 3D values were 9.7 (9.1-10.6) and 9.8 (9.1-10.9) (p=0.29), 
respectively.  Table S1 compares lens density between the two groups – as 
expected, age was a strong independent predictor of high lens density in both groups 
(p<0.0001). In the HIV-seronegative group, indoor work was protective against high 
lens density (OR 0.35; 95%C1: 0.12-1.00; p=0.05) as was greater income (p=0.06).  
 
Associations between lens density and HIV status (including both those on ART and 
ART-naïve) are shown in Table 2. After adjustment for potential confounding 
variables, there was a trend of a higher linear lens density associated with HIV 
infection (Odds ratio [OR]=1.42, 95% CI: 0.67-3.03 for highest vs lowest quartile), 
although this did not reach statistical significance (p-trend=0.31).  
 
Table 3 reports adjusted ORs of HIV status with lens density metrics using 
multinomial logistic regression. After adjustment for potential confounding variables, 
participants on ART with nadir CD4 count <200 cells/L were more likely to have 
high lens density than HIV-seronegative individuals (p-trend=0.04).  In contrast, there 
was no significant association between lens density and HIV infected participants 
who were ART-naïve or on ART with nadir CD4 count >200 cells/µL. 
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 We next assessed associations with lens density among HIV-infected 
participants. Table 4 reports lens density quartiles in relation to nadir CD4 count in 
participants on ART. In univariable analyses there was some evidence that HIV 
infected participants with a nadir CD4 count below 200 cells/L were more likely to 
have greater linear lens density than those with higher nadir CD4 counts (p-
trend=0.16). This trend strengthened after adjustment for demographic and HIV-
related covariates (p-trend=0.04).  A similar result was seen for the 3-D value of lens 
density but not peak value.  Duration of ART did not affect any of the three lens 
density metrics, neither were there any specific associations with different types of 
ART regimen. Current CD4 count was not related to lens density. There was a 
trend for uncontrolled HIV viremia (i.e. detectable VL [>50 copies/ml] despite ART) 
to be associated with higher lens density, however this was not significant for any of 
the metrics (See Supplementary Tables S2 and S3).  
 
Discussion  
We have previously demonstrated in this South African study population that HIV 
infection is associated with increased risk of frailty and with changes in the retinal 
vasculature that may reflect premature aging and increased cardiovascular risk.29,31 
These previous studies both provided important evidence that HIV infection is 
associated with a clinical phenotype that is consistent with accelerated senescence. 
The present study further builds on these findings, demonstrating that HIV-infected 
individuals receiving ART and who had low nadir CD4 cell counts (<200 cells/µL) 
also have a greater risk of increased ocular lens density when compared with HIV-
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 seronegative individuals. This provides corroborative evidence of accelerated aging 
and that this may be associated with delayed initiation of ART.      
 
As cataract is strongly related to aging, lens density might be expected to be 
greater in such individuals compared to age- and gender-matched HIV-seronegative 
individuals. We used an objective method to assess lens density rather than a clinical 
diagnosis of cataract. The association between low nadir CD4 counts and greater 
risk of high lens density persisted after adjustment for HIV-related covariates. ART 
duration or current CD4 count, however, did not affect lens density status.  
 
Low nadir CD4 count has been identified as an independent predictor of 
several premature age-related co-morbidities in HIV-infected individuals.9-11 The CD4 
count at which ART is initiated is likely to be a key modifiable risk factor with regard 
to the excess risk of non-AIDS conditions described in observational HIV study 
cohorts.10,32 There is also potential for a reduction in non-AIDS related morbidity 
and mortality from earlier initiation of ART.33 Initiating ART at higher CD4 counts 
may alter the ‘aging trajectory’, and may be an additional benefit derived from early 
treatment. Furthermore, improved survival of patients in African settings has been 
associated with CD4 counts >500 cells/L following ART.34 It is possible that the 
duration of time accumulated at low CD4 counts is associated with accrual of HIV-
related ‘aging damage’, and thus the rate of CD4 cell decline might be an important 
modifiable factor in alteration of the aging trajectory. We did not detect an 
association between ART duration or regimen with lens density. These parameters 
have been associated with some premature age-related morbidities, but not others. 
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 9,10,35,36 It is possible that in the eye ART may have a limited effect on lens fibres, as 
they are metabolically inactive.   
 
Despite differences in lens density between HIV-infected individuals with low 
nadir CD4 counts and HIV-seronegative individuals, a significant difference between 
the two overall groups was not observed. In sub-Saharan Africa, where ART 
coverage is still expanding, lens density changes may not yet be detectable along the 
life course aging trajectory compared to HIV-seronegative individuals.  Lens opacities 
typically occur over years, and so differences may become more marked if assessed 
over a longer period of time. Chronological age will be an important compounding 
factor in the development of lens opacities as the proportion of individuals over the 
age of 50 within ART cohorts continues to grow. Prospective longitudinal studies of 
similar study cohorts will be necessary to provide further information about the 
utility and validity of lens density as a biomarker of aging, particularly in relation to 
the possibility of accelerated aging and HIV infection.  Concurrent measurement of 
other biomarkers of aging (e.g. telomere length) may help to validate this as a tool.  
 
A key strength of our study is the inclusion of an age- and gender-matched 
control group with a similar socio-demographic profile as the HIV-infected 
individuals. The hypothesis of accelerated aging in HIV has received criticism 
primarily due to limitations in characterization of participants, particularly the 
possibility of differential exposure to potential risk factors between HIV-infected and 
uninfected populations.12,37,38 Since the HIV epidemic in South Africa is generalized 
and recruitment took place from the same community, the likelihood of differential 
risk exposure was minimized. Another strength is the objective assessment of lens 
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 status. A cohort study of HIV-infected individuals in Denmark reported a cataract 
surgery incidence risk ratio of 1.87 (95%CI: 1.50-2.33) compared to HIV-
seronegative individuals.35 It is difficult to directly compare our findings due to the 
different outcome measures. In resource-limited settings, access to cataract surgery 
is often limited, thus cataract surgery as an indicator of the presence of cataract/high 
lens density may provide inaccurate information. Measurement of lens density may 
therefore be a more accurate indicator of age-related lens changes. Indeed, the 
phenotype of ‘lens transparency’ has been described as a possible biomarker of 
aging.39  
Previous assessments of lens opacity for research purposes have used clinical 
grading systems such as the Lens Opacities Classification System (LOCS) III.40 
However, such systems are based on subjective grading using methods such as slit-
lamp evaluation and lens photography. Pentacam lens images have been validated 
against LOCSIII, and repeatability of measurements and correlation with clinical 
grading has been demonstrated.24,25 Lens density is also expressed as a continuous 
variable rather than graded steps (as in LOCSIII), which is useful for detecting small 
amounts of lens opacity. This was of particular importance for our study population 
(median age 40 years), where lens opacities would be difficult to discern clinically. 
We found the linear metric to be most informative. The peak metric tended to 
measure isolated ‘spikes’ of high lens density and was probably not representative of 
gradual age-related changes within the lens fibres.  
 
There are some limitations to our study. Although our hypothesis relates to 
accelerated aging in HIV, we cannot exclude the possibility of intraocular 
inflammation accounting for the observed relationship of nadir CD4 count with 
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 higher lens density. This could have arisen from immune recovery uveitis (IRU) in 
patients with cytomegalovirus (CMV) infection, for example. However, we did not 
detect any evidence of IRU and we have previously shown the prevalence of CMV 
retinitis to be very low within this population.41 Therefore, our current data are 
more likely to support the hypothesis of premature aging in line with other systemic 
co-morbidities.9,42 Reports of smoking and alcohol intake were considerably lower in 
HIV-infected individuals compared to HIV-seronegative individuals. This could 
partially explain the finding of similar lens density values between the two groups; 
smoking in particular is a risk factor for cataract,43 thus even if accelerated aging is 
occurring in HIV-infected individuals, low smoking status within this group may 
decrease the magnitude of difference between HIV-infected individuals and HIV-
seronegative individuals. It is possible HIV-infected participants may have adopted 
healthier lifestyle behaviours, or they may have not reported true smoking habits. 
 
In conclusion, we used measurement of lens density as a non-invasive method of 
assessing biological aging. We found HIV-infected individuals on ART with low nadir 
CD4 counts to have an increased risk of higher lens density compared to HIV-
seronegative individuals. These data support our previous findings in this study 
population that collectively provide evidence of HIV-related accelerated 
senescence.29,31 The present data may have implications relating to early initiation of 
ART to potentially avert some of these long-term but as yet unquantified 
complications. Premature aging may well have important socio-economic and 
healthcare implications for the many millions of people living with HIV long-term on 
ART in sub-Saharan Africa.   
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 23 
TABLES (FOR MAIN MANUSCRIPT) 
 
Table 1: Characteristics of study participants  
 
Variable HIV-infected 
(242) 
% (n) 
HIV-
seronegative 
(248) 
% (n) 
P-value 
Age (mean±SE) 41.2±0.5 42.3±0.6 0.14 
Age, years by group 
30-39 
40-49 
>50 
 
 
119 (49.2) 
81 (33.5) 
42 (17.4) 
 
117 (47.2) 
79 (31.8) 
52 (21.0) 
 
 
0.60 
Male gender 25.6 (62) 24.2 (60) 0.72 
Working location 
Indoors 
 
35.1 (85) 
 
28.2 (70) 
 
0.10 
Income 
>ZAR1000/month 
 
42.2 (102) 
 
31.5 (78) 
 
0.01 
Smoking status 
Smoker 
 
15.3 (37) 
 
27.4 (68) 
 
0.001 
Alcohol 
Yes 
 
30.2 (73) 
 
44.0 (109) 
 
0.002 
History of eye condition 
Yes 
 
16.9 (41) 
 
9.3 (23) 
 
0.01 
Visual acuity (presenting) 20/25 20/25 0.62 
% with visual acuity <20/40 6.2 (15) 9.7 (24) 0.16 
Clinical lens status 
Clear 
Non visually-significant cataracta 
Visually-significant cataract 
 
76.0 (184) 
19.4 (47) 
4.6 (11) 
 
71.4 (177) 
21.8 (54) 
6.9 (17) 
 
 
0.40 
HIV-related characteristics    
WHO stage 
1/2 
3/4 
 
27.3 (66) 
72.7 (176) 
  
HAART naïve  12.0 (29)   
CD4 count in HAART naïve group 
(n=29) 
170  (84-201)   
Log10VL in HAART naïve group (n=19) 4.81 (4.11-5.14)   
Current CD4 count in HAART group  468 (325-607)   
Nadir CD4 count in HAART group  127 (76-171)   
% with detectable VL in HAART group  16.0 (34)   
Peak Log10VL in HAART group  4.56 (3.84-4.98)   
Duration of HAART, months  58 (34-75)   
HAART Regimen  
Containing AZT/3TC 
Other 
 
59.6 (127) 
40.4 (86) 
  
 
a -Visually-significant cataract defined as clinically detectable cataract and vision in worse eye 
<20/40
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 24 
Table 2: Association of lens density with HIV 
 
 
 
 
 
 
 
 
 
 
 
 * - Refers to p-value for test of linear trend 
 a - Adjusted for age, gender, UV exposure status, smoking status, alcohol intake, income and history of eye condition 
Lens density N HIV cases 
(%) 
Univariate 
  OR (95%CI)             P-value 
Multivariatea 
  OR (95%CI)         P-value 
Linear value, all participants 
First quartile (lowest)  
Second quartile 
Third quartile 
Fourth quartile (highest) 
 
 
128 
121 
118 
117 
 
63(26.5) 
61 (25.6) 
58 (24.4) 
56 (23.5) 
 
1 
1.05 (0.64-1.72) 
1.00 (0.60-1.65) 
0.95 (0.57-1.56) 
 
 
 
0.80* 
 
1 
1.15 (0.87-1.94) 
1.36 (0.68-2.48) 
1.42 (0.67-3.03) 
 
 
 
0.31* 
Peak value, all participants 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
 
121 
127 
123 
113 
 
59 (24.8) 
65 (27.3) 
60 (25.6) 
54 (21.9) 
 
1 
1.14 (0.69-1.87) 
1.03 (0.63-1.71) 
0.90 (0.54-1.50) 
 
 
 
0.61* 
 
1 
1.30 (0.77-2.18) 
1.25 (0.73-2.15) 
1.05 (0.59-1.88) 
 
 
 
0.87* 
3-D value, all participants 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
133 
105 
120 
115 
 
71 (29.8) 
54 (22.7) 
65 (27.3) 
48 (20.2) 
 
1 
0.74 (0.45-1.21) 
0.96 (0.59-1.57) 
0.69 (0.41-1.14) 
 
 
 
0.37 
 
1 
0.83 (0.49-1.40) 
1.15 (0.62-2.11) 
0.79 (0.35-1.75) 
 
 
 
0.31 
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Table 3: Association of lens density with HIV status using multinomial logistic regression – uninfected controls represent baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* - Refers to p-value for test of linear trend 
b - Multivariate Odds ratios adjusted for age, gender, UV exposure status, smoking status, alcohol intake, income and history of eye condition 
c -Median CD4 count in this group was 127 cells/L 
 
 
 
 
 
 
Lens density HIV+ on HAART, nadir CD4 
count >200 cells/L 
HIV+ on HAART, nadir CD4 
count <200 cells/L 
HIV+, HAART-naïvec 
   OR (95%CI)b          P-value   OR (95%CI)b         P-value   OR (95%CI)b          P-value 
Linear value  
First quartile  
Second quartile 
Third quartile 
Fourth quartile  
 
 
1 
0.57 (0.18-1.82) 
0.62 (0.15-2.53) 
0.22 (0.03-1.62) 
 
 
 
0.16 
 
1 
1.57 (0.89-2.77) 
1.91 (1.00-3.67) 
2.16 (0.95-4.93) 
 
 
 
0.04* 
 
 
1 
0.37 (0.11-1.24) 
0.43 (0.12-1.52) 
0.58 (0.12-2.71) 
 
 
 
0.25* 
Peak value 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
 
1 
1.38 (0.43-4.45) 
1.14 (0.31-4.23) 
1.39 (0.37-5.21) 
 
 
 
 
0.71 
 
1 
1.20 (0.66-2.09) 
1.22 (0.69-2.17) 
1.03 (0.55-1.91) 
 
 
 
 
0.90 
 
1 
1.94 (0.65-5.80) 
1.54 (0.48-4.94) 
0.96 (0.25-3.64) 
 
 
 
0.91 
3-D value 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
1 
0.29 (0.06-1.15) 
0.63 (0.16-2.53) 
0.26 (0.04-1.92) 
 
 
 
0.19 
 
1 
1.09 (0.62-1.91) 
1.51 (0.78-2.91) 
0.99 (0.43-2.33) 
 
 
 
0.67 
 
1 
0.42 (0.13-1.31) 
0.41 (0.11-1.59) 
0.62 (0.11-3.32) 
 
 
 
0.33 
Sophia Pathai PhD Thesis Page 202
  
 
 
 
Table 4: Association of lens density with nadir CD4 count in HIV-infected participants on HAART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* - Refers to p-value for test of linear trend 
d – comparison group are HIV-infected individuals on HAART with a nadir CD4 count ≤200cells/L 
e - Adjusted for age, gender, UV exposure status, smoking status, alcohol intake, income, history of any eye condition, current CD4 count, current and peak viral 
load, TB status, WHO clinical stage, HAART duration and regimen 
 
Lens density N HIV+ on HAART; 
nadir CD4 >200 
cells/l (%)d 
Univariate 
  OR (95%CI)        P-value 
Multivariatee 
  OR (95%CI)        P-value 
Linear value 
First quartile (lowest)  
Second quartile 
Third quartile 
Fourth quartile (highest) 
 
 
50 
57 
53 
49 
 
10 (41.7) 
5 (20.8) 
6 (25.0) 
3 (12.5) 
 
1 
0.39 (0.12-1.21) 
0.51 (0.17-1.53) 
0.26 (0.07-1.01) 
 
 
 
0.16 
 
1 
0.29 (0.07-1.22) 
0.60 (0.10-3.67) 
0.05 (0.01-1.06) 
 
 
 
0.04 
Peak value 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
53 
55 
52 
49 
 
 
6 (25.0) 
7 (29.2) 
4 (16.7) 
7 (29.1) 
 
1 
1.14 (0.36-3.65) 
0.65 (0.17-2.46) 
1.31 (0.41-4.19) 
 
 
 
0.95 
 
1 
1.19 (0.29-4.91) 
0.59 (0.12-2.80) 
1.68 (0.36-7.72) 
 
 
 
0.60 
 
3-D value 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
59 
45 
57 
43 
 
11 (45.8) 
3 (12.5) 
5 (20.8) 
5 (20.8) 
 
1 
0.31 (0.08-1.19) 
0.42 (0.14-1.30) 
0.57 (0.18-1.79) 
 
 
 
 
0.25* 
 
1 
0.10 (0.02-0.72) 
0.40 (0.07-2.31) 
0.16 (0.01-2.16) 
 
 
 
0.08 
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 FIGURE (FOR MAIN MANUSCRIPT) 
Figure 1: Example of Pentacam image acquisition. A) and B) The linear and peak metrics were 
provided directly from the axis line appearing in the acquired image. The linear metric was the 
average lens opacity in one plane; the peak reflected the highest lens density within the scan. 
C) The 3D metric required the observer to select the size and position for analysis, and 
provided an overall average from the 3-dimensional acquired image. 
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 SUPPLEMENTARY TABLES 
Table S1: Comparison of lens density* in HIV-infected and HIV-seronegative groups  
Variable HIV-infected HIV-seronegative 
 Univariate ORa P-value Multivariate** 
OR 
P-value Univariate OR P-value Multivariate OR P-value 
Gender 
Male 
Female 
 
1 
1.22 (0.60-2.46) 
 
 
0.58 
 
1 
1.74 (0.58-5.23) 
 
 
0.32 
 
1 
1.08 (0.54-2.14) 
 
 
0.83 
 
1 
0.95 (0.30-2.95) 
 
 
0.92 
Age 
Per 10 year increase 
 
 
14.52  
(7.26-20.02) 
 
 
<0.0001 
 
15.61 
(7.34-33.23) 
 
 
<0.0001 
 
13.14 
(6.94-24.85) 
 
 
<0.0001 
 
16.82  
(7.63-37.11) 
 
 
<0.0001 
Income 
<1000 ZAR/month 
>1000 ZAR/month 
 
1 
1.56 (0.86-2.86) 
 
 
0.15 
 
1 
1.28 (0.54-3.06) 
 
 
0.57 
 
1 
1.02 (0.54-1.90) 
 
 
0.96 
 
1 
0.35 (0.13-1.04) 
 
 
0.06 
UV exposure 
Outdoor work 
Indoor work 
 
1 
0.53 (0.27-1.05) 
 
 
0.07 
 
1 
0.71 (0.28-1.81) 
 
 
0.48 
 
1 
0.35 (0.16-0.76) 
 
 
0.008 
 
1 
0.35 (0.12-1.00) 
 
 
0.05 
Cigarette use 
No 
Yes 
 
1 
1.06 (0.46-2.39) 
 
 
0.90 
 
1 
1.61 (0.49-5.28) 
 
 
0.43 
 
1 
1.04 (0.55-2.00) 
 
 
0.90 
 
1 
0.80 (0.26-2.45) 
 
 
0.69 
Alcohol consumption 
Nil 
Up to IL/week 
Over IL/week 
 
1 
0.91 (0.40-2.08) 
1.94 (0.79-4.72) 
 
 
0.33 
 
1 
0.75 (0.23-2.40) 
1.39 (0.39-4.90) 
 
 
0.71 
 
1 
0.89 (0.43-1.85) 
0.64 (0.29-1.40) 
 
 
0.52 
 
1 
1.40 (0.44-4.43) 
1.47 (0.42-5.16) 
 
 
0.77 
History of eye 
condition 
No  
Yes 
 
1 
1.06 (0.48-2.32) 
 
 
0.89 
 
1 
0.53 (0.16-1.73) 
 
 
0.29 
 
1 
3.87 (1.61-9.32) 
 
 
0.002 
 
1 
1.50 (0.43-5.32) 
 
 
0.53 
 
*Odds ratio for having ‘high’ lens density – denoted as greater than or equal to the 75th percentile of linear lens density referenced to the control population 
a- OR: odds ratio; ** Multivariate OR – adjusted for all other variables in the table. 
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 Table S2: Association of lens density with current CD4 count 
 
Lens density N HIV+ on 
HAART; 
current CD4 
>500 
a 
Univariate 
  OR (95%CI)          P-value 
Multivariateb 
  OR (95%CI)            P-value 
Linear value, all participants 
First quartile (lowest)  
Second quartile 
Third quartile 
Fourth quartile (highest) 
 
 
50 
57 
53 
49 
 
 
21 (23.6) 
31 (34.8) 
19 (21.4) 
18 (20.2) 
 
1 
1.65 (0.77-3.54) 
0.77 (0.35-1.71) 
0.80 (0.36-1.80) 
 
 
 
0.18 
 
1 
1.45 (0.59-3.56) 
0.71 (0.23-2.14) 
1.03 (0.26-4.01) 
 
 
 
0.53 
 
Peak value, all participants 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
 
53 
55 
52 
49 
 
23 (25.8) 
26 (29.2) 
22 (24.7) 
18 (20.2) 
 
1 
1.17 (0.55-2.50) 
0.96 (0.44-2.07) 
0.76 (0.34-1.68) 
 
 
 
0.43* 
 
1 
1.24 (0.51-3.00) 
1.19 (0.48-2.97) 
1.41 (0.50-3.96) 
 
 
 
0.93 
3-D value, all participants 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
59 
45 
57 
43 
 
25 (29.1) 
21 (24.4) 
22 (25.6) 
18 (20.9) 
 
1 
1.19 (0.55-2.60) 
0.85 (0.41-1.80) 
0.98 (0.44-2.17) 
 
 
 
0.88 
 
1 
0.97 (0.37-2.54) 
0.74 (0.24-2.27) 
1.98 (0.44-9.00) 
 
 
 
0.39 
 
a- Comparison group are HIV-  
b - Adjusted for age, gender, UV exposure status, smoking status, alcohol intake, income, history of any eye condition, nadir CD4 count, 
current and peak viral load, TB status, WHO clinical stage, HAART duration and regimen * - Refers to p-value for test of linear trend 
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 Table S3: association of lens density with detectable viral load 
Lens density N HIV+ on 
HAART; 
VL>50 
copies/ml
c (%) 
Univariate 
  OR (95%CI)               P-value 
Multivariated 
  OR (95%CI)             P-value 
Linear value, all participants 
First quartile (lowest)  
Second quartile 
Third quartile 
Fourth quartile (highest) 
 
 
50 
57 
53 
49 
 
 
8 (24.4) 
7 (21.2) 
10 (30.3) 
8 (24.2) 
 
1 
0.74 (0.25-2.20) 
1.22 (0.44-3.39) 
1.02 (0.35-2.99) 
 
 
 
0.82 
 
1 
0.89 (0.24-3.31) 
2.40 (0.51-11.41) 
3.12 (0.51-19.14) 
 
 
 
0.19* 
 
Peak value, all participants 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
 
53 
55 
52 
49 
 
7 (21.2) 
7 (21.2) 
9 (27.3) 
10 (30.3) 
 
1 
0.96 (0.31-2.95) 
1.38 (0.47-4.02) 
1.68 (0.59-4.84) 
 
 
 
0.25* 
 
1 
0.93 (0.24-3.59) 
1.50 (0.41-5.41) 
2.24 (0.58-8.64) 
 
 
 
0.19* 
3-D value, all participants 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
59 
45 
57 
43 
 
11 (33.3) 
6 (18.2) 
10 (30.3) 
6 (18.2) 
 
1 
0.67 (0.23-1.98) 
0.93 (0.36-2.39) 
0.71 (0.24-2.09) 
 
 
 
0.86 
 
1 
1.09 (0.29-4.13) 
1.25 (0.30-5.31) 
1.54 (0.21-11.08) 
 
 
 
0.67* 
 
c- comparison group are HIV-infected individuals on HAART with viral load <50 copies/ml. 
d - Adjusted for age, gender, UV exposure status, smoking status, alcohol intake, income, history of any eye condition, current nadir CD4 
count, peak viral load, TB status, WHO clinical stage, HAART duration and regimen  
* - Refers to p-value for test of linear trend 
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 SUPPLEMENTARY FIGURES 
Figure S1a: Linear metric from lens with minimal opacities 
 
Figure S1b: Peak metric from lens with minimal opacities 
 
Figure S1c: 3D-average metric from lens with minimal opacities 
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 Figure S2a: Linear metric from lens with mid-range lens opacities 
 
Figure S2b: Peak metric from lens with mid-range lens opacities 
 
Figure S2c: 3D-average metric from lens with mid-range lens opacities 
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 Figure S3a: Linear metric from lens with high lens opacities 
 
Figure S3b: Peak metric from lens with high lens opacities 
 
Figure S3c: 3D-average metric from lens with high lens opacities 
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 Figure S4: Example of very high lens density (clinical cataract) 
 
Figure S5: Comparison of lens with minimal (a) and high (b) lens opacities 
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 Chapter 9 
Corneal endothelial cells provide evidence 
of accelerated cellular senescence 
associated with HIV infection:  
a case-control study 
 
 
Corneal endothelial cells captured by specular microscopy with polymegathism and pleomorphism indices 
 
Research paper evaluating corneal endothelial cell 
parameters known to be associated with biological 
aging, and cellular senescence markers  
in HIV-infected adults. 
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 Abstract 
Background 
Cellular senescence may be a key factor in HIV-related premature biological aging. 
We assessed features of the corneal endothelium that are known to be associated with 
biological aging, and cellular senescence markers in HIV-infected adults.  
Methods: 
Case-control study of 242 HIV-infected adults and 249 matched controls. Using 
specular microscopy, the corneal endothelium was assessed for features of aging (low 
endothelial cell density [ECD], high variation in cell size, and low hexagonality 
index). Data were analysed by multivariable regression. CDKN2A (a cell senescence 
mediator) and 8-hydroxy-2′-deoxyguanosine (an oxidative DNA damage marker) 
were measured in peripheral blood leukocytes. 
Results: 
The median age of both groups was 40 years. Among HIV-infected adults, 88% were 
receiving antiretroviral therapy (ART); their median CD4 count was 468 cells/L. 
HIV infection was associated with increased odds of variation in cell size (OR=1.67; 
95%CI: 1.00-2.78, p=0.04). Among HIV-infected participants, low ECD was 
independently associated with current CD4 count <200 cells/L (OR=2.77; 95%CI: 
1.12-6.81, p=0.03).  In participants on ART with undetectable viral load, CDKN2A 
expression and 8-OHDG levels were higher in those with accelerated aging, as 
reflected by lower ECD. 
Conclusions: 
The corneal endothelium shows features consistent with HIV-related accelerated 
senescence, especially among those with poor immune recovery.  
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 MAIN TEXT 
Introduction 
Patients receiving antiretroviral therapy (ART) are at increased risk of age-related 
non-AIDS morbidity and mortality compared with HIV-seronegative persons [1,2]. It 
is speculated that as those with HIV age chronologically, they are also likely to 
undergo accelerated biological aging, mediated by increased cellular senescence. This 
may be due to replicative senescence (a state of irreversible cellular growth arrest) 
and stress-induced premature senescence (SIPS) from exposure to environmental 
stresses, including oxidative stress [3]. Senescent cells adopt an enlarged morphology 
and secrete inflammatory factors leading to low-level, chronic inflammation 
described as the senescence-associated secretory phenotype (SASP) [4].  
 
The eye may be a useful site for investigating cellular dynamics of aging, as 
the corneal endothelium can be readily visualized using non-invasive techniques. The 
corneal endothelium is a monolayer of mosaic-like cells which lines the inner surface 
of the cornea. Human corneal endothelial cells (HCEC) do not have substantial 
replicative potential in vivo and their form and quantity influence the health of the 
cornea [5]. Cells vary from 4 to 6 μm in thickness, are up to 20 μm in width, and have 
a stable, metabolically efficient hexagonal shape [6]. A key function of the corneal 
endothelium is to maintain corneal transparency via an ionic ‘pump’. Loss of HCEC 
beyond a critical threshold results in corneal oedema and loss of visual acuity.  
 
HCEC can be viewed non-invasively via specular microscopy which uses 
specular reflection [7]. Three endothelium parameters are commonly assessed. Firstly, 
the number of cells within a defined area - endothelial cell density (ECD), which 
Sophia Pathai PhD Thesis Page 217
 decreases [8-10] throughout life at an average rate of 0.3-0.6%/year [5,11]. Mean cell 
density is approximately 3400 cells/mm
2
 at age 15 years declining to approximately 
2300 cells/mm
2
 by 85 years [12]. The endothelial response to gradual cell loss is 
spreading and migration of neighbouring cells, leading to an increase in overall cell 
size and loss of hexagonal shape [5]. Thus, the second parameter that can be 
measured is variation in cell size (polymegathism) which is- measured using the 
coefficient of variation (CV) of cell area, which is the ratio between the observed 
standard deviation and the arithmetic mean of all the cells examined. An average 
value is less than 35. Variation in cell size increases with increasing chronological age. 
The final parameter is the hexagonality index – the proportion of cells with 6 sides 
and this decreases with increasing chronological age [13].   
 
Reduction in proliferative capacity of HCEC is partly mediated by an age-
related increase in expression of the cell cycle mediator CDKN2A [14,15] that 
functions to hold a cell in a state of growth arrest. Increasing levels of CDKN2A 
transcriptional expression occur with increasing age, in solid organs and peripheral 
blood leukocytes [16-19].  Reduction in HCEC proliferative capacity may also result 
from nuclear oxidative damage, which can be assessed by 8-hydroxy-2′-
deoxyguanosine (8-OHDG) levels, a physical marker of oxidative DNA damage 
[3,20]. If premature cellular senescence occurs in HIV infection, senescent changes in 
HCEC may be evident in HIV-infected individuals compared to age-matched 
uninfected controls. Nadir CD4 count, current CD4 count and ART duration have 
frequently been reported as predictors of increased risk of systemic age-related 
morbidities in HIV-infected people [21-24]. We have previously reported from a 
South African population that HIV infection is associated with a functional phenotype 
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 consistent with frailty [25], and that changes in retinal vessel calibre (as a proxy for 
systemic vasculature) are consistent with accelerated aging and increased 
cardiovascular risk [26]. We now report on the cellular aspects of aging within this 
study cohort, using corneal endothelial cells as readily accessible model of cellular 
senescence. The objective of this study was to assess differences and identify 
predictors of HCEC parameters and markers of cellular senescence in a cohort of 
HIV-infected individuals in comparison to healthy controls.  
 
Methods 
Study participants 
HIV-infected participants aged 30 years and above were enrolled from a community-
based HIV treatment centre in Nyanga district of Cape Town, South Africa [27,28]. 
Participant recruitment has been reported in detail elsewhere [25].  In brief, all 
participants had a confirmed serological diagnosis of HIV and were either about to 
commence ART (ART-naïve), or were already on first-line ART. A control group of 
HIV-seronegative participants was recruited using frequency-matching by gender and 
5-year age categories.  
The study was approved by the London School of Hygiene and Tropical 
Medicine Ethics Committee and the University of Cape Town Faculty of Health 
Sciences Ethics Committee, and adhered to the tenets of the Declaration of Helsinki. 
Written informed consent was obtained from all participants 
 
Data collection 
Socio-demographic information and medical history were obtained by questioning 
participants in their first language (Xhosa or English). Data were also collected on 
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 exposures that are known to affect aging and age-related parameters (e.g. smoking, 
work location as a proxy for UV exposure). Clinical information was obtained from 
medical case notes where required. All participants underwent a full ophthalmic 
examination including measurement of visual acuity, evaluation by slit lamp 
microscopy (for anterior segment structures e.g. cornea, anterior chamber) and 
indirect ophthalmoscopy (for retina and vitreous).  
 
Endothelium assessment 
A non-contact specular microscope was used (SP02, CSO; Florence, Italy) in 
automatic release mode to reduce operator-dependent variables. The operator focused 
and aligned a real-time image of the participant’s eye. The instrument captured the 
endothelium in the central corneal area, and was calibrated to account for varying 
thickness of the central cornea (which has the potential to affect endothelial cell 
counts). The instrument software automatically calculated the quality and reliability 
of a captured image; if an image was of poor quality (i.e. not ‘ok’ on the image 
quality specification), the measurement was repeated. Participants who had corneal 
pathology or evidence of past or current intraocular inflammation were excluded from 
analysis. Endothelial parameter values were extracted from the image captures in a 
masked fashion. Two assessments were taken per eye and the mean was used in 
analyses. Figure 1 shows an example of the output.  
 
CDKN2A expression determination and 8OHDG measurement 
Relative quantitative real-time PCR (qRT-PCR) was used to estimate mRNA levels 
corresponding to the candidate senescence associated gene - CDKN2A. Expression 
levels were measured against a reference HPRT housekeeping gene on an ABI 
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 Prism(R) 7500 Sequence Detection System. Sequences of human TaqMan™ 
Primer/Probe sets were designed by Primer Express algorithm (Applied Biosystems, 
Austin, TX, USA). The comparative threshold cycle method (CT) was employed 
to quantify relative gene expression. The quantification result was transformed to an 
exponential value, 2–Ct [29] where Ct is the threshold cycle, or the cycle when the 
product was first detected. Prior to this quantitative study we demonstrated that the 
efficiency of amplification of reference (HPRT) and test genes were approximately 
equal (data not shown). Plasma 8-OHDG concentration was quantified using ELISA 
kits (OxiSelect, Cell Biolabs, CA, USA) according to manufacturer's instructions. 
 
Statistical analyses 
One eye per person was randomly selected for analyses. Where an eye was not 
available, for example due to trauma, the contralateral eye was used. Endothelium 
parameters were assessed as categorical variables by division into quartiles defined in 
the HIV-seronegative participants. The association of HIV status with these quartiles 
was assessed in univariable and multivariable logistic regression models adjusted for 
risk factors and a priori confounders (UV exposure, smoking). Linear regression 
analyses were also performed to assess the rate of endothelial cell loss per year in the 
two groups using age as a continuous variable. The endothelial parameter phenotypes 
were further defined with binary categorization to denote ‘aging’ as follows:  low 
endothelial cell count (<25
th
 percentile: <2461cells/mm
2
), high polymegathism (>75
th
 
percentile: >39), and low hexagonality index (<25
th
 percentile: <46). Serum 
biomarkers (CDKN2A and 8-OHDG) were analysed as continuous variables and 
multiple linear regression models were used to examine the relationships of biomarker 
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 expression with endothelial cell parameters. All analyses were performed with Stata 
11 IC (Stata Corp, USA). 
 
Results 
Participant characteristics 
Characteristics of the 242 HIV-infected individuals and 249 uninfected age/gender 
frequency matched HIV-seronegative individuals are reported in Table 1. HIV-
infected participants tended to have a greater income (attributable to a government 
health-related grant), to be non-smokers, and reported less consumption of alcohol 
than HIV-seronegative individuals. HIV-infected participants were almost twice as 
likely to have a history of an eye condition (p=0.01), but there was little difference in 
visual acuity (Table 1). None of the participants had undergone intraocular surgery in 
either eye or had evidence of clinically active uveitis, both of which could have 
affected the endothelium. Among the HIV-infected participants, 88% were receiving 
ART, the current median CD4 count was 468 cells/L (interquartile range: [IQR]: 
325-607) and 84% had an undetectable plasma viral load (VL –defined as <50 
copies/mL).  
 
 
Corneal endothelium assessment 
Three participants had corneal pathology precluding accurate image acquisition 
(inactive corneal infiltrates of both eyes), leaving 488 eyes for analysis. Endothelium 
parameter images of sufficient quality were available for 468 (95.9%) eyes. 
Acquisition of sub-optimal images was related to participant movement and rapid 
blinking during image capture. Poor quality images were more frequent in 
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 participants with a history of an eye condition compared to those without (9.4% vs. 
3.3%, p=0.02) and in those who had HIV infection (5.8% vs. 2.4%, p=0.06).  
 
Endothelial cell density  
Median cell density values were 2660 cells/mm
2
 (IQR: 2433-2851) in HIV-infected 
participants and 2614 cells/mm
2
 (IQR: 2460-2802) in HIV-seronegative individuals 
(p=0.56).  The age-adjusted rate of endothelial cell loss was greater in HIV-infected 
participants compared to HIV-seronegative individuals (0.30% per year vs. 0.15%), 
although this did not reach statistical significance (p-interaction=0.16).  Table 2 
reports the association of the endothelial cell parameters with HIV status. Table 3 
reports associations of socio-behavioural and clinical factors with low cell density 
within the study population. Increasing age was strongly associated with low cell 
density, both in univariable and multivariable analysis (p-trend=0.001). In addition to 
increasing age and male gender, a key finding was that low current CD4 counts were 
independently associated with low cell density among HIV-infected individuals 
(Table 4). Participants with CD4 counts <200 cells/L were almost three times more 
likely to have a low cell density (OR=2.77; 95%CI: 1.12-6.81). This association was 
strengthened when restricted to participants on ART (n=198) (OR=4.63; 95%CI: 
1.48-14.50– data not shown). 
 
Endothelial cell polymegathism (variation in cell size) 
The median variation in cell size (polymegathism) was 36 (IQR: 33-39) in HIV-
infected participants and 35 ([IQR: 32-38], p=0.07) in HIV-seronegative individuals. 
HIV was associated with higher polymegathism quartiles in univariable analyses (p-
trend=0.04), and this association strengthened after adjustment (p-trend=0.006) 
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 (Table 2). HIV infection was also associated with high polymegathism as a binary 
variable (OR=1.67, 95%CI 1.00-2.78) (Table 5). Increasing age, an outdoor work 
location and increased duration of smoking were also associated with high 
polymegathism. However, despite the association of HIV infection with this variable, 
HIV-related covariates were not related.  Independent predictors in HIV-infected 
individuals were outdoor work (OR=2.20; 95%CI: 1.00-4.90) and cigarette smoking 
(OR=3.41; 95%CI: 1.13-10.31) (Table 4). 
 
Hexagonality index (cell shape) 
The median hexagonality index was similar in both groups (50 [IQR: 45-54] vs. 50 
[IQR: 46-54], p=0.55). Low hexagonality index was associated with increasing age 
(p-trend=0.006) and outdoor work location (OR=1.70; 95%CI 1.04-2.78) but there 
was little evidence of an associated with HIV infection (OR=1.40, 95%CI 0.90-2.17). 
In HIV-infected individuals, low hexagonality index was associated with outdoor 
work (OR=1.97; 95%CI: 1.00-3.95); and inversely related with a history of an eye 
condition (OR=0.18; 95%CI: 0.07-0.62) (Table 4). No HIV-related covariates were 
associated with this endothelial parameter.   
 
Association between markers of cellular senescence and endothelial cell density 
CDKN2A measurements were available for 430 participants, (221 HIV+/209 HIV-). 
CDKN2A transcriptional expression was higher in HIV-infected participants 
compared to HIV-seronegative individuals (0.46 vs. 0.37, p=0.007). In ART-treated 
participants with suppressed viral load (<50 copies/ml; n=155) adjusted CDKN2A 
expression was higher in those with low cell density compared to those with high cell 
density (0.57 vs. 0.43, p=0.04). There was no evidence to suggest an association 
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 between CDKN2A expression and cell density in HIV-seronegative individuals 
(p=0.33).  
 
8-hydroxy-2′-deoxyguanosine (8-OHDG) levels were available for 70 individuals. 
8OHDG levels were positively associated with CDKN2A expression in HIV-
seronegative individuals (r=0.13, p=0.33). Mean levels were 0.21ng/ml in HIV-
seronegative individuals and 0.22ng/ml in HIV-infected individuals (p=0.83). In 
participants on ART with undetectable viral load (n=28), those with low ECD count 
had higher 8OHDG levels compared to those with high cell density (0.25ng/ml vs. 
0.19ng/ml, p=0.04). There was no association between 8OHDG levels and cell 
density in HIV-seronegative individuals.  
 
 
Discussion 
We have already demonstrated in this South African study population that HIV 
infection is associated with an increased risk of frailty, providing evidence that this 
functional phenotype is associated with HIV-related accelerated aging [25]. We have 
also investigated for evidence of aging at an organ/systems level using the retinal 
vessels as a model of the systemic vasculature, and our findings suggested that HIV 
infection is associated with changes in the retinal vasculature that may reflect 
premature aging and increased cardiovascular risk [26]. These previous studies both 
provided important evidence that HIV infection is associated with accelerated 
senescence. The present study further builds on these findings, using corneal 
endothelial cells to represent a readily accessible cellular model of senescence. Here 
we have demonstrated that HIV-infected individuals have an increased risk of greater 
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 corneal endothelial cell size variation (polymegathism) when compared with HIV-
seronegative individuals. Furthermore, HIV-infected individuals with a current CD4 
count <200 cells/L were more likely to have low endothelial cell densities than those 
with higher CD4 counts. These data were corroborated by markers of cellular damage 
and senescence which were found to be higher in virally suppressed ART-treated 
individuals with low cell densities. These findings provide further evidence of 
accelerated aging in HIV, and that this may be influenced by the level of 
immunodeficiency, as reflected by CD4 count.      
 
Independent predictors of low cell density in HIV-infected individuals 
included age (as anticipated), male gender and low current CD4 count. The 
relationship with male gender is likely to be related to the anti-oxidant and anti-
inflammatory properties of oestrogen [20], while the relationship with low current 
CD4 count suggests that poor immune restoration may accelerate senescence. Our 
finding that UV exposure and smoking were also independent predictors of 
polymegathism in the overall study population and in HIV-infected individuals 
supports the findings of others that stress, including oxidative stress, is likely to be an 
important contributor to cellular senescence mechanisms in HCECs [30]. Our 
observation of increased CDKN2A levels in PBLs from HIV- infected individuals 
compared with HIV-seronegative individuals supports the mechanism of systemic 
oxidative stress. Furthermore, exposure to cigarette smoke has been demonstrated to 
degrade the function of the cornea through generation of reactive oxygen species [31]. 
It is surprising that polymegathism was not associated with current CD4 count or 
other HIV-related covariates in our study. This may suggest that ‘stress’ induced by 
HIV-related chronic inflammation may lead to HCEC senescence, the initial features 
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 of which are an enlarged (or variation in) morphology. Severe immunodeficiency 
(manifest as a low CD4 count) may be associated with later features of the senescence 
pathway, ultimately leading to cell cycle arrest and cell loss.  
 
Despite the association of greater polymegathism (variation in cell size) with 
HIV, we did not detect a difference in cell density between the two groups. The 
endothelial response to gradual cell loss is spreading and migration of neighbouring 
cells with an increase in overall cell size and adoption of a non-hexagonal shape [5]. 
Therefore an overall decrease in ECD might have been expected. However, as 
increased polymegathism reflects a variation in cell size (not simply an increase in 
cell size), similar ECD between the two groups is not an unusual finding: ECD can 
remain the same with different levels of polymegathism. Other studies have reported 
similar findings [32] and patients with diabetes develop increased polymegathism 
while retaining normal endothelial cell density for their age [33]. Stress to the 
endothelium can also lead to cell border changes, with cells expressing a large 
anterior surface area with a small posterior surface area or vice versa [34]. Capturing 
a two-dimensional image with the specular microscope may, therefore, provide 
unchanged cell density measures despite greater polymegathism.  
  
An aggregate of phenotypes has been described for senescent cells [4,35], 
including irreversible growth arrest, an enlarged morphology, expression of CDKN2A 
and the senescence-associated secretory phenotype (SASP). This cell phenotype is 
associated with secretion of cytokines, growth factors and proteases that can lead to 
low-level chronic inflammation that is a feature of normal aging, and also a key 
feature in HIV infection [36]. In our study, higher CDKN2A expression and 8OHDG 
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 levels in peripheral blood leukocytes were observed in participants on ART with 
undetectable viral load and low endothelial cell density, suggesting that accelerated 
cellular senescence may be occurring systemically. Markers of cellular senescence 
have also been detected within endothelial corneal tissue, from human subjects and 
mouse senescence models, showing greater CDKN2A expression with increasing age 
[37,38]. In addition, HCECs exhibit signs of oxidative DNA damage, and 
significantly higher levels of 8OHDG have been reported in corneas from older 
donors compared with younger donors [3]. Our findings suggest that corneal 
endothelial cells in HIV-infected individuals exhibit some of the phenotypic features 
of senescent cells. Consequently, they would be expected to express more CDKN2A 
and have the associated SASP compared to HIV-seronegative individuals. 
 
A key strength of our study is the inclusion of an age- and gender-matched 
control group with a similar socio-demographic profile to the HIV-infected 
participants. The hypothesis of accelerated aging in HIV has received criticism due to 
limitations in characterization of participants, in particular the possibility of 
differential exposure to potential risk factors between HIV-infected and uninfected 
populations [24,39,40]. By recruiting from the same community, we reduced the 
likelihood of differential risk exposure. HCEC change morphology and assume an 
‘aged phenotype’ in several chronic systemic diseases (e.g. renal failure and diabetes) 
[41]  [42,43], suggesting that they may be useful in assessing cellular senescence, 
particularly as measurement is objective and non-invasive. 
 
There are some limitations to our study. Although our hypothesis relates to 
accelerated aging in HIV, it is possible that subclinical intraocular inflammation could 
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 account for the observed relationship between lower CD4 counts and low endothelial 
cell density. HIV can replicate within the eye causing uveitis [44], and a low CD4 
count is a risk factor for immune recovery uveitis (IRU) [45] which could arise in 
patients with a history of cytomegalovirus (CMV) infection and could potentially 
cause subclinical endothelial damage. However, we did not detect any evidence of 
IRU, and we have previously shown the prevalence of CMV retinitis to be very low 
within this population [46]. Therefore, our data support the hypothesis of premature 
aging in line with systemic co-morbidities [21,47].  Another limitation is that 
misclassification of smoking and alcohol consumption status may have occurred, with 
HIV-infected participants wanting to demonstrate ‘healthy behaviour’, which could 
have led to confounding. Our measure of location of work as a proxy measure of 
ultra-violet exposure may also have been confounded by socio-economic status. 
Finally, CDKN2A expression and 8OHDG levels were determined in peripheral 
blood leukocytes, which may not directly reflect levels in corneal tissue. However, a 
number of studies indicate that CDKN2A transcriptional expression increases with 
increasing chronological age in both leukocytes and solid organs [16,17,19]. 
 
In summary, corneal endothelial cells demonstrate features of senescence in 
HIV-infected individuals, suggesting HIV infection contributes towards accelerated 
cellular senescence. Evaluation of corneal endothelial cells in longitudinal studies of 
HIV-related accelerated biological aging may reveal further insights into the 
mechanisms of cellular senescence in this population.  
 
Word count: 3070 
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 Table 1: Characteristics of study participants   
Variable HIV-infected 
participants 
(242) % (n) 
HIV-seronegative 
individuals  
(249)% (n) 
P-value 
Age (mean±SE) 41.2±0.5 42.5±0.6 0.10 
Age, years by group 
30-39 
40-49 
>50 
 
 
119 (49.2) 
81 (33.5) 
42 (17.4) 
 
117 (47.0) 
79 (31.7) 
53 (21.3) 
 
 
0.54 
Male gender 25.6 (62) 24.1 (60) 0.70 
Working location 
Indoors 
 
35.1 (85) 
 
28.1 (70) 
 
0.10 
Income 
>ZAR1000/month 
 
42.2 (102) 
 
31.7 (79) 
 
0.02 
Smoking status 
Non-smoker 
<10 years 
>10 years 
 
85.5 (207) 
4.6 (11) 
9.9 (43) 
 
72.7 (181) 
12.9 (32) 
14.5 (36) 
 
0.001 
Alcohol 
Yes 
 
30.2 (73) 
 
44.2 (110) 
 
0.001 
History of eye condition 
Yes 
 
16.9 (41) 
 
9.3 (23) 
 
0.01 
Visual acuity (presenting) 20/25 20/20 0.68 
% with visual acuity <20/40 6.2 (15) 10.0 (25) 0.12 
HIV-related characteristics (n=242)    
WHO stage 
1/2 
3/4 
 
27.3 (66) 
72.7 (176) 
  
ART* naïve  12.0 (29)   
CD4 count in ART naïve group (n=29)** 170  (84-201)   
Log10VL in ART naïve group (n=19)*** 4.81 (4.11-5.14)   
Current CD4 count in ART group  (n=213)** 468 (325-607)   
Nadir CD4 count in ART group ** 127 (76-171)   
% with detectable VL in ART group  16.0 (34)   
Peak Log10VL in ART group *** 4.56 (3.85-4.98)   
Duration of ART, months  58 (34-75)   
ART Regimen  
Containing AZT/3TC 
Other 
 
59.6 (127) 
40.3 (86) 
  
*ART= Anti-retroviral therapy; **=cells/l; ***=copies/ml 
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 Table 2: Association of endothelial cell parameters with HIV status 
*=p-value: test for trend; ** Adjusted for age, gender, UV exposure, BMI, alcohol and cigarette smoking 
status, any history of an eye condition
Endothelial cell 
parameters 
N 
(468) 
HIV-infected 
participants 
(%) 
Univariate 
  OR (95%CI)         P-value 
Multivariate** 
  OR (95%CI)      P-value 
Endothelial cell density 
(ECD) 
First quartile (lowest)  
Second quartile 
Third quartile 
Fourth quartile (highest) 
 
 
 
125 
98 
119 
126 
 
 
64(28.3) 
38 (16.8) 
58 (25.7) 
66 (29.2) 
 
 
1 
0.60 (0.35-1.03) 
0.91 (0.55-1.50) 
1.05 (0.64-1.72) 
 
 
 
0.18 
 
 
1 
0.62 (0.35-1.10) 
0.93 (0.55-1.57) 
1.10 (0.65-1.85) 
 
 
 
0.22 
Polymegathism (variation 
in cell size) 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
 
 
121 
129 
103 
115 
 
 
51 (22.5) 
59 (26.1) 
54 (23.9) 
62 (27.4) 
 
 
1 
1.16 (0.70-1.91) 
1.51 (0.89-2.57) 
1.61 (0.96-2.69) 
 
 
 
 
0.04* 
 
 
1 
0.99 (0.58.1.68) 
1.52 (0.87-2.67) 
1.99 (1.15-3.45) 
 
 
 
 
0.006* 
Hexagonality index (cell 
shape) 
First quartile  
Second quartile 
Third quartile 
Fourth quartile 
 
 
142 
117 
109 
100 
 
 
74 (32.7) 
56 (24.8) 
47 (20.8) 
49 (21.7) 
 
 
1 
0.84 (0.52-1.36) 
0.70 (0.42-1.15) 
0.88 (0.53-1.47) 
 
 
 
 
0.57 
 
 
1 
0.76 (0.46-1.27) 
0.59 (0.34-1.00) 
0.81 (0.48-1.39) 
 
 
 
 
0.27 
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 Table 3: Association of low endothelial cell density in study population (n=468)  
*=test for trend; **- Adjusted for all other variables in model 
Variable Univariate 
  OR (95%CI)     P-value 
Multivariate** 
  OR (95%CI)       P-value 
 
HIV infection 
No  
Yes 
 
 
1 
1.17 (0.78-1.77) 
 
 
 
0.45 
 
 
1 
1.14 (0.74-1.76) 
 
 
 
0.56 
Gender 
Male  
Female 
 
1 
0.74 (0.47-1.18) 
 
 
0.20 
 
1 
0.66 (0.39-1.14) 
 
 
0.14 
Age (years) 
30-39 
40-49 
>50 
 
1 
1.60 (0.99-2.57) 
2.41 (1.41-4.15) 
 
 
 
0.005* 
 
1 
1.60 (0.98-2.61) 
2.43 (1.39-4.24) 
 
 
 
0.001* 
Work location 
Outdoor worker 
Indoor worker 
 
0.96 (0.62-1.49) 
1 
 
 
 
0.85 
 
0.87 (0.55-1.37) 
1 
 
 
 
0.55 
Cigarette smoker 
No 
Yes 
 
1 
0.87 (0.52-1.46) 
 
 
0.60 
 
1 
0.66 (0.34-1.24) 
 
 
0.20 
Alcohol consumption 
No 
Yes 
 
1 
0.89 (0.58-1.36) 
 
 
0.58 
 
1 
0.83 (0.51-1.36) 
 
 
0.46 
History of eye condition 
No 
Yes 
 
1 
1.71 (0.96-3.06) 
 
 
0.07 
 
1 
1.41 (0.77-2.57) 
 
 
0.27 
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 Table 4: Multivariable models to demonstrate association of endothelial cell parameters in HIV-infected individuals (n=217) 
§  - Adjusted for all other variables in model;  *=test for trend 
 
 
 
Variable Low endothelial cell density§ High polymegathism§  
(cell variation) 
 Low hexagonality index§ 
(cell shape not 6-sided) 
 OR P-value OR P-value  
Gender 
Male 
Female 
 
1 
0.43 (0.19-0.91) 
 
 
0.04 
 
1 
2.19 (0.81-5.86) 
 
 
0.12 
 
1 
0.99 (0.44-2.29) 
 
 
0.98 
Age (years) 
30-39 
40-49 
>50 
 
1 
2.84 (1.35-5.97) 
5.42 (2.21-13.26) 
 
 
 
<0.0001* 
 
1 
1.00 (0.43-2.31) 
2.44 (0.97-6.13) 
 
 
 
0.09* 
 
1 
0.63 (0.30-1.34) 
1.69 (0.71-3.98) 
 
 
 
0.12 
Work location 
Outdoor worker 
Indoor worker 
 
0.57 (0.29-1.12) 
1 
 
 
0.11 
 
2.20 (1.00-4.90) 
1 
 
 
0.05 
 
1.97 (1.00-3.95) 
1 
 
 
0.05 
Cigarette smoker 
No 
Yes 
 
1 
1.04 (0.39-2.78) 
 
 
0.93 
 
1 
3.41 (1.13-10.31) 
 
 
0.03 
 
1 
1.09 (0.39-3.06) 
 
 
0.87 
History of eye condition 
No 
Yes 
 
1 
1.04 (0.44-2.49) 
 
 
0.93 
 
1 
0.95 (0.37-2.49) 
 
 
0.93 
 
1 
0.18 (0.05-0.62) 
 
 
0.01 
WHO clinical stage 
1/2 
3/4 
 
1 
1.58 (0.71-3.51) 
 
 
0.26 
 
1 
1.88 (0.80-4.54) 
 
 
0.16 
 
1 
1.11 (0.52-2.33) 
 
 
0.79 
Peak viral load 
<10,000 copies 
>10,000 copies 
 
1 
0.65 (0.32-1.31) 
 
 
0.23 
 
1 
0.87 (0.40-1.86) 
 
 
0.71 
 
1 
0.84 (0.42-1.69) 
 
 
0.62 
Current CD4 count 
<200 cells/L 
>200 cells/L 
 
2.77 (1.12-6.81) 
1 
 
 
 
0.03 
 
1.30 (0.49-3.48) 
1 
 
 
 
0.60 
 
0.62 (0.24-1.61) 
1 
 
 
0.33 
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 Table 5: Association of high polymegathism (increased variation of cell size) in study 
population (n=468) 
 *=test for trend; § - Adjusted for all other variables in model 
 
Variable Univariate 
OR (95%CI)               P-value 
Multivariate§ 
  OR (95%CI)              P-value 
HIV infection 
No  
Yes 
 
1 
1.26 (0.78-2.01) 
 
 
0.34 
 
1 
1.67 (1.00-2.78) 
 
 
0.04 
Gender 
Male  
Female 
 
1 
1.54 (0.86-2.78) 
 
 
0.15 
 
1 
2.79 (1.35-5.77) 
 
 
0.006 
Age (years) 
30-39 
40-49 
>50 
 
1 
1.43 (0.83-2.48) 
2.33 (1.28-4.25) 
 
 
 
0.02 
 
1 
1.31 (0.74-2.33) 
2.33 (1.23-4.40) 
 
 
 
0.01* 
Work location 
Outdoor worker 
Indoor worker 
 
1.78 (1.02-3.10) 
1 
 
 
0.04 
 
1.76 (.100-3.12) 
1 
 
 
0.05 
Cigarette smoker 
Nil  
5yrs or less  
 6-15  
16-20          
>20 
 
1 
1.91 (0.72-5.07) 
1.27 (0.46-3.16) 
1.69 (0.65-4.44) 
1.87 (0.75-4.64) 
 
 
 
 
 
0.43 
 
1 
2.07 (0.71-6.02) 
2.34 (0.73-7.44) 
2.47 (0.83-7.39) 
2.72 (0.9108.12) 
 
 
 
 
 
0.02* 
Alcohol consumption 
No 
Yes 
 
1 
0.77 (0.47-1.22) 
 
 
0.26 
 
1 
0.70 (0.39-1.24) 
 
 
0.22 
History of eye condition 
No 
Yes 
 
1 
1.71 (0.96-3.06) 
 
 
0.07 
 
1 
0.80 (0.38-1.72) 
 
 
0.57 
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 Figure legends: 
Figure 1: Example of corneal endothelial cells captured by specular microscopy 
A: Endothelial cells – density is 2454 cells/mm2 
B: Polymegathism assessment – measurement of cell size 
C: Pleomorphism assessment – proportion of cells that are hexagonal  
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 4 
Abstract 
Purpose: To investigate the relationships between contrast sensitivity (CS), 
retinal nerve fibre layer (RNFL) and HIV-1 infection in South African adults.  
 
Design: Case-control study 
 
Methods:  
 Setting: Township primary care clinics. 
 Study Population: 225 HIV-infected individuals without retinal 
opportunistic infections [OIs], and 203 gender/age-matched HIV-
seronegative individuals.  
 Observation Procedures: Peri-papillary RNFL thickness was 
determined with spectral domain optical coherence tomography in four 
quadrants. CS was measured using a Pelli-Robson chart.  
 Main Outcome Measures: RNFL thickness and CS were evaluated as 
continuous and binary variables. Multivariable linear and logistic 
regression were used to assess associations between HIV status and 
RNFL and CS. 
Results: The median age of both groups was similar (41.2 vs. 41.9 years, 
p=0.37). Antiretroviral therapy (ART) was being received by 88% of HIV-
infected individuals and their median CD4 count was 468 cells/l. Adjusted 
CS score was lower in HIV-infected participants compared to HIV-
seronegative individuals (1.76 vs. 1.82, p=0.002). Independent predictors of 
poor CS in the HIV-infected group were positive frailty status and current HIV 
viral load >2 log copies/ml. Lower CS score was also associated with thin 
temporal RNFL in HIV-infected individuals (p=0.04). Superior quadrant RNFL 
thickness was greatest in ART-naïve participants relative to the HIV-
uninfected group (p-trend=0.04). Longer ART duration was associated with 
decreased thickness of inferior and nasal RNFL quadrants (p-trend=0.03 and 
0.04, respectively).  
 
Conclusions: Contrast sensitivity is reduced in those with HIV-infection and 
functionally associated with systemic frailty and unsuppressed viraemia. This 
may reflect structural changes in the RNFL that are evident despite the 
absence of OIs.  
 
Abstract word count: 250 
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 5 
MAIN TEXT 
Introduction: 
In well-resourced settings, antiretroviral treatment (ART) has altered the 
spectrum of HIV-related eye disease in people living with HIV infection, 
leading to a lower prevalence of retinal opportunistic infections (OIs) such as 
cytomegalovirus (CMV) retinitis.1, 2 This trend is now becoming apparent in 
resource-constrained environments where scale-up of ART is being started in 
individuals with increasingly high CD4 counts. However, abnormalities in 
visual function, such as reduced contrast sensitivity (CS), altered colour vision 
and visual field loss also have also been reported in HIV-infected individuals 
despite effective viral suppression and the absence of retinal OIs. It is thought 
that these changes may be mediated by an HIV-associated ‘neuroretinal 
disorder’ (HIV-NRD) which is characterized by changes in the retinal nerve 
fibre layer (RNFL).3-5 
 
One mechanism that may potentially contribute to HIV-NRD is 
‘accelerated biological’ aging that is recognised to be associated with HIV 
infection.6  This refers to conditions which are classically associated with the 
normal ageing process but which occur at an earlier age in HIV-infected 
individuals compared with those of similar age who are seronegative.7-9 This 
may have major implications for long-term morbidity, including for the many 
millions of people receiving ART in sub-Saharan Africa.10, 11 However, there 
are limited data on visual function (in the absence of ocular OIs) in people 
living with HIV in this region. Although RNFL changes are strongly related to 
chronological age,12, 13 studies describing visual function, RNFL status and the 
possibility of HIV-NRD in HIV-infected individuals are needed, particularly as 
quality of life might be significantly compromised. Indeed, impaired contrast 
sensitivity (CS) can be more disabling than visual acuity loss.14  
 
We have recently undertaken a case-control study of adults in South 
Africa, and have shown that HIV infection is associated with retinal vessel 
calibre changes consistent with accelerated HIV-related aging and these may 
reflect an increased risk of cardiovascular disease.15 We have also shown in 
the same study population that HIV infection is associated with a functional 
phenotype consistent with frailty.6 This is a clinical syndrome initially 
described in geriatric populations, characterised by multiple pathologies, low 
physical activity and slow motor performance.16, 17 Frailty predicts cognitive 
and physical decline and is associated with an increased risk of morbidity and 
mortality. We now report the findings of visual function from this study, using 
CS and RNFL as representative measures of ocular aging. The objectives of 
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this study were to assess differences and identify predictors of CS and RNFL 
parameters in HIV-infected individuals compared to age-gender matched 
controls, and to assess whether visual function is related to the phenotype 
consistent with HIV-related accelerated biological aging that we have already 
reported.   
 
Methods: 
Study participants 
HIV-infected participants aged >30 years were enrolled from a community-
based HIV treatment centre in Nyanga district in Cape Town.18, 19 Participant 
recruitment has been reported in detail previously.6 In brief, all participants 
had a confirmed serological diagnosis of HIV and were either about to 
commence ART (ART-naïve), or were already on first-line ART. Individuals 
were excluded if they had a history or current ocular OI, which was confirmed 
from medical case notes. All participants had a best-corrected visual acuity of 
20/40 or better in order to be able to perform ophthalmic tests (i.e. CS) 
satisfactorily. A control group of HIV-seronegative participants was recruited 
from an HIV clinical prevention trials centre in a neighbouring community by 
frequency-matching using gender and 5-year age categories.  
 
Data collection 
Data on age, sex, weight and height, as well as socio-behavioural factors 
such as housing, income, smoking and alcohol consumption were collected. 
Data collected for HIV-infected participants included nadir and current CD4 
count, peak and current viral load, staging of HIV according to WHO clinical 
stage, ART status and regimen. Clinical information was obtained from 
medical case notes where required. Blood pressure (BP) was measured with 
a digital sphygmomanometer with a cuff of appropriate size. Mean arterial 
blood pressure (MABP) was defined as two-thirds of the diastolic plus one-
third of the systolic BP.20 Hypertension was defined as a systolic BP of 
140mmHg or higher, diastolic BP of 90mmHg or higher, or the combination of 
self-reported high BP diagnosis and the use of anti-hypertensive 
medications.21 Body mass index (BMI) was defined as weight (in 
kilograms)/height2.  
 
All participants underwent a full ophthalmic examination including 
measurement of visual acuity, evaluation by slit lamp microscopy and indirect 
ophthalmoscopy. Contrast sensitivity was measured with a Pelli-Robson chart 
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(Haag-Streit, Essex, UK). The chart has eight lines of letters with two groups 
of three letters per line. Testing was performed at 1 m with a 0.75 diopter lens 
added to the manifest refraction if necessary. The logarithm to the base 10 of 
the CS measurement was obtained from the Pelli-Robson chart and used in 
analyses. Investigators who conducted the tests were masked to other data. 
RFNL thickness was obtained using the Spectral OCT/SLO optical coherence 
tomography machine (Opko/OTI Inc, Miami, FL). The Spectral OCT/SLO uses 
a scanning laser diode of 830nm to provide images of ocular microstructures. 
A peripapillary protocol inbuilt in the software was used to determine the 
average and quadrant-specific RNFL thickness (superior, inferior, temporal 
and nasal).  
 
The study was approved by the Ethics Committees of the London 
School of Hygiene and Tropical Medicine and the University of Cape Town 
Faculty of Health Sciences, and adhered to the tenets of the Declaration of 
Helsinki. Written informed consent was obtained from all participants 
 
Statistical analyses: 
One eye was randomly selected for analysis. Where an eye was not available, 
for example due to trauma or corneal opacity, the contralateral eye was used. 
LogCS scores and RNFL were initially analysed as continuous variables. Age 
and sex-adjusted linear regression was performed to compare logCS score 
and RNFL parameters respectively by HIV status.  A binary categorisation of 
logCS was defined using the a-priori defined cutpoint of the 25th percentile in 
the control group to denote ‘poor CS’ (1.65). Further analyses were 
undertaken using the cut-off of 1.50 as defined by Shah and associates.22 
Similarly, a binary categorisation of RNFL was defined using the cut-off of the 
25th centile in the control group to denote ‘thin RNFL’ (≤ 25th percentile; 
average 101µm, superior 118µm, inferior 124µm, temporal 62µm, nasal 
74µm). Logistic regression was used to assess predictors of poor CS in those 
participants on ART. Multivariable linear regression models were used to 
examine the relationship of RNFL parameters as the dependent variable, with 
HIV status and other explanatory variables (age group [30-39; 40-49; >50 
years], gender, MABP; BMI, smoking) as independent variables. Separate 
models were used for HIV-infected participants to investigate the effects of 
HIV-related variables. Marginal adjusted means for RNFL parameters were 
estimated at the mean value of covariates in the model. The Wald test was 
used to assess statistical significance of the association of each explanatory 
variable on RNFL thickness. All analyses were performed with Stata 12 (Stata 
Corp, College Station, TX).  
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Results 
Participant characteristics: 
Characteristics of the 225 HIV-infected individuals and 203 HIV-seronegative 
age/gender frequency matched HIV-seronegative individuals are reported in 
Table 1. Although frequency matching was undertaken, some individuals did 
not have OCT images of adequate quality for analysis, resulting in a greater 
proportion of HIV-infected participants being included in the analyses. 
However, those with images did not differ from those without with respect to 
age, gender or other clinical/demographic characteristics (p>0.10 for all 
variables; data not shown). HIV-infected participants tended to have a greater 
income (attributable to a government health-related grant), to be non-
smokers, reported lower consumption of alcohol and had a lower BMI than 
HIV-seronegative individuals. There was little difference in visual acuity 
between the two groups. Among the HIV-infected participants, 88% of whom 
were receiving ART, the current median CD4 count was 468 cells/L 
(interquartile range: [IQR]: 327-607) and 84.9% had an undetectable plasma 
viral load (VL), defined as <50 copies/ml. 
 
Contrast sensitivity: 
Data on CS were available for 216 HIV-infected individuals and 215 HIV-
seronegative individuals. Mean logCS was lower in HIV-infected individuals 
compared to HIV-seronegative participants (1.77 vs. 1.82, p=0.005). After 
adjustment for age, sex, smoking status (yes/no), MABP and BMI, mean 
logCS values still remained lower in HIV-infected individuals (1.76 vs. 1.82, 
p=0.002). HIV-infected individuals were also more likely to have ‘poor CS’ 
(<1.65) compared to their uninfected counterparts (adjusted proportions: 43.5 
vs. 31.8%, p=0.01).   
 
In multivariable analysis among HIV-infected participants on ART, poor CS 
was associated with positive frailty status (OR 3.04; 95%CI: 1.25-7.35, 
p=0.01) (Table 2) and HIV viral load >2 log copies/ml (OR 3.03; 95%CI: 1.02-
8.97, p=0.05).  
 
Retinal nerve fibre layer:  
Table 3 shows the average and quadrant RNFL thickness stratified by HIV 
status and by viral load status. Average RNFL thickness was similar between 
two groups as stratified by HIV status (yes; no). RNFL thickness was also 
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stratified according to viral load status (Table 3). There was a trend of greater 
RNFL thickness of the superior quadrant with greater HIV viremia: the mean 
superior RNFL thickness in HIV-seronegative individuals was 132.2μm, 
compared to 133.8 μm in HIV-infected individuals on ART with non-detectable 
VL, and 140.0μm in HIV-infected individuals who were ART-naïve (and had 
detectable VL), p-trend=0.04. A similar trend was observed for the inferior 
quadrant (p-trend=0.13). Associations of RNFL thickness with current or nadir 
CD4 count were not observed. 
 
Among HIV-infected participants increasing age, as expected, was associated 
with thinning of the RNFL. Increasing duration of ART was associated with 
reduced thickness of the RNFL in nasal and inferior quadrants (Table 4). No 
association was detected with type of ART. Similarly, average and superior 
quadrant RNFL thickness was lower in those with advanced HIV infection at 
ART initiation, as defined by WHO clinical stage 3 or 4.  
 
Relationship between CS and RNFL thickness 
Finally, we assessed CS score according to RNFL thickness (thin or normal) 
in HIV-infected participants. Lower CS was associated with thin temporal 
RNFL (1.70; thin RNFL, vs. 1.78; normal RNFL, p=0.04). Logistic regression 
to assess the predictive value of poor CS as a risk factor for temporal thinning 
of the RNFL showed that the odds ratio using a cut off of 1.65 was not 
significant (OR: 1.46; 95%CI: 0.64-3.34, p=0.37). However, those with a CS 
value <1.5 had an almost threefold risk of thin temporal RNFL (OR: 2.78; 
95%CI: 1.03-7.54, p=0.04).  
 
Discussion 
This study provides clear evidence that HIV infection is strongly associated 
with poor contrast sensitivity in this South African population. Data from other 
regions, particularly the USA, demonstrate evidence of an HIV-related ‘neuro-
retinal disorder’, comprising subtle vision abnormalities in the absence of 
opportunistic infections.3, 5, 22, 23 However, this has not been investigated in 
sub-Saharan Africa to date, where access to ART and the aging HIV-infected 
population both continue to increase. In a study population from this region we 
assessed both structural and functional components of the RNFL. Our 
findings relating to RNFL thickness are novel: higher levels of HIV viremia 
were associated with increased RNFL thickness, whereas longer duration of 
ART was associated with decreased RNFL thickness. We also found frailty to 
be an important predictor of poor CS. These findings have potentially 
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important implications for long-term visual function particularly among the 
expanding HIV-infected aging population in sub-Saharan Africa.  
 
We have previously demonstrated that HIV infection is associated with 
an increased risk of frailty in this South African population, providing evidence 
that this functional phenotype is associated with HIV-related accelerated 
aging.6 The present study builds on these findings, demonstrating that frailty is 
an important predictor of poor CS. This suggests that there may be a visual 
component to frailty in HIV infection. This is further corroborated by the finding 
that abnormal CS is also independently associated with mortality in individuals 
with AIDS,24 and may be a sensitive indicator of generalized aging.25 
However, the present criteria for frailty assessment do not contain any visual 
function indicators. In light of these findings, a validation study that includes 
visual function as another measure of frailty may be warranted. Changes in 
the RNFL have been demonstrated in conditions with neuro-cognitive decline 
(e.g. Parkinson’s Disease; Alzheimer’s Disease)26, 27 and a neuro-cognitive 
component may also contribute to the frailty phenotype,28, 29 as well as HIV-
associated neurocognitive disorders30. Therefore measurement of RNFL may 
also be a useful novel predictor in this context. 
 
The frequency of poor CS was markedly higher in HIV-infected 
individuals compared to controls, yet the median visual acuity between the 
two groups was the same, and all participants had visual acuity better than 
20/40. Contrast sensitivity loss can be present even when visual acuity and 
fields are relatively intact.31 It is also a better predictor of mobility performance 
than visual acuity.32 These findings highlight that visual complaints from HIV-
infected individuals may be related to poor CS, and that visual acuity testing 
(often performed as a baseline ‘screen’ by HIV physicians to guide further 
referral) will often be normal.  Assessment of CS could be a useful aid in initial 
examination of patients with symptoms suggestive of visual dysfunction. 
 
In the context of accelerated aging and HIV, reduced thickness of the 
RNFL in HIV-infected individuals compared to uninfected counterparts of 
similar age might be expected as RNFL thickness decreases with increasing 
chronological age.12, 13 Other studies have compared RNFL thickness in HIV-
infected individuals with HIV-seronegative controls, but it is difficult to make 
comparisons as study populations differ in terms of demographic and HIV-
related characteristics as well as in the methods used to assess RNFL.  
Thinning of the RNFL has been detected in HIV-infected participants in the 
USA with low nadir CD4 count when compared with HIV-infected individuals 
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with higher nadir CD4 count and HIV-seronegative controls in using OCT.4, 33 
Significant thinning of the RNFL in HIV-infected participants (regardless of 
CD4 count) compared to uninfected controls, was observed with confocal 
scanning laser tomography,34 whereas a study from Brazil did not find a 
significant difference in RNFL thickness between HIV- infected and uninfected 
participants using OCT.35 In our study, we did not observe associations 
related to CD4 count and RNFL thickness, however we did detect 
associations with HIV viremia. It is therefore difficult to place our study in the 
context of previous work, as the epidemiology of HIV in sub-Saharan Africa is 
likely to be different to that in other regions. In addition, the HIV and ART 
‘trajectory’ may be at earlier stages compared to HIV cohorts in well-
resourced settings (where the majority of studies have been conducted) thus, 
our findings may reflect those seen relatively early on in chronic HIV infection.    
 
Our findings suggest that ART duration is an important factor in 
determining RNFL thickness (inferior and nasal quadrants) after adjusting for 
age and other co-variates, and we have previously shown that narrower 
retinal arterioles are associated with increasing duration of ART, 
independently of age.15 RNFL thinning and retinal arteriolar narrowing may be 
related to early vascular dysfunction in the nerve fibre layer, mediated by 
either HIV infection or ART. Longitudinal studies are required to evaluate the 
contribution of ART and HIV infection to possible accelerated aging changes 
in the RNFL.  
 
The association of detectable HIV viremia with an increase in RNFL 
thickness in our study population is biologically plausible. Medzhitov36 used 
the term “para-inflammation” to describe an intermediate tissue adaptive 
response: infection and injury lead to full inflammation, whereas chronic tissue 
stress initiates mild low-grade ‘para’-inflammation, a mechanism which 
attempts to maintain tissue homeostasis and monitor tissue malfunction. 
However, chronic para-inflammation can lead to disease progression and is 
thought to be an important process in age-related retinal diseases.37 
Increased levels of HIV viremia could initiate a para-inflammatory process in 
the retina, which may manifest as increased thickness of the RNFL. Kalyani 
and associates3 have also reported greater RNFL thickness in a subgroup of 
HIV-infected individuals in the USA.  They suggested that mitochondrial 
toxicity (mediated by HIV or ART) may cause axonal damage to the RNFL, 
leading to an initial phase of swelling before atrophy. Similar mechanisms are 
postulated in Leber’s hereditary optic neuropathy (LHON), a mitochondrial 
disorder where mitochondrial dysfunction leads to degeneration of retinal 
ganglion cells and their axons in the optic nerve.38 OCT measurements in 
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LHON patients show that RNFL thickness increases in the pre-symptomatic 
stage, followed by a reduction over time.39  Additionally, we found that lower 
CS score was associated with thinner RNFL in the temporal quadrant, a 
finding also demonstrated by Kalyani and associates.3 Anatomically, this 
could reflect preferential damage to the small-calibre axons of the 
maculopapillary bundle, similar to proposed mechanisms occurring in LHON.3, 
38  
 A key strength of this study is the inclusion of an age/gender-matched 
control group with a similar socio-demographic profile as the HIV-infected 
individuals. By recruiting from the same community, we aimed to reduce the 
likelihood of differential risk exposure in line with the recommendation for 
careful study design when investigating premature aging in HIV.40 Moreover, 
this allowed us to directly reference findings in HIV-infected individuals to a 
comparable control population, rather than recourse to normative data from 
other populations. As there are few data relating to normative visual function 
or RNFL in African populations, reference to other ethnic or geographical 
populations could produce erroneous comparisons. Our study population is 
also large compared to several studies of RNFL and visual function in HIV, 
and we used the same OCT machine and operator for the duration of the 
study to minimize potential variability in measurements, which can occur with 
different OCT machines and operators.41  
 
This study had some limitations. The study design means we cannot 
infer whether HIV is causally related to poor CS function or changes in RNFL, 
nor can a temporal relationship be established. The measurement of CS is 
subjective, however we adhered to standardized protocols (e.g. lighting, 
measurement distance) and used the same chart and examiner in the same 
location. Another potential limitation is that misclassification of smoking and 
alcohol consumption may have occurred, with HIV-infected participants 
wanting to demonstrate ‘healthy behaviour’ which could have led to 
confounding. Finally, in the context of further defining the HIV-neuroretinal 
disorder it would have been ideal to have data on visual fields and colour 
vision, however, this initial data provide an informative basis from which to 
plan further studies in this study population or region. Further investigations 
such as micro-perimetry and retinal electrophysiology would also help to 
elucidate possible mechanisms and pathways of HIV-associated neuro-retinal 
disorder. 
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In summary, HIV-infected individuals in South Africa demonstrate 
abnormal CS, and changes in RNFL thickness related to viremic status. 
Longitudinal studies are needed to determine whether changes in RNFL and 
systemic indicators such as frailty predict change in visual function, and 
equally importantly, the role of ophthalmic indicators in predicting the 
biologically aged phenotype in chronic HIV infection.  
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Table 1: Characteristics of study participants  
Variable HIV-infected  
(225) 
HIV-seronegative  
(203) 
P-
value 
Age (mean±SE)  41.2±0.5  41.9±0.6 0.37 
 N % N %  
Age, years by group 
30-39 
40-49 
>50 
 
112 
73 
40 
 
49.7  
32.4  
17.8  
 
98  
65 
40 
 
48.3  
32.0  
19.7  
 
 
0.88 
Gender 
Male 
Female 
 
60  
165 
 
26.7  
73.3  
 
49 
 
154 
 
24.1  
75.9  
 
 
0.55 
Income 
<ZAR1000/month 
>ZAR1000/month 
 
128  
97 
 
56.9  
43.1  
 
140 
63 
 
69.0  
31.0  
 
0.01 
Smoking status 
Non-smoker 
Smoker 
 
190  
35 
 
84.4  
15.6  
 
146 
57 
 
71.9  
28.1  
 
0.002 
Alcohol consumption 
No 
Yes 
 
156  
69 
 
69.3  
30.7  
 
112 
91 
 
55.2  
44.8  
 
0.002 
Hypertension 
No 
Yes 
 
144 
81 
 
64.0  
36.0  
 
122 
81 
 
60.1  
39.9  
 
0.41 
Body mass index (kg/height2)  28.0±0.4  31.9±0.6 0.0001 
Visual acuity (presenting)(median)  20/20 
(20/20-20/25) 
 20/20 
(20/20-20/32) 
0.34 
HIV-related characteristics (n=225)     
WHO stage 
1/2 
3/4 
 
62 
163 
 
27.6  
72.4  
   
ART naïve  27 12.0     
CD4 count in ART naïve group (cells/μl) 27 170 (81-201)    
Log10VL in ART naïve group (copies/ml) 16 4.79 (4.07-5.09)    
Current CD4 count - ART group (cells/μl)  468 (327-607)    
Nadir CD4 count - ART group (cells/μl)  136 (77-175)    
% with detectable VL in ART group  30 15.1     
Peak Log10VL in ART group (copies/ml)  4.47 (3.74-4.97)    
Duration of ART, months  198 56.5 (34-74)    
ART Regimen  
Containing AZT/3TC 
Other 
 
118  
80 
 
59.6  
40.4  
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Table 2: Predictors of poor contrast sensitivity among HIV-infected participants on ART 
(N=190) 
Variable Odds ratio (OR)*  
For reduced contrast 
sensitivity 
P 
Age group  
30 years 
per 10 year increase 
 
 
1 
1.22 (0.75-2.00) 
 
 
0.43 
Sex 
Male 
Female 
 
1 
1.73 (0.66-4.57) 
 
 
0.27 
 
Frailty status 
Not frail 
Frail 
 
1 
3.04 (1.25-7.35) 
 
 
0.01 
 
Smoking status 
Non-smoker 
Current 
 
1 
0.49 (0.17-1.45) 
 
 
0.20 
 
Current CD4 count 
<400 cells/μl 
>400 cells/ μl 
 
1 
0.84 (0.40-1.77) 
 
 
0.64 
 
Nadir CD4 count 
<100 cells/μl 
100-200 cells/ μl 
>201 cells/ μl 
 
1 
1.66 (0.79-3.50) 
2.30 (0.69-7.63) 
 
 
0.28 
Current viral load 
<2 log copies/ml 
>2 log copies/ml 
 
1 
3.03 (1.02-8.97) 
 
 
0.05 
Peak viral load 
<4.5 log copies/ml 
>4.5 log copies/ml 
 
1 
0.85 (0.43-1.68) 
 
 
0.64 
WHO clinical stage 
1/2 
3/4 
 
1 
1.84 (0.78-4.32) 
 
 
0.17 
ART duration (months) 
<24  
25-48  
49-72  
>73  
 
1 
2.28 (0.74-7.08) 
2.73 (0.85-8.75) 
1.68 (0.50-5.61) 
 
 
 
0.30 
ART regimen 
Containing AZT/3TC 
Other 
 
1 
1.20 (0.61-2.34) 
 
 
0.60 
*Adjusted for all variables in table, and mean arterial blood pressure and BMI, age group used 
as a linear term in model 
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Table 3: RNFL thickness in μm (standard error) by HIV and viral load status – adjusted 
for age, gender, mean arterial blood pressure, smoking status and BMI: 
 
RNFL 
Thickness 
in m  
(SE) 
HIV- 
 
 
(n=203) 
All HIV+ 
 
 
(n=225) 
P-
valuea 
 
On ART 
VL<50 
copies/ml 
(n=168) 
On ART 
VL>50 
copies/ml 
(n=30) 
ART-naive 
 
(n=27) 
P-
valueb 
Average** 108.7 
(0.9) 
109.7  
(0.8) 
0.41 109.0 
(1.0) 
111.9 
(2.4) 
111.3 
(2.5) 
0.52 
Superior 132.2 
(1.5) 
135.1 
(1.4) 
0.16 133.8 
(1.6) 
138.5 
(3.8) 
140.0 
(4.1) 
0.04* 
Inferior 137.9 
(1.5) 
135.6 
(1.4) 
0.27 134.7 
(1.7) 
137.7 
(4.0) 
139.5 
(4.3) 
0.50 
Nasal 88.4 
(1.5) 
91.1 
(1.5) 
0.19 91.2 
(1.7) 
89.5 
(4.0) 
95.1 
(4.4) 
0.13* 
Temporal 72.5 
(0.9) 
73.1 
(0.9) 
0.65 73.1 
(1.0) 
73.3 
(2.4) 
70.7 
(2.7) 
0.85 
**Limited images in this group; total n=402 (188/160/28/26) 
a - for difference between HIV-infected and HIV-seronegative groups 
b – for difference between HIV-seronegative and HIV groups by viral load status 
* - refers to p-value using test for trend
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Table 4: RNFL thickness in μm in HIV-infected participants (n=198); *=p-value for test of trend 
 Retinal nerve fibre layer thickness (m) 
Parameter Average Superior Inferior Nasal Temporal 
Age group, years 
30-39 
40-49 
>50 
 
112.0 
109.5 
102.2 
 
 
 
<0.0001* 
 
138.3 
133.7 
124.9 
 
 
0.004* 
 
139.7 
133.4 
125.2 
 
 
0.001* 
 
89.3 
93.7 
88.5 
 
 
0.29 
 
76.6 
70.6 
69.3 
 
 
 
0.006* 
ART duration, 
months 
<36  
37-72 
>73 
 
 
110.4 
110.1 
107.7 
 
 
 
0.37* 
 
 
136.6 
135.1 
131.4 
 
 
 
0.27* 
 
 
138.5 
137.0 
128.6 
 
 
 
0.02* 
 
 
93.0 
93.4 
84.1 
 
 
 
0.04* 
 
 
72.3 
73.2 
74.5 
 
 
 
0.81 
WHO clinical stage 
1/2 
3/4 
 
 
112.5 
108.7 
 
 
0.07 
 
 
141.1 
132.7 
 
 
0.03 
 
 
139.7 
133.8 
 
 
0.14 
 
 
90.2 
90.7 
 
 
0.92 
 
 
74.7 
72.9 
 
 
0.56 
Current viral load 
<2 log copies/ml 
>2 log copies/ml 
 
109.2 
111.8 
 
 
0.37 
 
134.1 
137.1 
 
 
0.58 
 
134.8 
136.5 
 
 
0.92  
 
91.1 
87.5 
 
 
0.29 
 
73.0  
75.4 
 
 
0.47 
Adjusted for age, gender, smoking status, mean arterial blood pressure, BMI, nadir and current CD4 count, ART regimen and all parameters displayed in table
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Abstract: 
Certain anatomic and functional parameters of the eye change with increasing chronological age. They 
may, therefore, serve as potential biomarkers of ageing. We investigated associations between four 
such ocular parameters (lens density, retinal vessel calibre, corneal endothelial cells and retinal nerve 
fibre layer thickness) and two ‘cellular’ biomarkers of ageing (leukocyte telomere length and CDKN2A 
expression) and with frailty (a clinical correlate of biological ageing) in a population of South African 
adults. All ocular parameters revealed an association with either telomere length or CDKN2A 
expression. However, lens density was most strongly correlated with age, increased CDKN2A 
expression, and with frailty (p=0.05 and 0.03, respectively). Narrow retinal arteriolar diameter, 
associated with increased chronological age, was also associated with increased CDK2NA expression 
(0.42 vs. 0.31, p=0.02) but not with frailty. Ocular parameters may aid in determining biological age, 
warranting investigation in longitudinal studies. 
 
Word count: 141  
 
 
Keywords: Telomeres; CDKN2A; lens density; retinal vessel calibre; corneal endothelium; retinal nerve 
fiber layer; frailty 
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1. Introduction 
There is substantial variation in the health and functional status of older populations in many developing 
countries as well as in developed countries (Lloyd-Sherlock et al., 2012). The reasons for these 
variations are poorly understood, highlighting the need for translational age-related research within a 
global context (Salomon et al., 2013; Wang et al., 2013). Chronological age is an imprecise measure of 
biological ageing, due to inter-individual differences in rates of ageing. The disconnection between 
chronological age and lifespan has led to a search for effective and validated biomarkers of ageing 
(BoA), defined as “biological parameters of an organism that either alone or in some multivariate 
composite will better predict functional capability at some late age, than will chronological age”(Baker 
and Sprott, 1988).  
 
 It is acknowledged that many age-related chronic diseases such as cardiovascular disease and 
Alzheimer’s disease share common pathways of early dysregulation, and that the development of 
markers and diagnostic techniques is fundamental to understanding healthy biological ageing and thus 
these diseases (Franco et al., 2007). The need for research on how healthy ageing can be achieved in 
the context of life-time trajectories has led to concept of the ‘Healthy Ageing Phenotype’ (Franco et al., 
2009). With demonstrable molecular, epigenetic and clinical correlates of ageing, the eye may be a 
model system for validating potential biomarkers (Pathai et al., 2013).  
 
The unique access to and visibility of ocular tissues and range of visual functions permits 
investigation of a wide variety of physiological and pathological mechanisms.  Many age-related ocular 
changes also have systemic associations or correlates of ageing in other end-organs or body systems 
but may be easier and less invasive to measure in the eye (Table 1). For example, changes in the lens, 
which has an extremely high protein content, may reflect systemic changes in protein structure and 
function in other organs (Truscott, 2010, 2011; Wormstone and Wride, 2011). Corneal endothelial cell 
parameters, lens density, retinal vessel calibre and thickness of the retinal nerve fibre layer (RNFL) are 
ocular parameters that vary with age that can be objectively and non-invasively imaged and assessed.  
 
Ideally, proposed ocular biomarkers should be assessed in relation to established and 
validated BoA at a clinical or cellular level. Only two validated BoA, telomere length (TL) and CDKN2A 
expression, have so far been found to satisfy the majority of the criteria proposed by Baker and Sprott 
(Baker and Sprott, 1988). Telomeres are nucleoprotein complexes at the ends of eukaryotic 
chromosomes. Their DNA component shortens with somatic cell division and upon reaching a critically 
short length, a DNA damage signal leads to growth cycle arrest, resulting in replicative senescence 
(Saretzki and Von Zglinicki, 2002; von Zglinicki, 2002). Telomere shortening is associated with 
increasing chronological age and several pathologies, including cardiovascular disease (Starr et al., 
2007) and renal dysfunction (Carrero et al., 2008). TL may be useful as a composite measure of healthy 
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ageing, but not as a BoA when used in isolation (Der et al., 2012; von Zglinicki, 2012). Expression 
levels of the cell cycle regulator CDKN2A may represent a more robust BoA (Shiels, 2010). CDKN2A 
acts as a tumour suppressor and maintains cells in a state of growth arrest, both in replicative and 
stress induced-senescence. Increasing levels of CDKN2A transcriptional expression occur with 
increasing age and decreasing function of solid organs and peripheral blood leucocytes (PBLs) 
(Koppelstaetter et al., 2008; Krishnamurthy et al., 2004; Liu et al., 2009; McGlynn et al., 2009). 
However, there are limited data on how these parameters correlate with measures of physical frailty 
(Woo et al., 2008),  a functional state characterised by an increased risk of multiple pathologies, low 
physical activity and slow motor performance (Fried et al., 2001a). Frailty predicts cognitive and 
physical decline and is associated with an increased risk of morbidity and mortality, and may therefore 
act as a ‘clinical’ biomarker of ageing (Fried et al., 2001a). 
 
There are few data on biological ageing in sub-Saharan Africa, a region where the population 
of elderly people is rapidly expanding, and where the incidence of age-related non-communicable 
diseases is steadily increasing (Marquez and Farrington, 2012). The aim of this study was to investigate 
the association of a variety of ocular candidate BoA with ‘systemic’ BoA and frailty status in a South 
African adult population.  
 
2. Methods: 
2.1 Study population: 
Individuals aged ≥ 30 years from an HIV prevention trials site in a township community of Cape Town, 
South Africa (Emavundleni Centre, Crossroads) were recruited as HIV-seronegative controls as part a 
case-control study investigating HIV and ageing (Pathai et al., 2012a; Pathai et al., 2012b). Socio-
demographic information and medical history were obtained by interviewing participants in their first 
language (Xhosa or English). Data collected included factors known to affect ageing (e.g. UV exposure, 
smoking history). All participants underwent a full ophthalmic examination including measurement of 
visual acuity, evaluation by slit lamp microscopy and indirect ophthalmoscopy.  
 
The study was approved by the Ethics Committees of the London School of Hygiene and Tropical 
Medicine and the University of Cape Town Faculty of Health Sciences, and adhered to the tenets of the 
Declaration of Helsinki. Written informed consent was obtained from all participants. 
 
2.2 Anthropometry, blood pressure and physical function including frailty assessment: 
Blood pressure (BP) was measured with a digital sphygmomanometer. Mean arterial blood pressure 
(MABP) was defined as two-thirds of the diastolic plus one-third of the systolic BP (Wong et al., 2003). 
Hypertension was defined as a systolic BP of 140mmHg or higher, diastolic BP of 90mmHg or higher, or 
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the combination of self-reported high BP diagnosis and the use of anti-hypertensive medications (Wong 
et al., 2005). Body mass index (BMI) was defined as weight (in kilograms)/height2.  
 
Physical frailty was defined by the presence of ≥3 of 5 criteria: i) unintentional weight loss (self reported 
and verified from clinic records where possible) ii) self-reported low physical activity, iii) self-reported 
exhaustion, iv) weak grip strength and v) slow walking time. Pre-frailty was defined as the presence of 
one or two of these criteria. Detailed information is available in the Supplementary Methods. 
 
2.3 Blood-based biomarkers:  
DNA/RNA extraction 
DNA was extracted from PBLs using the Maxwell™ Automated Purification System according to 
manufacturer’s instructions (Promega, USA). DNA concentration and purity were quantified by 
Nanodrop Spectrophotometer (ThermoFisher Scientific, USA). RNA was extracted using Trizol reagent 
(Invitrogen, UK) following manufacturer’s guidelines. DNA/RNA extraction was performed in Cape Town 
and samples shipped on dry ice to the University of Glasgow.  
 
Telomere length determination 
Telomere lengths were determined by QPCR following the method of Cawthon (Cawthon, 2002). 
Telomere length determination was performed blindly using a Roche Light Cycler LC480. Briefly, 
telomere length analyses were performed in triplicate for each sample, using a single-copy gene 
amplicon primer set (acidic ribosomal phosphoprotein, 36B4) and a telomere-specific amplicon primer 
set (Koppelstaetter et al., 2008). Refer to Supplementary Methods for futher detail.  
 
CDKN2A expression determination  
Relative quantitative real-time PCR (qRT-PCR) was used to estimate mRNA levels corresponding to the 
candidate senescence associated gene - CDKN2A. Expression levels were measured against a 
reference hypoxanthine phosphoribosyltransferase (HPRT) housekeeping gene on an ABI Prism(R) 
7500 Sequence Detection System. Sequences of human TaqMan™ Primer/Probe sets were designed 
by Primer Express algorithm (Applied Biosystems, Austin, TX, USA). The comparative threshold cycle 
method (ΔΔCT)(Livak and Schmittgen, 2001) was employed to quantify relative gene expression.  
 
2.4 Ocular biomarkers  
The following four ocular parameters were selected (Table 1). Detailed methods are supplied in the 
Supplementary Methods.  
i) Lens density: Pentacam imageing (Oculus, Wetzlar, Germany) was used to obtain “Scheimpflug 
images” of the lens and to obtain an objective estimate of lens density on a continuous scale. Lens 
density increases with increasing chronological age.  
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ii) Retinal vessel calibre: Participants had stereoscopic 30° colour retinal photographs taken under 
pharmacological pupil dilation with a fundus camera (CF-2; Canon Inc., Tokyo, Japan). Vessel calibre 
indices were determined in a semi-automated manner using the IVAN computer program (Singapore 
Eye Research Institute, Singapore) and a standardized protocol described previously (Wong et al., 
2004). Narrowing of retinal arterioles is associated with increasing chronological age (Leung et al., 
2003; Wong et al., 2003).  
iii) Corneal endothelial cell parameters: A non-contact specular microscope was used (SP02, CSO; 
Florence, Italy). The operator focused and aligned a real-time image of the participant’s eye. Endothelial 
cell parameters were automatically calculated from this image by the microscope software. Endothelial 
cell density (ECD) decreases with age, whereas the change in cell size (coefficient of variation) 
increases with age. The proportion of cells with six sides (hexagonality index) decreases with age.  
iv) Retinal Nerve Fibre Layer (RNFL): Measured using Spectral OCT/SLO optical coherence 
tomography (Opko/OTI Inc, Miami, FL) which uses a scanning laser diode of 830nm to provide images 
of ocular microstructures. A peripapillary (around optic nerve head) protocol inbuilt in the software was 
used to determine the average and quadrant-specific RNFL thickness (superior, inferior, temporal and 
nasal). The RNFL becomes thinner with increasing age (Chi et al., 1995; Kanamori et al., 2003).  
 
2.5 Statistical analysis: 
One eye was randomly selected for analysis. Where an eye was not available, for example due to 
trauma or corneal opacity, the contralateral eye was used. Analyses were performed using Stata 12 
(Stata Corp, College Station, TX). Clinical and biological data were summarized as the median with 
interquartile range (IQR) or mean with standard error (SE), as appropriate. Analyses were conducted on 
log10-transformed values of telomere length and mean CDKN2A expression to satisfy the assumption 
of normally distributed residuals. Results are displayed back-transformed to the original scale. 
Validation of the biomarkers was performed using linear regression models with age in years as a 
continuous or categorical variable. Ocular biomarker measurements were divided into quartiles. 
Univariable linear regression was performed to compare the quartiles of ocular parameters with mean 
telomere length and CDKN2A expression and frailty status respectively. Multivariable linear regression 
models were used to examine the relationships of telomere length, CDKN2A expression as the 
respective dependent variable with ocular biomarker quartiles and frailty status and explanatory 
variables (age group [30-39; 40-49; >50 years], gender, MABP; BMI, smoking, UV exposure) as 
independent variables. Marginal adjusted means for telomere length and CDKN2A expression were 
estimated at the mean value of covariates in the model.  The Wald test was used to assess statistical 
significance of the association of each ocular parameter on systemic biomarker levels. 
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3. Results 
3.1 Participant characteristics and biomarker distributions: 
256 participants underwent assessment. Their median age was 40 years (IQR: 35-49) and 25% (n=64) 
were male. Characteristics of the participants by gender are given in Table 2. Women reported less 
alcohol consumption and cigarette use than men (p<0.0001 for both). Men had a higher frequency of 
hypertension and had lower BMI (p=0.01 and p<0.0001, respectively). The number of participants 
providing data for each parameter varied, as not every participant was able to complete every 
ophthalmic test or had a blood sample available for analysis. Summary statistics for each biomarker, 
stratified by gender and age group are displayed in Table S1. For the majority of biomarkers, there was 
no evidence of gender differences; however for RNFL parameters, the average, inferior and temporal 
quadrants were thinner in men (p=0.01, p=0.0008 and p=0.02, respectively).  
 
3.2 Validation of blood-based and ocular biomarkers against chronological age: 
Blood-based and ocular parameters were validated against chronological age (Table S2). All 
parameters except retinal venular diameter and the RNFL nasal quadrant were related to chronological 
age and so these parameters were not analysed further. The association of the prospective biomarkers 
with chronological age is presented in Supplementary Figures 1a-1o. The R-squared values of the 
regressions against chronological age were highest for lens density parameters (linear lens density 
R2=0.67); other biomarkers including TL and CDKN2A had R2 values <0.10.  All analyses thereafter 
were adjusted for age, gender and other possible confounding variables related to the parameter of 
interest.  
 
3.3 Association of ocular parameters with blood-based biomarkers: 
Shorter TL was associated with decreasing endothelial cell density (p-trend=0.08). CDKN2A expression 
was related to increased variation in endothelial cell size in a non-linear fashion (p=0.05) (Table 3). The 
linear parameter of lens density was most informative (Table 3). CDKN2A expression increased with 
increased lens density (p-trend=0.05); the 3-D average lens density parameter also displayed a similar 
trend (p-trend=0.08).  
 
Expression of CDKN2A was associated with changes in the calibre of retinal arterioles (p=0.06) and in 
AVR (p=0.03) (Table 3), however a linear trend was not detected. When arteriolar diameter was 
categorised as a binary variable, (‘thin’ or ‘thick’, i.e. either side of the median value) CDKN2A 
expression was greater in those with thin compared to thick retinal arterioles (0.42 vs. 0.31, p=0.02). TL 
was not related to arteriolar diameter.  
 
In view of the difference in RNFL thickness between genders (Table S1), data were analysed for RNFL 
by gender. After adjustment, there were no differences between genders (data not shown), thus data for 
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both men and women combined are presented. Telomere length was informative for the superior 
quadrant of the RNFL (Table 3), with shorter telomere length associated with thinner RNFL (p-
trend=0.05).  
 
3.4 Association of frailty status with blood-based and ocular biomarkers: 
There was a significant trend of increased TL with worsening frailty status (p-trend=0.02) (Table 4). 
CDKN2A expression also increased with frailty status, however this trend was not statistically significant 
(p-trend=0.12). Among the ocular biomarkers, lens density was the only parameter associated with 
frailty status, with increased linear lens density related to greater frailty status (p-trend=0.03). 
 
4. Discussion  
In this study we compared several ocular parameters with established and validated systemic BoA (TL 
and CDKN2A expression) as well as frailty, a clinical correlate of ageing. Objective measurement of 
lens density was the most informative ocular biomarker, with greater lens density associated with 
increased CDKN2A expression and with increased frailty status. Retinal arteriolar narrowing was also 
associated with greater CDKN2A expression. In contrast, lower endothelial cell density and thinning of 
the RNFL were associated with shorter TL. These findings suggest that a range of structural features of 
the eye, which can be objectively imaged and measured, may reflect different physiological parameters 
of ageing. These ocular BoA may provide insights into biological age, ageing trajectories and a range of 
chronic systemic diseases.  
 
 Lens density parameters had the strongest association with chronological age compared to the 
other biomarkers and fulfil the Baker and Sprott criteria (Baker and Sprott, 1988). Lens density was the 
most informative ocular biomarker in that it was related to CDKN2A expression, a cellular biomarker of 
ageing, as well as with frailty status, a clinical correlate of systemic ageing.  The human lens is 
considered an ideal tissue for studying macromolecular ageing, and physiological ageing in general, as 
biochemical mechanisms in lens proteins may reflect ageing processes elsewhere in the body (Eldred 
et al., 2011; Michael and Bron, 2011; Truscott, 2010, 2011; Truscott and Zhu, 2010; Wormstone and 
Wride, 2011). Epidemiological research has demonstrated that individuals with cataracts have a 
significantly higher mortality rate than those without, even after adjusting for known confounders (Wang 
et al., 2001; West et al., 2000). Crystallins represent the major structural proteins of the lens and are 
responsible for the refractive power of the lens (Horwitz, 2000). In other tissues crystallins are also 
involved in several cellular pathways involving the stress response, apoptosis and cell survival at a 
systemic and ocular level (Andley, 2008). Thus, crystallins are not only involved in regulatory roles 
within the eye but also play important roles in several other organs, leading to the suggestion that 
cataract is a ‘bio-indicator’ for less obvious, more severe age-related disorders (Graw, 2009). The 
concept of ‘lens transparency’ as a biomarker of ageing has already been described (Sanders et al., 
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2011), and clinical diagnosis of cataract is associated with leukocyte TL. However clinical cataract is 
generally diagnosed in later years of life, whereas Scheimpflug imaging of lens density provides 
objective measurements at any given age. Evaluation of lens density across the age spectrum would be 
essential to evaluate fully the usefulness of the lens as a biomarker of ageing, and testing whether lens 
transparency is a predictor of mortality or longevity would provide the strongest evidence. However, this 
approach may be limited in well-resourced settings where surgical extraction of the lens often occurs 
with minimal lens opacities, rendering the lens unavailable for assessment. However, lens density 
measurement from early ages until lens extraction may still provide insight into healthy ageing 
trajectories.  
 
The retina represents a unique location where the microvasculature can be directly and non-
invasively visualised. The technique of semi-automated software applied to digital retinal photographs 
(Wong et al., 2004) is established as a valid and efficient biomarker of systemic vascular disease (Ikram 
et al., 2006; Wong T and et al., 2006; Wong et al., 2002).  Retinal vascular calibre is considered a 
structural marker of vascular pathology reflecting the interplay of systemic, environmental and genetic 
factors (Sun et al., 2009). The strong association between increasing age and narrowed retinal vessels 
has been demonstrated in several study populations (Leung, 2003; Wong, 2003). Small reductions in 
retinal arteriolar calibre are associated with clinically relevant changes in blood pressure, e.g. a 10-
mmHg increase in systolic BP is associated with a 1.1 µm reduction in arteriolar calibre (Ikram et al., 
2004). We found that retinal arteriolar narrowing was associated with increased CDKN2A expression, 
thus the retinal microvasculature reflect senescent microvascular changes. However, retinal vessels 
can also be affected by systemic pathology e.g. rheumatoid arthritis, smoking and inflammatory 
diseases (Ikram et al., 2004; Klein et al., 2006; Van Doornum et al., 2011) and may be manifest as a 
change in retinal vessel calibre. This could affect the measurement of ‘true’ biological ageing, therefore 
the lens might be a better model and biomarker of ageing as it is less susceptible to systemic pathology, 
and therefore representing a true biomarker of ageing and not disease (Simm et al., 2008).  
 
Corneal endothelial cells change morphology and assume an ‘aged phenotype’ in several 
chronic systemic diseases (e.g. renal failure, diabetes) (Larsson et al., 1996; Ohguro et al., 1999) 
suggesting that they may be useful in assessing cellular dynamics of ageing, particularly as 
measurement is objective and non-invasive. Reduction in the proliferative capacity of corneal 
endothelial cells is partly mediated by an age-related increase in expression of CDKN2A that functions 
to hold a cell in a state of growth arrest (Wang et al., 2012). Increased CDKN2A expression was noted 
in those with the lowest endothelial cell density, however this trend was not significant. In contrast, we 
found a trend of decreasing endothelial cell density with shorter TL. Evaluation of corneal endothelial 
cells via specular microscopy may provide a unique way of measuring biological ageing at a cellular 
level.   
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 Thinning of the RNFL is associated with older age (Chi et al., 1995; Kanamori et al., 2003), 
manifest functionally as deficits in colour vision and contrast sensitivity. Our findings of thinner superior 
RNFL associated with shorter TL are in alignment with data from individuals with age-related 
neurocognitive disease. Thinning of the superior RNFL in Alzheimer’s disease has been observed (Lu 
et al., 2010; Paquet et al., 2007) and similar findings have been noted in Parkinson’s disease and 
spinocerebellar ataxias (Hajee et al., 2009; Pula et al., 2011). OCT measurement of the RNFL is a quick 
non-invasive procedure, of importance for patients with cognitive impairment. The retrograde loss of 
nerve fibre layer tissue in the retina and optic nerve may be an early biomarker of Alzheimer’s disease, 
and possibly the earliest sign of disease, prior to damage to the hippocampal region that impacts 
memory (Valenti, 2011). Thus RNFL analysis may be best suited in detection of early neurocognitive 
decline as a marker of ‘neurobiological ageing’.  
 
In relation to frailty and TL, a study (Woo et al., 2008) showed no correlation between TL and 
frailty index. Indeed, women had higher frailty scores and longer TLs. We also detected longer TL with 
increasing frailty status which is not intuitive, as shorter telomeres would be expected. One possible 
explanation for this is that induction of stress induced premature senescence (SIPS) (Shay and Wright, 
2000), leads to acute growth arrest (in contrast to gradual replicative senescence). This may occur in 
frailty by a non-quantified factor (e.g. genetics, environment, lifestyle) acting on the affected cell 
population. Our finding that CDKN2A expression does not follow a similar trend is supportive of such a 
hypothesis. This would then be expected to result in longer TLs in cells under SIPS contributing to 
frailty. An alternative explanation is a ‘survivor effect’ i.e. individuals with poor biological ageing may die 
earlier, thus participants comprise survivors who have different biological characteristic to non-survivors, 
accounting for frail ‘survivors’ having longer telomeres. The relationship between the functional 
phenotype of frailty (reflecting changes in multi-organ systems) and cellular senescence represents two 
extremes of biological ageing likely influenced by several external factors, thus a well-defined 
relationship between these parameters maybe unlikely in any case. Lens density was the only ocular 
parameter to be associated with frailty, reinforcing its potential role as a biomarker of ageing with 
associations with cellular BoA as well as the clinical presentation of frailty.  
 
This study has some limitations. Study participants were matched by age, gender and socio-
economic status to HIV-infected individuals as part of a case-control study, and are not therefore 
representative of the general population in South Africa. For example, the gender composition of 
participants was three-quarters female, reflective of the HIV epidemic in Africa, but not representative of 
the South African population. There were also differences between genders (smoking, alcohol 
consumption) that may truly exist or may have been misclassified (e.g. misreporting true smoking 
habits) and this could have confounded associations of the ocular parameters with the other 
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biomarkers. Participants were recruited from a community of considerable socio-economic depravation, 
and therefore likely to have been exposed to factors known to increase biological ageing such as high 
UV exposure from outdoor work. Therefore, our data might over-estimate associations related to 
ageing. Lastly, as study participants are of African ancestry, our results are generalizable to the African 
population.  
 
In conclusion, our study suggests that the eye has a useful and valid contribution to make in 
the assessment of biological age.. The non-invasive and objective nature of the techniques is an added 
benefit. Our data suggest that assessment of retinal vessel calibre and lens density may be most 
informative. Further studies could involve development of an ‘ocular ageing index’ using ocular 
parameters to predict not only visual morbidity (visual impairment/blindness), but also systemic 
morbidity and mortality. RNFL parameters may be useful in developing an index for age-related 
neurocognitive decline, whereas endothelial cell parameters may aid in understanding cellular 
mechanisms of senescence. In resource-constrained settings access to facilities and personnel capable 
of measuring biomarkers extracted from PBLs is likely to be limited. Thus, ocular biomarkers in parallel 
with more easily measurable systemic biomarkers (e.g. frailty status, blood counts) to assess biological 
ageing may be more feasible in these environments. Finally, we have proposed a research agenda to 
further define and validate ocular biomarkers of ageing (Pathai et al., 2013). Longitudinal studies in 
different populations are needed to assess how ocular parameters change over time in relation to 
blood-based biomarkers and to other candidate biomarkers that have been previously evaluated 
(Martin-Ruiz et al., 2011; Simm et al., 2008). These parameters could also be measured in longitudinal 
evaluation of the ‘healthy ageing phenotype’ from early adult life onwards to characterise the 
development of biological capital and ageing trajectories in terms of a ‘life course’ approach (Kuh, 2007) 
leading to an improvement in our understanding of how to achieve healthy ageing in societies with 
rapidly increasing ageing populations.   
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Table 1: Biomarkers of aging, methods of measurement and the impact of aging 
 
 
 
 
 
 
 
Anatomical 
site 
Parameter Method of measurement Age-related 
changes 
Peripheral 
blood 
leukocytes 
Telomere length (TL) 
 
CDKN2A expression 
qPCR 
 
qRT-PCR to estimate mRNA 
levels 
TL shortens 
 
Increased 
expression 
Corneal 
endothelium 
Endothelial cell density 
(ECD) 
Coefficient of variation (CV) 
Hexagonality index (Ex) 
Specular microscopy Decreased ECD 
Increased CV 
Decreased Ex 
    
Lens Lens opacity 
Linear value 
Peak 
3-D average 
Pentacam – lens densitometry 
 
 
 
All increase 
    
Retina Retinal nerve fibre layer 
(RNFL) thickness  
(Average, superior, inferior, 
nasal, temporal quadrants) 
 
Retinal vessel caliber 
Optical coherence tomography 
(OCT) 
 
 
 
Semi-automated retinal analysis 
software applied to fundus 
photographs 
Thinner RNFL- all 
quadrants 
 
 
 
Reduced diameter 
of arterioles and 
arterio-venous 
ratio (AVR)  
Systemic Frailty status 
Non-frail (no criteria) 
Pre-frail (1-2 criteria) 
Frail: ≥3 of 5 criteria 
 
Assessment of walking speed, 
grip strength, self-report of weight 
loss, exhaustion and low physical 
activity 
 
 
Frailty status 
increases  
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Table 2: Characteristics of study participants, n=256 
 
Variable Male (N=64) 
N (%) 
Female (N=192) 
N (%) 
P 
Age (mean ± SE) 42.0±1.00 42.8±0.7 0.61 
Median age, IQR 41 (35-48) 40 (35-49) 0.96 
Age, years by group 
30-39 
40-49 
>50 
 
 
27 (42.2) 
28 (43.7) 
9 (14.1) 
 
91 (47.4) 
56 (29.2) 
45 (23.4) 
 
 
 
0.07 
Education 
Did not complete high school 
Completed high school 
 
15 (23.4) 
49 (76.6) 
 
32 (16.7) 
160 (83.3) 
 
 
0.23 
Income 
<ZAR1000/month 
>ZAR1000/month 
 
41 (64.1) 
23 (35.9) 
 
133 (69.3) 
59 (30.7) 
 
 
0.44 
Location of work 
Outdoors or grant-holder 
Indoors 
 
44 (68.8) 
20 (31.2) 
 
140 (72.9) 
52 (27.1) 
 
 
0.52 
Housing 
Formal 
Informal 
 
38 (59.4) 
26 (40.6) 
 
114 (59.4) 
78 (40.6) 
 
 
0.99 
Shared WC 
No 
Yes 
 
19 (29.7) 
45 (70.3) 
 
52 (27.1) 
140 (72.9) 
 
 
0.69 
Number of people in household 
Up to 5 
≥6 
 
40 (72.7) 
15 (27.3) 
 
125 (68.7) 
57 (31.3) 
 
 
0.57 
Smoking status 
Non-smoker 
Smoker; <10 years 
Smoker >10 years 
 
23 (35.9) 
16 (25.0) 
25 (39.1) 
 
162 (83.4) 
17 (8.9) 
13 (6.8) 
 
 
 
<0.0001 
Alcohol 
Nil 
<1L/week 
>1L/week 
 
14 (21.9) 
14 (21.9) 
36 (56.2) 
 
128 (66.7) 
43 (22.4) 
21 (10.9) 
 
 
 
<0.0001 
Hypertension 
No 
Yes 
 
36 (56.3) 
28 (43.7) 
 
141 (73.4) 
51 (25.6) 
 
 
0.01 
BMI 
<20 
20-24.9 
25.0-29.9 
>30 
 
14 (21.9) 
29 (45.3) 
13 (20.3) 
8 (12.5) 
 
4 (2.1) 
17 (8.9) 
42 (21.9) 
129 (67.2) 
 
 
 
 
<0.0001 
Tuberculosis status 
No history 
Previous history 
Current 
 
52 (81.3) 
12 (18.7) 
0 
 
173 (90.1) 
18 (9.4) 
1 (0.5) 
 
 
 
0.12 
 
 
 
 
 
Sophia Pathai PhD Thesis Page 281
Table 3: Association of ocular parameters with blood-based biomarkers 
 
Endothelial cell 
parameters 
 Telomere 
Length 
  CDKN2A 
Expression 
 
 N Rel T/S P N Mean P 
ECDa quartiles cells/mm2       
1st  
(1952-2461) 
59 1.06 
(0.99-1.14) 
 47 0.42 
(0.33-0.53) 
 
2nd   
(2466-2612) 
59 1.03 
(0.96-1.10) 
 52 0.32 
(0.25-0.40) 
 
3rd    
(2617-2798) 
58 1.10 
(1.03-1.18) 
 54 0.36 
(0.29-0.45) 
 
4th  
(2812-3391) 
60 1.14 
(1.06-1.22) 
P-trend 
0.08 
51 0.36 
(0.29-0.46) 
0.30 
CVb quartiles       
1st  
(26-32) 
66 1.03 
(0.97-1.10) 
 47 0.35  
(0.28-0.38) 
 
2nd  
(33-35) 
70 1.08 
(0.99-1.15) 
 52 0.31 
(0.25-0.38) 
 
3rd  
(36-38) 
49 1.13 
(1.04-1.22) 
 54 0.49 
(0.38-0.64) 
 
4th  
(39-57) 
51 1.10 
(1.02-1.19) 
0.33 
 
51 0.36 
(0.28-0.46) 
0.05 
Exc quartiles       
1st  
(24-46) 
67 1.13 
(1.06-1.20) 
 57 0.36  
(0.29-0.45) 
 
2nd  
(47-50) 
59 1.05 
(0.98-1.13) 
 61 0.40 
(0.32-0.51) 
 
3rd  
(51-54) 
60 1.08 
(1.00-1.15) 
 40 0.35 
(0.28-0.44) 
 
4th  
(55-70) 
50 1.06 
(0.98-1.14) 
0.50 
 
46 0.33 
(0.25-0.42) 
0.66 
Lens density**       
Linear quartiles       
1st (7.8-9.2) 62 1.01 
(0.94-1.10) 
 51 0.29 
(0.22-0.38) 
 
2nd  (9.25-9.8) 59 1.08 
(1.00-1.17) 
 53 0.31 
(0.24-0.40) 
 
3rd  (9.85-10.75) 58 1.14 
(1.06-1.22) 
 50 0.37 
(0.29-0.47) 
 
4th (10.8-14.5) 61 1.09 
(0.99-1.19) 
P-trend 
0.22 
54 0.50 
(0.37-0.68) 
P-trend 
0.05 
Peak quartiles       
1st (10.65-15.35) 61 0.93 
(1.00-1.16) 
 57 0.36 
(0.28-0.45) 
 
2nd (15.4-18.0) 58 1.07 
(1.00-1.15) 
 50 0.33 
(0.26-0.41) 
 
3rd (18.05-20.5) 61 1.10 
(1.03-1.18) 
 51 0.37 
(0.29-0.46) 
 
4th (20.6-52.1) 60 1.07 
(0.99-1.15) 
0.92 50 0.39 
(0.30-0.51) 
0.81 
3D-average quartiles       
1st (8.3-9.1) 58 1.01 
(0.92-1.09) 
 52 0.28 
(0.21-0.37) 
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2nd (9.15-9.75) 64 1.08 
(1.00-1.16) 
 54 0.39 
(0.31-0.50) 
 
3rd (9.8-10.85) 57 1.14 
(1.06-1.23) 
 50 0.33 
(0.26-0.43) 
 
4th (10.9-19.7) 61 1.10 
(1.00-1.20) 
P-trend 
0.16 
52 0.46 
(0.34-0.62) 
P-trend 
0.08 
Retinal vessels       
Retinal arteriolar 
quartiles (µm) 
      
1st 
 (102.62-150.30) 
57 1.05  
(0.98-1.13) 
 48 0.40 
(0.31-0.51) 
 
2nd   
(150.36-161.09) 
59 1.13 
(1.05-1.21) 
 50 0.43 
(0.34-0.54) 
 
3rd  
 (161.35-172.72) 
60 1.02 
(0.95-1.09) 
 55 0.28 
(0.22-0.35) 
 
4th 
(172.74-209.71) 
61 1.10 
(1.03-1.19) 
0.15 53 0.34 
(0.27-0.44) 
0.06 
RNFL Quartiles (µm)       
Average       
1st  
(65-101) 
49 1.06 
(0.99-1.15) 
 45 0.42 
(0.33-0.54) 
 
2nd   
(102-109) 
48 1.10 
(1.02-1.18) 
 44 0.28  
(0.22-0.36) 
 
3rd    
(110-117) 
45 1.11 
(1.03-1.20) 
 40 0.30 
(0.24-0.39) 
 
4th  
(118-149) 
46 1.07 
(1.00-1.16) 
0.84 46 0.40 
(0.31-0.51) 
0.07 
Superior        
1st  
(61-118) 
48 1.02 
(0.95-0.10) 
 41 0.27 
(0.21-0.35) 
 
2nd  
(119-131) 
50 0.99 
(0.94-1.09) 
 43 0.39 
(0.31-0.50) 
 
3rd  
(132-146) 
53 1.11 
(0.96-1.20) 
 48 0.32 
(0.25-0.40) 
 
4th  
(147-199) 
46 1.11 
(0.98-1.20) 
P-trend 
0.05 
43 0.40 
(0.32-0.52) 
0.09 
Inferior        
1st  
(78-124) 
48 1.03 
(0.95-1.11) 
 41 0.33 
(0.26-0.43) 
 
2nd  
(125-138) 
51 1.07 
(0.99-1.15) 
 43 0.34 
(0.27-0.44) 
 
3rd  
(139-151) 
50 1.08 
(1.00-1.17) 
 48 0.33 
(0.26-0.43) 
 
4th  
(151-201) 
48 1.07 
(0.99-1.16) 
0.80 43 0.36 
(0.28-0.47) 
0.97 
Temporal       
1st  
(38-62) 
47 1.04 
(0.96-1.12) 
 41 0.31 
(0.24-0.40) 
 
2nd  
(63-71) 
53 1.07 
(1.00-1.15) 
 51 0.32 
(0.26-0.40) 
 
3rd  
(72-81) 
48 1.10 
(1.02-1.19) 
 43 0.42 
(0.33-0.53) 
 
4th  
(82-131) 
49 1.04 
(0.97-1.12) 
0.73 40 0.34 
(0.26-0.43) 
0.33 
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Footnote to Table 3: 
Endothelial parameters: Adjusted for age, gender, smoking, UV exposure, income 
a: ECD: endothelial cell density -  lowest quartile denotes aged phenotype 
b: coefficient of variation – i.e. difference in cell shape; highest quartile denotes aged phenotype 
c: Hexagonality index – i.e. proportion of cells that are hexagonal; lowest quartile denotes aged phenotype 
Lens density: Adjusted for age, gender, smoking, UV exposure 
** -measured on a continuous scale 0-100, 100 being an opaque (completely dense) lens; 4th quartile denotes 
aged phenotype for all lens parameters  
Vessels: Adjusted for age, gender, smoking, BMI, hypertension and venular retinal calibre; 1st quartile denotes 
aged phenotype 
RNFL: Adjusted for age, gender, smoking, BMI, mean arterial blood pressure; 1st quartile denotes aged phenotype 
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Table 4: Association of frailty with systemic and ocular biomarkers of aging 
 
Biomarker Not-frail Pre-frail Frail P 
Telomere length (N) 
Rel T/S 
89 127 34  
 1.01 
(0.96-1.08) 
1.09 
(1.04-1.14) 
1.17 
(1.06-1.29) 
P-trend 
0.02 
CDKN2A (N) 
Mean expression 
75 110 32  
 0.32 
(0.26-0.39) 
0.36 
(0.31-0.42) 
0.44 
(0.32-0.60) 
P-trend 
0.12 
Ocular parameter     
Lens density (N) 
Scale: 0-100 
92 123 31 P 
Linear 9.94 
(9.77-10.13) 
10.10 
(9.94-10.25) 
10.38 
(10.05-10.71) 
P-trend 
0.03 
Peak 18.82 
(17.78-19.85) 
18.68 
(17.81-19.54) 
18.86 
(17.01-20.71) 
 
0.97 
3D-Average 10.02 
(9.81-10.24) 
10.14 
(9.95-10.31) 
10.31 
(9.92-10.70) 
P-trend 
0.22 
Vessel calibre (N) 
µm 
92 120 31  
CRAE 160.13 
(156.56-163.70) 
160.99 
(157.97-164.01) 
166.30 
(159.87-172.72) 
P-trend 
0.19 
AVR 0.60  
(0.58-0.61) 
0.60 
(0.58-0.61) 
0.61 
(0.58-0.64) 
 
0.64 
Endothelial cell 
parameters (N) 
91 121 31  
ECDa 
cells/mm2 
2637  
(2580-2695) 
2587 
(2539-2635) 
2675 
(2572-2779) 
0.18 
CVb 35.1 
(34.1-36.1) 
35.3  
(34.4-36.1) 
36.9 
(35.1-38.8) 
P-trend 
0.18 
Exc 49.9  
(48.6-51.3) 
50.3 
(49.1-51.4) 
47.6 
(42.3-50.0) 
 
0.15 
RNFL parameters (N) 
µm 
75 104 24  
Average 109.9 
(106.7-113.2) 
108.9 
(105.6-110.6) 
106.9 
(101.4-112.4) 
P-trend 
0.31 
Superior 131.1 
(126.2-136.1) 
133.4 
(129.3-137.4) 
130.6 
(121.5-139.6) 
 
0.73 
Inferior 137.6 
(132.6-142.6) 
138.2 
(134.1-142.3) 
137.3 
(127.2-146.5) 
 
0.97 
Temporal 72.3 
(69.1-75.4) 
72.6 
(70.1-75.2) 
72.2 
(66.4-77.9) 
 
0.98 
 
Adjusted for age, gender, socio-economic status, smoking, alcohol consumption and TB status 
a: ECD: endothelial cell density -  lowest quartile denotes aged phenotype 
b: CV: coefficient of variation – i.e. difference in cell shape; highest quartile denotes aged phenotype 
c: Hexagonality index – i.e. proportion of cells that are hexagonal; lowest quartile denotes aged phenotype 
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Supplementary Methods 
Telomere length determination: 
Quality control parameters for the amplifications comprised a cut off of 0.15 for the standard deviation 
(SD) of the threshold cycle (Ct) for sample replicates. At a SD above 0.15 the sample was reanalysed. 
The average SD across plates was 0.05. Relative telomere length was estimated from Ct scores using 
the comparative Ct method after confirming that telomere and control gene assays yielded similar 
amplification efficiencies. This method determines the ratio of telomere repeat copy number to single 
copy gene number (T/S) ratio in experimental samples relative to a control sample DNA. This 
normalised T/S ratio was used as the estimate of relative telomere length (Relative T/S).  The inter-
assay variation was assessed by comparing the relative telomere estimates (T/S ratio) estimates across 
assays for the positive controls, assayed on every assay plate. The average inter-assay coefficient of 
variance was 0.6% for telomere length and 0.23% for 36B4.   
 
Frailty determination 
All of these five components described in the original phenotype by Fried et al (Fried et al., 2001b) were 
used to determine the presence of frailty. However, we used the proxy described by Önen et al (Onen 
et al., 2009) for the physical activity measure (see Table 1 below for description). Grip strength of the 
dominant hand was measured three times using a grip dynamometer (Jamar Plus+ Digital Hand 
Dynamometer, Jamar, US). The average of three weight measurements was recorded in kilograms (kg) 
to one decimal point. Walking time was assessed using the method of Cesari et al (Cesari et al., 2005). 
The average of two trials (in m/s) was used for analysis. Participants were excluded from the 
determination of grip strength if they had pain or arthritis of the dominant hand, and excluded from the 
walking test if they had paralysis of an extremity or side of the body, or needed to use a walking aid. 
 
Lens density measurement:  
Following pupil dilatation with 1% tropicamide, two lens density measurements were made on each eye, 
and the mean value calculated. The instrument automatically calculated the quality and reliability of a 
captured image. If an image was found to be of poor quality (i.e. not ‘OK’ on the image quality 
specification), the measurement was repeated. Reproducibility of the lens density evaluation in two 
scans was performed for 50 eyes. Lens densitometry output values were extracted from the image 
captures in a masked fashion. Image section 90-270 degrees was used for the right eye and image 
section 270-90 degrees was used for the left eye (Kirkwood et al., 2009). All of the densitometry metrics 
available from the scan (linear, peak and 3D) were analysed as they reflect different parameters of the 
lens. The lens density output was presented on a continuous scale from 0 (transparent) to 100 (fully 
opaque).  
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Retinal vessel measurement 
All participants had stereoscopic 30 degree colour retinal photographs taken of both eyes under 
pharmacological pupil dilation with a fundus camera (model CF-2; Canon Inc., Tokyo, Japan). Images 
were centred on the optic disc. Vessel calibre indices were determined in a semi-automated manner 
using the IVAN computer program (Singapore Eye Research Institute, Singapore) using a standardized 
protocol described previously (Wong et al., 2004). In summary, the 6 largest arterioles and venules in a 
ring-shaped area located between 0.5 and 1.0 disc diameter from the optic disc margin were identified 
(Figure 1). Computer software measured the calibre of these individual vessels, then combined them 
into 2 summary variables for the eye: the projected calibre size of the central retinal artery (central 
retinal artery equivalent [CRAE]), and the projected calibre size of the central retinal vein (central retinal 
vein equivalent [CRVE]), using formulas derived by Parr and Spears (Parr and Spears, 1974a, b) and 
Hubbard (Hubbard et al., 1999), with revision by Knudtson (Knudtson et al., 2003). A retinal photograph 
was considered ungradable if eyes had <4 acceptable measurements of either vessel type. The 
intergrader and intragrader grading reliabilities were assessed using a random subsample of 100 
photographs reviewed four weeks after the initial grading. The intra- and intergrader intraclass 
correlation coefficients ranged from 0.71 to 0.93.  Retinal arteriolar and venular calibre are highly 
correlated, and to account for potential confounding we adjusted for the fellow vessel in multivariable 
analyses (i.e. adjustment for arteriolar calibre in analyses of venular calibre and vice versa) (Liew et al., 
2006). 
 
Table 1: Frailty criteria: adapted from Fried et al.(Fried et al., 2001b) and Önen et al.(Onen et al., 2009) 
 
Criteria Definition 
Unintentional weight loss >10 pounds weight loss documented in last year or ≥5% of previous year’s body weight 
 
Low physical activity* Participants answering 3 when asked whether their health limits vigorous activities such as running, 
lifting heavy objects 
1= not at all, 2 = yes, limited a little or 3 = yes, limited a lot 
 
Exhaustion  Participants answering 2 or 3 to either one of two statements –  
“How often have you felt that:” 
a) Everything you did was an effort or  
b) I could not ‘get going’ 
0 = rarely (<1 day), 1= some of the time (1-2 days),  
2 = occasionally (3-4 days) or 3 = most of the time (5-7 days) 
 
Weak grip strength Male BMI kg/m2 
≤24 
24.1-26.0 
26.1-28.0 
>28 
 
Kg 
≤29 
≤30 
≤30 
≤32 
Female BMI kg/m2 
≤23 
23.1-26.0 
26.1-29 
>29.0 
Kg 
≤17 
≤17.3 
≤18 
≤21 
Slow walking time  Male height (cm) 
≤173 
>173 
Seconds 
 
≥7 
≥6 
Female height (cm) 
 
≤159 
>159 
Seconds 
 
≥7 
≥6 
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*Estimation of physical activity adopted from Önen et al.(Onen et al., 2009); the estimation of physical activity 
described in the original phenotype used a weighted score of kilocalories expended 
 
References: 
Cesari, M., Kritchevsky, S.B., Penninx, B.W., Nicklas, B.J., Simonsick, E.M., Newman, A.B., Tylavsky, 
F.A., Brach, J.S., Satterfield, S., Bauer, D.C., Visser, M., Rubin, S.M., Harris, T.B., Pahor, M., 2005. 
Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and 
Body Composition Study. J Am Geriatr Soc 53, 1675-1680. 
Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., 
Kop, W.J., Burke, G., McBurnie, M.A., 2001a. Frailty in older adults: evidence for a phenotype. J 
Gerontol A Biol Sci Med Sci 56, M146-156. 
Hubbard, L.D., Brothers, R.J., King, W.N., Clegg, L.X., Klein, R., Cooper, L.S., Sharrett, A.R., Davis, 
M.D., Cai, J., 1999. Methods for evaluation of retinal microvascular abnormalities associated with 
hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 106, 2269-
2280. 
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Liew, G., Wong, T.Y., Mitchell, P., Wang, J.J., 2006. Are narrower or wider retinal venules associated 
with incident hypertension? Hypertension 48, e10; author reply e11. 
Onen, N.F., Agbebi, A., Shacham, E., Stamm, K.E., Onen, A.R., Overton, E.T., 2009. Frailty among 
HIV-infected persons in an urban outpatient care setting. J Infect 59, 346-352. 
Parr, J.C., Spears, G.F., 1974a. General caliber of the retinal arteries expressed as the equivalent width 
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Table S1: Median values of candidate biomarkers by gender and age group 
P-value for difference between genders 
  Men Women P-value 
Measure Age group, 
years 
N Median IQR N Median IQR  
Systemic 
biomarkers 
        
Telomere length 
Rel T/S 
Overall 60 1.04 0.86-1.29 190 1.09 0.91-1.32 0.62 
 30-39 26 1.07 0.93-1.29 90 1.13 0.94-1.30  
 40-49 25 1.15 0.92-1.30 55 1.10 0.94-1.34  
 >50 9 0.96 0.57-1.17 45 0.99 0.88-1.29  
CDKN2A 
expression 
Overall 54 0.43 0.20-0.67 163 0.37 0.20-0.59 0.79 
 30-39 25 0.29 0.17-0.60 73 0.28 0.15-0.49  
 40-49 21 0.44 0.19-0.72 49 0.52 0.30-0.80  
 >50 
 
8 0.46 0.27-0.95 41 0.40 0.21-0.69  
Lens density 
Scale 0-100 
        
Linear Overall 59 9.8 9.2-10.8 187 9.8 9.2-10.8 0.89 
 30-39 26 9.3  9.0-9.7 91 9.3 8.9-9.6  
 40-49 24 9.9 9.5-11.1 54 10.3 9.8-11.0  
 >50 9 11.5 10.9-12.4 
 
42 11.3 10.7-12.11  
Peak Overall 59 17.7 15.4-19.3 187 18.2 15.4-20.8 0.39 
 30-39 26 17.2 13.6-19.2 91 16.2 14.8-18.7  
 40-49 24 18 15.6-19.0 54 18.8 15.7-20.1  
 >50 9 20.3 
 
16.8-23.4 42 22.4 19.6-24.8  
3-D average Overall 59 9.8 9.1-10.7 187 9.8 9.1-10.9 0.77 
 30-39 26 9.1 8.8-9.6 91 9.2 8.8-9.6  
 40-49 24 9.9 9.5-10.8 54 10.2 9.7-11.1  
 >50 9 11.6 10.7-12.7 
 
42 11.4 10.8-12.6  
Retinal vessel 
calibre µm 
        
CRAE Overall 59 161.49 148.11-173.6 184 160.95 150.95-172.59 0.91 
 30-39 26 167.03 156.15-175.63 91 160.81 151.01-171.43  
 40-49 25 159.12 140.14-173.3 54 158.08 146.40-169.72  
 >50 8 158.9 152.67-168.5 
 
39 167.90 155.58-177.18  
CRVE Overall 59 273.00 258.59-287.24 184 267.74 258.17-279.53 0.15 
 30-39 26 273.10 258.95-287.53 91 270.15 258.92-278.53  
 40-49 25 278.88 256.62-292.41 54 265.68 254.25-279.92  
 >50 8 269.17 256.92-274.30 
 
39 270.51 258.06-284.57  
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Endothelial cell 
parameters 
        
ECD Overall 59 2646 2461-2784 183 2582 2458-2812 0.85 
 30-39 25 2715 2546-2861 91 2602 2448-2894  
 40-49 25 2662 2315-2778 52 2650 2534-2788  
 >50 9 2561 2211-2802 
 
40 2526 2382-2747  
CV Overall 59 35 32-37 183 35 32-38 0.85 
 30-39 25 35 31-38 91 35 31-37  
 40-49 25 34 32-37 52 36 33-39  
 >50 9 
 
36  35-38 40 36 33-40  
Ex Overall 59 49 47-53 183 50 45-54 0.97 
 30-39 25 50 48-53 91 51 46-55  
 40-49 25 49 48-54 52 49 44-54  
 >50 
 
9 48 42-52 40 49 44-52  
RNFL 
thickness, µm 
        
Average Overall 42 104 96-112 146 110 102-120 0.01 
 30-39 18 110 98-118 72 113 107-121  
 40-49 17 103 98-111 42 106 99-115  
 >50 
 
7 96 95-101 32 105 98-116  
Superior Overall 49 130 115-147 154 132 121-146 0.36 
 30-39 20 132 116-149 78 139 123-149  
 40-49 21 133 116-146 44 129 121-141  
 >50 
 
8 116 102-138 32 128 116-146  
Inferior Overall 48 131 111-143 154 140 127-154 0.0008 
 30-39 20 141 115-150 78 148 133-157  
 40-49 20 127 110-140 44 136 124-149  
 >50 
 
8 127 105-137 32 136 123-144  
Nasal Overall 49 86 63-101 154 89 76-103 0.19 
 30-39 20 97 69-109 78 85 71-102  
 40-49 21 84 61-94 44 91 75-107  
 >50 
 
8 85 51-86 32 88 81-102  
Temporal Overall 49 69 60-74 154 73 63-82 0.02 
 30-39 20 67 59-73 78 78 70-85  
 40-49 21 70  65-76 44 68 61-80  
 >50 
 
8 66 54-84 32 67 59-81  
Frailty status  N %  N %  P-value 
Non-frail Overall 22 34.4  70 36.4  0.29 
 30-39 11 40.7  48 52.8   
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 40-49 9 32.1  18 32.1   
 >50 
 
2 22.2  4 8.9   
Pre-frail Overall 39 60.9  91 47.4  0.28 
 30-39 16 59.2  40 44.0   
 40-49 17 60.7  28 50.0   
 >50 
 
6 66.7  23 51.1   
Frail Overall 3 4.7  31 16.2  0.47 
 30-39 0 0  3 3.3   
 40-49 2 7.1  10 17.9   
 >50 
 
1 11.1  18 40.0   
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Table S2: Regression coefficients of biomarkers with chronological age in years 	   	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Linear regression models using age in years as a continuous variable in years or as a 
categorical variable for retinal vessel parameters 
 
**ECD: endothelial cell density - lowest quartile denotes aged phenotype 
CV: coefficient of variation – i.e. difference in cell shape; highest quartile denotes aged 
phenotype 
Ex: Hexagonality index – i.e. proportion of cells that are hexagonal; lowest quartile denotes 
aged phenotype 	  
 
 
 
 
Biomarker N Coefficient R-
squared 
P-value 
Telomere length  250 -0.0015 0.02 0.05 
CDKN2A 217 0.006 0.02 0.02 
     
Lens density     
Linear 246 0.11 0.67 <0.0001 
Peak 246 0.30 0.25 <0.0001 
Average 3D 246 0.12 0.63 <0.0001 
     
Retinal vessel 
calibre 
    
Arteriolar diameter 243 40-49 years: -4.45 
>50 years: 4.15 
0.03 0.02 
Venular diameter 243 -0.02 0.0001 0.86 
     
Endothelial cell 
parameters** 
    
ECD 242 -5.40 0.04 0.003 
CV 242 0.06 0.01 0.07 
Ex 242 -0.14 0.04 0.001 
     
Retinal nerve fibre 
layer thickness 
    
Average 188 -0.39 0.07 <0.0001 
Superior 203 -0.40 0.03 0.02 
Inferior 202 -0.51 0.04 0.003 
Nasal 203 -0.03 0.0001 0.88 
Temporal 203 -0.36 0.06 0.003 
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Supplementary Figures – Scatter plots of biomarkers: regression with 
chronological age in years 
 
1a: Telomere length  
 
 
 
1b: CDKN2A expression 
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1c: Linear lens density  
 
  
 
1d: Peak lens density 
 
 
 
1e: 3-D average lens density 
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1f: Retinal arteriolar diameter 
 
 
 
1g: Retinal venular diameter 
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1h: Endothelial cell density 
 
 
 
1i: Variation in cell size 
 
 
 
1j: Hexagonality index – proportion of cells that have 6 sides 
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1k: Average retinal nerve fibre layer (RNFL) thickness 
 
 
 
1l: Superior RNFL thickness 
 
 
 
 
 
1m: Inferior RNFL thickness 
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1n: Nasal RNFL thickness 
 
 
 
1o: Temporal RNFL thickness 
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  Chapter 12 
 
Ocular parameters of biological aging in 
HIV-infected individuals in South Africa: 
relationship with chronological age and 
systemic biomarkers of aging 
 
 
 
Old Main Building, Groote Schuur Hospital and Devil’s Peak in the background  
 
 
 
Research paper investigating the association of 
potential ocular biomarkers of aging in HIV infection in 
relation to systemic biomarkers and chronological age 
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  Abstract 
Background: HIV-infected individuals have increased risk of age-related morbidity 
despite antiretroviral treatment (ART). Several anatomic and functional 
ophthalmological parameters are associated with increasing chronological age. 
These may, therefore, potentially serve as biomarkers of aging either individually or 
as a composite index.  
 
Methods: Cross-sectional study of 216 HIV-infected South African individuals 
receiving ART. We investigated associations between four ocular parameters (lens 
density, retinal vessel calibre, corneal endothelial cells and retinal nerve fibre layer 
thickness) and two ‘cellular’ biomarkers of aging (leukocyte telomere length and 
CDKN2A expression).  We also investigated the association of these ocular 
parameters with frailty (a clinical correlate of aging). 
 
Results: The median age of participants was 40 years (IQR:35-46 years) and 75% 
were female. The median CD4 count was 468 cells/µL and 94% had an undetectable 
viral load. All ocular parameters, telomere length and frailty were associated with 
chronological age, whereas CDKN2A expression was not (R2=0.007, p=0.25). 
Retinal venular diameters and linear lens density values were associated with shorter 
telomere length (p-trend=0.04, and 0.08, respectively), whereas CDKN2A expression 
and frailty status were not associated with any of the ocular parameters.  
 
Conclusions: Lens density and retinal venular calibre may be of value in the 
assessment of biological aging in HIV infection. Longitudinal studies are warranted to 
assess the integration of these data with systemic markers to develop an overall 
index of biological aging. 
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  Introduction 
 
Major reductions in HIV-associated mortality have occurred largely due to the global 
scale-up of antiretroviral therapy (ART). However, evidence is emerging that patients 
receiving ART are at an increased risk of age-related non-AIDS morbidity and 
mortality compared with HIV-seronegative individuals (1-3). Several of these 
conditions are classically associated with the normal aging process but appear to 
occur at an earlier age in HIV-infected persons compared to age-matched HIV-
seronegative individuals. It is possible that not only are HIV cohorts aging 
chronologically, but they may also be undergoing accelerated biological aging.  
 
 Chronological age is an imprecise measure of biological aging, due to inter-
individual differences in rates of aging. The disconnection between chronological age 
and lifespan has led to a search for effective and validated biomarkers of aging 
(BoA), defined as “biological parameters of an organism that either alone or in some 
multivariate composite will better predict functional capability at some late age, than 
will chronological age” (4). In HIV infection, heightened inflammation and immune 
dysfunction is likely to play a role in accelerated aging (1). This has stimulated 
assessment of several of biomarkers of inflammation and immune dysfunction, 
including C-reactive protein (CRP), interleukin-6 (IL-6) and D-dimer and their 
associations with age-related morbidity and HIV infection (5). 
 
 Only two validated BoA, telomere length (TL) and CDKN2A expression, have 
so far been found to satisfy the majority of the criteria proposed by Baker and Sprott 
(4). Telomeres are nucleoprotein complexes at the ends of eukaryotic chromosomes. 
Their DNA component shortens with somatic cell division and upon reaching a 
critically short length, a DNA damage signal leads to growth cycle arrest, resulting in 
replicative senescence (6, 7). Telomere shortening is associated with increasing 
chronological age and several pathologies. Telomere length (TL) may be useful as a 
composite measure of healthy aging, but not as a BoA when used in isolation (8, 9). 
Expression levels of the cell cycle regulator CDKN2A may represent a more robust 
BoA in healthy aging (10). CDKN2A acts as a tumour suppressor and maintains cells 
in a state of growth arrest, both in replicative and stress induced-senescence. 
Increasing levels of CDKN2A transcriptional expression occur with increasing age 
and decreasing function of solid organs and peripheral blood leucocytes (PBLs) (11-
14). However, in disease or pro-inflammatory states such as HIV infection, evaluation 
of CDKN2A expression may be compromised by mechanisms such as stress-
induced premature senescence (SIPS) (15). Furthermore, measurement of telomere 
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  length may be affected by the use of nucleoside reverse transcriptase inhibitors 
(NRTIs) (16). Thus, novel biomarkers are required to evaluate biological aging in HIV 
infection (17).  
 
Certain anatomic and functional parameters of the eye change with 
increasing chronological age. They may, therefore, serve as potential biomarkers of 
aging (18). We have reported on ocular parameters related to the accelerated aging 
phenotype in HIV, including retinal vessel calibre and objective measurement of lens 
density (19) (and Pathai et al, 2013 JAIDS; in press).  Furthermore, we have shown 
frailty to be part of this phenotype (20). Frailty is a functional state characterised by 
an increased risk of multiple pathologies, low physical activity and slow motor 
performance (21). Frailty predicts cognitive and physical decline and is associated 
with an increased risk of morbidity and mortality, and may therefore act as a ‘clinical’ 
biomarker of aging (21). There are limited data on how these parameters correlate 
with cellular BoA in the context of HIV as such markers are typically used in the 
evaluation of healthy biological aging. In addition, there are few data relating to 
biological aging in sub-Saharan Africa, a region where the population of HIV-infected 
elderly people is rapidly expanding and where the AIDS epidemic is most severe 
(22). 
 
With the need for novel BoA that could be valid in disease as well as health, 
the aim of this study was to investigate the association between eye parameters, 
frailty and cellular BoA in HIV infection.  
 
Methods: 
Study population: 
Individuals aged ≥ 30 years from community HIV treatment clinic in a township of 
Cape Town, South Africa (Hannan Crusaid Centre, Gugulethu) were recruited as 
HIV-infected ‘cases’ as part a case-control study investigating HIV and aging (19, 
20). Participants in this study were receiving ART at the time of enrolment. Socio-
demographic information and medical history were obtained by interviewing 
participants in their first language (Xhosa or English). Data collected included factors 
known to affect aging (e.g. UV exposure, smoking history). All participants underwent 
a full ophthalmic examination including measurement of visual acuity, evaluation by 
slit lamp microscopy and indirect ophthalmoscopy.  
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  The study was approved by the Ethics Committees of the London School of Hygiene 
and Tropical Medicine and the University of Cape Town Faculty of Health Sciences, 
and adhered to the tenets of the Declaration of Helsinki. Written informed consent 
was obtained from all participants. 
 
Anthropometry, blood pressure and physical function including frailty 
assessment: 
Blood pressure (BP) was measured with a digital sphygmomanometer. Mean arterial 
blood pressure (MABP) was defined as two-thirds of the diastolic plus one-third of 
the systolic BP (23). Hypertension was defined as a systolic BP of 140mmHg or 
higher, diastolic BP of 90mmHg or higher, or the combination of self-reported high 
BP diagnosis and the use of anti-hypertensive medications (24). Body mass index 
(BMI) was defined as weight (in kilograms)/height2.  
 
Physical frailty was defined by the presence of ≥3 of 5 criteria: i) unintentional weight 
loss (self reported and verified from clinic records where possible) ii) self-reported 
low physical activity, iii) self-reported exhaustion, iv) weak grip strength and v) slow 
walking time. Pre-frailty was defined as the presence of one or two of these criteria. 
Detailed information is available in the Supplementary Methods. 
 
Blood-based biomarkers:  
DNA/RNA extraction 
DNA was extracted from PBLs using the Maxwell™ Automated Purification System 
according to manufacturer’s instructions (Promega, USA). DNA concentration and 
purity were quantified by Nanodrop Spectrophotometer (ThermoFisher Scientific, 
USA). RNA was extracted using Trizol reagent (Invitrogen, UK) following 
manufacturer’s guidelines. DNA/RNA extraction was performed in Cape Town and 
samples shipped on dry ice to the University of Glasgow.  
 
Telomere length determination 
TL were determined by QPCR following the method of Cawthon (25). TL 
determination was performed blindly using a Roche Light Cycler LC480. Briefly, 
telomere length analyses were performed in triplicate for each sample, using a 
single-copy gene amplicon primer set (acidic ribosomal phosphoprotein, 36B4) and a 
telomere-specific amplicon primer set (14). Refer to Supplementary Methods for 
further detail.  
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  CDKN2A expression determination  
Relative quantitative real-time PCR (qRT-PCR) was used to estimate mRNA levels 
corresponding to the candidate senescence associated gene - CDKN2A. Expression 
levels were measured against a reference hypoxanthine phosphoribosyltransferase 
(HPRT) housekeeping gene on an ABI Prism(R) 7500 Sequence Detection System. 
Sequences of human TaqMan™ Primer/Probe sets were designed by Primer 
Express algorithm (Applied Biosystems, Austin, TX, USA). The comparative 
threshold cycle method (ΔΔCT)(26) was employed to quantify relative gene 
expression.  
 
Ocular biomarkers  
The following four ocular parameters were selected (Table 1). Detailed methods are 
supplied in the Supplementary Methods.  
i) Lens density: Pentacam imaging (Oculus, Wetzlar, Germany) was used to obtain 
“Scheimpflug images” of the lens and an objective estimate of lens density on a 
continuous scale. Lens density increases with increasing chronological age.  
ii) Retinal vessel calibre: Participants had stereoscopic 30° colour retinal 
photographs taken under pharmacological pupil dilation with a fundus camera (CF-2; 
Canon Inc., Tokyo, Japan). Vessel calibre indices were determined in a semi-
automated manner using the IVAN computer program (Singapore Eye Research 
Institute, Singapore) and a standardized protocol described previously (27). 
Narrowing of retinal arterioles is associated with increasing chronological age (23, 
28).  
iii) Corneal endothelial cell parameters: A non-contact specular microscope was used 
(SP02, CSO, Florence, Italy). The operator focused and aligned a real-time image of 
the participant’s eye. Endothelial cell parameters were automatically calculated from 
this image by the microscope software. Endothelial cell density (ECD) decreases 
with age, whereas the change in cell size (coefficient of variation) increases with age. 
The proportion of cells with six sides (hexagonality index) decreases with age.  
iv) Retinal Nerve Fibre Layer (RNFL): Measured using Spectral OCT/SLO optical 
coherence tomography (Opko/OTI Inc, Miami, FL) which uses a scanning laser diode 
of 830nm to provide images of ocular microstructures. A peri-papillary (around optic 
nerve head) protocol inbuilt in the software was used to determine the average and 
quadrant-specific RNFL thickness (superior, inferior, temporal and nasal). The RNFL 
becomes thinner with increasing age (29, 30).  
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  Statistical analysis: 
One eye was randomly selected for analysis. Where an eye was not available, for 
example due to trauma or corneal opacity, the contralateral eye was used. Analyses 
were performed using Stata 12 (Stata Corp, College Station, TX). Clinical and 
biological data were summarized as the median with interquartile range (IQR) or 
mean with standard error (SE), as appropriate. Analyses were conducted on log10-
transformed values of telomere length and mean CDKN2A expression to satisfy the 
assumption of normally distributed residuals. Results are displayed back-transformed 
to the original scale. Validation of the biomarkers was performed using linear 
regression models with age in years as a continuous or categorical variable. Ocular 
biomarker measurements were divided into quartiles. Univariable linear regression 
was performed to compare the quartiles of ocular parameters with mean telomere 
length and CDKN2A expression and frailty status respectively. Multivariable linear 
regression models were used to examine the relationships of telomere length, 
CDKN2A expression as the respective dependent variable with ocular biomarker 
quartiles and frailty status and explanatory variables (age group [30-39; 40-49; >50 
years], gender, MABP; BMI, smoking, UV exposure, current and nadir CD4 count, 
peak and current HIV viral load) as independent variables. Marginal adjusted means 
for telomere length and CDKN2A expression were estimated at the mean value of 
covariates in the model.  The Wald test was used to assess statistical significance of 
the association of each ocular parameter on systemic biomarker levels. 
 
Results 
Participant characteristics and biomarker distributions: 
216 participants underwent assessment. The median age was 40 years (IQR: 35-46) 
and 25% (n=54) were male. Characteristics of the participants by gender are given in 
Table S1. Women reported less alcohol consumption and cigarette use compared to 
men (p<0.0001 for both). Men had lower BMI and lower current CD4 counts 
(p<0.0001 and p=0.04, respectively). The number of participants providing data for 
each parameter varied, as not every participant was able to complete all ophthalmic 
tests or had a blood sample available for analysis. Summary statistics for each 
biomarker, stratified by gender and age group are displayed in Table S2. For the 
majority of biomarkers, there was no evidence of gender differences; however for 
endothelial cell parameters, the cell density was greater in women compared to men, 
and women were more frail than men  (p=0.03 for both).  
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  Validation of biomarkers against chronological age: 
All biomarkers were initially validated against chronological age in a HIV-
seronegative control group of similar age and gender, recruited as part of a case-
control study (Pathai et al; unpublished data). Assessment within this study 
population was subsequently performed. (Table S3). Telomere length was 
associated with chronological age (p=0.03), however CDKN2A expression was not 
(p=0.25). All ocular parameters except the RNFL nasal quadrant and hexagonality 
index of endothelial cells were associated with chronological age, therefore these 
ocular parameters were not analysed further. The association of the prospective 
biomarkers with chronological age is presented in Supplementary Figures 1a-1o. The 
R-squared values of the regressions against chronological age were highest for lens 
density parameters (linear lens density R2=0.63). All analyses thereafter were 
adjusted for age, gender and other possible confounding variables related to the 
parameter of interest.  
 
Association of ocular parameters with blood-based biomarkers: 
Shorter telomere length was associated with increasing retinal venular diameter  (p-
trend=0.04) - Table 2. Telomere length was not related to retinal arteriolar diameter. 
Table 3 reports associations with lens density: there was a trend of shorter telomere 
length with increasing lens density (p=trend=0.08). Endothelial cell parameters and 
RNFL thickness were not related to TL or CDKN2A expression (data not shown).  
 
Association of frailty status with blood-based and ocular biomarkers: 
There was no association of frailty status with either telomere length or CDKN2A 
expression (p=0.54 and p=0.76, respectively). Similarly, none of the ocular 
parameters were associated with frailty (data not shown).  
 
Discussion 
We compared several ocular parameters and frailty, a clinical correlate of aging, with 
TL and CDKN2A expression as established and validated biomarkers of aging. 
Retinal venular diameter was the most informative ocular biomarker, showing 
increased venular diameter with decreasing TL. Objective measurement of lens 
density also showed a strong trend of decreasing TL with increasing lens density. In 
contrast, CDKN2A expression, a validated biomarker of aging in health, was not 
associated with frailty or any of the ocular parameters. These findings suggest that 
the ocular lens and retinal vasculature, which reflect different physiological systems, 
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  may have a role to play in the determination of biological age and aging trajectories 
in HIV infection, which may differ from that seen in physiological ‘healthy aging’. 
 
 We have already established in this same study population that HIV infection 
is associated with increased frailty (20), changes in retinal vessel calibre that are 
consistent with aging and increased cardiovascular risk (19), and an increase in lens 
density in patients with severe HIV-related immunodeficiency (Pathai et al 2013; 
JAIDS, in press). These findings indicate the presence of an HIV-related accelerated 
aging phenotype, which is likely to have important clinical and health systems 
implications as HIV-infected populations continue to increase and live longer. 
Associations of these ocular and clinical parameters with validated BoA have not 
been investigated to date. The need for evaluated biomarkers in determining 
biological age is gaining increasing importance as data emerge about the excess risk 
of age-related morbidity in HIV-infected individuals despite suppression of viral load 
(17).  
 
Of a wide range of BoA evaluated, only TL and CDKN2A are thought to meet 
the Baker and Sprott criterion (4). The majority of putative BoA assessed fail on the 
basis that they are unable to predict functional capacity in the absence of disease 
(31). The issue is further compounded in HIV infection as BoA are typically used to 
evaluate physiological, ‘healthy’ aging. Measurement of ‘accelerated’ biological aging 
HIV infection may involve different mechanisms, and therefore render some BoA 
invalid in their measurement. This is pertinent to the lack of association between 
CDKN2A and chronological age in our HIV-infected study population, where the 
disease state decouples CDKN2A expression from correlation with chronological 
ageing. We have found CDKN2A expression to be significantly higher in HIV-infected 
individuals compared to age- and gender-matched controls (Pathai et al., -
unpublished data). However, as well as functioning as a tumour suppressor, 
CDKN2A is also a component of stress-induced premature senescence (SIPS) (15) 
which prevents T-cell replication following acute insult (32). The decoupling of the 
relationship between CDKN2A expression and chronological age in HIV infected 
individuals is a direct consequence of HIV-associated premature T-cell senescence 
(33), and lack of further T cell replication with HIV infection.  SIPS causes 
populations of cells to ‘freeze’ in time with respect to age, confounding the 
determination of rate changes in replicative senescence and therefore biological 
aging. The Baker and Sprott criterion state “The biomarker should reflect some basic 
biological process of aging and certainly not the predisposition toward a disease 
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  state or some error in metabolism” (4). Thus, the induction of SIPS by CDKN2A in 
disease states such as HIV infection suggests that this is an unreliable BoA in these 
circumstances.  
 
 Telomere length has also been shown to be significantly shorter in HIV-
infected individuals compared to HIV-seronegative controls in this population (Pathai 
et al - unpublished data), and may better satisfy the Baker and Sprott criteria in 
disease states. However, telomere attrition is affected by psychosocial confounders, 
genetics and potentially by NRTIs used in the treatment of HIV infection (16), leading 
to the suggestion TL may be useful as a composite measure of healthy aging, but not 
as a BoA when used in isolation (8, 9). The trend of increasing lens density with 
shortening of telomere length in intuitive, and the strong association of lens density 
with chronological age (when compared to TL), suggests that in this population, lens 
density may be an attractive BoA as it is less susceptible to changes caused by 
systemic disease states.  
 
The frailty phenotype was initially described in HIV-infected individuals in 
2007 (34), with frailty prevalence for 55-year-old men infected with HIV for ≤ 4 years 
similar to that of uninfected men ≤ 65 years old. Similarly, we have found an 
increased prevalence of frailty in this study population (20). However, we did not 
detect an association between frailty and cellular BoA or ocular parameters. In 
contrast, in an HIV-seronegative study population from the same community we 
found increasing lens density to be associated with frailty status (Pathai et al., -
unpublished data). This suggests that the frailty phenotype in HIV, while sharing 
some characteristics with the original description in the geriatric population (21), has 
other characteristics perhaps unique to HIV infection and/or use of ART. This is 
corroborated by the finding that CD4 count is also associated with the development 
of frailty (20, 35), suggesting that compromise of the immune system in HIV-infected 
individuals contributes to the development of the frailty phenotype. Furthermore, HIV-
infected frail individuals have higher concentrations of pro-inflammatory cytokines 
such as IL-6, and tumour necrosis factor-alpha (TNF-α), and C-reactive protein (36). 
Age-related comorbidities and AIDS predict conversion from being non-frail to frail, 
and having a persistent frailty-like phenotype before HAART initiation predicts 
mortality (37). Collectively, these findings suggest that frailty in HIV infection is not 
simply an accelerated version of geriatric frailty, and so the lack of relationship with 
BoA at a cellular or ocular level may be expected.  
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  Retinal arteriolar and venular calibre typically narrow with increasing 
chronological age (23, 28), thus shortening of TL might be expected to be associated 
with narrowing of venular diameter. However, our observation that shortened TL was 
associated with increasing retinal venular diameter is nevertheless plausible in the 
context of HIV infection. Inflammation is recognised as a key pathogenic process in 
HIV infection, and also in HIV-related accelerated aging (1). Larger retinal venular 
calibre is associated with systemic inflammatory markers such as CRP, fibrinogen, 
IL-6 and smoking, independently of age (38-40). This suggests that the heightened 
inflammatory processes observed in HIV infection are consistent with a biologically 
aged phenotype as manifest by shorter TL. Patients with HIV infection are at 
increased risk of developing cardiovascular disease (41). Although factors potentially 
contributing to this elevated risk include traditional cardiovascular risk factors and 
antiretroviral medications, it is likely that inflammatory and immunologic factors also 
contribute. Endothelial dysfunction is also associated with larger retinal venules 
independent of traditional cardiovascular risk factors (42). We therefore postulate 
that HIV-related inflammation and/or endothelial dysfunction manifests as retinal 
venular dilation and contributes to the biologically aged phenotype. Furthermore, 
retinal arteriolar narrowing which is associated with increased cardiovascular risk 
(43), is related to increasing duration of ART, independent of age (19). Thus, 
assessment of retinal vessel diameters may be a novel and non-invasive method of 
assessing vascular risk and biological aging in this population.  
 
This study has some limitations. The gender composition of participants was 
three-quarters female, but this is reflective of the HIV epidemic in Africa. There were 
also differences between genders (smoking, alcohol consumption) that may truly 
exist or may have been misclassified (e.g. misreporting true smoking habits) and this 
could have confounded associations of the ocular parameters with the other 
biomarkers. Participants were recruited from a community of considerable socio-
economic deprivation, and therefore likely to have been exposed to factors known to 
increase biological aging such as high UV exposure from outdoor work. Therefore, 
our data might over-estimate associations related to aging. Lastly, as study 
participants are of African ancestry, our results are generalizable to the African 
population.  
 
Biomarkers are used extensively in the assessment of HIV infection, from 
monitoring of CD4 count and HIV RNA viral load to assess response to ART, to the 
use of indices such as the VACS Index to predict morbidity and mortality (44). Our 
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  findings indicate that measurement of biological aging in HIV infection may be 
complicated by inflammation and immune dysfunction such that BoA validated in 
healthy aging are no longer accurate predictors. This suggests that other biomarkers 
are needed; our data indicate that measurement of lens density and retinal vessel 
calibre may be useful additions in the assessment of biological aging. We have 
proposed a research agenda to further define and validate ocular biomarkers of 
aging (18). Vessel calibre assessment may provide information about inflammation 
and systemic vascular changes, whereas lens density evaluation may be indicative 
of true biological aging. Longitudinal studies are warranted to assess the integration 
of these data with systemic markers to develop an overall estimate of biological 
aging and possibly mortality risk. In conclusion, the eye may prove to be a useful 
addition in the assessment of biological aging and to improve our understanding of 
HIV-related accelerated aging.   
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  Table 1: Biomarkers of aging, methods of measurement and the impact of aging 
 
 
 
 
 
 
 
 
 
 
Anatomical 
site 
Parameter Method of measurement Age-related 
changes 
Peripheral 
blood 
leukocytes 
Telomere length (TL) 
 
CDKN2A expression 
qPCR 
 
qRT-PCR to estimate mRNA 
levels 
TL shortens 
 
Increased 
expression 
Corneal 
endothelium 
Endothelial cell density 
(ECD) 
Coefficient of variation (CV) 
Hexagonality index (Ex) 
Specular microscopy Decreased ECD 
Increased CV 
Decreased Ex 
Lens Lens opacity 
Linear value 
Peak 
3-D average 
Pentacam – lens densitometry 
 
 
 
All increase 
Retina Retinal nerve fibre layer 
(RNFL) thickness  
(Average, superior, inferior, 
nasal, temporal quadrants) 
 
Retinal vessel caliber 
Optical coherence tomography 
(OCT) 
 
 
 
 
Semi-automated retinal analysis 
software applied to fundus 
photographs 
Thinner RNFL- all 
quadrants 
 
 
 
Reduced diameter 
of arterioles and 
arterio-venous 
ratio (AVR)  
Systemic Frailty status 
Non-frail (no criteria) 
Pre-frail (1-2 criteria) 
Frail: ≥3 of 5 criteria 
 
Assessment of walking speed, 
grip strength, self-report of weight 
loss, exhaustion and low physical 
activity 
 
 
Frailty status 
increases  
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Table 2: Association of retinal arteriolar and venular diameter with systemic biomarkers  
 
Vessel parameter  TL   CDKN2A  
Retinal arteriolar 
quartiles (µm) 
N Rel T/S P N Mean P 
1st 
 (113.16-150.13) 
38 0.89 
(0.81-0.97) 
 37 0.37 
(0.29-0.47) 
 
2nd   
(150.56-161.06) 
42 0.87 
(0.80-0.95) 
 40 0.54 
(0.43-0.68) 
 
3rd  
 (161.53-171.89) 
62 0.92 
(0.87-0.99) 
 61 0.43 
(0.36-0.51) 
 
4th 
(172.79-207.80) 
54 0.93 
(0.87-1.00) 
P-trend 
0.25 
53 0.44 
(0.36-0.54) 
 
0.19 
Retinal venular 
quartiles (µm) 
      
1st 
(218.31-258.35) 
66 1.04 
(0.92-1.17) 
 64 0.54 
(0.39-0.74) 
 
2nd 
 (258.78-269.99) 
57 0.89 
(0.83-0.95) 
 56 0.41 
(0.34-0.49) 
 
3rd  
(270.24-281.54) 
40 0.87 
(0.79-0.97) 
 40 0.48 
(0.36-0.63) 
 
4th  
(281.7-326.08) 
33 0.74 
(0.63-0.86) 
P-trend 
0.04 
31 0.31 
(0.20-0.51) 
 
0.15 
 
Adjusted for age, gender, smoking, BMI, hypertension and venular/arteriolar retinal calibre (where 
appropriate) and HIV-related co-variates (current and nadir CD4 count, current and peak viral load, ART 
duration and ART type) 
 
 
 
Table 3: Association of lens density with systemic biomarkers, n=198 
 
Lens density**  TL   CDKN2A  
Linear quartiles N Rel T/S P N Mean P 
1st  
(7.5-9.2) 
48 0.95 
(0.87-1.03) 
 47 0.42 
(0.33-0.55) 
 
2nd   
(9.25-9.8) 
54 0.97 
(0.90-1.04) 
 53 0.45 
(0.37-0.55) 
 
3rd   
(9.85-10.7) 
48 0.87 
(0.81-0.94) 
 48 0.44 
(0.36-0.55) 
 
4th  
(10.8-13.9) 
48 0.84 
(0.77-0.93) 
P-trend 
0.08 
46 0.48 
(0.36-0.62) 
0.94 
 
Adjusted for age, gender, smoking, UV exposure and HIV-related parameters (current and nadir CD4 
count, current and peak viral load, ART duration and ART type) 
 
** - Measured on a continuous scale 0-100, 100 being an opaque (completely dense) lens 
4th quartile denotes aged phenotype  
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  Supplementary Methods 
 
Telomere length determination: 
Quality control parameters for the amplifications comprised a cut off of 0.15 for the standard deviation 
(SD) of the threshold cycle (Ct) for sample replicates. At a SD above 0.15 the sample was reanalysed. 
The average SD across plates was 0.05. Relative telomere length was estimated from Ct scores using 
the comparative Ct method after confirming that telomere and control gene assays yielded similar 
amplification efficiencies. This method determines the ratio of telomere repeat copy number to single 
copy gene number (T/S) ratio in experimental samples relative to a control sample DNA. This 
normalised T/S ratio was used as the estimate of relative telomere length (Relative T/S).  The inter-
assay variation was assessed by comparing the relative telomere estimates (T/S ratio) estimates across 
assays for the positive controls, assayed on every assay plate. The average inter-assay coefficient of 
variance was 0.6% for telomere length and 0.23% for 36B4.   
 
 
Frailty determination 
All of these five components described in the original phenotype by Fried et al [1] were used to 
determine the presence of frailty. However, we used the proxy described by Önen et al [2] for the 
physical activity measure (see Table 1 below for description). Grip strength of the dominant hand was 
measured three times using a grip dynamometer (Jamar Plus+ Digital Hand Dynamometer, Jamar, US). 
The average of three weight measurements was recorded in kilograms (kg) to one decimal point. 
Walking time was assessed using the method of Cesari et al [3]. The average of two trials (in m/s) was 
used for analysis. Participants were excluded from the determination of grip strength if they had pain or 
arthritis of the dominant hand, and excluded from the walking test if they had paralysis of an extremity 
or side of the body, or needed to use a walking aid. 
 
Lens density measurement:  
Following pupil dilatation with 1% tropicamide, two lens density measurements were made on each eye, 
and the mean value calculated. The instrument automatically calculated the quality and reliability of a 
captured image. If an image was found to be of poor quality (i.e. not ‘OK’ on the image quality 
specification), the measurement was repeated. Reproducibility of the lens density evaluation in two 
scans was performed for 50 eyes. Lens densitometry output values were extracted from the image 
captures in a masked fashion. Image section 90-270 degrees was used for the right eye and image 
section 270-90 degrees was used for the left eye [4]. All of the densitometry metrics available from the 
scan (linear, peak and 3D) were analysed as they reflect different parameters of the lens. The lens 
density output was presented on a continuous scale from 0 (transparent) to 100 (fully opaque).  
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  Retinal vessel measurement 
All participants had stereoscopic 30 degree colour retinal photographs taken of both eyes under 
pharmacological pupil dilation with a fundus camera (model CF-2; Canon Inc., Tokyo, Japan). Images 
were centred on the optic disc. Vessel calibre indices were determined in a semi-automated manner 
using the IVAN computer program (Singapore Eye Research Institute, Singapore) using a standardized 
protocol described previously [5]. In summary, the 6 largest arterioles and venules in a ring-shaped area 
located between 0.5 and 1.0 disc diameter from the optic disc margin were identified (Figure 1). 
Computer software measured the calibre of these individual vessels, then combined them into 2 
summary variables for the eye: the projected calibre size of the central retinal artery (central retinal 
artery equivalent [CRAE]), and the projected calibre size of the central retinal vein (central retinal vein 
equivalent [CRVE]), using formulas derived by Parr and Spears [6,7] and Hubbard [8], with revision by 
Knudtson [9]. A retinal photograph was considered ungradable if eyes had <4 acceptable 
measurements of either vessel type. The intergrader and intragrader grading reliabilities were assessed 
using a random subsample of 100 photographs reviewed four weeks after the initial grading. The intra- 
and intergrader intraclass correlation coefficients ranged from 0.71 to 0.93.  Retinal arteriolar and 
venular calibre are highly correlated, and to account for potential confounding we adjusted for the fellow 
vessel in multivariable analyses (i.e. adjustment for arteriolar calibre in analyses of venular calibre and 
vice versa) [10]. 
 
Table 1: Frailty criteria: adapted from Fried et al.[1] and Önen et al.[2] 
 
Criteria Definition 
Unintentional weight loss >10 pounds weight loss documented in last year or ≥5% of previous year’s body weight 
 
Low physical activity* Participants answering 3 when asked whether their health limits vigorous activities such as running, 
lifting heavy objects 
1= not at all, 2 = yes, limited a little or 3 = yes, limited a lot 
 
Exhaustion  Participants answering 2 or 3 to either one of two statements –  
“How often have you felt that:” 
a) Everything you did was an effort or  
b) I could not ‘get going’ 
0 = rarely (<1 day), 1= some of the time (1-2 days),  
2 = occasionally (3-4 days) or 3 = most of the time (5-7 days) 
 
Weak grip strength Male BMI kg/m2 
≤24 
24.1-26.0 
26.1-28.0 
>28 
 
Kg 
≤29 
≤30 
≤30 
≤32 
Female BMI kg/m2 
≤23 
23.1-26.0 
26.1-29 
>29.0 
Kg 
≤17 
≤17.3 
≤18 
≤21 
Slow walking time  Male height (cm) 
≤173 
>173 
Seconds 
 
≥7 
≥6 
Female height (cm) 
 
≤159 
>159 
Seconds 
 
≥7 
≥6 
*Estimation of physical activity adopted from Önen et al.[2]; the estimation of physical activity described in the 
original phenotype used a weighted score of kilocalories expended 
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  Table S1: Characteristics of study participants, n=216  
 
Variable Male (N=54) 
N (%) 
Female (N=162) 
N (%) 
P 
Age (mean ± SE) 41.5±0.9 41.2±0.6 0.82 
Median age, IQR 40 (37-46) 40 (35-47) 0.52 
Age, years by group 
30-39 
40-49 
>50 
 
25 (46.3) 
22 (40.7) 
7 (13.0) 
 
80 (49.4) 
52 (30.1) 
30 (18.5) 
 
 
 
0.43 
Education 
Did not complete high school 
Completed high school 
 
9 (16.7) 
45 (83.3) 
 
16 (9.9) 
146 (90.1) 
 
 
0.18 
Income 
<ZAR1000/month 
>ZAR1000/month 
 
32 (59.3) 
22 (40.7) 
 
89 (54.9) 
73 (45.1) 
 
 
0.58 
Location of work 
Outdoors or grant-holder 
Indoors 
 
38 (70.4) 
16 (29.6) 
 
98(60.5) 
64(39.5) 
 
 
0.19 
Housing 
Formal 
Informal 
 
24 (44.4) 
30 (55.6) 
 
88 (54.3) 
74 (45.7) 
 
 
0.21 
Smoking status 
Non-smoker 
Smoker; <10 years 
Smoker >10 years 
 
32 (59.3) 
5 (9.3) 
17(31.4) 
 
152 (93.8) 
5 (3.1) 
5 (3.1) 
 
 
 
<0.0001 
Alcohol 
Nil 
<1L/week 
>1L/week 
 
25 (46.3) 
18 (33.3) 
11 (20.4) 
 
126 (77.8) 
23 (14.2) 
13 (8.0) 
 
 
 
<0.0001 
Hypertension 
No 
Yes 
 
42 (77.8) 
12 (22.2) 
 
111 (68.5) 
51 (31.5) 
 
 
0.20 
BMI 
<20 
20-24.9 
25.0-29.9 
>30 
 
12 (22.2) 
29 (53.7) 
10 (18.5) 
3 (5.6) 
 
5 (3.1) 
31(19.1) 
56 (34.6) 
70 (42.2) 
 
 
 
 
<0.0001 
Tuberculosis status 
No history 
Previous history 
Current 
 
8 (14.8) 
43 (79.6) 
3 (5.6) 
 
52 (32.1) 
109 (67.3) 
1 (0.6) 
 
 
 
0.005 
Current CD4 count, median (IQR) 410  
(270-610) 
481  
(345-607) 
 
0.04 
Nadir CD4 count, median (IQR) 135 
(81-166) 
122 
(70-174) 
 
0.69 
Viral load 
<50 copies/ml 
>50 copies/ml 
 
49 (90.7) 
5 (9.3) 
 
154 (95.0) 
8 (5.0) 
 
 
0.25 
Duration of ART*, median (IQR) 
 
55 
(41-72) 
60 
(33-76) 
 
0.96 
*ART; anti-retroviral treatment 	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  Table S2: Median values of candidate biomarkers by gender and age group 
P-value for difference between genders 
  Men Women P-value 
Measure Age group, 
years 
N Median IQR N Median IQR  
Systemic 
biomarkers 
        
Telomere length 
Rel T/S 
Overall 48 0.96 0.78-1.09 156 0.92 0.78-0.92 0.51 
 30-39 23 1.00 0.80-1.13 78 0.97 0.79-1.10  
 40-49 20 0.94 0.81-1.07 49 0.91 0.78-1.11  
 >50 5 0.74 0.64-1.27 29 0.82 0.74-1.00  
CDKN2A 
expression 
Overall 47 0.46 0.24-0.72 152 0.50 0.29-0.70 0.48 
 30-39 22 0.34 0.21-0.65 77 0.50 0.27-0.70  
 40-49 20 0.50 0.25-0.81 46 0.47 0.31-0.66  
 >50 
 
5 0.68 0.41-0.81 29 0.56 0.42-0.74  
Lens density 
Scale 0-100 
        
Linear Overall 52 9.8 9.2-10.5 157 9.8 9.3-10.5 0.42 
 30-39 24 9.2 8.9-9.7 77 9.4 9.0-9.6  
 40-49 22 10 9.8-10.6 50 10.3 9.8-10.9  
 >50 6 
 
11.0 10.5-12.1 30 11.5 11.0-12.0  
Peak Overall 52 17.9 14.9-19.5 157 17.9 15.6-20.1 0.57 
 30-39 24 18.0 15.4-18.8 77 16 14.7-18.1  
 40-49 22 16.8 14.8-19.1 50 18.5 16.1-21.1  
 >50 6 21.6 15.8-25.0 30 20.5 18.8-24.7  
3-D average Overall 52 9.7 9.1-10.3 157 9.8 9.1-10.8 0.33 
 30-39 24 9.1 8.8-9.7 77 9.1 8.9-9.5  
 40-49 22 10 9.5-10.3 50 10.3 9.8-10.8  
 >50 6 11.2 10.5-12.5 30 11.7 11.0-12.4  
Retinal vessel 
calibre µm 
        
CRAE Overall 50 161.7 151.5-170.6 157 164.8 152.5-173.4 0.36 
 30-39 22 160.7 151.5-167.6 77 167.1 155.5-176.5  
 40-49 22 164.1 158.7-172.4 51 161.7 152.3-171.9  
 >50 6 139.3 122.1-170.3 29 162.4 144.8-169.4  
CRVE Overall 50 262.2 250.6-273.9 157 266.2 255.7-279.9 0.15 
 30-39 22 263.8 258.3-274.4 77 269.9 259.8-282.8  
 40-49 22 260.9 246.2-272.9 51 263.3 251.9-276.1  
 >50 6 260.7 238.1-277.4 29 263.7 254.2-271.3  
Endothelial cell 
parameters 
        
ECD Overall 48 2598 2337-2730 150 2690 2463-2858 0.03 
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   30-39 23 2671 2514-2850 74 2720 2554-2880  
 40-49 20 2466 2125-2762 49 2665 2400-2816  
 >50 5 2402 2122-2590 27 2566 2382-2729  
CV Overall 48 36 34-38 150 36 33-39 0.84 
 30-39 23 36 34-39 74 35 32-37  
 40-49 20 36 33-38 49 37 33-39  
 >50 5 36 33-41 27 38 34-41  
Ex Overall 48 49 45-54 50 50 45-54 0.91 
 30-39 23 49 44-54 74 50 45-53  
 40-49 20 50 46-54 49 50 46-55  
 >50 
 
5 46 38-53 27 48 42-51  
RNFL 
thickness, µm 
        
Average Overall 45 110 101-116 143 112 102-118 0.47 
 30-39 21 115 106-117 74 114 107-122  
 40-49 19 107 98-115 42 114 100-117  
 >50 
 
5 102 93-113 27 102 89-113  
Superior Overall 50 132 124-145 147 137 121-151 0.22 
 30-39 23 133 125-145 74 142 128-157  
 40-49 21 132 125-145 46 131 120-146  
 >50 
 
6 119 100-130 27 126 109-142  
Inferior Overall 50 133 121-144 149 141 124-152 0.18 
 30-39 23 141 126-156 75 144 129-154  
 40-49 21 129 123-142 46 142 118-149  
 >50 
 
6 119 96-134 28 124 110-141  
Nasal Overall 50 92 76-104 147 94 76-103 0.92 
 30-39 23 89 76-103 74 93 78-101  
 40-49 21 94 77-107 46 94 75-110  
 >50 
 
6 87 52-134 27 91 61-99  
Temporal Overall 50 73 64-81 148 73 63-84 0.63 
 30-39 23 74 65-83 74 78 67-88  
 40-49 21 71 64-77 46 69 57-78  
 >50 
 
6 65 49-82 28 66 60-73  
Frailty status  N %  N %  P-value 
Non-frail Overall 20 37.0  50 30.8  0.56 
 30-39 10 40.0  32 40.0   
 40-49 9 40.9  16 30.8   
 >50 
 
1 14.3  2 6.7   
Pre-frail Overall 27 50.0  80 49.4  0.68 
 30-39 12 48.0  38 47.5   
 40-49 9 40.9  30 57.7   
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 >50 
 
6 85.7  12 40.0   
Frail Overall 7 13.0  32 19.8  0.03 
 30-39 3 12.0  10 12.5   
 40-49 4 18.2  6 11.5   
 >50 
 
0 0  16 53.3   
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  Table S3: Regression coefficients of biomarkers with chronological age in years 	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Linear regression models using age in years as a continuous variable in years  
 
**ECD: endothelial cell density - lowest quartile denotes aged phenotype 
CV: coefficient of variation – i.e. difference in cell shape; highest quartile denotes aged phenotype 
Ex: Hexagonality index – i.e. proportion of cells that are hexagonal; lowest quartile denotes aged 
phenotype 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
Biomarker N Coefficient R-
squared 
P-value 
Telomere length  204 -0.002 0.02 0.03 
CDKN2A 199 0.003 0.007 0.25 
     
Lens density     
Linear 209 0.11 0.63 <0.0001 
Peak 209 0.23 0.18 <0.0001 
Average 3D 246 0.13 0.71 <0.0001 
     
Retinal vessel 
calibre 
    
Arteriolar diameter 207 -0.40 0.03 0.01 
Venular diameter 207 -0.58 0.06 0.001 
     
Endothelial cell 
parameters** 
    
ECD 198 -9.91 0.06 <0.0001 
CV 198 0.13 0.06 <0.0001 
Ex 198 -0.12 0.01 0.12 
     
Retinal nerve fibre 
layer thickness 
    
Average 188 -0.60 0.14 <0.0001 
Superior 197 -0.89 0.10 <0.0001 
Inferior 199 -0.95 0.11 <0.0001 
Nasal 197 -0.20 0.005 0.30 
Temporal 198 -0.46 0.06 <0.0001 
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  Supplementary Figures – Scatter plots of biomarkers – linear regression with 
chronological age 
 
1a: Telomere length  
 
 
 
1b: CDKN2A expression 
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1c: Linear lens density  
 
  
 
1d: Peak lens density 
 
 
 
1e: 3-D average lens density 
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  1f: Retinal arteriolar diameter 
 
 
 
1g: Retinal venular diameter 
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  1h: Endothelial cell density 
 
 
 
1i: Variation in cell size 
 
 
 
 
1j: Hexagonality index – proportion of cells that have 6 sides 
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  1k: Average retinal nerve fibre layer (RNFL) thickness 
 
 
 
 
1l: Superior RNFL thickness 
 
 
 
1m: Inferior RNFL thickness 
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  1n: Nasal RNFL thickness 
 
 
 
1o: Temporal RNFL thickness 
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Chapter 13 
 
Overall conclusions and future work 
 
 
 
 
Table Mountain, Cape Town 
 
 
 
 
 
General discussion drawn from all of the contributing 
work including details of ongoing projects and potential 
future studies 
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13.1 Summary of findings 
The proportion of individuals aging with HIV infection continues to increase 
worldwide [1]. The aim of this study was to assess whether HIV contributes to 
accelerated aging in a sub-Saharan African population; a region where there are few 
data relating to this concept. The eye was used as a model of aging as several of its 
component structures can be objectively measured and assessed. Furthermore, 
there are limited data on the eye and visual morbidity in HIV-related accelerated 
aging.  
 
This study demonstrated accelerated biological aging, as measured by telomere 
length determination and CDKN2A expression, in HIV-infected individuals compared 
to age- and gender- frequency-matched controls. The observation of accelerated 
biological aging was corroborated by the finding that HIV is associated with clinical 
frailty, and that current CD4 count is an independent predictor of frailty status.  
Within the eye, increasing duration of ART was independently associated with both 
narrower retinal arterioles and thinning of the RNFL; both of these changes are also 
associated with increasing chronological age in ‘physiological’ aging. Greater lens 
density was observed in participants on ART with low nadir CD4 counts suggesting 
that higher levels of immunodeficiency contribute to the development of the 
accelerated aging phenotype. Investigation of the corneal endothelium, which 
provides a unique view of a cellular monolayer, demonstrated that HIV infection was 
associated with greater variation in cell size, a feature of cellular senescence. In HIV-
infected individuals, low endothelial cell density, another feature of cellular aging, was 
associated with current CD4 count. These data suggest that as well as increased 
biological aging at a cellular and systemic level, ocular aging also occurs as part of the 
accelerated aging phenotype in HIV infection, particularly in clinical sub-groups such 
as those with greater levels of immunodeficiency pre-ART or active viremia despite 
ART.  
 
Table 13 summarizes the main findings and outcomes from this study. 
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Table 13: Main findings from studies in this population 
Parameter Method of 
measurement 
Sample size Outcome  
 
Telomere length 
CDKN2A expression 
 
 
 
qPCR from PBL 
 
 
 
486 
236 HIV+/250 HIV- 
 
Telomere length shorter in HIV+ group  
CDKN2A expression higher in HIV+ group 
Participants on ART with undetectable VL – shorter telomere 
length and greater CDKN2A expression associated with lower 
CD4 counts 
 
Frailty 
 
Clinical assessment 
 
504 
248 HIV+/256 HIV- 
 
HIV associated with frailty – OR: 2.14 (1.16-3.92), p=0.01 
Low current CD4 count (<500cells/L) independently associated 
with frailty – OR: 2.84 (1.02-7.92), p=0.04 
 
 
Retinal vessel calibre 
 
Semi-automated analysis of 
retinal vessel diameter 
 
491 
242 HIV+/249 HIV- 
 
Similar retinal arteriolar and venular diameters between cases and 
controls.  
Retinal arteriolar diameters narrowed with increasing duration of 
ART, independently of age, and with HIV VL >10,000 copies/mL 
while on ART 
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 Lens density 
 
Objective measurement 
using Pentacam 
 
490  
242 HIV+/248 HIV- 
 
Adjusted lens densities similar by HIV serostatus 
Nadir CD4 count <200 cells/L associated with higher lens density 
(in participants on ART) 
Lens density weakly associated with HIV viremia despite ART 
 
 
Corneal endothelium 
 
Specular microscopy to 
obtain ECD, variation in cell 
size and hexagonality index 
 
491 
242 HIV+/249 HIV- 
 
HIV infection associated with increased variation in cell size – OR: 
1.67 (1.00-2.78), p=0.04 
Among HIV group, low ECD associated with current CD4 count 
<200 cells/L – OR: 2.77 (1.12-6.81), p=0.03 
 
 
Retinal nerve fibre layer 
 
Contrast sensitivity 
 
Spectral optical coherence 
tomography 
Pelli-Robson chart 
 
428 
225 HIV+/203 HIV- 
 
CS score lower in HIV+ group compared to HIV-  
Predictors of low CS in HIV+ group: frailty and HIV VL >2 log 
copies/mL 
Longer ART duration associated with decreased thickness of 
inferior and nasal RNFL quadrants 
Superior RNFL thickness greatest in ART-naïve participants 
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13.2 Limitations of the study 
Knowledge of time since exposure to HIV (date of HIV sero-conversion) would have been 
ideal. In practice this is hard to define. The nature of the infection means the majority of 
individuals are unaware when they have sero-converted, and so ascertainment of the time of 
infection is impossible. Large sero-converter cohorts do exist - CASCADE is a collaboration 
of 23 cohorts: 20 cohorts from Europe, two from Australia, and one from Canada [2]. In 
the CASCADE cohort the date of HIV sero-conversion is estimated as the midpoint 
between the first positive HIV antibody test and the last documented negative HIV antibody 
test result. This type of information is not available for this study population, or indeed for 
many other cohorts. Other investigators have used surrogate markers of exposure such as 
time since nadir CD4 count (pre-ART), or a minimum duration of ART. In this study in 
Cape Town the clinic database was well-maintained [3]; and the majority of participants had 
complete data for HIV-related parameters.  
 
A cross-sectional study design means that the temporal relationship between exposures and 
outcome cannot be definitively established. In addition, the small proportion of ART-naïve 
participants enumerated means that inferences about the role or contribution of ART 
cannot be made. Low recruitment of these participants may have been for two reasons: 
firstly, the majority of participants newly diagnosed with HIV and fulfilling the criteria for 
ART in South Africa were under the age of 30, thus recruitment of participants fulfilling the 
study entry criteria had to use a smaller pool of individuals. Secondly, ART-naïve patients, by 
the nature of their clinical status tended to be in poor health and were not willing to travel 
in order to attend for a full assessment at the study site. Ultimately, it would be ideal to 
collect longitudinal data, and this current study may be used to inform future related work 
(See Section 13.5). 
 
All study participants are subject to some selection biases. In the Gugulethu HIV clinic 
where the HIV-infected individuals were enumerated approximately 8-10% of individuals die 
in the first year of CART, and 1-2% per year thereafter [3,4]. Those individuals with more 
advanced HIV (and likely greater measures of aging) may have been at greater risk of 
mortality. In addition, it is possible that clinic attendees with eye symptoms were more likely 
to agree to participate in the study. However, previous experience when collecting initial 
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pilot data suggested that all patients from the Gugulethu clinic were keen to avail of an 
ophthalmic examination regardless of symptoms.  
 
Measurement of other systemic biomarkers would have been ideal, particularly those that 
have already been demonstrated to be raised in HIV infection in other studies e.g. D-dimer, 
CRP, soluble CD14 [5,6]. Budgetary and time constraints precluded the investigation of 
these markers. However, serum has been saved from the majority of participants and could 
be used for future work (see below). Other ophthalmic tests e.g. visual fields, extensive 
colour vision testing could have been performed to add to the body of ocular parameters 
measured, however the additional time to perform these tests (with limited study 
personnel) would have reduced the number of individuals able to participate in the study, 
and thus the sample size. Logistics and practical issues limited the total sample size initially 
determined from power calculations. However, the sample size obtained for the study still 
provided adequate power to detect the required differences between the two groups 
(Chapter 4, section 4.3).   
 
13.3 Does HIV accelerate the aging process? 
The finding of shortened telomere length and increased CDKN2A expression in HIV-
infected individuals compared to age- and gender-matched HIV-seronegative controls 
provides important evidence that HIV infection is associated with increased biological aging 
in this study population. The study design does not permit assessment of a temporal 
relationship or any inferences relating to causation. However, the finding of increased frailty 
in the HIV-infected population adds to the body of evidence of increased biological aging in 
HIV. Recruitment of the study populations from communities with similar socio-economic 
deprivation should have minimized the possibility of confounding due to differential risk 
behaviours and exposures between the two populations. At cellular (CDKN2A, telomere 
length) and systemic (frailty) levels, HIV-infected individuals in this study appeared to display 
greater biological aging compared to their uninfected counterparts.  
 
The assessment of accelerated aging using ocular parameters is more complex to 
understand. The studies indicate that there was little difference in measurement of ocular 
parameters between the two groups overall, for example lens density and retinal vessel 
measurements were similar between HIV-infected and HIV-seronegative individuals. The 
Sophia Pathai PhD Thesis Page 336
main differences were found in sub-groups such as those with greater levels of 
immunodeficiency or HIV viremia despite ART. A plausible explanation is that ocular 
changes related to aging may take place over a longer period of time. It is possible that the 
aging trajectory in this South African population is different compared to US and European 
HIV populations, as it is likely that African HIV populations will have experienced a shorter 
duration of ART and initiated treatment at lower CD4 counts (Figure 3b, Chapter 3). This 
may lead to differences in manifestations of ocular aging. Longitudinal studies in different 
geographical populations would be needed to assess this definitively. It is also unclear 
whether HIV infection or treatment with ART is primarily responsible for ocular aging. In 
addition, epigenetic and genetic variation may contribute to an individual’s susceptibility to 
non-HIV age-related morbidity including ocular structures and their function.   
 
13.4 Does the eye represent a ‘good’ model of aging? 
Validation of the ocular parameters against chronological age in HIV-seronegative individuals 
indicated that all ocular parameters were associated with chronological age (Chapter 11). 
Indeed, the R-squared values in linear regression models to assess the relationship between 
the prospective biomarkers and chronological age were considerably higher for the majority 
of ocular parameters when compared to telomere length and CDKN2A expression. Thus, 
several of the structural and functional parameters of the eye may have use as biomarkers of 
aging. Longitudinal data will be necessary to definitively assess this. Of note, objective 
measurement of lens density was strongly associated with chronological age and with 
CDKN2A expression in healthy controls. The ocular lens may be particularly well-suited to 
a role as a biomarker of aging as it contains isolated cells that are long-lived and not subject 
to rapid turnover, and as so it fulfils the Baker and Sprott criteria of a biomarker of aging [7] 
(Chapter 2). Measurement of retinal vascular calibre has already been established as a valid 
and efficient biomarker of systemic vascular disease [8,9]. The findings from this study 
suggest that retinal vessel measurement deserves attention as a tool in HIV-related vascular 
risk estimation (Chapter 7).  
13.5 Future work 
This study provides a ‘snapshot’ in time of likely associations in HIV-related accelerated 
aging. It would be ideal to follow-up this population in a longitudinal study as it is likely that 
changes in age-related parameters may manifest over a longer time period. The Strategic 
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Timing of AntiRetroviral Treatment (START) study is an on-going multicentre international 
trial designed to assess the risks and benefits of initiating ART earlier than is currently 
practiced [10]; some of the START trial cohorts are based at sites in South Africa. Data 
from this study will be used to design a prospective study related to clinical, ocular and 
serum biomarkers of aging, nested within these South African cohorts. It would also be 
useful to concurrently measure other clinical markers such as neurocognitive function and 
disability to better understand the health needs of this increasing population. 
 
The study findings also raise further important research questions: prospective assessment 
of biological age in HIV-infected and HIV-seronegative individuals is needed to ascertain 
whether the accelerated aging trajectory develops as soon as HIV infection is acquired. 
Further questions include whether biological age is dependent upon the duration of 
untreated disease or nadir CD4 count, and if the biological age of the two groups continues 
to diverge during long-term ART, or rather is modified by ART. In the long-term it will be 
important to ascertain whether HIV infection accelerates or accentuates the aging process. 
Accelerated aging suggests that aging occurs earlier; however, if aging is not accelerated is it 
accentuated – i.e. morbidity occurs at the same age, but with higher prevalence? Does HIV 
both accelerate and accentuate aging? Prospective data with recruitment of both ART-
treated and ART-naïve cohorts are required to address these issues.  
 
The need for evaluated biomarkers in determining biological age is gaining increasing 
importance as data emerge about the excess risk of age-related morbidity in HIV-infected 
individuals despite suppression of viral load [11]. Several studies have investigated the role 
of clinical and biochemical biomarkers in determining HIV-related outcomes (Table 1b), 
however, very few data originate from resource-limited settings or sub-Saharan Africa. 
Further work is needed to assess the role of these biomarkers in such populations where 
the aging trajectories in HIV infection may differ compared to well-resourced environments. 
Stored serum samples are available from this study cohort; further work will involve 
measurement of e.g. pro-inflammatory cytokines, CRP, D-dimer in this population and 
relating these to the ocular parameters measured in the current study. Epigenetic markers 
such as methylation of DNA in peripheral blood leukocytes from this study population will 
also be evaluated in future work. 
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PARTICIPANT INFORMATION SHEET  
 
Study Title:  
Does HIV accelerate the aging process? An assessment of ophthalmic, clinical and 
serum parameters of aging in a cohort of HIV-infected individuals in South Africa. 
 
Who is conducting this study? 
Chief investigator: Dr. Sophia Pathai  
Other Study Staff: Sr. Eudoxia Raditlhalo (079 337 6369) 
 
Please read this form carefully. Take time to ask the study doctor or study staff 
as many questions about the study as you would like. The study doctor or 
study staff can explain words or information that you do not understand. 
Reading this form and talking to the study doctor or study staff may help you 
decide whether to take part or not. If you decide to take part in this study, you 
will need to sign your name at the end of this form.  
 
Why is this study being done? 
Aging leads to changes in your physical appearance and overall health. Several 
conditions are linked to age like heart disease, brittle bone disease, kidney disease. It 
thought that HIV infected persons might be at risk from such conditions at an earlier 
age, compared to uninfected people of the same age. Similarly, many eye conditions 
are related to age and this can lead to problems with seeing clearly. This study will 
assess what kind of age-related eye conditions might be seen in HIV-infected people 
and if they are different or occur more commonly than in uninfected people. It will 
also assess other measures relating to age such as physical strength and markers of 
aging in cells of the body. This study will help us to find out if early aging in HIV 
infected people does occur. This knowledge can help us to make provision for future 
healthcare. 
 
Why are you being asked to take part? 
You are being asked to take part in this study, so that we can measure the ‘amount 
of aging’ in your body in different ways. Your information (data) will be compared with 
non-infected people of similar age and gender. This will help us find out whether HIV 
may be related to early aging. Results from this study will help us to understand more 
about this process.  
 
How many people will take part in the study? 
A total of 740 patients will be recruited for this study. Of these 370 will be HIV 
patients and 370 will be non-HIV individuals of similar age and sex. 
 
How long will the study last? 
This study will last for a period of 1 year. However, you will not be required to visit 
the hospital more than once. 
 
What do we do to decide if you are eligible to take part? 
We will review clinic records based on a list of factors which suggest you might be 
suitable for the study (e.g. your age). If you are within this group you will be asked if 
you would like to participate. If you are interested, the study will be explained to you 
and you will be allowed to make a decision.  
 
What will happen if you decide to take part in the study? 
If you choose to take part,  
§ You will be asked to first sign a consent form or give a thumb impression 
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§ You will be asked to attend the Department of Ophthalmology at Groote Schuur 
Hospital for the examination (your travel and time will be reimbursed, see below) 
§ Your personal information (like age, sex, occupation) and your general 
medical history (like heart problems, blood pressure) will be noted. 
§ We will check your physical strength and balance with some simple tests such 
as rising from a chair and walking along a path. 
§ Following this, your eyes will be examined by an experienced eye doctor  
§ Your eye doctor will first check your eye sight: 
− The vision in each eye will be measured using vision-testing charts.  
− If we find that you need glasses for close vision, these will be given for free 
§ The front of your eye will be examined using a microscope called a “slit-lamp”  
§ The back of your eye (retina) will be examined: 
− Eye drops will be put into each eye, to enlarge the pupil (black circle in 
middle) of the eye. The eye drops may sting for a few seconds. It can take 20-
30 minutes for the eye drops to take effect. If your pupils do not dilate widely 
enough a second drop may be needed. 
− The drops will enable us to examine the back of the eyes (retina). The 
examination will involve using a bright light to illuminate the back of your eye. 
The examination may last 10-15 minutes. 
§ Some photos will be taken of the back of your eyes using a special camera 
(fundus camera); it will not be possible to identify you directly from the photos. 
We will also take some measures of the back of the eyes.  
§ None of these tests hurt. Your HIV status will not be disclosed to anyone. 
§ After the examination you may experience blurring of vision, lights may seem 
extra bright and you may have difficulty reading or focusing close up. This lasts 
2-3 hours and then your eyes and vision will return to normal. 
− In the unlikely event you develop eye pain or more severe blurring of vision 
you should return to the hospital. 
§ We will take a blood sample. 
− This sample will be taken to measure the degree of aging in the blood cells. 
To do this we need to extract DNA from cells (DNA is present inside all the 
cells of your body. It is a code that carries instructions for the form of your 
body. It is responsible for e.g. the colour of your eyes and hair). This sample 
will only be used to measure aging of cells, and cannot be used to 
determine your complete genetic identity. 
− At the end of the study your sample will be transported to UK for analysis. 
Only we will use this blood sample, and no one else will have access to it.  
 
What are the risks and discomforts of this study? 
The eye drops may cause temporary stinging of the eyes. Very rarely these eye 
drops will increase your the pressure in your eye, which may cause pain. If this 
occurs, it is treatable by medication. If you have eye pain after the eye drops are put 
in your eyes, you should inform us as soon as possible. 
 
Are there any benefits to you for being in the study? 
The examination will detect any eye condition, including those related to HIV. The 
study doctor is an eye doctor. If she detects an eye problem (whether or not related 
to HIV) she will explain this to you. She will explain the options available; this will 
probably include arranging an appointment at the hospital eye clinic to see the clinic 
eye doctors for some further tests and/or treatment. The study doctor can directly 
refer any eye problem to the eye clinic. You will not need to go back to your 
community doctor for a referral. The appointment may be on a separate occasion(s) 
and treatment, if needed, will be provided free. If the hospital eye clinic contacts you 
to arrange an appointment it will only be via the phone number you have given us. 
The study doctor will also keep a record of your eye condition, and with your 
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permission will provide this information to the doctors at Hannan Crusaid Clinic. If 
you need glasses for reading, cooking etc these will be given for free.  
 
What other choices do you have? 
You have the following choices:  
− You can choose not to take part in the study. 
− If you choose to take part, and then wish to dropout (at any point during the 
study), you may do so. This will not affect your treatment at the clinic. 
− If you wish to withdraw your permission for use of your stored blood sample, you 
may request this. We will make sure that it is destroyed and never used. 
− If you do not wish for your identity to be kept with your stored blood samples, you 
may inform us. We will make sure your identity is kept secret.  
− If you do not wish to be contacted after the study is over, for disclosure of any 
study results, you may request this. 
 
You may refer to the diagrams below to understand the study process better. 
 
 
 
What will happen when the study is over? 
The clinic staff will receive training on how to detect basic eye problems and will be 
able arrange referral to the eye clinic as needed. They will also learn how to detect 
the need for glasses so should you need them in future this will be picked up and you 
will either be given glasses or an appointment to see an optometrist (optician).  
 
Will your test results be shared with you? 
If you would like access to your test results these will be shared with you.  
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Will the results of the research be shared with you? 
If you would like to have access to the results/ findings of this study after it is 
completed, they will be shared with you.  
 
Will any of your blood, tissue or other samples be stored and used for research 
in the future? 
You will be asked to give an additional blood sample at the time of your routine 
testing. The sample will be stored in a deep freeze. At the end of the study, samples 
will be transported to UK for analysis. These analyses will be conducted by the study 
team laboratory only. No one else will have access to your blood sample, except for 
study staff. This sample will help us understand aging in HIV patients better. If you do 
not wish for your identity to be kept with your stored blood sample, it will be kept 
secret. Only your eye doctor will have access to your full information. If there is any 
sample remaining this may be stored for research in the future with your permission. 
Future work will be related to the current project. We will keep your identity 
anonymous.  
 
Will you receive any reward (money or food vouchers) for taking part in this 
study? 
You will be given a total of ZAR 200, which will cover your travel expenses and time 
spent participating in the study.  
 
Who will see the information which is collected about you during the study? 
§ The examination information will be kept confidential and will not be given to 
anyone outside the study.  Your name will only be written on the special 
enrolment form that has your personal details like name, address, etc. These will 
be kept in a secure area.  
§ Your name will never be used in any reports or your HIV status. No quotes or 
other results arising from your participation in this study will be included in any 
reports, even anonymously, without your agreement. 
§ Once your blood sample is transported to UK, no one except for the study doctor 
will have access to your full information. If you do not want your identity to be 
kept with your blood sample, it will be removed. 
§ All study reports/ results will be stored in a computer system. To avoid anyone 
from identifying you directly all your data will be coded. To ensure that no one 
outside the study has access to your data, the computer will be password 
protected. Only the study doctor will have full access. 
§ If we contact you to provide information or results this will involve only one phone 
call to the number provided by you. We will not inform anyone else about your 
HIV status or any other findings. 
 
Who do I speak to (or contact) if I have any questions about the study? 
If you have any questions about the study, you can contact the study doctor, Dr. 
Sophia Pathai or the Research Assistant/Nurse (079 337 6369). In case you require 
a translator, one will be provided for you.  
	  
Before you make a decision, we welcome any questions that you may have. 
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IPHEPHA LOLWAZI LOMTHATHI-NXAXHEBA  
 
ISihloko soPhononongo: Ingaba i-HIV iyiqhubela phambili imo yokwaluphala? 
Ukuhlolwa kobunjani obunokubalwa bokwaluphala kwamehlo (ophthalmic), kokugula 
(clinical) nokwencindi yegazi (serum) kwiqela labantu abosuleleke yi-HIV eMzantsi 
Afrika. 
 
Ngubani oqhuba olu phononongo? 
Umphandi oyintloko: UGqirha Sophia Pathai  
Esinye iSitafu soPhononongo: Eudoxia Raditlhalo (079 337 6369) 
 
Nceda ufunde le fom ngononophelo. Thatha ixesha ubuze ugqirha 
wophononongo okanye isitafu sophononongo imibuzo emininzi kangangoko 
malunga nophononongo kangangoko ufuna. Ugqirha wophononongo okanye 
isitafu sophononongo bangakuchazela amagama okanye ulwazi 
ongaluqondiyo. Ukufunda le fom nokuthetha nogqirha wophononongo okanye 
isitafu sophononongo kungakunceda ukuba wenze isigqibo sokuthatha 
inxaxheba okanye ungasithathi. Ukuba ugqiba ekubeni uthathe inxaxheba kolu 
phononongo, kuza kufuneka usayine igama lakho ekupheleni kwale fom.  
 
Kutheni kusenziwa olu phononongo? 
Ukwaluphala kungakhokelela kwiinguqulelo kwimbonakalo yomzimba wakho nempilo 
yakho jikelele. Izigulo ezininzi zinxulunyaniswa nokwaluphala njengesifo sentliziyo, 
isifo sokubaqwathaqwatha kwamathambo, isifo sezintso. Kucingwa ukuba abantu 
abosuleleke yi-HIV bangabasemngciphekweni wezigulo ezinjalo besebancinci, xa 
bethelekiswa nabantu ababudala bufanayo. Ngokufanayo, izigulo zamehlo ezininzi 
zinxulunyaniswa nokwaluphala yaye oku kungakhokelela kwiingxaki zokungaboni 
ngokucacileyo. Olu phononongo luza kuhlola ukuba zeziphi izigulo zamehlo 
ezinxulumene nokwaluphala ezinokubonwa kubantu abosuleleke yi-HIV yaye nokuba 
ngaba zahlukile na okanye zenzeka ngokuxhaphakileyo na kubantu 
abangosulelekanga. Luza kuhlola kwakhona amanye amanyathelo anxulumene 
nokwaluphala anje ngamandla omzimba neziphawuli zokwaluphala kwiiseli 
zomzimba. Olu phononongo luza kusinceda ukuba sifumanise ukuba ngaba 
ukwaluphala msinya kubantu abosuleleke yi-HIV kuyenzeka na. Olu lwazi 
lungasinceda ukuba silungiselele unakekelo lwempilo lwexesha elizayo. 
 
Kutheni ucelwa ukuba uthathe inxaxheba? 
Uyacelwa ukuba uthathe inxaxheba kolu phononongo, ukuze sikwazi ukulinganisela 
'ubungakanani bokwaluphala' emzimbeni wakho ngendlela ezahlukeneyo. Ulwazi 
lwakho (idatha) luza kuthelekiswa nolwabantu abangosulelekanga ababudala 
bulinganayo kwanobuni. Oku kuza kusinceda ukuba sifumanise ukuba ingaba i-HIV 
inxulumene na nokwaluphala kwamsinya. Iziphumo zolu phononongo ziza kusinceda 
ukuba siqonde ngokungaphaya malunga nale nkqubo.  
 
Bangaphi abantu abaza kuthatha inxaxheba kuphononongo? 
Zizonke zizigulane ezingama-740 eziza kufunelwa olu phononongo. Kwezi ama- 
370 aza kuba zizigulane ze-HIV yaye ama-370 aza kuba ngabantu abangekho HIV 
bobudala obufanayo kwanesini. 
 
Uphononongo luza kuthatha ixesha elingakanani? 
Olu phononongo luza kuthatha isithuba sonyaka om-1. Nangona kunjalo, 
awuzukulindeleka ukuba utyelele isibhedlele ngaphezulu kunakanye. 
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Senza ntoni ukwenza isigqibo sokuba ufanelekile na ukuthatha inxaxheba? 
Siza kujonga kwakhona iirekhodi zaseklinikhi ngokusekelwe kuluhlu lweemeko 
ezicebisa ukuba unokululungela uphononongo (umz. Ubudala bakho). Ukuba 
uphakathi kweli qela uza kubuzwa ukuba ungayithatha na inxaxheba. Ukuba 
unomdla, uphononongo uza kuluchazelwa yaye uza kuvunyelwa ukuba wenze 
isigqibo.  
 
Kuza kwenzeka ntoni ukuba ugqiba ekubeni uthathe inxaxheba 
kuphononongo? 
Ukuba ukhetha ukuthatha inxaxheba,  
§ Uza kucelwa ukuba uqale usayine ifom yemvume okanye unike uphawu 
lukabhontsi 
§ Uza kucelwa ukuba uye kwiSebe lezaMehlo (Department of Ophthalmology) 
esiBhedlele iGroote Schuur ukuvavanywa (uhambo lwakho nexesha ziza 
kuhlawulwa kwakhona, jonga apha ngezantsi) 
§ Ulwazi lobuqu lwakho (njengobudala, isini, isikhundla) kunye nembali 
yokugula kwakho jikelele (njengeengxaki zentliziyo, uxinzelelo lwegazi) ziza 
kuqwalaselwa. 
§ Siza kukhangela amandla omzimba wakho nokuzinza ngeemvavanyo 
ezithile ezilula ezinje ngokuphakama esitulweni nokuhamba kwindledlana. 
§ Ukulandela oku, amehlo akho aza kuvavanywa ngugqirha wamehlo 
onamava  
§ Ugqirha wakho wamehlo uza kuqala akhangele ukubona kwakho: 
− Ukubona kwimehlo ngalinye kuza kulinganiswa kusetyenziswa iitshati 
zokuvavanywa kokubona.  
− Ukuba sifumanisa ukuba ufuna iiglasi zokubona kufutshane, ezi ziza kunikwa 
mahala 
§ Umphambili wemehlo lakho uza kuvavanywa kusetyenziswa 
ngesibonakhulu (microscope) esibizwa ngokuba sisi-“slit-lamp”  
§ Umva wemehlo lakho (iretina) uza kuvavanywa: 
- Amaqabaza amehlo aza kufakwa kwimehlo ngalinye, ukwandisa ukhozo 
lwemehlo (isangqa esimnyama esizikithini) semehlo. Amaqabaza amehlo 
angatsweba imizuzwana embalwa. Kungathatha 20-30 imizuzu ukuba 
amaqabaza amehlo asebenze. Ukuba iinkozo zamehlo akho azandi 
ngokubanzi ngokwaneleyo iqabaza lesibini linokufuneka. 
− Amaqabaza aza kusinceda ukuba sivavanye umva wamehlo (iretina). 
Uvavanyo luza kubandakanya ukusetyenziswa kokukhanya okuqaqambileyo 
ukukhanyisela umva wemehlo lakho. Uvavanyo lungathatha 10-15 imizuzu. 
§ Iifoto ezithile zomva wamehlo akho ziza kuthathwa kusetyenziswa ikhamera 
ekhethekileyo (ikhamera i-fundus); akuzi kukwazeka ukukubona ngokuthe ngqo 
kwiifoto. Siza kuthatha nemilinganiselo ethile kumva wamehlo akho.  
§ Akukho nanye kwezi mvavanyo ebuhlungu. Imeko yakho ye-HIV 
ayizukudandalaziswa nakubani na. 
§ Emva kovavanyo ungafumanisa ukubona ngokumfiliba, izibane 
zingabonakala ziqaqambile yaye kunganzima ukufunda okanye ukujonga 
kufutshane. Oku kuthatha 2-3 iiyure kuze ke amehlo akho nokubona kubuyele 
kwisiqhelo. 
− Kwimeko engaqhelekanga uqaqanjelwa limehlo okanye ubona 
ngokumfiliba okugqithisileyo kufuneka ubuyele esibhedlele. 
§ Siza kuthatha isampuli yegazi. 
− Le sampuli iza kuthathelwa ukulinganisa ubungakanani bokwaluphala 
kwiiseli zegazi. Ukwenza oku kufuneka sitsale i-DNA kwiiseli (i-DNA ikhona 
phakathi kweeseli zonke zomzimba wakho. Yikhowudi equlatha imiyalelo 
yemo yomzimba wakho. Inoxanduva umz. webala lamehlo akho neenwele). 
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Le sampuli iza kusetyenziswa kuphela ukulinganisa ukwaluphala kweeseli, 
yaye ayinakusetyenziselwa ukufumanisa ukwaziwa kwakho kofuzo 
okugqibeleleyo (complete genetic identity). 
− Ekupheleni kophononongo isampuli yakho iza kuthunyelwa e-UK ukuba 
ihlalutywe. Sithi kuphela abaza kusebenzisa le sampuli yegazi, yaye akukho 
mntu ungomnye uza kuba nokufikelela kuyo.  
 
Zeziphi iingozi nokungonwabi kolu phononongo? 
Amaqabaza amehlo angabangela ukutsweba kwexeshana emehlweni. Ngokunqabe 
kakhulu la maqabaza amehlo aza kunyusa uxinzelelo emehlweni lakho, 
okunokubangela ubuhlungu. Ukuba oku kuyenzeka, kuyanyangeka ngamayeza. 
Ukuba uyaqaqanjelwa emehlweni emva kokuba amaqabaza amehlo efakwe 
emehlweni akho, kufuneka usazise ngokukhawuleza kangangoko. 
 
Ingaba kukho naziphi na iinzuzo kuwe ngokuba kuphononongo? 
Uvavanyo luza kufumanisa nasiphi na isigulo samehlo, ukuquka nezo zinxulumene 
ne-HIV. Ugrirha wophononongo ngugqirha wamehlo. Ukuba ufumanisa ingxaki 
yamehlo (nokuba ngaba inxulumene ne-HIV okanye hayi) uza kukuchazela oku. Uza 
kukuchazela okukhethwayo okukhoyo; oku mhlawumbi kungaquka ukulucwangcisa 
idinga kwiklinikhi yamehlo esibhedlele ukubona oogqirha bamehlo baseklinikhi 
ngeemvavanyo ezingaphaya kunye/okanye unyango. Ugqirha wophononongo 
angadlulisela ngokuthe ngqo nayiphi na ingxaki yamehlo kwiklinikhi yamehlo. Akuzi 
kufuneka ukuba ubuyele kugqirha wakho wengingqi ngodluliselo. Idinga linokuba 
nge(ngama)xesha elo(awo)hlukeneyo yaye unyango, ukuba luyafuneka, luza 
kunikwa mahala. Ukuba iklinikhi yamehlo yesibhedlele iqhagamshelana nawe 
ukucwangcisa idinga kuya kuba kuphela ngenombolo yomnxeba osinike yona. 
Ugqirha wophononongo uza kugcina kwakhona irekhodi yesigulo sakho samehlo, 
yaye ngemvume yakho uza kunikeza olu lwazi koogqirha kwi-Hannan Crusaid Clinic. 
Ukuba ufuna iiglasi zokufunda, ukupheka njl.njl ziya kunikwa mahala.  
 
Kokuphi ukukhetha okukokunye onako? 
Unoku kukhetha kulandelayo:  
− Ungakhetha ukungathathi nxaxheba kuphononongo. 
− Ukuba ukhetha ukuthatha inxaxheba, uze ke unqwenele ukurhoxa (nanini na 
ngexesha lophando), ungenza njalo. Oku akuzi kuchaphazela unyango lwakho 
eklinikhi. 
− Ukuba unqwenela ukurhoxisa imvume yakho yokusetyenziswa kwesampuli 
yegazi yakho egciniweyo, ungakucela oku. Siza kuqinisekisa ukuba 
iyatshatyalaliswa yaye ayisoze isetyenziswe. 
− Ukuba awunqweneli ukuba ukwaziwa kwakho kugcinwe neesampuli zegazi 
lakho, ungasazisa. Siza kuqinisekisa ukuba ukwaziwa kwakho kugcinwa 
kuyimfihlo.  
− Ukuba awunqweneli ukuba kuqhagamshelwane nawe emva kokuba 
uphononongo luphelile, ngokudandalaziswa kwazo naziphi na iziphumo 
zophononongo, ungakucela oku. 
 
Ungajonga kwiidayagram apha ngezantsi ukuqonda inkqubo yophononongo 
ngokungcono. 
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Kuza kwenzeka ntoni lusakube uphononongo luphelile? 
Isitafu saseklinikhi siza kufumana uqeqesho ngendlela yokufumanisa iingxaki 
zamehlo ezingundoqo yaye siza kubanako ukucwangcisa udluliselo kwiklinikhi 
yamehlo njengoko kufunwa. Baza kufunda nendlela yokufumanisa imfuneko yeeglasi 
ngako oko xa unokuthi uzifune kwixesha elizayo oku kuza kufunyaniswa yaye uza 
kuthi mhlawumbi ufumane iiglasi okanye idinga lokubona ugqirha wamehlo (ingcali 
yamehlo).  
 
Ingaba iziphumo zovavanyo zakho kuza kwabelwana ngazo nawe? 
Ukuba uyakufuna ukufikelela kwiziphumo zakho zovavanyo kuza kwabelwana ngazo 
nawe.  
 
Ingaba iziphumo zophando kuza kwabelwana ngazo nawe? 
Ukuba uyakufuna ukufikelela kwiziphumo/ izinto ezifunyanisiweyo zolu phononongo 
emva kokuba lugqityiwe, kuza kwabelwana ngazo nawe.  
 
Ingaba naziphi na iisampuli zakho zegazi, isihlunu okanye naziphi na iisampuli 
ezizezinye ziza kugcinwa zize zisetyenziselwe uphando kwixesha elizayo? 
Uza kucelwa ukuba unike isampuli yegazi eyongezelelweyo ngexesha lovavanyo 
lwakho lwesiqhelo. Isampuli iza kugcinwa kwisikhenkcisi esibandisa kakhulu 
(deep freeze). Ekupheleni kophononongo, iisampuli ziza kuthunyelwa e-UK ukuba 
zihlalutywe. Olu hlalutyo luza kuqhutywa yilebhu yeqela lophando kuphela. Akukho 
mntu wumbi uza kufikelela kwisampuli yakho yegazi, ngaphandle kwesitafu 
sophononongo. Le sampuli iza kusinceda ukuqonda ukwaluphala kwizigulane ze-HIV 
ngokungcono. Ukuba awunqweneli ukuba ukwaziwa kwakho kugcinwe nesampuli 
yegazi yakho, oku kuza kugcinwa ngokuyimfihlo. Ngugqirha wakho wamehlo kuphela 
oza kufikelela kulwazi lwakho olupheleleyo. Ukuba kukho nayiphi na isampuli 
eseleyo inokuthi igcinelwe uphando lwexesha elizayo ngemvume yakho. Umsebenzi 
wexesha elizayo uza kunxulumana neprojekthi yangoku. Siza kugcina ukwaziwa 
kwakho kungaziwa.  
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Uza kufumana nawuphi na umvuzo (imali okanye iivawutsha zokutya) 
ngokuthatha inxaxheba kolu phononongo? 
Uza kunikwa iyonke i-ZAR 200, eza kuhlawula iindleko zohambo zakho nexesha 
olichithileyo ngokuthatha inxaxheba kuphononongo.  
 
Ngubani oza kubona ulwazi oluqokelelweyo ngawe ngexesha lophononongo? 
§ Ulwazi lovavanyo luza kugcinwa luyimfihlo yaye aluzi kunikwa nabani na 
ongaphandle kophononongo.  Igama lakho liza kubhalwa kuphela kwifom 
yobhaliso olukhethekileyo eneenkcukacha zakho zobuqu ezinje ngegama, 
idilesi, njl.njl. Ezi ziza kugcinwa kwindawo ekhuselekileyo.  
§ Igama lakho alisoze lisetyenziswe nakwiziphina iingxeloi okanye isimo sakho 
se-HIV. Akukho manqaku okanye ezinye iziphumo ezivela ekuthabatheni 
kwakho inxaxheba kolu phononongo ziya kuthi ziqukwe kuzo naziphi na iingxelo, 
nokuba ngaba kungokungaziwayo, ngaphandle kwemvume yakho. 
§ Ukuba nje isampuli yegazi yakho ithunyelwe e-UK, akukho nabani na 
ngaphandle kogqirha wophononongo oya kuthi afikelele kulwazi lwakho 
olupheleleyo. Ukuba awufuni ukuba ukwaziwa kwakho kugcinwe nesampuli 
yegazi yakho, kuza kususwa. 
§ Zonke iingxelo/iziphumo zophando ziza kugcinwa kwinkqubo yekhompyutha. 
Ukunqanda nabani na ukuba akwazi ngokungqalileyo yonke idatha yakho iza 
kukhowudwa. Ukuqinisekisa ukuba akukho nabani na ongaphandle oya uthi 
afikelele kwidatha yakho, ikhompyutha iza kukhuselwa nge-password. 
Ngugqirha wophando kuphela oza kubanokufikelela okupheleleyo. 
§ Ukuba siqhagamshelana nawe ukukunika ulwazi okanye iziphumo oku kuya 
kubandakanya utsalo lomnxeba olunye kuphela kwinombolo enikwe nguwe. 
Asizukwazisa nabani na ongomnye malunga nesimo sakho se-HIV okanye 
naziphi na izinto ezifunyanisiweyo. 
 
Ndithetha nabani (okanye uqhagamshelwano) ukuba ndinayo nayiphi na 
imibuzo malunga nophononongo? 
Ukuba unayo nayiphi na imibuzo malunga nophononongo, ungaqhagamshelana 
nogqirha wophononongo, uGqirha Sophia Pathai okanye iSekela loPhando/uNesi 
(079 337 6369). Xa unokuthi ufune umguquli, uza kumnikwa.  
	  
Phambi kokuba wenze isigqibo, samkela nayiphi na imibuzo onokuthi ube 
nayo. 
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PARTICIPANT INFORMATION SHEET 
 
Study Title:  
Does HIV accelerate the aging process? An assessment of ophthalmic, clinical and 
serum parameters of aging in a cohort of HIV-infected individuals in South Africa. 
 
Who is conducting this study? 
Chief investigator: Dr. Sophia Pathai  
Other Study Staff: Sr Eudoxia Radithalo (079 337 6369) 
Please read this form carefully. Take time to ask the study doctor or study staff 
as many questions about the study as you would like. The study doctor or 
study staff can explain words or information that you do not understand. 
Reading this form and talking to the study doctor or study staff may help you 
decide whether to take part or not. If you decide to take part in this study, you 
will need to sign your name at the end of this form.  
 
Why is this study being done? 
Aging leads to changes in your physical appearance and overall health. Several 
conditions are linked to age like heart disease, brittle bone disease, kidney disease. It 
thought that HIV infected persons might be at risk from such conditions at an earlier 
age, compared to uninfected people of the same age. Similarly, many eye conditions 
are related to age and this can lead to problems with seeing clearly. This study will 
assess what kind of age-related eye conditions might be seen in HIV-infected people 
and if they are different or occur more commonly than in uninfected people. It will 
also assess other measures relating to age such as physical strength and markers of 
aging in cells of the body. This study will help us to find out if early aging in HIV 
infected people does occur. This knowledge can help us to make provision for future 
healthcare. 
 
Why are you being asked to take part? 
You are being asked to take part in this study, so that we can measure the ‘amount 
of aging’ in your body in different ways. Your information (data) will be compared with 
HIV-infected people of similar age and gender – therefore you will be used as a 
‘comparison’. This will help us find out whether HIV may be related to early aging. 
Results from this study will help us to understand more about this process. Your 
participation is greatly valued as we need to examine a comparison group who are 
not infected with HIV. We will use pre-existing information from the Emavundleni 
Clinic and you will not be required to undergo any additional HIV tests.  
 
How many people will take part in the study? 
A total of 740 patients will be recruited for this study. Of these 370 will be HIV 
patients and 370 will be non-HIV individuals of similar age and sex. 
 
How long will the study last? 
This study will last for a period of 1 year. However, you will not be required to visit 
the hospital more than once. 
 
What do we do to decide if you are eligible to be take part? 
We will review clinic records based on a list of factors which suggest you might be 
suitable for the study (e.g. your age). If you are within this group you will be asked if 
you would like to participate. If you are interested, the study will be explained to you 
and you will be allowed to make a decision.  
 
What will happen if you decide to take part in the study? 
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If you choose to take part,  
§ You will be asked to first sign a consent form or give a thumb impression 
§ You will be asked to attend the Department of Ophthalmology at Groote Schuur 
Hospital for the examination (your travel and time will be reimbursed, see below) 
§ Your personal information (like age, sex, occupation) and your general 
medical history (like heart problems, blood pressure) will be noted. 
§ We will check your physical strength and balance with some simple tests such 
as rising from a chair and walking along a path. 
§ Following this, your eyes will be examined by an experienced eye doctor  
§ Your eye doctor will first check your eye sight, which will be done as follows: 
− The vision in each eye will be measured using vision-testing charts.  
− If we find that you need glasses for close vision, these will be given for free. 
§ The front of your eye will be examined using a special microscope called a “slit-
lamp”  
§ The back of your eye (retina) will be examined as follows: 
− Eye drops will be put into each eye, to enlarge the pupil (black circle in 
middle) of the eye. The eye drops may sting for a few seconds. It can take 20-
30 minutes for the eye drops to take effect. If your pupils do not dilate widely 
enough a second drop may be needed. 
− The drops will enable us to examine the back of the eyes (retina). The 
examination will involve using a bright light to illuminate the back of your eye. 
The examination may last 10-15 minutes. 
§ Some photos will be taken of the back of your eyes using a special camera 
(fundus camera); it will not be possible to identify you directly from the photos. 
We will also take some measures of the back of the eyes.  
§ None of these tests hurt. We will make sure that the eye examination is as 
quick and pain free as possible.  
§ After the examination you may experience blurring of vision, lights may seem 
extra bright and you may have difficulty reading or focusing up close. This lasts 
2-3 hours and then your eyes and vision will return to normal. 
− In the unlikely event that you develop eye pain or more severe blurring of 
vision you should return to the hospital. 
§ We will take a blood sample. 
− This sample will be taken to measure the degree of aging in the blood cells. 
To do this we need to extract DNA from cells (DNA is present inside all the 
cells of your body. It is a code that carries instructions for the form of your 
body. It is responsible for e.g. the colour of your eyes and hair). This sample 
will only be used to measure aging of cells, and cannot be used to 
determine your complete genetic identity. 
− At the end of the study your sample will be transported to UK for analysis. 
Only we will use this blood sample, and no one else will have access to it.  
 
What are the risks and discomforts of this study? 
The eye drops may cause temporary stinging of the eyes. Very rarely these eye 
drops will increase your the pressure in your eye, which may cause pain. If this 
occurs, it is treatable by medication. If you have eye pain after the eye drops are put 
in your eyes, you should inform us as soon as possible. 
 
Are there any benefits to you for being in the study? 
The examination will detect any eye condition you may have. The study doctor is an 
eye doctor. If she detects an eye problem she will explain this to you. She will explain 
the options available; this will probably include arranging an appointment at the 
hospital eye clinic to see the clinic eye doctors for some further tests and/or 
treatment. The study doctor can directly refer any eye problem to the eye clinic. You 
Sophia Pathai PhD Thesis Page 354
Appendix 3c – Version 2 (HIV-uninfected) English 
	  
	   3	  
will not need to go back to your community doctor for a referral. The appointment 
may be on a separate occasion(s) and treatment, if needed, will be provided free. If 
the hospital eye clinic contacts you to arrange an appointment it will only be via the 
phone number you have given us. The study doctor will also keep a record of your 
eye condition, and with your permission will provide this information to your 
community doctor. If you need glasses for reading, cooking etc these will be given for 
free.  
 
You may refer to the diagrams below to understand the study better 
 
 
 
What other choices do you have? 
You have the following choices:  
− You can choose not to take part in the study. 
− If you choose to take part, and then wish to dropout (at any point during the 
study), you may do so. This will not affect your current or future treatment or 
management at the clinic. 
− If you wish to withdraw your permission for use of your stored blood sample, you 
may request this. We will make sure that it is destroyed and never used. 
− If you do not wish for your identity to be kept with your stored blood samples, you 
may inform us. We will make sure your identity is kept secret.  
− If you do not wish to be contacted after the study is over, for disclosure of any 
study results, you may request this. 
 
What will happen when the study is over? 
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Once the study is over you will be able to access eye care services as usual. We will 
train the clinic staff to detect basic eye conditions and the need for glasses so this 
can be picked up if you have any eye-related symptoms.  
Will your test results be shared with you? 
If you would like access to your test results these will be shared with you.  
 
Will the results of the research be shared with you? 
If you would like to have access to the results/ findings of this study after it is 
completed, they will be shared with you.  
 
Will any of your blood, tissue or other samples be stored and used for research 
in the future? 
You will be asked to give an additional blood sample at the time of your routine 
testing. The sample will be stored in a deep freeze. At the end of the study, samples 
will be transported to UK for analysis. These analyses will be conducted by the study 
team laboratory only. No one else will have access to your blood sample, except for 
study staff. This sample will help us understand aging in cells better. At the end of the 
analysis, if you choose to have access to these results, they will be shared with you. 
If you do not wish for your identity to be kept with your stored blood sample, it will be 
kept secret. Only your eye doctor will have access to your full information.  
If there is any sample remaining this may be stored for research in the future with 
your permission. Future work will be related to this project. We will keep your identity 
anonymous.  
 
Will you receive any reward (money or food vouchers) for taking part in this 
study? 
You will be given a total of ZAR 200, which will cover your travel expenses and time 
spent participating in the study.  
 
Who will see the information which is collected about you during the study? 
§ The examination information will be kept confidential and will not be given to 
anyone outside the study.  Your name will only be written on the special 
enrolment form that has your personal details like name, address, etc. These will 
be kept in a secure area.  
§ Your name will never be used in any reports. No quotes or other results arising 
from your participation in this study will be included in any reports, even 
anonymously, without your agreement. 
§ Once your blood sample is transported to UK, no one except for the study doctor 
will have access to your full information. If you do not want your identity to be 
kept with your blood sample, it will be removed. 
§ All study reports/ results will be stored in a computer system. To avoid anyone 
from identifying you directly all your data will be coded. To ensure that no one 
outside the study has access to your data, the computer will be password 
protected. Only the study doctor will have full access. 
§ If we contact you to provide information or results this will involve only one phone 
call to the number provided by you.  
 
Who do I speak to (or contact) if I have any questions about the study? 
If you have any questions about the study, you can contact your the study doctor, Dr. 
Sophia Pathai or the Research Assistant/Nurse (079 337 6369). In case you require 
a translator, one will be provided for you.  
	  
Before you make a decision, we welcome any questions that you may have. 
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IPHEPHA LOLWAZI LOMTHATHI-NXAXHEBA 
 
ISihloko soPhononongo:  
Ingaba i-HIV iyiqhubela phambili imo yokwaluphala? Ukuhlolwa kobunjani 
obunokubalwa bokwaluphala kwamehlo (ophthalmic), kokugula (clinical) nokwencindi 
yegazi (serum) kwiqela labantu abosuleleke yi-HIV eMzantsi Afrika. 
 
Ngubani oqhuba olu phononongo? 
 
Umphandi oyintloko: UGqirha Sophia Pathai  
Esinye iSitafu soPhononongo: (Sr Eudoxia Radithalo) 
 
Nceda ufunde le fom ngononophelo. Thatha ixesha ubuze ugqirha 
wophononongo okanye isitafu sophononongo imibuzo emininzi kangangoko 
malunga nophononongo kangangoko ufuna. Ugqirha wophononongo okanye 
isitafu sophononongo bangakuchazela amagama okanye ulwazi 
ongaluqondiyo. Ukufunda le fom nokuthetha nogqirha wophononongo okanye 
isitafu sophononongo kungakunceda ukuba wenze isigqibo sokuthatha 
inxaxheba okanye ungasithathi. Ukuba ugqiba ekubeni uthathe inxaxheba kolu 
phononongo, kuza kufuneka usayine igama lakho ekupheleni kwale fom.  
 
Kutheni kusenziwa olu phononongo? 
Ukwaluphala kungakhokelela kwiinguqulelo kwimbonakalo yomzimba wakho nempilo 
yakho jikelele. Izigulo ezininzi zinxulunyaniswa nokwaluphala njengesifo sentliziyo, 
isifo sokubaqwathaqwatha kwamathambo, isifo sezintso. Kucingwa ukuba abantu 
abosuleleke yi-HIV bangabasemngciphekweni wezigulo ezinjalo besebancinci, xa 
bethelekiswa nabantu ababudala bufanayo. Ngokufanayo, izigulo zamehlo ezininzi 
zinxulunyaniswa nokwaluphala yaye oku kungakhokelela kwiingxaki zokungaboni 
ngokucacileyo. Olu phononongo luza kuhlola ukuba zeziphi izigulo zamehlo 
ezinxulumene nokwaluphala ezinokubonwa kubantu abosuleleke yi-HIV yaye nokuba 
ngaba zahlukile na okanye zenzeka ngokuxhaphakileyo na kubantu 
abangosulelekanga. Luza kuhlola kwakhona amanye amanyathelo anxulumene 
nokwaluphala anje ngamandla omzimba neziphawuli zokwaluphala kwiiseli 
zomzimba. Olu phononongo luza kusinceda ukuba sifumanise ukuba ngaba 
ukwaluphala msinya kubantu abosuleleke yi-HIV kuyenzeka na. Olu lwazi 
lungasinceda ukuba silungiselele unakekelo lwempilo lwexesha elizayo. 
 
Kutheni ucelwa ukuba uthathe inxaxheba? 
Uyacelwa ukuba uthathe inxaxheba kolu phononongo, ukuze sikwazi ukulinganisela 
'ubungakanani bokwaluphala' emzimbeni wakho ngendlela ezahlukeneyo. Ulwazi 
lwakho (idatha) luza kuthelekiswa nolwabantu abosuleleke yi-HIV ababudala 
bulinganayo kwanobuni –ngoko ke uza kusetyenziswa ‘njengothelekiso’. Oku kuza 
kusinceda ukuba sifumanise ukuba ingaba i-HIV inxulumene na nokwaluphala 
kwamsinya. Iziphumo zolu phononongo ziza kusinceda ukuba siqonde 
ngokungaphaya malunga nale nkqubo. Ukuthatha kwakho inxaxheba kuxabiseke 
kakhulu nanjengoko kufuneka sihlole iqela lothelekiso elingosulelekanga yi-HIV. Siza 
kusebenzisa ulwazi obelusele lukhona kwangaphambili kwiKlinikhi yaseMavundleni 
(Emavundleni Clinic) yaye awuzukulindeleka ukuba wenziwe naziphi na iimvavanyo 
ze-HIV ezongezelelweyo. 
 
Bangaphi abantu abaza kuthatha inxaxheba kuphononongo? 
Zizonke zizigulane ezingama-740 eziza kufunelwa olu phononongo. Kwezi ama- 
370 aza kuba zizigulane ze-HIV yaye ama-370 aza kuba ngabantu abangekho HIV 
bobudala obufanayo kwanesini.  
Uphononongo luza kuthatha ixesha elingakanani? 
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Olu phononongo luza kuthatha isithuba sonyaka om-1. Nangona kunjalo, 
awuzukulindeleka ukuba utyelele isibhedlele ngaphezulu kunakanye. 
 
Senza ntoni ukwenza isigqibo sokuba ufanelekile na ukuthatha inxaxheba? 
Siza kujonga kwakhona iirekhodi zaseklinikhi ngokusekelwe kuluhlu lweemeko 
ezicebisa ukuba unokululungela uphononongo (umz. Ubudala bakho). Ukuba 
uphakathi kweli qela uza kubuzwa ukuba ungayithatha na inxaxheba. Ukuba 
unomdla, uphononongo uza kuluchazelwa yaye uza kuvunyelwa ukuba wenze 
isigqibo.  
 
Kuza kwenzeka ntoni ukuba ugqiba ekubeni uthathe inxaxheba 
kuphononongo? 
Ukuba ukhetha ukuthatha inxaxheba,  
§ Uza kucelwa ukuba uqale usayine ifom yemvume okanye unike uphawu 
lukabhontsi 
§ Uza kucelwa ukuba uye kwiSebe lezaMehlo (Department of Ophthalmology) 
esiBhedlele iGroote Schuur ukuvavanywa (uhambo lwakho nexesha ziza 
kuhlawulwa kwakhona, jonga apha ngezantsi) 
§ Ulwazi lobuqu lwakho (njengobudala, isini, isikhundla) kunye nembali 
yokugula kwakho jikelele (njengeengxaki zentliziyo, uxinzelelo lwegazi) ziza 
kuqwalaselwa. 
§ Siza kukhangela amandla omzimba wakho nokuzinza ngeemvavanyo 
ezithile ezilula ezinje ngokuphakama esitulweni nokuhamba kwindledlana. 
§ Ukulandela oku, amehlo akho aza kuvavanywa ngugqirha wamehlo   
§ Ugqirha wakho wamehlo uza kuqala akhangele ukubona kwakho, okuza 
kwenziwa ngale ndlela ilandelayo: 
− Ukubona kwimehlo ngalinye kuza kulinganiswa kusetyenziswa iitshati 
zokuvavanywa kokubona.  
− Ukuba sifumanisa ukuba ufuna iiglasi zokubona kufutshane, ezi ziza kunikwa 
mahala 
§ Umphambili wemehlo lakho uza kuvavanywa kusetyenziswa 
ngesibonakhulu esikhethekileyo (microscope) esibizwa ngokuba sisi-“slit-lamp”  
§ Umva wemehlo lakho (iretina) uza kuvavanywa ngale ndlela ilandelayo: 
− Amaqabaza amehlo aza kufakwa kwimehlo ngalinye, ukwandisa 
ukhozo lwemehlo (isangqa esimnyama esizikithini) semehlo. Amaqabaza 
amehlo angatsweba imizuzwana embalwa. Kungathatha 20-30 imizuzu ukuba 
amaqabaza amehlo asebenze. Ukuba iinkozo zamehlo akho azandi 
ngokubanzi ngokwaneleyo iqabaza lesibini linokufuneka. 
− Amaqabaza aza kusinceda ukuba sivavanye umva wamehlo (iretina). 
Uvavanyo luza kubandakanya ukusetyenziswa kokukhanya okuqaqambileyo 
ukukhanyisela umva wemehlo lakho. Uvavanyo lungathatha 10-15 imizuzu. 
§ Iifoto ezithile zomva wamehlo akho ziza kuthathwa kusetyenziswa ikhamera 
ekhethekileyo (ikhamera i-fundus); akuzi kukwazeka ukukubona ngokuthe ngqo 
kwiifoto. Siza kuthatha nemilinganiselo ethile kumva wamehlo akho.  
§ Akukho nanye kwezi mvavanyo ebuhlungu.Siza kuqinisekisa ukuba 
ukuxilongwa kwamehlo akho kukhawuleza yaye akukho buhlungu kangangoko.  
§ Emva kovavanyo ungafumanisa ukubona ngokumfiliba, izibane 
zingabonakala ziqaqambile yaye kunganzima ukufunda okanye ukujonga 
kufutshane. Oku kuthatha 2-3 iiyure kuze ke amehlo akho nokubona kubuyele 
kwisiqhelo. 
− Kwimeko engaqhelekanga yokuba uqaqanjelwe limehlo okanye ubone 
ngokumfiliba okugqithisileyo kufuneka ubuyele esibhedlele. 
§ Siza kuthatha isampuli yegazi. 
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− Le sampuli iza kuthathelwa ukulinganisa ubungakanani bokwaluphala 
kwiiseli zegazi. Ukwenza oku kufuneka sitsale i-DNA kwiiseli (i-DNA ikhona 
phakathi kweeseli zonke zomzimba wakho. Yikhowudi equlatha imiyalelo 
yemo yomzimba wakho. Inoxanduva (umz. webala lamehlo akho neenwele). 
Le sampuli iza kusetyenziswa kuphela ukulinganisa ukwaluphala kweeseli, 
yaye ayinakusetyenziselwa ukufumanisa ukwaziwa kwakho kofuzo 
okugqibeleleyo (complete genetic identity). 
− Ekupheleni kophononongo isampuli yakho iza kuthunyelwa e-UK ukuba 
ihlalutywe. Sithi kuphela abaza kusebenzisa le sampuli yegazi, yaye akukho 
mntu ungomnye uza kuba nokufikelela kuyo.  
 
Zeziphi iingozi nokungonwabi kolu phononongo? 
Amaqabaza amehlo angabangela ukutsweba kwexeshana emehlweni. Ngokunqabe 
kakhulu la maqabaza amehlo aza kunyusa uxinzelelo emehlweni lakho, 
okunokubangela ubuhlungu. Ukuba oku kuyenzeka, kuyanyangeka ngamayeza. 
Ukuba uyaqaqanjelwa emehlweni emva kokuba amaqabaza amehlo efakwe 
emehlweni akho, kufuneka usazise ngokukhawuleza kangangoko. 
Ingaba kukho naziphi na iinzuzo kuwe ngokuba kuphononongo? 
Uvavanyo luza kufumanisa nasiphi na isigulo samehlo onokuba unaso. Ugrirha 
wophononongo ngugqirha wamehlo. Ukuba ufumanisa ingxaki yamehlo uza 
kukuchazela oku. Uza kukuchazela okukhethwayo okukhoyo; oku mhlawumbi 
kungaquka ukulucwangcisa idinga kwiklinikhi yamehlo esibhedlele ukubona oogqirha 
bamehlo baseklinikhi ngeemvavanyo ezingaphaya kunye/okanye unyango. Ugqirha 
wophononongo angadlulisela ngokuthe ngqo nayiphi na ingxaki yamehlo kwiklinikhi 
yamehlo. Akuzi kufuneka ukuba ubuyele kugqirha wakho wengingqi ngodluliselo. 
Idinga linokuba nge(ngama)xesha elo(awo)hlukeneyo yaye unyango, ukuba 
luyafuneka, luza kunikwa mahala. Ukuba iklinikhi yamehlo yesibhedlele 
iqhagamshelana nawe ukucwangcisa idinga kuya kuba kuphela ngenombolo 
yomnxeba osinike yona. Ugqirha wophononongo uza kugcina kwakhona irekhodi 
yesigulo sakho samehlo, yaye ngemvume yakho uza kunikeza olu lwazi kugqirha 
wakho wengingqi. Ukuba ufuna iiglasi zokufunda, ukupheka njl.njl ziya kunikwa 
mahala.  
 
Ungajonga kwiidayagram apha ngezantsi ukuqonda inkqubo yophononongo 
ngokungcono. 
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Kokuphi ukukhetha okukokunye onako? 
Unoku kukhetha kulandelayo:  
− Ungakhetha ukungathathi nxaxheba kuphononongo. 
− Ukuba ukhetha ukuthatha inxaxheba, uze ke unqwenele ukurhoxa (nanini na 
ngexesha lophando), ungenza njalo. Oku akuzi kuchaphazela unyango lwakho 
lwangoku okanye lwexesha elizayo okanye ulawulo lwalo eklinikhi. 
− Ukuba unqwenela ukurhoxisa imvume yakho yokusetyenziswa kwesampuli 
yegazi yakho egciniweyo, ungakucela oku. Siza kuqinisekisa ukuba 
iyatshatyalaliswa yaye ayisoze isetyenziswe. 
− Ukuba awunqweneli ukuba ukwaziwa kwakho kugcinwe neesampuli zegazi 
lakho, ungasazisa. Siza kuqinisekisa ukuba ukwaziwa kwakho kugcinwa 
kuyimfihlo.  
− Ukuba awunqweneli ukuba kuqhagamshelwane nawe emva kokuba 
uphononongo luphelile, ngokudandalaziswa kwazo naziphi na iziphumo 
zophononongo, ungakucela oku. 
 
Kuza kwenzeka ntoni lusakube uphononongo luphelile? 
Ukuba nje uphando lugqitywe uza kubanako ukufikelela kwiinkonzo zonakekelo 
lwamehlo njengesiqhelo. Siza kuqeqesha isitafu saseklinikhi   ukufumanisa izigulo  
zamehlo ezingundoqo kunye nemfuneko yeeglasi  ukuze   kufunyaniswe ukuba 
unazo naziphi na iimpawu ezinxulumene namehlo. 
 
Ingaba iziphumo zovavanyo zakho kuza kwabelwana ngazo nawe? 
Ukuba uyakufuna ukufikelela kwiziphumo zakho zovavanyo kuza kwabelwana ngazo 
nawe.  
 
Ingaba iziphumo zophando kuza kwabelwana ngazo nawe? 
Ukuba uyakufuna ukufikelela kwiziphumo/ izinto ezifunyanisiweyo zolu phononongo 
emva kokuba lugqityiwe, kuza kwabelwana ngazo nawe.  
 
Ingaba naziphi na iisampuli zakho zegazi, isihlunu okanye naziphi na iisampuli 
ezizezinye ziza kugcinwa zize zisetyenziselwe uphando kwixesha elizayo? 
Uza kucelwa ukuba unike isampuli yegazi eyongezelelweyo ngexesha lovavanyo 
lwakho lwesiqhelo. Isampuli iza kugcinwa kwisikhenkcisi esibandisa kakhulu 
(deep freeze). Ekupheleni kophononongo, iisampuli ziza kuthunyelwa e-UK ukuba 
zihlalutywe. Olu hlalutyo luza kuqhutywa yilebhu yeqela lophando kuphela. Akukho 
mntu wumbi uza kufikelela kwisampuli yakho yegazi, ngaphandle kwesitafu 
sophononongo. Le sampuli iza kusinceda ukuqonda ukwaluphala kweeseli 
ngokungcono. Ekupheleni kohlalutyo, ukuba ukhetha ukufikelela kwezi ziphumo, 
kuza kwabelwana ngazo nawe. Ukuba awunqweneli ukuba ukwaziwa kwakho 
kugcinwe nesampuli yegazi yakho, oku kuza kugcinwa ngokuyimfihlo. Ngugqirha 
wakho wamehlo kuphela oza kufikelela kulwazi lwakho olupheleleyo. Ukuba kukho 
nayiphi na isampuli eseleyo inokuthi igcinelwe uphando lwexesha elizayo ngemvume 
yakho. Umsebenzi wexesha elizayo uza kunxulumana  nale projekthi. Siza kugcina 
ukwaziwa kwakho kungaziwa.  
 
Uza kufumana nawuphi na umvuzo (imali okanye iivawutsha zokutya) 
ngokuthatha inxaxheba kolu phononongo? 
Uza kunikwa iyonke i-ZAR 200, eza kuhlawula iindleko zohambo zakho nexesha 
olichithileyo ngokuthatha inxaxheba kuphononongo.  
 
Ngubani oza kubona ulwazi oluqokelelweyo ngawe ngexesha lophononongo? 
§ Ulwazi lovavanyo luza kugcinwa luyimfihlo yaye aluzi kunikwa nabani na 
ongaphandle kophononongo.  Igama lakho liza kubhalwa kuphela kwifom 
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yobhaliso olukhethekileyo eneenkcukacha zakho zobuqu ezinje ngegama, 
idilesi, njl.njl. Ezi ziza kugcinwa kwindawo ekhuselekileyo.  
§ Igama lakho alisoze lisetyenziswe nakwiziphina iingxeloi. Akukho zingxelo 
okanye ezinye iziphumo ezivela ekuthabatheni kwakho inxaxheba kolu 
phononongo ziya kuthi ziqukwe kuzo naziphi na iingxelo, nokuba ngaba 
kungokungaziwayo, ngaphandle kwemvume yakho. 
§ Ukuba nje isampuli yegazi yakho ithunyelwe e-UK, akukho nabani na 
ngaphandle kogqirha wophononongo oya kuthi afikelele kulwazi lwakho 
olupheleleyo. Ukuba awufuni ukuba ukwaziwa kwakho kugcinwe nesampuli 
yegazi yakho, kuza kususwa. 
§ Zonke iingxelo/iziphumo zophando ziza kugcinwa kwinkqubo yekhompyutha. 
Ukunqanda nabani na ukuba akwazi ngokungqalileyo yonke idatha yakho iza 
kukhowudwa. Ukuqinisekisa ukuba akukho nabani na ongaphandle oya uthi 
afikelele kwidatha yakho, ikhompyutha iza kukhuselwa nge-password. 
Ngugqirha wophando kuphela oza kubanokufikelela okupheleleyo. 
§ Ukuba siqhagamshelana nawe ukukunika ulwazi okanye iziphumo oku kuya 
kubandakanya utsalo lomnxeba olunye kuphela kwinombolo enikwe nguwe.  
 
Ndithetha nabani (okanye uqhagamshelwano) ukuba ndinayo nayiphi na 
imibuzo malunga nophononongo? 
Ukuba unayo nayiphi na imibuzo malunga nophononongo, ungaqhagamshelana 
nogqirha wakho wophononongo, uGqirha Sophia Pathai okanye iSekela 
loPhando/uNesi (xxxxx). Xa unokuthi ufune umguquli, uza kumnikwa.  
 
Phambi kokuba wenze isigqibo, samkela nayiphi na imibuzo onokuthi ube 
nayo. 
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Aging study – University of Cape Town 
 
Thank you for agreeing to be part of this study. This leaflet explains what will 
happen when you come to Groote Schuur Hospital.  
 
Physical tests 
We will measure the strength in your arms and how fast you can walk and sit 
up and down. 
 
 
Eye tests 
We will perform some eye tests, none of them hurt. You will need to have 
some eye drops that make the vision blurred for a few hours but then it will go 
back to normal.  
 
 
 
 
We will take some pictures of the eye – you cannot be identified from them. 
 
 
 
We will also take a blood sample. 
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Important points: 
 
• When you come to the hospital you will be asked to sign a ‘consent 
form’ that says you agree to take part in the study and for the 
information to be used in our research. 
 
• We will not share this information with anyone else.  
 
• You will get a complete eye examination. If you need glasses for 
reading you will get these too. We will also give you a total of R200 for 
your travel and time to attend the hospital.  
 
• If you have an eye problem the doctor will explain this to you and will 
arrange for the Eye Clinic doctors to see you (at another appointment) 
 
• We have asked for your contact details. If we call you or your 
friend/relative all we will mention is that we want to talk to you, not that 
you are taking part in study.  
 
 
 
A more detailed information sheet is available in English and Xhosa.  
 
 
 
Date of appointment: ___________________________________ 
 
Time: ___________________ 
 
 
If you have any questions you can contact the Study Coordinator, Tshidi on 
079 337 6369 
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                    Uphononongo lobudala – eUniversity ya se Kapa 
 
Siyabulela ukuba uvume ukuza kolopononongo. Lamaphepha axela ukuba 
kuzakwenzeka ntoni xa ofika esibhedlele iGroote Schuur Hospital. 
 
Sizojonga ezizinto zilandelayo: 
 
Siza kukhangela amandla omzimba wakho  nokuzinza ngeemvavanyo ezinje 
ngokuphakama esitulweni, nokuhamba kwindledlana. 
 
Amehlo 
Amaqabaza amehlo aza kufakwa kwimehlo ngalinye, ukwandisa ukhozo 
lwemehlo isangqa esimyama esizikithini semehlo. Siza kuqiniseka ukuba 
ukuxilongwa kwamehlo akho kukhauleza yaye akukho buhlungu kangako.  
 
 
 
Iifoto ezithile zomva wamehlo akho ziza kuthatwa kusetyenzizwa ikhamera 
ekhethekileyo, akuzi kukwazeka ukubona ngokuthe ngqo kwiifoto 
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Siza kuthatha isapuli yegazi 
 
      Important points: 
 
• Xa uza esibhedlele uza usayina ifom yeMvumo yabo baNokuba ngaba 
Thathi-nxaxheba kulophononongo. 
 
• Asizuku xelela mtu ngalento. 
 
• Amehlo akho aza kuvavanywa ngugqirha wamehlo. Ukubaa sifumanisa 
ukuba ufuna iiglasi zokubona kufutshane, ezi ziza kunikwa mahala. 
Uzaphiwa iR200.00 kwindleko zakho zokuza esibedlele. 
 
• Kwimeko engaqhelekanga yokuba uqaqanjelwe limehlo okanye ubone 
ngokumfiliba okugqithisileyo kufuneka ubuye esibhedlele samehlo 
apha. 
 
• Ukuba siqhaqhelekanga nawe ukukunika ulwazi okanye iziphumo oku 
kuya kubandadakanya utsala lomnxeba olunye kuphela kwinombolo 
enikwe nguwe. 
 
          Iphephalinye linge English ne sXhosa elichaza kakuhle  
 
 
 
Umhla wokuhlolwa: ___________________________________ 
 
Ixesha: ___________________ 
 
 
Xa unemibuzo thetha noTshidi kwilenombolo on 079 337 6369 
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Willingness to participate form – Aging Study, UCT 
 
 
 
I _______________________________, agree to participate in this study. 
 
 
I am willing to travel to Eye Clinic Groote Schuur Hospital to take part in the 
study. 
 
I am willing to come to the hospital on __________________at 
_____________.  
 
My contact details are: 
Cell no (1)_____________________ 
Cell no (2) ____________________ Contact person: __________________ 
Other: _______________________ Contact person: __________________ 
 
Signed: _____________________     Date:__________________________ 
 
For office use:  Clinic ID: _____________ 
Gugs new ______  Green clinic______  Ema _____(tick appropriate) 
Current CD4 count: __________          Current VL: _____________ 
Nadir CD4 count: _____________ When: _____________________ 
Nadir VL: ___________________  When: _____________________ 
WHO clinical stage: 1   2   3   4  (circle appropriate) 
Treatment regimen: _________________________  Duration: _______ 
Other comments: 
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Consent form 
 
Does HIV accelerate the aging process? An assessment of ophthalmic, clinical and 
serum parameters of aging in a cohort of HIV-infected individuals in South Africa. 
 
Consent Form for Potential Participants 
 
1. I have read the information sheet concerning this study (or have understood the 
verbal explanation) and I clearly understand what will be required of me and 
what will happen to me if I take part in it. 
2. My questions concerning this study have been answered by  
3. I understand that at anytime I may withdraw from this study without giving a 
reason and without affecting my normal care and management. 
4. I am aware that all the information that I give, all the findings of the clinician, and 
all the laboratory results will be kept secret. 
5. I do / do not agree to results arising from my participation in the study being 
included. 
6. I do / do not agree that my blood sample can be stored for future use at the end 
of this study. 
7. I do / do not want my identity to be kept with my stored blood sample. 
8. I do / do not wish to be contacted after the study is over for its results.  
9. I agree to take part in this study. 
 
 
Name (CAPITAL LETTERS) 
 
Signature      Date _________________________ 
 
 
If participant is illiterate:     
 
Name of witness     AND   Thumb print of participant 
 
 
Signature of witness    
 
Date 
 
 
 
Tick box is the participant is illiterate and refuses to have a witness present  
 
For study staff:  
I have accurately read or witnessed the accurate reading of the consent form to the 
potential participant, and the individual has had the opportunity to ask questions. I 
confirm that the individual has given consent freely. 
Name of staff 
 
Signature            Date 
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 Ifom yemvume 
 
Ingaba i-HIV iyiqhubela phambili imo yokwaluphala? Ukuhlolwa kobunjani  obunokubalwa 
kokwaluphala kwamehlo (ophthalmic), kokugula (clinical) nokwencindi yegazi (serum) 
kwiqela labantu abosuleleke yi-HIV eMzantsi Afrika. 
 
Ifom yeMvume yabo baNokuba ngabaThathi-nxaxheba  
 
1. Ndilifundile iphepha lolwazi ngokuphathelene nolu phononongo (okanye ndiyiqondile 
inkcazelo yomlomo) yaye ndikuqonda ngokucacileyo okuza kufuneka kum yaye nokuza 
kwenzeka kum ukuba ndithatha inxaxheba kulo.  
2. Iimibuzo yam ngokuphathelene nolu phononongo iphendulwe ngu  
3. Ndiyaqonda ukuba nanini na ndingarhoxa kolu phononongo ndinganikanga sizathu yaye 
ngaphandle kokuchaphazeleka konakekelo lwam lwesiqhelo nolawulo. 
4. Ndiyaqonda ukuba lonke ulwazi endilunikayo, zonke iziphumo zikasoklinikhi (clinician), 
yaye zonke iziphumo zaselebhu ziza kugcinwa ziyimfihlo. 
5. Ndiyavuma / andivumi ukuba iziphumo zam ezivela ekuthatheni kwam inxaxheba kolu 
phononongo zibandakanywe.  
6. Ndiyavuma / andivumi ukuba isampuli yam yegazi igcinelwe ukuba isetyenziswe 
kwixesha elizayo ekupheleni kolu phononongo. 
7. Ndiyavuma / andifuni  ukuba ukwaziwa kwam kugcinwe nesampuli yam yegazi 
egciniweyo. 
8. Ndiyanqwenela / andinqweneli ukuba kuqhagamshelwane nam emva kokuba 
uphononongo luphelile malunga neziphumo.  
9. Ndiyavuma ukuthatha inxaxheba kolu phononongo. 
 
 
Igama (OONOBUMBA ABAKHULU)   ____________________________________ 
 
Usayino       Umhla_________________________ 
 
 
Ukuba umthathi-nxaxheba akafundanga:     
 
Igama lengqina KUNYE   Nobhontsi womthathi-nxaxheba 
 
 
Usayino lwengqina  _________________    
 
Umhla   __________________________ 
 
 
 
Phawula ibhokisi ukuba umthathi-nxaxheba akafundanga yaye akafuni ukuba kubekho 
ingqina  
 
Okwesitafu sophononongo:  
Ndifunde ngokuchanekileyo okanye ndikungqinile ukufundwa okuchanekileyo kwefom 
yemvume kulowo unokuba ngumthathi-nxaxheba, yaye umntu lowo ulifumene ithuba 
lokubuza imibuzo. Ndiqinisekisa ukuba umntu lowo uyinike imvume yakhe 
ngokukhululekileyo. 
Igama lesitafu  _______________________________________________________ 
 
Usayino ______________________          Umhla  ________________ 
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Data entry form – Aging Study 
 
Demographic details 
 
Date  Study ID
day month Clinic ID
Age yrs D.O.B. Sex 1 M 2 F
Education 1 None Marital status 1 Single
2 Some 2 Married
3 Highschool 3 Divorced
4 College 4 Widowed
Income per month Occupation 1 Unemployed Location of job 1 Out
Nil 1 500-750 3 2 Grant support 2 In 
<250 2 750-1K 4 3 Domestic 3 N/A
250-500 3 1-1.5K 5 4 Skilled
>1.5K 6
No of sibs M No ppl in home
F
TB Cancer Hx No 1 Medical Hx Y N BP            /
No 1 Yes 2 1 2 None
Curr 2 1 2 BP Height (cms)
Prev 3 If yes type: 1 2 CVD Weight (Kg)
1 2 Renal BMI (cal)
FHx eye dis 1 2
Frality 
Weight loss 1 Yes Exhaustion 0 3 P A 1 Karnofsky score if not avail sel '9'
2 No 1 2 10 30 50 70 90 9
2 3 20 40 60 80 100
RVD? 1 Yes HAART naïve? 1 Yes If NO, treatment Yrs Months
2 No 2 No duration (yrs/months)
Regimen 1 CBV + EFV 3 TDF +3TC/FTC+EFV/NVP CD4 - current
2 CBV + NVP 4 Other: CD4 - nadir
VL - current
WHO clinical stage 1 2 3 4 VL - nadir
Opportunistic Infections if CD4 and VL not avail enter '9999'
1 Yes If yes 1 TB 3 crypto 5 Kaposi 7 PPE
2 No 2 toxo 4 diarrhoea 6 CMV
2011
year
Affix study ID label 
Checked: _____________ 
Scanned: _____________ 
Database entry: ________ 
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Socioeconomic details    2 
 
Physical capability measures 
 
Housing Electricity Toilet Toilet
Formal 1 Yes 1 In house? Yes 1 Shared? Yes 1
Informal 2 No 2 No 2 No 2
In home:
Stove Yes 1 TV Yes 1 Water tap shared? Yes 1
No 2 No 2 No 2
Alcohol Yes 1 Type Homemade 1 Amount per None 1
No 2 Refined 2 week <500ml 2
N/A 3 500-1L 3
1 - 2L 4
>2L 5
Cigarettes Yes 1 How many per day? How long? years Ever smoked? Yes
No 2 No
Drugs Yes 1 What? >3 times/wk? 1 Yes How long? years Taken Yes 1
No 2 2 No this wk? No 2
3 N/A N/A 3
Snaff Yes 1 >3times/wk? Yes 1 How long? years Taken Yes 1
No 2 No 2 this wk? No 2
N/A 3 N/A 3
Family/personal:
Where lived as  a child? Rural 1 Where did their mother live Rural 1
Periurban 2 while pregnant P/u 2
Urban 3 with participant? Urban 3
Don't know 9 D.K 9
Number of times No of live births No of breast fed babies
preganant N/A 99 (male)
No  of partners (now and past) Hx of STD Yes 1
No 2
1. Grip Strength *RIGHT HAND Unable *Dominant Hand* LEFT HAND Unable
Trial-1 kg 99 kg 99
Trial-2       SD RIGHT 1       SD
Trial-3       CV LEFT 2       CV
Average
2. Chair Rises Unable 99 Time to complete 5 stands secs If fail, no/time
3. Walking speed Unable 99 trial-1 secs trial-2 secs (to 1 d.p.)
4. Walking balance Unable 99 trial-1: No. of Deviations T ime
trial-2: No. of Deviations T ime
trial-3: No. of Deviations T ime secs
5. Balance one leg secs
6. Up and go test secs
(sit walk 3m sit)
7. Hx of eye disease 1 Yes If yes 1 Cataract 3 Other
2 No 2 Diabetes 4 N/A
Checked: _____________ 
Scanned: _____________ 
Database entry: ________ 
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 3 
 
 
 
Ophthalmic parameters (enter ‘99’ if not possible)        Office use only: 
 
 Comments: 
 
 
RIGHT EYE Ophthalmic Examination LEFT EYE 
Eye symptoms 1 Yes Eye symptoms 1 Yes
2 No 2 No
If yes: 1 Dec vision If yes: 1 Dec vision
2 Pain 2 Pain
3 Floaters 3 Floaters
4 Other 4 Other
5 Diff near wk 5 Diff near wk
6 None ↓ 6 None
NEAR VISION
Wearing gls? 1 No BOTH EYES - presenting Chars
2 Dist only BOTH EYES - uncorrected Chars
3 Near only
4 Dist + Near VA =20/x?
DISTANCE Presenting    No of chars Chars
VA Uncorrected
Pinhole
Best
VA = 20/x? VA = 20/x?
Sphere Cyl Axis Add Sphere Cyl Axis Add
AA (cm) Both eyes
Colour vision (x/13)
Contrast sens Both eyes
MT Yes 1 Yes 1
Other No 2 No 2
parameters
ONH 1 1
2 2
Fundus photos 1 1
2 2
Checked: _____________ 
Scanned: _____________ 
Database entry: ________ 
 
 
Affix study ID label 
Checked: _____________ 
Scanned: _____________ 
Database entry: ________ 
 
 
 
RIGHT LEFT 
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RIGHT EYE LEFT EYE
Eyelids Normal 0 0
Kaposi sarcoma 1 1
Molluscum 2 2
Conjunctiva Normal 0 0
Pterygium 1 1
?SCC 2 2
Other 3 3
Cornea Clear 0 0
Infiltrates 1 1
KP 2 2
Other 3 3
IOP mmHg 9 9
if patient unable to complete encircle ' 9 '
Uveitis Cells -grade 9 9
Flare - grade 9 9
Post synechiae None 0 0
Yes 1 1
Unknown 9 9
Lens Aphakia 0 0 Right Grade
Phakia, clear 1 1 NS 1
Non-visually sig. cat 2 2 CLO 2
Visually sig. cat 3 3 PSC 3
Pseudophakia open capsule 4 4
Pseudophakia, no PCO 5 5 Left Grade
Psuedophakia +PCO 6 6 NS 1
Unknown 9 9 CLO 2
PSC 3
Vitreous Clear 0 0
Trace 0.5 0.5
1+ 1 1
2+ 2 2
3+ 3 3
4+ 4 4
Unknown 9 9
Retina Normal 0 0
HIV R 1 1
TB 2 2
DR 3 3
Other 4 4
UTE 9 9
CMVR No CMVR 0 0
Unsure 1 1
Lesion <1/4 DA 2 2
Definite CMVR 3 3
UTE 9 9
Checked: _____________ 
Scanned: _____________ 
Database entry: ________ 
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Figure 1: Lohse N, et al, Survival of persons with and without HIV infection in Denmark, 1995-
2005.Ann Intern Med. 2007 Jan 16;146 
 
Permission is granted to print the preceding material with the understanding that you will give 
appropriate credit to Annals of Internal Medicine as the original source of the material. Any 
translated version must carry a disclaimer stating that the American College of Physicians is not 
responsible for the accuracy of the translation. This permission grants non-exclusive, worldwide 
rights for this edition in print (Thesis) format for not for profit only. ACP does not grant permission 
to reproduce entire articles or chapters on the Internet unless explicit permission is given.  This 
letter represents the agreement between ACP and Sophia Pathai for request WAA1217892 and 
supersedes all prior terms from the requestor. 
 
Thank you for your interest in Annals of Internal Medicine. If you have any further questions or 
would like to discuss the matter further, please contact me at 856-489-4446 or fax 856-489-4449. 
 
Sincerely, 
 
Gina Brown 
Permissions Coordinator 
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